



(51) International Patent Classification:

C12Q 1/68 (2018.01) C07K 16/28 (2006.01)

C07K 14/71 (2006.01) C07K 16/46 (2006.01)

C07K 14/435 (2006.01) A61K 35/17 (2015.01)

C07K 14/705 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2018/036357

(22) International Filing Date:

06 June 2018 (06.06.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/516,639 07 June 2017 (07.06.2017) US

(71) Applicant: INTREXON CORPORATION [US/US];
1750 Kraft Drive, Suite 1400, Blacksburg, Virginia 24060 (US).

(72) Inventors: SHAH, Rutul; 14302 Harvest Moon Road, Boyds, Maryland 20841 (US). EMTAGE, Peter; 3573 Terrace Way, Apt. 47, Lafayette, California 94549 (US).

YARLAGADDA, Ramya; 327 West Side Drive, Apt. 302, Gaithersburg, Maryland 20878 (US).

(74) Agent: GIRINATH, Prashant; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: EXPRESSION OF NOVEL CELL TAGS




FIG. 14

(57) Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

EXPRESSION OF NOVEL CELL TAGS

CROSS-REFERENCE TO RELATED APPLICATION

[0001] The present application claims the benefit of U.S. Provisional Patent Application No. 62/516,639 filed June 7, 2017, which is hereby incorporated by reference in its entirety.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 30, 2018, is named 50471-708_601_SL.txt and is 464,445 bytes in size.

BACKGROUND OF THE DISCLOSURE

[0003] Cell therapies offer the promise of treating diseases that cannot be treated adequately by conventional pharmaceuticals. Blood transfusions were the first type of cell therapy to treat hematological malignancies. Recent advances in cell isolation, induction and gene transfer technologies has allowed for genetic modification of various cell types (primary and immortalized) for treatment of variety of diseases *e.g.* cancer, cardiovascular, dermatological, neurological, and ophthalmological diseases. In many cases, it is critical to enrich for genetically modified cell therapy product to achieve necessary purity to allow for expansion of select cells of therapeutic interest and/or eliminate non-genetically modified or other cell types prior to infusion in patients. In addition, adoptive cell immunotherapy using for example, cytokines, chimeric antigen receptors (CAR) and T-cell receptors (TCR) has shown great promise to successfully direct killing of tumor cells. While this innovative technology is promising, the administration of modified immune cells into tumor bearing individuals has not been without safety issues, for instance toxicity, tumor lysis and cytokine release syndrome (*i.e.*, “cytokine storm”) in the case of CAR-T cell therapy. In order to take full advantage of the therapeutic potential offered by adoptive T cell immunotherapy techniques, it is imperative that side effects such as cytokine storm be controlled during therapy.

INCORPORATION BY REFERENCE

[0004] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

SUMMARY OF THE DISCLOSURE

[0005] Provided are polypeptide constructs and polynucleotides which can be expressed in cells to address one or more of the above deficiencies.

[0006] Provided is a polypeptide construct and polynucleotide encoding the polypeptide construct, the polypeptide construct comprising a truncated variant of a natural polypeptide. In some embodiments, the polypeptide construct can further comprise a transmembrane domain or a fragment thereof, a signal peptide and/or a peptide linker. Also provided herein are engineered cells expressing the polynucleotides and polypeptide constructs. The engineered cells can express the polypeptide constructs at the cell surface thereby providing for a cell marker (or “cell tag”) which in some embodiments uniquely identifies the engineered cells.

[0007] Further provided herein is a polypeptide construct and polynucleotide encoding the polypeptide construct, the polypeptide construct comprising a truncated variant of a natural polypeptide and a transmembrane domain. In certain embodiments, the truncated variant comprises an extracellular domain or portion thereof and a transmembrane domain or portion thereof. In some embodiments, the polypeptide construct can comprise a transmembrane domain and a truncated variant derived from different natural proteins. In some cases, the truncated variant transmembrane domain of a polypeptide construct is a single-pass transmembrane domain. In other cases, the transmembrane domain of a polypeptide construct is a multiple-pass transmembrane domain.

[0008] Provided herein is a polypeptide construct and a polynucleotide encoding the polypeptide construct, the polypeptide construct including a transmembrane dimerization domain capable of coupling a cell surface polypeptide (*e.g.*, a truncated variant fused to the transmembrane domain) at the cell surface to a second cell surface polypeptide. In certain embodiments, the coupling of cell surface polypeptides via a transmembrane dimerization domain can amplify a signal originating at the cell surface polypeptides relative to a non-dimerized configuration.

[0009] Still further provided herein is a polypeptide construct and a polynucleotide encoding the polypeptide construct, the polypeptide construct comprising domains or fragments thereof which originate from different natural proteins. In some embodiments, a polypeptide construct described herein can comprise a truncated variant of a natural polypeptide, a transmembrane domain, an optional peptide linker connecting the truncated variant to the transmembrane domain, and a signal peptide directing the polypeptide construct to a cell surface. For example, in some embodiments, a polypeptide construct contains a truncated variant or fragment thereof which is derived from a different natural protein than a transmembrane domain or fragment thereof fused either directly or indirectly to the truncated variant or fragment thereof. In some embodiments, a particular domain (*e.g.* extracellular domain) of a polypeptide construct described herein is chimeric and contains amino acid sequences derived from different natural proteins.

[0010] In some cases provided are methods and compositions comprising a polypeptide construct including a cell surface polypeptide and a trans-membrane dimerization domain, wherein the trans-membrane dimerization domain induces dimerization of the cell surface polypeptide and the cell surface polypeptide binds a predetermined antibody or a variant or fragment thereof. Also provided herein are polynucleotide sequences encoding a polypeptide construct described herein.

[0011] Provided herein are methods and compositions comprising cell tags that include truncated variants of polypeptides, such as HER1, CD20, LNGFR and CD52. In some cases, the truncated variants of the polypeptides do not bind an endogenous receptor. The disclosed truncated non-immunogenic polypeptides can be used as cell tags for example as a cell marker, depletion marker or kill tag.

[0012] Provided herein are compositions comprising engineered cells that express polypeptide constructs or polynucleotides as described herein. In some cases, the engineered cells further express at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR) and/or a cytokine.

[0013] Provided herein are methods of regulating activity of genetically engineered cells in a subject (*e.g.*, undergoing immunotherapy), comprising providing to the subject genetically engineered cells encoding a polynucleotide construct disclosed herein, and further providing to the subject a predetermined binding partner that binds and regulates the activity of the cells. Also provided are systems and kits for use in the methods.

[0014] Provided is a polypeptide construct comprising a cell surface polypeptide and a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide, and wherein said cell surface polypeptide binds a predetermined antibody or a variant or fragment thereof.

[0015] In some embodiments, said cell surface polypeptide comprises at least one of a HER1 polypeptide, a LNGFR polypeptide, a CD20 polypeptide and a CD52 polypeptide. In some cases, said cell surface polypeptide comprises a HER1 polypeptide, and said HER 1 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID Nos.:211, 212, 213, 214, 215, 216 or 217. In some instances, said HER1 polypeptide comprises a polypeptide sequence comprising a sequence shown in SEQ ID NOs: 211, 212, 213, 214, 215, 216 or 217.

[0016] In some embodiments, said cell surface polypeptide comprises a CD20 polypeptide, and said CD20 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:218, SEQ ID NO:219 or SEQ ID NO:220. In some cases said CD20 polypeptide comprises a polypeptide sequence comprising a sequence shown in SEQ ID NO:218, SEQ ID NO:219 or SEQ ID NO:220.

[0017] In some embodiments, said cell surface polypeptide comprises a LNGFR polypeptide, and said LNGFR polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:156, SEQ ID NO:158 or SEQ ID NO:160. In some cases said cell surface polypeptide comprises a LNGFR polypeptide, and said LNGFR polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:156, SEQ ID NO:158 or SEQ ID NO:160.

[0018] In some instances, said cell surface polypeptide does not bind an endogenous receptor. In some cases, said trans-membrane dimerization domain can form either a homodimer or a heterodimer with a complementary dimerization domain. In some instances, said trans-membrane dimerization domain comprises at least one cysteine residue. In some embodiments, said trans-membrane dimerization domain comprises a glycoporphin A transmembrane domain or fragment or variant thereof, a glycoporphin A-integrin $\beta 3$ chimeric transmembrane domain or fragment or variant thereof or a CD3 zeta transmembrane domain. In some cases, such a cell surface polypeptide comprises at least a HER1 polypeptide.

[0019] In some cases, said polypeptide construct is expressed in an engineered cell. In some embodiments, said engineered cell is an animal cell. In some instances, said animal cell is a human cell. In some embodiments, said human cell is a T cell or NK cell. In some cases, said engineered cell further comprises a Sleeping Beauty transposase.

[0020] In some instances, said engineered cell further expresses at least one additional exogenous polypeptide. In some cases, said engineered cell further expresses at least one exogenous receptor polypeptide or fragment thereof. In some instances, said engineered cell further expresses at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR) and a cytokine. In some embodiments, said engineered cell further expresses at least one CAR and wherein said CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R- α 2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2.

[0021] In some cases, said engineered cell further expresses at least one recombinant cytokine. In some instances, said recombinant cytokine comprises at least one of IL-15, mbIL-15, IL-2, IL-12, and IL-21. In some embodiments, said polypeptide construct is encoded by a polynucleotide incorporated into said engineered cell by genome editing. In some cases, said genome editing comprises use of at least a site specific serine recombinase system. In some instances, said polypeptide construct comprises a linker that fuses said cell surface polypeptide to said trans-membrane dimerization domain. In some cases, a polypeptide homo-dimer or heterodimer comprises the polypeptide construct.

[0022] Provided is a polynucleotide encoding a polypeptide construct comprising a non-immunogenic cell surface polypeptide fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide. In some embodiments, said cell surface polypeptide does not bind an endogenous receptor. In some cases, said cell surface polypeptide does not contain any endogenous signaling or trafficking functions.

[0023] In some instances, said polynucleotide comprises at least one sequence encoding at least one heterologous gene. In some embodiments, said at least one heterologous gene is modulated by an inducible promoter. In some cases said at least one heterologous gene comprises at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR) and a cytokine. In some embodiments, said at least one heterologous gene comprises said CAR, and wherein said CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA,

EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2.

[0024] In some embodiments, said at least one heterologous gene comprises a cytokine. In some cases, said cytokine comprises at least one of IL-15, IL-2, IL-12, IL-21, and a fusion of IL-15 and IL-15R α . In some embodiments, said cytokine is in secreted form. In some instances, said cytokine is in membrane bound form.

[0025] In some embodiments, said polynucleotide comprises at least one sequence comprising a polypeptide linker selected from the group consisting of 2A, GSG-2A, GSG linker (SEQ ID NO: 16), SGSG linker (SEQ ID NO: 18), furinlink variants and derivatives thereof. In some embodiments, said 2A linker is a p2A linker a T2A linker, F2A linker or E2A linker.

[0026] In some instances, said polypeptide construct acts as a tag to enrich cells, select cells, or induce cell death in cells expressing said cell surface molecule. In some cases, said cell surface polypeptide comprises at least one of a HER1 polypeptide, a LNGFR polypeptide, a CD20 polypeptide and a CD52 polypeptide. In some embodiments, said trans-membrane dimerization domain comprises a glycoporphin A transmembrane domain or fragment or variant thereof, a glycoporphin A-integrin β 3 chimeric transmembrane domain or fragment or variant thereof, or a CD3 zeta transmembrane domain.

[0027] In some cases, a vector comprises the polynucleotide. In some instances, said vector is a lentivirus vector, a retroviral vector, or a non-viral vector. In some embodiments, the non-viral vector is a Sleeping Beauty transposon. In some cases, said polynucleotide is incorporated into an engineered cell by genome editing. In some cases, said genome editing comprises use of at least a site specific serine recombinase system.

[0028] Provided is a method of regulating activity of genetically engineered cells in a subject comprising: providing to said subject an amount of genetically engineered cells encoding a polypeptide construct comprising a cell surface polypeptide fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide, and wherein said cell surface polypeptide binds a predetermined binding partner or a variant or fragment thereof; and providing to said subject said predetermined binding partner in an amount sufficient to bind and thereby regulating activity of said genetically engineered cells.

[0029] In some embodiments, said cell surface polypeptide is a non-immunogenic polypeptide. In some embodiments, said cell surface polypeptide comprises at least one of a HER1

polypeptide, a LNGFR polypeptide, a CD20 polypeptide and a CD52 polypeptide. In some instances, said cell surface polypeptide does not bind an endogenous receptor. In some cases, said trans-membrane dimerization domain can form either a homodimer or a heterodimer with a complementary dimerization domain. In some embodiments, said trans-membrane dimerization domain comprises at least one cysteine residue. In some instances, said trans-membrane dimerization domain comprises a glycoporphin A transmembrane domain or fragment or variant thereof, a glycoporphin A-integrin $\beta 3$ chimeric transmembrane domain or fragment or variant thereof, or a CD3 zeta transmembrane domain.

[0030] In some cases, said binding partner comprises an antibody, or cell surface polypeptide binding region thereof. In some embodiments, said antibody comprises at least one of: monoclonal antibody, scFv, scFab, diabody, and camelid antibody. In some instances, said antibody comprises at least one of: rituximab, cetuximab, alemtuzumab, panitumumab and necitumumab.

[0031] In some cases, said genetically engineered cells comprise at least one of: T cells and NK cells. In some embodiments, at least one of said genetically engineered cells further expresses at least one additional exogenous polypeptide. In some instances, at least one of said genetically engineered cells further expresses at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR) and a cytokine. In some cases, at least one of said genetically engineered cells further expresses at least one CAR and wherein said CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2.

[0032] In some embodiments, at least one of said genetically engineered cells further expresses at least one recombinant cytokine. In some instances, said recombinant cytokine comprises at least one of IL-15, mbIL-15, IL-2, IL-12, and IL-21. In some cases, said predetermined binding partner is provided in an amount sufficient to cause a reduction in at least one symptom associated with a cytokine storm or a systemic inflammatory response. In some embodiments, said predetermined binding partner is provided in an amount sufficient to cause a reduction in at least one symptom associated with tumor lysis syndrome. In some instances, said polypeptide construct is encoded by a polynucleotide incorporated into said engineered cells by genome editing. In some cases, said genome editing comprises use of at least a site specific serine recombinase system.

[0033] Provided is a polynucleotide encoding a truncated non-immunogenic CD20 polypeptide that binds an anti-CD20 antibody, wherein said truncated non-immunogenic CD20 polypeptide does not bind an endogenous receptor.

[0034] In some embodiments, said CD20 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the sequence shown in SEQ ID NO:109. In some cases, said CD20 polypeptide comprises a polypeptide sequence comprising the sequence of SEQ ID NO:109. In some instances, said CD20 polypeptide binds said anti-CD20 antibody with at least 50%, 60%, 70%, 80% or 90% the binding efficiency as native CD20. In some embodiments, said anti-CD20 antibody comprises at least one of: rituximab, cetuximab, tositumomab, veltuzumab, afutuzumab, blontuvetmab and obinutuzumab.

[0035] Provided is a polynucleotide encoding a truncated non-immunogenic HER1 polypeptide consisting of at least a HER1 Domain III or fragment thereof, and a truncated HER1 Domain IV, wherein said HER1 polypeptide binds an anti-HER1 antibody, and wherein said HER1 polypeptide is expressed in an engineered cell.

[0036] In some embodiments, said truncated HER1 Domain IV comprises a truncation of at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% of said HER1 Domain IV.

[0037] In some cases, said truncated HER1 Domain IV comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NOs:203, 204, 205, 206, 207, 208 or 209. In some instances, said truncated HER1 Domain IV comprises a polypeptide sequence comprising a sequence shown in SEQ ID NOs: 203, 204, 205, 206, 207, 208 or 209. In some embodiments, said HER1 Domain III or fragment thereof comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the sequence shown in SEQ ID NO:200. In some cases, said HER1 Domain III comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:200.

[0038] In some instances, said polynucleotide further encodes a CD28 trans-membrane domain and a peptide linker for coupling said HER1 polypeptide to said CD28 trans-membrane domain. In some cases, said polynucleotide encodes a polypeptide construct comprising a polypeptide sequence comprising the sequence shown in SEQ ID NO:57. In some embodiments, said anti-HER1 antibody comprises at least one of: rituximab, cetuximab, futuximab, depatuxizumab, imgatuzumab, laprituximab, matuzumab, necitumumab, nimotuzumab, panitumumab, and zalutumumab.

[0039] Provided is a polynucleotide encoding a truncated non-immunogenic CD52 polypeptide that binds an anti-CD52 antibody, wherein said truncated non-immunogenic CD52 polypeptide does not bind an endogenous receptor, and wherein said non-immunogenic CD52 polypeptide is expressed in an engineered cell.

[0040] In some cases, said CD52 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the sequence shown in SEQ ID NO:143. In some instances, said CD52 polypeptide comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:143.

[0041] In some embodiments, a polynucleotide is expressed in a cell further comprising at least one sequence encoding at least one heterologous gene. In some embodiments, said at least one heterologous gene is modulated by an inducible promoter. In some instances, said at least one heterologous gene comprises at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR) and a cytokine. In some embodiments, said at least one heterologous gene comprises a CAR, and wherein said CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2.

[0042] In some embodiments, said at least one heterologous gene comprises a cytokine. In some embodiments, said cytokine comprises at least one of IL-15, IL-2, IL-12, IL-21, and a fusion of IL-15 and IL-15R α . In some cases, said cytokine is in secreted form. In some instances, said cytokine is in membrane bound form.

[0043] In some embodiments, a vector comprises said polynucleotide. In some cases, said vector is a lentivirus vector, a retroviral vector, or a non-viral vector. In some instances, said non-viral vector is a Sleeping Beauty transposon. In some embodiments, said polynucleotide is incorporated into an engineered cell by genome editing. In some instances, said genome editing comprises use of at least a site specific serine recombinase system. In some cases, an engineered cell encodes the polynucleotide. In some cases, the engineered cell is a T cell or an NK cell. In some cases, the polynucleotide encodes a polypeptide.

[0044] Further provided herein is a method of treating cancer comprising administering to a subject an effective amount of an engineered cell comprising a polynucleotide. In some embodiments, the method further comprises administering at least one binding partner capable of binding to a polypeptide expressed on said engineered cell. In some cases, said binding partner is an antibody.

[0045] Provided herein is a method of regulating activity of genetically engineered cells in a subject comprising providing to said subject an amount of genetically engineered cells encoding a polypeptide construct comprising a cell surface polypeptide which is a chimeric polypeptide comprising a first truncated non-immunogenic polypeptide and a second truncated non-immunogenic polypeptide, and wherein said cell surface polypeptide binds at least one predetermined binding partner or a variant or fragment thereof; and providing to said subject said predetermined binding partner in an amount sufficient to bind and thereby regulating activity of said genetically engineered cells.

[0046] In some embodiments, said first truncated non-immunogenic polypeptide comprises a fragment or derivative of a member of the EGFR family. In some cases, said second truncated non-immunogenic polypeptide comprises a fragment or derivative of a member of the EGFR family. In some instances, said first truncated non-immunogenic polypeptide comprises a HER1 polypeptide. In some embodiments, said HER1 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NOs:211, 212, 213, 214, 215, 216 or 217. In some embodiments, said HER1 polypeptide comprises a polypeptide sequence comprising a sequence shown in SEQ ID NOs: 211, 212, 213, 214, 215, 216 or 217. In some cases, said HER1 polypeptide comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:211.

[0047] In some cases, said second truncated non-immunogenic polypeptide comprises at least one of a HER2 polypeptide, an ErbB3 polypeptide and an ErbB4 polypeptide. In some embodiments, said polypeptide construct comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:101 or SEQ ID NO:105.

[0048] In some embodiments, said at least one predetermined binding partner binds said HER1 polypeptide. In some instances, said at least one predetermined binding partner comprises at least one of rituximab, cetuximab, futuximab, depatuxizumab, imgatuzumab, laprituximab, matuzumab, necitumumab, nimotuzumab, panitumumab, and zalutumumab. In some cases, said at least one predetermined binding partner further includes a second predetermined binding partner that binds said second truncated non-immunogenic polypeptide. In some cases, said second truncated non-immunogenic polypeptide is a HER2 polypeptide, and said second predetermined binding partner is pertuzumab.

[0049] In some instances, said polypeptide construct further comprises a signal peptide. In some instances, said polypeptide construct further comprises a trans-membrane domain. In some

embodiments, said trans-membrane domain comprises a trans-membrane dimerization domain. In some cases, said trans-membrane dimerization domain comprises a glycoporphin A transmembrane domain, a glycoporphin A-integrin $\beta 3$ chimeric transmembrane domain or a CD3 zeta transmembrane domain. In some cases, said trans-membrane dimerization domain comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30 or SEQ ID NO:32. In some embodiments, said trans-membrane dimerization domain comprises a polypeptide sequence comprising a sequence shown in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30 or SEQ ID NO:32.

[0050] In some instances, said first truncated non-immunogenic polypeptide comprises a CD20 polypeptide. In some embodiments, said CD20 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:218, SEQ ID NO:219 or SEQ ID NO:220. In some cases, said CD20 polypeptide comprises a polypeptide sequence comprising a sequence shown in SEQ ID NO:218, SEQ ID NO:219 or SEQ ID NO:220. In some embodiments, said at least one predetermined binding partner comprises at least one of: rituximab, tositumomab, veltuzumab, afutuzumab, blontuvetmab and obinutuzumab.

[0051] Provided is a polypeptide construct comprising a truncated non-immunogenic HER1 polypeptide consisting of a HER1 Domain III and a truncated HER1 Domain IV, wherein said HER1 polypeptide binds an anti-HER1 antibody; a CD28 trans-membrane domain; and a peptide linker for coupling said HER1 polypeptide to said CD28 transmembrane domain; wherein said polypeptide construct is expressed in an engineered cell.

[0052] In some embodiments, said HER1 Domain III comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:200 and said HER1 Domain IV comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:203. In some instances, said CD28 trans-membrane domain comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:36 and said peptide linker comprises a G4S peptide linker (SEQ ID NO: 221). In some cases, said G4S peptide linker (SEQ ID NO: 221) comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:22. In some embodiments, said polypeptide construct comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:57.

[0053] In some cases, said anti-HER1 antibody comprises at least one of rituximab, cetuximab, futuximab, depatuxizumab, imgatuzumab, laprituximab, matuzumab, necitumumab, nimotuzumab, panitumumab, and zalutumumab.

[0054] Provided is a polypeptide construct comprising a truncated non-immunogenic CD20 polypeptide, wherein said CD20 polypeptide binds an anti-CD20 antibody; wherein said polypeptide construct is expressed in an engineered cell.

[0055] In some embodiments, said polypeptide construct has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the sequence shown in SEQ ID NO:109. In some cases, said polypeptide construct comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:109. In some instances, said anti-CD20 antibody comprises at least one of: rituximab, tositumomab, veltuzumab, afutuzumab, blontuvetmab and obinutuzumab.

BRIEF DESCRIPTION OF THE DRAWINGS

[0056] The features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:

[0057] **FIG. 1** shows expression levels of full-length CD20 cell tag (corresponding to SEQ ID NO:107) and two forms of truncated CD20 (CD20t1 corresponding to SEQ ID NO:109 and CD20t4 corresponding to SEQ ID NO:115) in HEK-293T cells as detected by flow cytometry using rituximab compared to a control cell tag. Shaded areas denote mock-transfected control cells whereas non-shaded areas denote expression of cell tags from transfected cells. Each transfection was performed in triplicate.

[0058] **FIG. 2** shows co-expression of CD20t1 cell tag (corresponding to SEQ ID NO:109; y-axis) and a chimeric antigen receptor (CAR; x-axis) in human peripheral mononuclear cells (PBMCs) co-transfected with Sleeping Beauty transposon vectors encoding both genes (right panel) compared to non-transfected cells (left panel).

[0059] **FIG. 3** shows specific dose dependent antibody-dependent cell-mediated cytotoxicity (represented by fold-induction; y-axis) induced by rituximab in Jurkat cell line transfected with CD20t-1. Non-transfected parental Jurkat cells and non-specific antibody cetuximab showed no activity.

[0060] FIG. 4A is a schematic diagram illustrating embodiments of a polypeptide construct described herein. The top panel shows an embodiment of a polypeptide construct comprising a signal peptide for directing the polypeptide construct to the cell surface, truncated variant of a natural polypeptide, an optional linker, and a transmembrane (TM) domain. The bottom panel illustrates an embodiment of a polypeptide construct expressed in an engineered cell described herein. The polypeptide construct is anchored to the cell surface by a transmembrane (TM) domain, which is fused to an extracellular-oriented truncated variant via an optional peptide linker. In the embodiment shown, the linker serves as an extension to direct and extend the truncated variant from cell surface, thus optimizing binding of an antibody or binding partner (represented by anti-truncated variant antibody) to an epitope of the truncated variant.

[0061] FIG. 4B is a schematic diagram illustrating an embodiment of a polypeptide construct described herein. The truncated variant and optional linker from FIG. 4A are replaced in FIG. 4b by a HER(m) Domain III and HER(n) Domain IV, where m and n represent any member of the EGFR/HER family including HER1, HER2, ErbB3 and ErbB4 (*i.e.*, m=1-4 and n=1-4, but n $\neq$ m). In the embodiment shown, each of the HER(m) Domain III and HER(n) Domain IV present different epitopes which are recognized by different antibodies (*i.e.*, Anti-HER(m) and Anti-HER(n) antibody, respectively).

[0062] FIG. 4C is a schematic diagram illustrating a specific embodiment in which the HER(m) Domain III of FIG. 4B corresponds to an EGFR Domain III, recognized by an Anti-EGFR antibody, which is fused to Domain IV of either HER2, ErbB3 or ErbB4 at c-terminus followed by a TM domain.

[0063] FIG. 4D shows expression of truncated HER1 (HER1t) polypeptide expressed in human donor PBMCs transfected with different EGFR–Erb4 chimeras (truncated EGFR-ErbB4 (JM-a) corresponding to SEQ ID NO:101 and truncated EGFR-ErbB4 (JM-b) corresponding to SEQ ID NO:105) and stained with an anti-HER1t antibody (“stain”) compared to isotype control (“isotype”) and mock cells that have not been transfected with HER1t.

[0064] FIG. 4E shows expression of HER1t polypeptide in human donor PBMCs transfected with different HER1t variants (HER1t1 corresponding to SEQ ID NO:57, HER1t2 corresponding to SEQ ID NO:59, HER1t3 corresponding to SEQ ID NO:61, HER1t4 corresponding to SEQ ID NO:63, HER1t5 corresponding to SEQ ID NO:65, HER1t6 corresponding to SEQ ID NO:67, and HER1t7 corresponding to SEQ ID NO:69) compared to mock cells that have not been transfected with HER1t.

[0065] **FIG. 5A** shows antibody-based detection of HER1t1 expression (corresponding to SEQ ID NO:57; y-axis) and expression of CAR (x-axis) as measured by flow cytometry in cells co-transfected with lentiviral vector encoding both proteins (right panel) compared to control cells not transfected with HER1t or CAR (left panel).

[0066] **FIG. 5B** shows levels of HER1t1 (corresponding to SEQ ID NO:57; y-axis) and a CAR (x-axis) in cells transfected with Sleeping Beauty transposon vectors encoding CAR alone (left panel) and CAR together with HER1t1 (right panel) and stained with anti-HER1 antibody and CAR specific proteins (bottom panel) compared to an isotype control (top panel).

[0067] **FIG. 6** shows cetuximab- and alemtuzumab-mediated ADCC activity (expressed as % specific killing; y-axis) in NK cells (left), CD16 NK cells (middle), and CD16 NK cells transfected with CAR and HER1t1 (right). Cetuximab showed specific ADCC in presence of HER1t1.

[0068] **FIG. 7A** shows expression of a CAR and HER1t1 cell tag (corresponding to SEQ ID NO:57) as measured by flow cytometry in genetically modified SUP-T1 reporter cell line (SUP-T1/CAR-HER1t1). SUP-T1/CAR-HER1t1 cell line was sorted by FACS to enrich for high (middle panel) or medium (right panel) level of HER1t1 expression as detected by flow cytometry. Left panel shows staining of SUP-T1/CAR-HER1t1 using isotype antibody control for flow cytometry. **FIG. 7B** shows specific ADCC (represented by fold-induction; y-axis) of SUP-T1/CAR-HER1t1 cell line induced by cetuximab which is dependent on HER1t1 expression as well as cetuximab dose levels. Non-specific antibody rituximab showed no ADCC of SUP-T1/CAR-HER1t1.

[0069] **FIG. 8** shows a Western blot analysis showing expression of HER1t1 cell tag in genetically modified SUP-T1 cell lines. Lane 1: IP antibody only; Lane 2: Jurkat cells only; Lane 3: SUP-T1/HER1t1 (high levels of HER1t1); Lane 4: SUP-T1/HER1t1 (low levels of HER1t1); Lane 5: A431 cells expressing full-length HER1; Lane 6: Marker. Bold arrow points to protein pulled down by cetuximab in all lines except A431. HER1t1 corresponds to SEQ ID NO:57.

[0070] **FIG. 9** shows the efficacy of elimination of CD19 CAR-T cells co-expressing HER1t1 cell tag by ADCC (left panel) and CDC (right panel) in the presence of cetuximab or non-specific antibody rituximab.

[0071] **FIG. 10** is a schematic diagram showing different embodiments of polypeptide constructs described herein. First-generation truncated cell tags (top) comprise a truncated variant and a non-dimerizing transmembrane domain (TM) connected by an optional peptide

linker. Next-generation truncated cell tags (bottom panel) include a transmembrane dimerization domain (TM-A) that facilitates dimerization of truncated variants on the cell surface. In both cases, anti-truncated variant antibody binds to an epitope on the truncated variant.

[0072] FIG. 11 demonstrates expression levels of CD19 CAR in primary T cells modified to co-express CD19 CAR and HER1t cell tag. HER1t cell tags utilized include truncated HER1 polypeptide with a transmembrane dimerization domain (variants HER1t8 corresponding to SEQ ID NO:71, HER1t9 corresponding to SEQ ID NO:75, and HER1t10 corresponding to SEQ ID NO:79) and a polypeptide construct comprising a truncated HER1 polypeptide without a transmembrane dimerization domain (HER1t1 corresponding to SEQ ID NO:57) compared to T cells expressing CD19 CAR alone (% of Parent).

[0073] FIG. 12 demonstrates expression levels of HER1t cells tag in primary T cells modified to co-express CD19 CAR and HER1t cell tag. HER1t cell tags utilized include a truncated HER1 polypeptide with a transmembrane dimerization domain (variants HER1t8 corresponding to SEQ ID NO:71, HER1t9 corresponding to SEQ ID NO:75, and Her1t10 corresponding to SEQ ID NO:79) and a polypeptide construct comprising a truncated HER1 polypeptide without a dimerization domain (HER1t1 corresponding to SEQ ID NO:57) compared to T cells expressing CD19 CAR alone (% of Parent).

[0074] FIG. 13A and FIG. 13B shows the superior effects of cetuximab -mediated ADCC (represented by % specific lysis; y-axis) of CD19 CAR-T target cells co-expressing a polypeptide construct comprising a truncated HER1 polypeptide with a dimerization domain (variants HER1t8 corresponding to SEQ ID NO:71, HER1t9 corresponding to SEQ ID NO:75, and HER1t10 corresponding to SEQ ID NO:79) over a polypeptide construct comprising a truncated HER1 polypeptide without a dimerization domain (HER1t control corresponding to SEQ ID NO:57). NK cells were utilized as effector cells. Rituximab was utilized as non-specific antibody control for ADCC assay.

[0075] FIG. 14 shows selective elimination of genetically modified-T cells (CD19 CAR-mbIL-15-T cells) expressing HER1t1 by cetuximab-mediated ADCC.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0076] The following description and examples illustrate embodiments of the invention in detail. It is to be understood that this invention is not limited to the particular embodiments described herein and as such can vary. Those of skill in the art will recognize that there are

numerous variations and modifications of this invention, which are encompassed within its scope.

[0077] All terms are intended to be understood as they would be understood by a person skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains.

[0078] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0079] Although various features of the invention may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the invention may be described herein in the context of separate embodiments for clarity, the invention may also be implemented in a single embodiment.

[0080] The following definitions supplement those in the art and are directed to the current application and are not to be imputed to any related or unrelated case, *e.g.*, to any commonly owned patent or application. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present disclosure, the preferred materials and methods are described herein. Accordingly, the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0081] In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting.

[0082] Reference in the specification to “some embodiments,” “an embodiment,” “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the inventions.

[0083] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with

respect to any method or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.

[0084] The term “about” in relation to a reference numerical value and its grammatical equivalents as used herein can include the numerical value itself and a range of values plus or minus 10% from that numerical value. For example, the amount “about 10” includes 10 and any amounts from 9 to 11. For example, the term “about” in relation to a reference numerical value can also include a range of values plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from that value.

[0085] By “isolated” is meant the removal of a nucleic acid from its natural environment. By “purified” is meant that a given nucleic acid, whether one that has been removed from nature (including genomic DNA and mRNA) or synthesized (including cDNA) and/or amplified under laboratory conditions, has been increased in purity, wherein “purity” is a relative term, not “absolute purity.” It is to be understood, however, that nucleic acids and proteins may be formulated with diluents or adjuvants and still for practical purposes be isolated. For example, nucleic acids typically are mixed with an acceptable carrier or diluent when used for introduction into cells.

[0086] “Polynucleotide” or “oligonucleotide” as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double and single stranded DNA, triplex DNA, as well as double and single stranded RNA. It also includes modified, for example, by methylation and/or by capping, and unmodified forms of the polynucleotide. The term is also meant to include molecules that include non-naturally occurring or synthetic nucleotides as well as nucleotide analogs.

[0087] “Polypeptide” is used interchangeably with the terms “polypeptides” and “protein(s),” and refers to a polymer of amino acid residues. A “mature protein” is a protein which is full-length and which, optionally, includes glycosylation or other modifications typical for the protein in a given cellular environment.

[0088] Polypeptides and proteins disclosed herein (including functional portions and functional variants thereof) can comprise synthetic amino acids in place of one or more naturally-occurring amino acids. Such synthetic amino acids are known in the art, and include, for example, aminocyclohexane carboxylic acid, norleucine, α -amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β -phenylserine β -

hydroxyphenylalanine, phenylglycine, α -naphthylalanine, cyclohexylalanine, cyclohexylglycine, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, α -aminocyclopentane carboxylic acid, α -aminocyclohexane carboxylic acid, α -aminocycloheptane carboxylic acid, α -(2-amino-2-norbornane)-carboxylic acid, α,γ -diaminobutyric acid, α,β -diaminopropionic acid, homophenylalanine, and α -tert-butylglycine. The present disclosure further contemplates that expression of polypeptides described herein in an engineered cell can be associated with post-translational modifications of one or more amino acids of the polypeptide constructs. Non-limiting examples of post-translational modifications include phosphorylation, acylation including acetylation and formylation, glycosylation (including N-linked and O-linked), amidation, hydroxylation, alkylation including methylation and ethylation, ubiquitylation, addition of pyrrolidone carboxylic acid, formation of disulfide bridges, sulfation, myristoylation, palmitoylation, isoprenylation, farnesylation, geranylation, glypiation, lipoylation and iodination.

[0089] “Antibody” as used herein refers to monoclonal or polyclonal antibodies. A whole antibody typically consists of four polypeptides: two identical copies of a heavy (H) chain polypeptide and two identical copies of a light (L) chain polypeptide. Each of the heavy chains contains one N-terminal variable (VH) region and three C-terminal constant (CH1, CH2 and CH3) regions, and each light chain contains one N-terminal variable (VL) region and one C-terminal constant (CL) region. The variable regions of each pair of light and heavy chains form the antigen binding site of an antibody. The VH and VL regions have a similar general structure, with each region comprising four framework regions, whose sequences are relatively conserved. The framework regions are connected by three complementarity determining regions (CDRs). The three CDRs, known as CDR1, CDR2, and CDR3, form the “hypervariable region” of an antibody, which is responsible for antigen binding.

[0090] “Antigen recognition moiety or domain” refers to a molecule or portion of a molecule that specifically binds to an antigen. In some embodiments, the antigen recognition moiety is an antibody, antibody like molecule or fragment thereof and the antigen is a tumor antigen.

[0091] “Antibody like molecules” may be for example proteins that are members of the Ig-superfamily which are able to selectively bind a partner. MHC molecules and T cell receptors are such molecules. In some embodiments the antibody-like molecule is a TCR. In some embodiments the TCR has been modified to increase its MHC binding affinity.

[0092] The terms “fragment of an antibody,” “antibody fragment,” “functional fragment of an antibody,” and “antigen-binding portion” are used interchangeably herein to mean one or more fragments or portions of an antibody that retain the ability to specifically bind to an antigen (see, generally, Holliger et al., *Nat. Biotech.*, 23(9):1126-1129 (2005)). The antibody fragment desirably comprises, for example, one or more CDRs, the variable region (or portions thereof), the constant region (or portions thereof), or combinations thereof. Examples of antibody fragments include, but are not limited to, (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')₂ fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the stalk region; (iii) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (iv) a single chain Fv (scFv), which is a monovalent molecule consisting of the two domains of the Fv fragment (*i.e.*, VL and VH) joined by a synthetic linker which enables the two domains to be synthesized as a single polypeptide chain (see, *e.g.*, Bird et al., *Science*, 242: 423-426 (1988); Huston et al., *Proc. Natl. Acad. Sci. USA*, 85: 5879-5883 (1988); and Osbourn et al., *Nat. Biotechnol.*, 16: 778 (1998)) and (v) a diabody, which is a dimer of polypeptide chains, wherein each polypeptide chain comprises a VH connected to a VL by a peptide linker that is too short to allow pairing between the VH and VL on the same polypeptide chain, thereby driving the pairing between the complementary domains on different VH-VL polypeptide chains to generate a dimeric molecule having two functional antigen binding sites. Antibody fragments are known in the art and are described in more detail in, *e.g.*, U.S. Pat. No. 8,603,950.

[0093] Nucleic acids and/or nucleic acid sequences are “homologous” when they are derived, naturally or artificially, from a common ancestral nucleic acid or nucleic acid sequence. Proteins and/or protein sequences are homologous when their encoding DNAs are derived, naturally or artificially, from a common ancestral nucleic acid or nucleic acid sequence. The homologous molecules can be termed homologs. For example, any naturally occurring proteins, as described herein, can be modified by any available mutagenesis method. When expressed, this mutagenized nucleic acid encodes a polypeptide that is homologous to the protein encoded by the original nucleic acid. Homology is generally inferred from sequence identity between two or more nucleic acids or proteins (or sequences thereof). The precise percentage of identity between sequences that is useful in establishing homology varies with the nucleic acid and protein at issue, but as little as 25% sequence identity is routinely used to establish homology. Higher levels of sequence identity, *e.g.*, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% or more can also be used to establish homology.

[0094] The terms “identical” or “sequence identity” in the context of two nucleic acid sequences or amino acid sequences of polypeptides refers to the residues in the two sequences which are the same when aligned for maximum correspondence over a specified comparison window. In some embodiments, a polypeptide herein is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 98% 99% or 100% identical to a reference polypeptide, or a fragment thereof, *e.g.*, as measured by BLASTP (or CLUSTAL, or any other available alignment software) using default parameters. Similarly, nucleic acids can also be described with reference to a starting nucleic acid, *e.g.*, they can be 50%, 60%, 70%, 75%, 80%, 85%, 90%, 98%, 99% or 100% identical to a reference nucleic acid or a fragment thereof, *e.g.*, as measured by BLASTN (or CLUSTAL, or any other available alignment software) using default parameters. When one molecule is said to have certain percentage of sequence identity with a larger molecule, it means that when the two molecules are optimally aligned, said percentage of residues in the smaller molecule finds a match residue in the larger molecule in accordance with the order by which the two molecules are optimally aligned.

[0095] “Transposon” or “transposable element” (TE) is a vector DNA sequence that can change its position within the genome, sometimes creating or reversing mutations and altering the cell’s genome size. Transposition often results in duplication of the TE. Class I TEs are copied in two stages: first, they are transcribed from DNA to RNA, and the RNA produced is then reverse transcribed to DNA. This copied DNA is then inserted at a new position into the genome. The reverse transcription step is catalyzed by a reverse transcriptase, which may be encoded by the TE itself. The characteristics of retrotransposons are similar to retroviruses, such as HIV. The cut-and-paste transposition mechanism of class II TEs does not involve an RNA intermediate. The transpositions are catalyzed by several transposase enzymes. Some transposases non-specifically bind to any target site in DNA, whereas others bind to specific DNA sequence targets. The transposase makes a staggered cut at the target site resulting in single-strand 5’ or 3’ DNA overhangs (sticky ends). This step cuts out the DNA transposon, which is then ligated into a new target site; this process involves activity of a DNA polymerase that fills in gaps and of a DNA ligase that closes the sugar-phosphate backbone. This results in duplication of the target site. The insertion sites of DNA transposons may be identified by short direct repeats which may be created by the staggered cut in the target DNA and filling in by DNA polymerase, followed by a series of inverted repeats important for the TE excision by transposase. Cut-and-paste TEs may be duplicated if their transposition takes place during S phase of the cell cycle when a donor site has already been replicated, but a target site has not yet

been replicated. Transposition can be classified as either “autonomous” or “non-autonomous” in both Class I and Class II TEs. Autonomous TEs can move by themselves while non-autonomous TEs require the presence of another TE to move. This is often because non-autonomous TEs lack transposase (for class II) or reverse transcriptase (for class I).

[0096] “Transposase” refers an enzyme that binds to the end of a transposon and catalyzes the movement of the transposon to another part of the genome by a cut and paste mechanism or a replicative transposition mechanism. In some embodiments, the transposase’s catalytic activity can be utilized to move gene(s) from a vector to the genome.

[0097] The nucleic acid sequences and vectors disclosed or contemplated herein may be introduced into a cell by “transfection,” “transformation,” “nucleofection” or “transduction.” “Transfection,” “transformation,” or “transduction,” as used herein, refer to the introduction of one or more exogenous polynucleotides into a host cell by using physical or chemical methods. Many transfection techniques are known in the art and include, for example, calcium phosphate DNA co-precipitation (see, *e.g.*, Murray E. J. (ed.), *Methods in Molecular Biology*, Vol. 7, *Gene Transfer and Expression Protocols*, Humana Press (1991)); DEAE-dextran; electroporation; cationic liposome-mediated transfection; tungsten particle-facilitated microparticle bombardment (Johnston, *Nature*, 346: 776-777 (1990)); and strontium phosphate DNA co-precipitation (Brash et al., *Mol. Cell Biol.*, 7: 2031-2034 (1987)); and nucleofection (Trompeter et al., *J. Immunol. Methods* 274:245-256 (2003)). Phage or viral vectors can be introduced into host cells, after growth of infectious particles in suitable packaging cells, many of which are commercially available.

[0098] “Tumor antigen” as used herein refers to any antigenic substance produced or overexpressed in tumor cells. It may, for example, trigger an immune response in the host. Alternatively, for purposes of this disclosure, tumor antigens may be proteins that are expressed by both healthy and tumor cells but because they identify a certain tumor type, are a suitable therapeutic target.

[0099] “Promoter” refers to a region of a polynucleotide that initiates transcription of a coding sequence. Promoters are located near the transcription start sites of genes, on the same strand and upstream on the DNA (towards the 5’ region of the sense strand). Some promoters are constitutive as they are active in all circumstances in the cell, while others are regulated becoming active in response to specific stimuli, *e.g.*, an inducible promoter.

[0100] The term “promoter activity” refers to the extent of expression of nucleotide sequence that is operably linked to the promoter whose activity is being measured. Promoter activity may

be measured directly by determining the amount of RNA transcript produced, for example by Northern blot analysis or indirectly by determining the amount of product coded for by the linked nucleic acid sequence, such as a reporter nucleic acid sequence linked to the promoter.

[0101] “Inducible promoter” as used herein refers to a promoter which is induced into activity by the presence or absence of transcriptional regulators, *e.g.*, biotic or abiotic factors. Inducible promoters are useful because the expression of genes operably linked to them can be turned on or off at certain stages of development of an organism or in a particular tissue. Examples of inducible promoters are alcohol-regulated promoters, tetracycline-regulated promoters, steroid-regulated promoters, metal-regulated promoters, pathogenesis-regulated promoters, temperature-regulated promoters and light-regulated promoters. In some embodiments, the inducible promoter is part of a genetic switch.

[0102] The term “enhancer,” as used herein, refers to a DNA sequence that increases transcription of, for example, a nucleic acid sequence to which it is operably linked. Enhancers can be located many kilobases away from the coding region of the nucleic acid sequence and can mediate the binding of regulatory factors, patterns of DNA methylation, or changes in DNA structure. A large number of enhancers from a variety of different sources are well known in the art and are available as or within cloned polynucleotides (from, *e.g.*, depositories such as the ATCC as well as other commercial or individual sources). A number of polynucleotides comprising promoters (such as the commonly-used CMV promoter) also comprise enhancer sequences. Enhancers can be located upstream, within, or downstream of coding sequences. The term “Ig enhancers” refers to enhancer elements derived from enhancer regions mapped within the immunoglobulin (Ig) locus (such enhancers include for example, the heavy chain (μ) 5’ enhancers, light chain (κ) 5’ enhancers, κ and μ intronic enhancers, and 3’ enhancers (see generally Paul W. E. (ed), *Fundamental Immunology*, 3rd Edition, Raven Press, New York (1993), pages 353-363; and U.S. Pat. No. 5,885,827).

[0103] “Coding sequence” as used herein refers to a segment of a polynucleotide that codes for a polypeptide. The region or sequence is bounded nearer the 5’ end by a start codon and nearer the 3’ end with a stop codon. Coding sequences may also be referred to as open reading frames.

[0104] “Operably linked” as used herein refers to the physical and/or functional linkage of a DNA segment to another DNA segment in such a way as to allow the segments to function in their intended manners. A DNA sequence encoding a gene product is operably linked to a regulatory sequence when it is linked to the regulatory sequence, such as, for example, promoters, enhancers and/or silencers, in a manner which allows modulation of transcription of

the DNA sequence, directly or indirectly. For example, a DNA sequence is operably linked to a promoter when it is ligated to the promoter downstream with respect to the transcription initiation site of the promoter, in the correct reading frame with respect to the transcription initiation site and allows transcription elongation to proceed through the DNA sequence. An enhancer or silencer is operably linked to a DNA sequence coding for a gene product when it is ligated to the DNA sequence in such a manner as to increase or decrease, respectively, the transcription of the DNA sequence. Enhancers and silencers may be located upstream, downstream or embedded within the coding regions of the DNA sequence. A DNA for a signal sequence is operably linked to DNA coding for a polypeptide if the signal sequence is expressed as a pre-protein that participates in the secretion of the polypeptide. Linkage of DNA sequences to regulatory sequences is typically accomplished by ligation at suitable restriction sites or via adapters or linkers inserted in the sequence using restriction endonucleases known to one of skill in the art.

[0105] The term “transcriptional regulator” refers to a biochemical element that acts to prevent or inhibit the transcription of a promoter-driven DNA sequence under certain environmental conditions (*e.g.*, a repressor or nuclear inhibitory protein), or to permit or stimulate the transcription of the promoter-driven DNA sequence under certain environmental conditions (*e.g.*, an inducer or an enhancer).

[0106] The term “induction” refers to an increase in nucleic acid sequence transcription, promoter activity and/or expression brought about by a transcriptional regulator, relative to some basal level of transcription.

[0107] A “target” gene or “heterologous” gene, or “gene of interest (GOI)” refers to a gene introduced into the host cell by gene transfer.

[0108] “Recombinase” as used herein refers to a group of enzymes that can facilitate site-specific recombination between defined sites, where the sites are physically separated on a single DNA molecule or where the sites reside on separate DNA molecules. The DNA sequences of the defined recombination sites are not necessarily identical. Initiation of recombination depends on protein-DNA interaction, within the group there are a large number of proteins that catalyze phage integration and excision (*e.g.*, λ integrase, ϕ C31), resolution of circular plasmids (*e.g.*, Tn3, gamma delta, Cre, FIp), DNA inversion for expression of alternate genes (*e.g.*, Hin, Gin, Pin), assembly of genes during development (*e.g.*, Anabaena nitrogen fixation genes), and transposition (*e.g.*, IS607 transposon). Most site-specific recombinases fall into one of the two families, based on evolutionary and mechanistic relatedness. These are λ integrase family or

tyrosine recombinases (*e.g.*, Cre, Flp, Xer D) and resolvase/integrase family or serine recombinase family (*e.g.*, ϕ C31, TP901-1, Tn3, gamma delta).

[0109] “Recombination attachment sites” are specific polynucleotide sequences that are recognized by the recombinase enzymes described herein. Typically, two different sites are involved (termed “complementary sites”), one present in the target nucleic acid (*e.g.*, a chromosome or episome of a eukaryote or prokaryote) and another on the nucleic acid that is to be integrated at the target recombination site. The terms “attB” and “attP,” which refer to attachment (or recombination) sites originally from a bacterial target and a phage donor, respectively, are used herein although recombination sites for particular enzymes may have different names. The recombination sites typically include left and right arms separated by a core or spacer region. Thus, an attB recombination site consists of BOB’, where B and B’ are the left and right arms, respectively, and O is the core region. Similarly, attP is POP’, where P and P’ are the arms and O is again the core region. Upon recombination between the attB and attP sites, and concomitant integration of a nucleic acid at the target, the recombination sites that flank the integrated DNA are referred to as “attL” and “attR.” The attL and attR sites, using the terminology above, thus consist of BOP’ and POB”, respectively. In some representations herein, the “O” is omitted and attB and attP, for example, are designated as BB’ and PP’, respectively.

[0110] The term “gene editing” or “genome editing” refers to the insertion, deletion or replacement of nucleotides of DNA in the genome of a living organism. Typically genome editing uses engineered nucleases which can create site-specific double-stranded breaks at a pre-determined location of the genome. The present disclosure contemplates any means for editing genomes. Non-limiting examples of genome editing techniques include CRISPR, Argonaute and AttSite site-specific serine recombinase systems. Herein a “CRISPR gene editing system” of “CRISPR system” refers to any RNA-guided Cas protein-mediated process for targeting a change in DNA sequence to a specific region of a genome. Herein “Argonaute gene editing system” refers to any single-stranded DNA guided Argonaute endonuclease-mediated process for targeting a change in DNA sequence to a specific region of a genome. Herein “AttSite gene editing system” or “site-specific serine recombinase gene editing system” or “site specific serine recombinase system” refer to any process that involves providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination

attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a *Listeria monocytogenes* phage recombinase, a *Streptococcus pyogenes* phage recombinase, a *Bacillus subtilis* phage recombinase, a *Mycobacterium tuberculosis* phage recombinase and a *Mycobacterium smegmatis* phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP and when the first recombination attachment site is attP, the second recombination attachment site is attB.

Examples of embodiments of an AttSite serine recombinase system are provided in U.S. Patent No. 9,034,650, all of which is incorporated herein by reference.

[0111] The terms “endogenous” as used herein in reference to a molecule such as a polynucleotide or polypeptide refers to the naturally occurring form of the molecule which can be found in a wildtype cell or organism. A molecule which is found in an organism endogenously can be contrasted with an engineered molecule as described herein which typically does not occur naturally. For example, an engineered molecule can comprise a variant of a naturally occurring polypeptide or polynucleotide. In some embodiments, the variant of a naturally occurring polypeptide is a truncated variant of a naturally occurring polypeptide. Herein the term “truncated variant” refers to a protein or polypeptide which is missing one or more sequences of amino acids and/or domains relative to the endogenous version of the protein or polypeptide. For example, a truncated variant incorporated into a polypeptide construct described herein can be missing a sequence of amino acids which corresponds to a domain (e.g., intracellular signaling domain, transmembrane domain, ligand binding domain, etc) normally present in the endogenous protein. The natural version of the truncated polypeptide can be derived from any organism, including mammalian species such as mice, rats, rabbits and humans. Engineered polynucleotides and polypeptides described herein can be expressed in an engineered cell. Herein an engineered cell is a cell which has been modified from its natural or endogenous state. An example of an engineered cell is a cell described herein which has been modified (e.g., by transfection of a polynucleotide into the cell) to encode a truncated variant of a natural polypeptide or a truncated variant of a natural polynucleotide.

Polypeptide Constructs

[0112] Disclosed herein are polypeptide constructs, polynucleotides encoding the same, engineered cells harboring and/or expressing the polypeptide constructs and polynucleotides and

methods of regulating activity of the engineered cells. Engineered cells as described herein can include immune effector cells engineered to encode and to express cytokines, chimeric antigen receptors and T-cell receptors.

[0113] Herein the term “regulating” or “regulation” when used with reference to engineered cells or polypeptide constructs expressed therein, refers generally to a regulation of the activity or amount of the engineered cells after administration to a subject. In some embodiments, regulating activity of engineered cells refers to a depletion of the engineered cells in a subject. In some embodiments, regulating activity of the engineered cells refers to depletion of some engineered cells in a subject as a result of administering to the subject an amount of an antibody or binding partner that binds a polypeptide construct expressed on the engineered cells. In some embodiments, regulating activity of the engineered cells refers to a depletion of the engineered cells as a result of activating cell death via binding of an antibody or binding partner to a polypeptide construct described herein expressed on or associated with said engineered cell. In some embodiments, regulating activity of the engineered cells refers to activating an ADCC or CDC pathway in the engineered cells.

[0114] The polypeptides, polynucleotides and engineered cells disclosed herein collectively represent a suite of therapeutic tools which can be used to improve the efficacy of conventional immunotherapies, and in particular adoptive cell therapies. For example, engineered cells described herein can encode and express a polypeptide construct at the cell surface as a novel cell tag. A cell tag can in some embodiments function as a cell marker which labels, marks or flags a cell expressing the cell tag as an engineered cell. In embodiments where the cell tag has been engineered to lack epitopes recognized by endogenous proteins, such a cell tag can function to uniquely distinguish an engineered cell from other cells in an organism, for example during adoptive cell immunotherapy.

[0115] In other examples, the polypeptides, polynucleotides and engineered cells described herein can be used to minimize or eliminate toxicities of immunotherapy in subjects where safety is a concern (*e.g.* due to a potential for onset of cytokine storm). The cell tags described herein can include one or more epitopes recognized by an antibody introduced during immunotherapy to thereby induce a cellular mechanism that will slow therapeutic output and/or mitigate possible side effects of therapy. In some embodiments, the antibody binds to the epitope to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC). Accordingly, the cell tags described herein can provide for a depletion

marker or “kill tag” unique to engineered cells allowing practitioners to control therapeutic output and thereby optimize efficacy and safety of therapy.

[0116] The immunotherapeutic arsenal described herein improves upon conventional immunotherapy by providing the potential for control over adoptive cell therapeutic interventions. In some embodiments, engineered cells can be sensitized to cell depletion strategies by expressing a polypeptide construct capable of dimerizing or multimerizing at the surface of engineered cells. Such dimerized or multimerized polypeptides can be used to amplify a depletion signal and thereby rapidly downregulate or eliminate the engineered immune cell therapy in subjects who are prone to or are experiencing side effects related to therapy. The administration of engineered cells expressing a dimerizing or multimerizing polypeptide construct can provide for further control and optimization over cell depletion interventions. In further embodiments, implementation of the polynucleotide constructs disclosed herein as a part of a “kill switch” (or “suicide switch”) system employing an inducible promoter can allow for control over when a particular polypeptide construct is expressed, thereby conferring additional control points over immunotherapy at both the transcriptional and post-translational levels.

[0117] In another embodiment, the cell tags described herein can be used to enrich for engineered cells that specifically express such cell tags. For example, the cell tags can be used to enrich for certain engineered cells to isolate certain engineered cells that only express such cell tags to achieve necessary purity to allow for expansion of select cells of therapeutic interest. Various methods such as FACs, column purification or magnetic beads based methods can be utilized as appropriate.

[0118] The polypeptide constructs disclosed herein can comprise one or more domains or specific fragments thereof. Typically the polypeptide construct can comprise a signal peptide sequence, an extracellular domain, a peptide linker and a transmembrane domain, each of which functions to confer a particular desired property to the polypeptide construct. For example, the polypeptide construct can include a signal peptide to post-translationally direct the polypeptide construct to the cell surface; a transmembrane domain to anchor the polypeptide domain to the cell; an extracellular portion, which can include a truncated variant of a natural polypeptide; and a peptide linker connecting the transmembrane domain to the extracellular portion. In some embodiments, the peptide linker functions as an extracellular peptide extension to position the extracellular portion of the polypeptide in the extracellular matrix and thereby make it available to confer cell tag functionality (*e.g.*, to present or to extend an epitope to allow access to bind an antibody). In certain embodiments, one or more of the above domains may not be present in the

polypeptide construct. For example, a polypeptide construct described herein can be engineered to lack a peptide linker domain. In other embodiments, a polypeptide construct comprises one or more domains derived from different proteins (*i.e.*, the polypeptide construct is chimeric).

[0119] Herein the term “extracellular” when used with reference to a portion of a polypeptide construct refers to the amino acids of the polypeptide which are positioned on the exterior of the cell membrane. In some embodiments, the extracellular portion can be referred to as a cell surface polypeptide. Typically a portion (*e.g.*, distal portion) of a cell surface polypeptide extends or protrudes distally into the extracellular space from the plasma membrane of a cell. In some instances, the extending portion may be bound and thereby recognized by an antibody or antigen-recognizing polypeptide that has a structure complementary to and specific for the structure of the extending portion. A cell surface polypeptide can encompass polypeptides or fragments thereof which occur naturally at the surface of the cell as well as polypeptides or fragments thereof which are not found naturally at the cell surface (*e.g.*, a truncated variant of a natural polypeptide).

[0120] The extracellular portion or cell surface polypeptide can include a truncated variant of a natural polypeptide. The truncated variant can for example, extend from the exterior of the plasma membrane (*e.g.* via a linker connected to or adjacent to the transmembrane domain) into the extracellular space. In certain embodiments, the truncated variant is missing amino acids which in the natural version of the polypeptide contribute to an intracellular domain and/or a transmembrane domain. The truncated variant can be modified from an endogenous polypeptide in any way to produce an extracellular portion of a cell tag. For example, the truncated variant can be modified to reduce or eliminate amino acids which normally function to comprise an epitope in the extracellular domain which can be recognized by an endogenous protein, such as an antigen or receptor. By removing amino acids which normally interface (*e.g.*, in cell signaling pathways) with extracellular molecules, the truncated variant can be made unreactive or immunologically/epitopically silent at the cell surface, or reduced or minimized in its reactivity or binding with endogenous molecules. Any modification to a natural polypeptide to remove natural epitopes is contemplated herein, including truncation of all or part of an extracellular domain, and removal of one or more amino acids which form part of an epitope, or are post-translationally modified to form part of an epitope.

[0121] Although a truncated variant described herein can be epitopically silent with respect to endogenous signaling pathways, the truncated variant can include one or more epitopes which are capable of being recognized by a molecule (*e.g.*, antibody) that does not normally contact a

surface of a cell corresponding to an engineered cell described herein. In some embodiments, an antibody or binding partner specific for an epitope of the truncated variant is introduced exogenously (*e.g.*, during immunotherapy using adopted cells). In this respect, an epitope of the truncated variant capable of being recognized by an introduced antibody or fragment thereof can be referred to as dormant or quiescent. That is, a cell tag incorporated at the cell surface of an engineered cell used for adoptive immunotherapy can contain an epitope which lies dormant until the proper molecule is introduced into a subject to trigger or activate the cell tag (*i.e.*, via recognition of the epitope). Such an epitope does not interfere with the therapeutic output of the engineered cells where therapy is proceeding as desired (*i.e.*, the epitope remains silent or quiescent), but embodies a trigger which can be activated to downregulate cellular output where for any reason the immunotherapy needs to be subdued. The present disclosure contemplates the use of any antibody or small molecule which is capable of recognizing an epitope of a cell tag to suppress the therapeutic output of an engineered cell expressing the tag via elimination of such cells (*e.g.*, via ADCC or CDC). Non-limiting examples of antibodies which can be used to recognize an epitope of an extracellular domain (*e.g.*, truncated variant) of a cell tag include rituximab, cetuximab, gefitinib, erlotinib, afatinib, brigatinib, icotinib, osimertinib, panitumumab, zalutumumab, nimotuzumab, matuzumab, afutuzumab, blontuvetmab, obinutuzumab, ibritumomab tiuxetan, tositumomab, ofatumumab, ocaratuzumab, ocrelizumab, TRU-015 (Trubion), veltuzumab (IMMU-106), alemtuzumab, ANT1034, HI 186(Bio Rad), YTH34.5 (Bio Rad) and YTH66.9HL (Bio-Rad), trastuzumab and pertuzumab.

[0122] Another example of a modification which can be made to an endogenous polypeptide to produce a truncated variant as contemplated herein is to remove one or more amino acids which normally contribute to or participate in intracellular signaling and/or trafficking pathways. Truncation of an endogenous polypeptide to remove signaling domains reinforces the function of a cell tag as a dormant, inducible cell marker which in its dormant state does not interfere with cellular function (*e.g.* in adopted cells during adoptive cell therapy).

[0123] In some embodiments, the cell surface polypeptide of the polypeptide construct can comprise a truncated variant of a receptor tyrosine kinase. Non-limiting examples include a truncated variant of a receptor from the EGF receptor family (*e.g.*, a truncated variant of HER1), PDGF receptor family, VEGF receptor family, insulin receptor family, FGF receptor family, Trk receptor family and Eph receptor family. In other embodiments, the cell surface polypeptide can comprise a truncated variant of a CD protein (*e.g.*, CD20 or CD52) or a truncated variant of LNFGR (CD271).

[0124] In certain embodiments, the cell surface polypeptide of the cell tag can include a truncated variant which has been modified to remove a transmembrane domain and intracellular signaling portion of the natural or endogenous polypeptide. The truncation of the transmembrane domain and intracellular signaling portion frees the cell surface or extracellular portion of the polypeptide from its endogenous context, for example making it available for incorporation into a chimeric polypeptide construct that includes the cell surface polypeptide fused to a transmembrane domain (*e.g.*, via a linker) derived from a different natural protein. Such chimeric polypeptide constructs in turn can confer the cell surface polypeptide (*e.g.*, truncated variant) with altered activity or characteristics compared to the endogenous version of the polypeptide. In some embodiments, a cell surface polypeptide is capable of dimerizing when expressed in a chimeric polypeptide construct.

[0125] The present disclosure contemplates that multiple different polypeptide constructs can be expressed in the same engineered cell. For example, a cell disclosed herein can express multiple polypeptide constructs that differ in the identity of the cell surface polypeptide and/or transmembrane domain.

[0126] A polypeptide construct described herein can include a cell surface polypeptide comprising a truncated variant of a natural polypeptide, a transmembrane domain fused to the cell surface polypeptide, optionally a linker connecting the truncated variant to the transmembrane domain, and a signal peptide directing the cell tag to a cell surface of an engineered cell.

Signal Peptide

[0127] A signal peptide is a sequence of amino acids typically located at the N-terminus of a newly synthesized protein or polypeptide which directs the protein or polypeptide to the cell surface. In some embodiments, the signal peptide directs the polypeptide to the cell surface to be inserted (*e.g.*, via a transmembrane domain) into the cellular membrane. In some embodiments, a polypeptide construct described herein is synthesized with the signal peptide, but then post-translationally processed to cleave the signal peptide such that the mature polypeptide construct lacks the signal peptide amino acid sequence. In other embodiments, the signal peptide sequence is not cleaved and remains in the mature polypeptide construct.

[0128] The present disclosure provides for a polypeptide construct comprising any known or unknown signal peptide capable of directing and/or trafficking the polypeptide construct to the cell surface. For example, in some embodiments, a polypeptide construct comprises a signal

sequence corresponding to the signal peptide of GMCSFR α , Ig Kappa, Immunoglobulin E, CD8 α , TVB2 (T21A), CD52 or Low-affinity nerve growth factor receptor (LNGFR, TNFRSF16).

[0129] In embodiments, the signal peptide is encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity with a nucleotide sequence selected from the list consisting of SEQ ID NO:1; SEQ ID NO:3; SEQ ID NO:5; SEQ ID NO:7; SEQ ID NO:9; SEQ ID NO:11; or SEQ ID NO:13. In embodiments, the signal peptide comprises an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity with an amino acid sequence selected from the list consisting of SEQ ID NO:2; SEQ ID NO:4; SEQ ID NO:6; SEQ ID NO:8; SEQ ID NO:10; SEQ ID NO:12; and SEQ ID NO:14.

Peptide Linker

[0130] A polypeptide construct described herein can comprise a peptide linker to connect a domain or fragment thereof of the polypeptide construct to a different domain or fragment thereof of the polypeptide construct. In some embodiments, a peptide linker connects the transmembrane domain of the polypeptide construct to a cell surface polypeptide (*e.g.* truncated variant of a natural polypeptide) of the polypeptide construct. For example, a polypeptide construct can comprise a peptide linker comprising a GSG linker (SEQ ID NO: 16), SGSG linker (SEQ ID NO: 18), (G4S)₃ linker (SEQ ID NO: 20), (G4S)₄ linker (SEQ ID NO: 22) and/or a Whitlow linker.

[0131] Provided herein is a peptide linker of any length or size to link a transmembrane domain to a cell surface polypeptide (*e.g.* truncated variant). For example, in some embodiments, a peptide linker is sized to maintain the distance between the truncated variant and the transmembrane domain at about the same distance as occurs between the natural non-truncated version of the polypeptide and its endogenous transmembrane domain. In embodiments, truncated variants as described herein are linked to a transmembrane domain via different size G4S linkers (G4S)_n, wherein n = 0, 1, 2, 3, 4, 5 (SEQ ID NO: 222), to maintain the “natural” distance between the HER1t and the transmembrane protein. For example, where two different truncated variants of the same natural polypeptide are of different lengths, the smaller-length truncated variant may be compensated by a larger sized linker in order to position both truncated variants at approximately the same distance from the cell surface.

[0132] In certain embodiments, a peptide linker can be used to link together domains or portions thereof other than a transmembrane domain. For example, a peptide linker can connect two protein moieties of the cell surface polypeptide. In some cases, the cell surface polypeptide can be chimeric and comprise truncated variants from multiple natural polypeptides which can be connected via a peptide linker. An example is a polypeptide construct comprising HER1t together with one or more truncated variants of another member of the EGFR family (*e.g.*, HER2, ErbB3 and ErbB4). In other cases, the cell surface polypeptide can comprise a concatemer of two or more copies of a truncated variant connected via a peptide linker (*e.g.* SEQ ID NO: 123 comprising two copies of a CD20 truncated polypeptide linked via an SGS linker).

[0133] In embodiments, the peptide linker is encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:15; SEQ ID NO:17; SEQ ID NO:19; SEQ ID NO:21; and SEQ ID NO:23. In embodiments, the peptide linker comprises an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:16; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:22; and SEQ ID NO:24.

Transmembrane Domain

[0134] A polypeptide construct described herein can include a transmembrane domain that can be inserted into a plasma membrane to anchor the polypeptide construct at the cell surface. The present disclosure provides for a polypeptide construct comprising one or more of any known or unknown transmembrane domains or fragments thereof. In some embodiments, the transmembrane domain of the polypeptide construct can comprise a transmembrane domain derived from and/or homologous to one or more natural proteins. In some embodiments, the transmembrane domain of the polypeptide construct comprises an amino acid sequence corresponding to the transmembrane domain of a single natural protein. In some embodiments, the transmembrane domain of the polypeptide construct comprises a chimeric transmembrane domain comprising amino acid sequences derived from two or more natural proteins.

[0135] A polypeptide construct described herein can comprise a transmembrane domain which is single-pass or multi-pass. CD8 α is an example of a protein having a single-pass transmembrane domain. In some embodiments, a polypeptide construct disclosed herein comprises a transmembrane domain corresponding to and/or homologous to a transmembrane domain or fragment thereof from the CD8 α protein. In embodiments, the transmembrane domain

of the polypeptide construct is encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence of SEQ ID NO:33. In embodiments, the transmembrane domain comprises an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence of SEQ ID NO:34.

[0136] An example of a multi-pass protein is CD28. In some embodiments, the transmembrane domain of a polypeptide construct can comprise a transmembrane domain corresponding to and/or homologous to a transmembrane domain or fragment thereof from the CD28 protein. In embodiments, the transmembrane domain of the polypeptide construct is encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence of SEQ ID NO:35. In embodiments, the transmembrane domain comprises an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence of SEQ ID NO:36.

[0137] In some embodiments, the transmembrane domain is a transmembrane dimerization domain. Herein “transmembrane dimerization domain” refers to a transmembrane domain or fragment thereof that is capable of physically interacting or “dimerizing” within the plasma membrane of a cell with a second transmembrane domain or fragment thereof. Typically the transmembrane dimerization domain is comprised within a first polypeptide construct which dimerizes via the transmembrane dimerization domain with a second polypeptide. Where a transmembrane dimerization domain of a first polypeptide is fused at its distal (extracellular oriented) end to a first cell surface polypeptide, and a transmembrane dimerization domain of a second polypeptide is fused at its distal end to a second cell surface polypeptide, physical interaction of the first and second transmembrane domains within the cell membrane can result in the dimerization of the first and second cell surface polypeptides. In some embodiments, the transmembrane domain can multimerize to form a trimer, a tetramer or a multimer.

[0138] In certain embodiments, a transmembrane dimerization domain induces dimerization of cell surface polypeptides without the requirement for any extracellular inducing agent (*e.g.*, ligand or antibody specific for an epitope of the cell surface polypeptide). For example, a transmembrane dimerization domain can induce dimerization of a cell surface polypeptide by spontaneously physically interacting or coupling with a second transmembrane dimerization domain within the cell membrane of a cell. It will thus be understood that a cell expressing a polypeptide construct described herein can display dimerized cell surface polypeptides on a cell

surface of the cell prior to the administration of any extracellular cell surface binding agent comprising an antibody, protein, ligand or molecule described herein. Dimerization of cell surface polypeptides via a transmembrane dimerization domain can leverage a cell expressing such a polypeptide construct towards an enhanced cellular response when the dimerized cell surface polypeptides contact and recognize a ligand or antibody. For example, where a polypeptide construct comprises a cell surface polypeptide comprising HER1t, a pair of HER1t cell surface polypeptides can be dimerized prior to or at the time of contact with a CDC- or ADCC-inducing agent such as cetuximab. As a result of the dimerized configuration of the cetuximab-binding cell surface polypeptides, administration of the binding agent at times of distress (*e.g.* during a cytokine storm) can amplify the cytotoxic effect thereby increasing the likelihood that a cell will be killed. In some embodiments, an agent that binds to a cell surface polypeptide (*e.g.* dimerized cell surface polypeptide) to induce a cellular response in an engineered cell expressing a polypeptide construct disclosed herein is provided exogenously and/or does not exist endogenously. The present disclosure provides for a transmembrane dimerization domain to facilitate dimerization of any cell surface polypeptide, including truncated variants of natural polypeptides, such as HER1t, LNGFRt, CD20t and CD52t.

[0139] In some embodiments, a transmembrane dimerization domain can form a covalent link with a second transmembrane domain to induce dimerization of the cell surface polypeptide. In some embodiments, the covalent connection is in the form of a disulfide bond formed between cysteine amino acids present in each of the adjacent transmembrane domains. In other embodiments, a transmembrane dimerization domain within the cell membrane can form a non-covalent connection with a second transmembrane domain to induce dimerization of the cell surface polypeptide.

[0140] A polypeptide construct described herein can have a transmembrane dimerization domain that physically interacts with another transmembrane dimerization domain. In such cases, the first and second transmembrane dimerization domains of the respective first and second polypeptide constructs can either have the same amino acid sequence (*i.e.*, homodimer with respect to the transmembrane dimerization domain) or different amino acid sequences (*i.e.*, heterodimer with respect to the transmembrane dimerization domain). In certain embodiments, each respective transmembrane dimerization domain of a dimerized polypeptide pair comprises at least one cysteine residue that mediates formation of a disulfide bridge between corresponding cysteine residues in the first and second transmembrane dimerization domains.

[0141] The transmembrane domain of a polypeptide construct can comprise an amino acid sequence corresponding to and/or homologous to an amino acid sequence of the protein glycophorin A. In some embodiments, a glycophorin A amino acid sequence incorporated into a polypeptide construct described herein includes the transmembrane domain or fragment thereof of glycophorin A. In some embodiments, the transmembrane domain of the polypeptide construct can include one or more amino acids that normally flank the glycophorin A transmembrane domain. In some embodiments, a polypeptide construct comprising all or part of a glycophorin A transmembrane domain is capable of dimerizing (*e.g.*, homodimerizing) with a second polypeptide construct comprising all or part of a glycophorin A transmembrane domain. In such cases, the amino acid sequence incorporated from glycophorin A into the polypeptide construct can define a transmembrane dimerization domain. For example, the glycophorin A dimerization domain can comprise the dimerization motif GXXXG.

[0142] In some embodiments, a polypeptide construct comprises a transmembrane domain including at least amino acids E91-R116 of glycophorin A. In some embodiments, a polypeptide construct comprises a transmembrane domain including at least amino acids I92-I114 of glycophorin A. In embodiments, a polypeptide construct comprises a transmembrane domain corresponding to a glycophorin A domain or fragment thereof encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:25 and SEQ ID NO:27. In embodiments, the polypeptide construct comprises a transmembrane domain corresponding to a glycophorin A domain or portion thereof which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:26 and SEQ ID NO:28.

[0143] A polypeptide construct described herein can include a transmembrane domain which is a chimera of amino acid sequences from two or more natural polypeptides. For example, the transmembrane domain can include an amino acid sequence corresponding to a glycophorin A domain or portion thereof linked or fused to an amino acid sequence from a second protein. In some embodiments, such a chimeric transmembrane domain is capable of dimerization with a second transmembrane domain (*e.g.*, chimeric or non-chimeric) and thus embodies a transmembrane dimerization domain. For example, an amino acid sequence corresponding to a glycophorin A transmembrane domain or fragment thereof can be fused to an amino acid sequence corresponding to a domain or fragment thereof of integrin β 3 to form a chimeric transmembrane domain of a polypeptide construct. In some embodiments, the polypeptide

construct comprises a transmembrane domain comprising amino acids I92-L109 of glycophorin A fused to amino acids A737-W741 of integrin $\beta 3$. In embodiments, a polypeptide construct comprises a transmembrane domain corresponding to a glycophorin A-integrin $\beta 3$ chimeric sequence encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity with the nucleotide sequence of SEQ ID NO:29. In embodiments, the polypeptide construct comprises a transmembrane domain which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity with the amino acid sequence of SEQ ID NO:30.

[0144] The transmembrane domain of a polypeptide construct can comprise an amino acid sequence corresponding to and/or homologous to an amino acid sequence within a transmembrane domain of the CD3 zeta chain. In some embodiments, a polypeptide construct comprising a transmembrane domain or fragment thereof of a CD3 zeta chain is capable of dimerizing (*e.g.*, homodimerizing) with a second polypeptide construct comprising a transmembrane domain or fragment thereof of a CD3 zeta chain transmembrane domain. In such cases, the amino acid sequence corresponding to the CD3 zeta chain transmembrane domain can define a transmembrane dimerization domain. In some embodiments, the polypeptide construct comprises a transmembrane domain encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence of SEQ ID NO:31. In other embodiments, the transmembrane domain is encoded by a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31. In embodiments, the polypeptide construct comprises a transmembrane domain which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence of SEQ ID NO:32.

[0145] In other embodiments, the transmembrane domain of a polynucleotide construct herein can comprise an amino acid sequence corresponding to and/or homologous to a transmembrane domain or fragment thereof from the proteins CTLA4 (cytotoxic T-lymphocyte protein 4) and/or LNGFR (TNFRSF16). For example, the polypeptide construct can comprise a transmembrane domain encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:37 and SEQ ID NO 39. In embodiments, the polypeptide construct comprises a transmembrane domain which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO: 38 and SEQ ID NO: 40.

Truncated Variants

[0146] A polypeptide construct described herein can comprise a cell surface polypeptide linked to the transmembrane domain. In certain embodiments, the cell surface polypeptide comprises a truncated variant of a natural polypeptide. Herein a wide variety of natural polypeptides are provided as a precursor or substrate to produce a truncated variant incorporated into a polypeptide construct. Each natural polypeptide precursor can further be subject to multiple different truncations to yield a large number of possible truncated variants for use in the polypeptide constructs described herein.

[0147] Examples of precursors include epidermal growth factor receptor (EGFR or HER1) isoform a precursor (*e.g.*, SEQ ID NO:50); receptor tyrosine protein kinase ErbB2 (HER2) isoform a precursor (*e.g.*, SEQ ID NO:51); receptor tyrosine-protein kinase ErbB3 (HER3) isoform 1 precursor (*e.g.*, SEQ ID NO:52), receptor tyrosine protein kinase ErbB4 (HER4) isoform JM-a/CVT-1 precursor (*e.g.*, SEQ ID NO:53), receptor tyrosine protein kinase ErbB4 (HER4) isoform JM-b isoform X7 (*e.g.*, SEQ ID NO:54), CD20 precursor (*e.g.*, SEQ ID NO:108), CD52 precursor, and LNGFR precursor (*e.g.*, SEQ ID NO:154).

[0148] In certain embodiments, the cell surface polypeptide comprises a truncated HER1 polypeptide (herein designated HER1t or EGFRt). Natural HER1 includes an extracellular region comprising Domain I, II, III and IV, a transmembrane domain, and an intracellular tyrosine kinase and regulatory region. Certain antibodies capable of inducing ADCC (*e.g.*, panitumumab and cetuximab) are known to bind to Domain III of endogenous HER1.

[0149] Provided herein are polypeptide constructs comprising HER1 polypeptides which are truncated for any amino acids, domains or fragments of endogenous HER1. Herein a HER1 polypeptide can comprise a HER1t polypeptide. In some embodiments, a HER1 polypeptide consists of or consists essentially of a HER1t polypeptide. In other embodiments, a HER1 polypeptide can comprise a HER1t polypeptide in addition to other HER1 domains (*e.g.* a HER1 transmembrane domain). In embodiments, a HER1 polypeptide can lack an intracellular domain or fragment thereof normally found in HER1, including the tyrosine kinase domain and regulatory region. In some embodiments, the HER1 polypeptide can lack a transmembrane domain or fragment thereof normally found in HER1. In some embodiments, the HER1 polypeptide can lack an extracellular domain or fragment thereof normally found in HER1, including all or part of Domain I, Domain II and Domain IV normally found in HER1.

[0150] In some embodiments, a cell surface polypeptide comprises a HER1t polypeptide lacking a fragment of Domain III normally found in HER1. In some embodiments, the HER1t

polypeptide consists of or consists essentially of all or a part of Domain III of the endogenous HER1 protein. In some embodiments, the HER1t polypeptide consists of or consists essentially of all of Domain III of the endogenous HER1 protein. In an embodiment, HER1t Domain III incorporated into the cell surface polypeptide is encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence of SEQ ID NO:199. In an embodiment, HER1t Domain III incorporated into the cell surface polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence of SEQ ID NO:200.

[0151] In some embodiments, a HER1t polypeptide incorporated into the cell surface polypeptide comprises Domain IV or a fragment thereof of endogenous HER1. An endogenous HER1 Domain IV can be encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence of SEQ ID NO:201. In an embodiment, an endogenous HER1t Domain IV has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence of SEQ ID NO:202. In other embodiments, the HER1t polypeptide incorporated into a cell surface polypeptide can comprise a truncated Domain IV. The HER1t truncated Domain IV can comprise a truncation of at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of Domain IV of natural HER1. In an embodiment, the HER1t truncated Domain IV incorporated into the cell surface polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:203, SEQ ID NO: SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207 SEQ ID NO:208, and SEQ ID NO:209.

[0152] A polypeptide construct described herein can comprise a HER1t polypeptide comprising HER1 Domain III and Domain IV. In an embodiment, a HER1t polypeptide comprises HER1 Domain III and Domain IV having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:210.

[0153] A polypeptide construct described herein can comprise a HER1t polypeptide comprising HER1 Domain III and a fragment of Domain IV. In an embodiment, a HER1t polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, and SEQ ID NO:217.

[0154] Natural HER1 also contains multiple disulfide bond pairs in Domain IV. In some embodiments, the HER1t truncated Domain IV can comprise truncation at positions to preserve

disulfide bond pairs. In further embodiments, HER1t variants as described herein are linked to a transmembrane domain via different size G4S linkers (G4S)_n, wherein n = 0, 1, 2, 3, 4, 5 (SEQ ID NO: 222), to maintain the “natural” distance between the HER1t and the transmembrane protein. In further embodiments, 7 residue linker between domain IV and EGFR transmembrane domain can be further removed as this linker plays a role in dimerization of EGFR receptors, which leads to EGF ligand activation.

[0155] A HER1t polypeptide incorporated into a cell surface polypeptide described herein can include an epitope that can be recognized by an exogenously introduced binding partner or antibody. In some embodiments, a HER1t polypeptide can incorporate a cetuximab-binding domain in order to facilitate targeted depletion of cells expressing a polypeptide construct described herein. Depletion can be due for example to cell death resulting from CDC and/or ADCC. Non-limiting examples of molecules which can be endogenously introduced to bind to and/or recognize an epitope on a cell surface polypeptide comprising HER1t can include cetuximab, gefitinib, erlotinib, afatinib, brigatinib, icotinib, osimertinib, panitumumab, zalutumumab, nimotuzumab, and matuzumab. In various embodiments, the antibody can be a monoclonal antibody, scFv, scFab, diabody, or camelid antibody. In another embodiment, the antibody can be conjugated to a drug or a toxin.

[0156] A cell surface polypeptide incorporated into a polypeptide construct described herein can comprise truncated variants of multiple different natural polypeptides. For example, the cell surface polypeptide can comprise a polypeptide chimera comprising multiple truncated polypeptides from the EGFR family. FIG. 4B illustrates an embodiment of a polypeptide construct conferring cell tag functionality, wherein the cell surface polypeptide comprises Domain III from one member of the HER/EGFR family (HER(m)) and Domain IV or a fragment thereof from a different member of the HER/EGFR family (HER(n)). Provided herein are chimeric cell surface polypeptides comprising any combination of extracellular domains from two or more of EGFR/HER1, HER2, ErbB3 and ErbB4. FIG. 4C depicts the specific case where Domain III is derived from EGFR/HER1. An advantage of such chimeric cell surface polypeptides is that each individual truncation can remove epitopes from the respective natural polypeptide which are prone to binding endogenous molecules, while preserving an epitope which can be recognized by an exogenously introduced antibody during adoptive cell therapy. For example, where the chimeric cell surface polypeptide comprises Domain III from EGFR and Domain IV from HER2, engineered cells expressing the polypeptide can be susceptible to both the antibodies cetuximab (recognizing Domain III of EGFR) and trastuzumab (recognizing

Domain IV of HER2). Thus, the chimeric cell surface polypeptides described herein provide a further mechanism to control immune cell behavior during immunotherapy, by providing for binding sites for multiple antibiotics/binding partners. For example, in a circumstance where a subject experiencing side effects during adoptive cell therapy does not respond to an administered antibiotic (*e.g.*, cetuximab) targeting an epitope on one of the truncated variants in the chimeric cell surface polypeptide, a different antibody (*e.g.*, trastuzumab) can be administered to the subject to target the same engineered cell via a different epitope on the other truncated variant of the chimeric cell surface polypeptide.

[0157] In some embodiments, a chimeric cell surface polypeptide can be fused to a transmembrane domain which is homologous to an EGFR family member. For example, the transmembrane domain can correspond to a transmembrane domain from EGFR/HER1, HER2, ErbB3 or ErbB4. In other embodiments, the transmembrane domain can be homologous to a non-EGFR transmembrane domain, including a transmembrane domain corresponding to SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40.

[0158] In some embodiments, a chimeric cell surface polypeptide can comprise a chimera of a HER1t polypeptide and a truncated HER2 (HER2t) polypeptide or fragment thereof. For example, the polypeptide construct can comprise a HER1t/EGFRt polypeptide comprising HER1 Domain III and a HER2t polypeptide comprising a HER2 Domain IV and HER2 transmembrane domain. In an embodiment, the EGFR-HER2 chimeric cell surface polypeptide fused to the HER2 transmembrane domain can be encoded by a polynucleotide comprising a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to a nucleotide sequence selected from the group consisting of SEQ ID NO:88 and SEQ ID NO:92 (delta 16). In an embodiment, the EGFR-HER2 chimeric cell surface polypeptide fused to the HER2 transmembrane domain has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:89 and SEQ ID NO:93 (delta 16).

[0159] In some embodiments, a chimeric cell surface polypeptide can comprise a chimera of a HER1t polypeptide and a truncated ErbB3 (ErbB3t) polypeptide or fragment thereof. For example, the polypeptide construct can comprise a HER1t/EGFRt polypeptide comprising HER1 Domain III and an ErbB3t polypeptide comprising an ErbB3 Domain IV and ErbB3 transmembrane domain. In an embodiment, the EGFR-ErbB3 chimeric cell surface polypeptide fused to the ErbB3 transmembrane domain can be encoded by a polynucleotide comprising a

nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to the nucleotide sequence of SEQ ID NO:96. In an embodiment, the EGFR-ErbB3 chimeric cell surface polypeptide fused to the ErbB3 transmembrane domain has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to the amino acid sequence of SEQ ID NO:97.

[0160] In some embodiments, a chimeric cell surface polypeptide can comprise a chimera of a HER1t polypeptide and a truncated ErbB4 (ErbB4t) polypeptide or fragment thereof. For example, the polypeptide construct can comprise a HER1t/EGFRt polypeptide comprising Domain III and an ErbB4t polypeptide comprising ErbB4 Domain IV and ErbB4 transmembrane domain. In some embodiments, an ErbB4t polypeptide can comprise a JM-a extracellular juxtamembrane domain encoded by the ErbB4 JM-a alternative transcript. In some embodiments, an ErbB4t polypeptide can comprise a JM-b extracellular juxtamembrane domain encoded by the ErbB4 JM-b alternative transcript. In an embodiment, the chimeric cell surface polypeptide fused to the ErbB4 transmembrane domain can be encoded by a polynucleotide comprising a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:100 (EGFR-ErbB4 (JM-a)) and SEQ ID NO:104 (EGFR-ErbB4 (JM-b)). In an embodiment, the EGFR-ErbB4 chimeric cell surface polypeptide fused to the ErbB4 transmembrane domain has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to the amino acid sequence selected from the list consisting of SEQ ID NO:101 (EGFR-ErbB4 (JM-a)) and SEQ ID NO:105 (EGFR-ErbB4 (JM-b)).

[0161] A polypeptide construct described herein can comprise any combination of signal peptide, cell surface polypeptide comprising a HER1t polypeptide (*e.g.*, comprising only HER1t or a chimeric polypeptide comprising HER1t), transmembrane domain and optionally a linker. For example, a polypeptide construct can comprise a cell surface polypeptide comprising a HER1t polypeptide or a chimeric polypeptide comprising HER1t linked or fused to a derivative or fragment of a CD28 transmembrane domain via a linker (*e.g.*, one or more (*e.g.*, 1-4) copies of (G4S (SEQ ID NO: 221))). In some embodiments, the cell surface polypeptide can include a HER1t polypeptide encoded by a polynucleotide comprising a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:56 (HER1t1); SEQ ID NO:58 (HER1t2); SEQ ID NO:60 (HER1t3); SEQ ID NO:62 (HER1t4); SEQ ID NO:64 (HER1t5); SEQ ID NO:66 (HER1t6); SEQ ID NO:68 (HER1t7); SEQ ID NO:72 (HER1t8); SEQ ID NO:76 (HER1t9); SEQ ID NO:80 (HER1t10); and SEQ ID NO:84 (HER1t11). In some embodiments, the cell surface polypeptide

can include a HER1t polypeptide comprising an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:55 (HER1t); SEQ ID NO:57 (HER1t1); SEQ ID NO:59 (HER1t2); SEQ ID NO:61 (HER1t3); SEQ ID NO:63 (HER1t4); SEQ ID NO:65 (HER1t5); SEQ ID NO:67 (HER1t6); SEQ ID NO:69 (HER1t7); SEQ ID NO:73 (HER1t8); SEQ ID NO:77 (HER1t9); SEQ ID NO:81 (HER1t10); and SEQ ID NO:85 (HER1t11).

[0162] In some embodiments, a polypeptide construct can comprise a signal peptide, a cell surface polypeptide comprising a HER1t polypeptide or a chimeric polypeptide comprising a HER1t polypeptide, a transmembrane domain comprising a transmembrane dimerization domain, and a linker to connect the transmembrane domain and cell surface polypeptide. For example, a polypeptide construct can comprise an Ig Kappa signal peptide, a particular truncated variant of HER1, a linker (*e.g.* (G4S)₄ (SEQ ID NO: 22)) and a transmembrane dimerization domain (*e.g.*, comprising I92-I114 of glycoporphin A or the transmembrane domain from CD3 zeta). In embodiments, a polypeptide construct comprising a HER1t polypeptide and a transmembrane dimerization domain is encoded by a polynucleotide comprising a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:70 (glycoporphin A; HER1t8); SEQ ID NO:74 (glycoporphin A; HER1t9); SEQ ID NO:78 (glycoporphin A; HER1t10); and SEQ ID NO:82 (CD3 zeta; HER1t11). In embodiments, a polypeptide construct comprising a HER1t polypeptide and a transmembrane dimerization domain comprises an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:71 (glycoporphin A; HER1t8); SEQ ID NO:75 (glycoporphin A; HER1t9); SEQ ID NO:79 (glycoporphin A; HER1t10); and SEQ ID NO:83 (CD3 zeta; HER1t11).

[0163] In another embodiment, a polypeptide construct can comprise a cell surface polypeptide comprising a HER1t-HER2t chimera linked to a HER2 transmembrane domain. The truncated HER1t-HER2t chimera and transmembrane domain can be further connected to a signal peptide (*e.g.*, GMCSFR α) which directs the polypeptide construct to the cell surface. In an embodiment, the polypeptide construct is encoded by a polynucleotide having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:86 and SEQ ID NO:90 (delta 16). In an embodiment, the polypeptide construct has an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity

to an amino acid sequence selected from the list consisting of SEQ ID NO:87 and SEQ ID NO:91 (delta 16).

[0164] In another example, a polypeptide construct can comprise a cell surface polypeptide comprising a HER1t-ErbB3t chimera linked to an ErbB3 transmembrane domain. In an embodiment, the HER1t-ErbB3t chimera and transmembrane domain is further connected to a signal peptide (*e.g.*, GMCSFR α) which directs the polypeptide construct to the cell surface. In an embodiment, the polypeptide construct is encoded by a polynucleotide having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence of SEQ ID NO:94. In an embodiment, the polypeptide construct has an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:95.

[0165] In still another example, a polypeptide construct can comprise a cell surface polypeptide comprising a HER1t-ErbB4t chimera linked to an ErbB4 transmembrane domain. In an embodiment, the HER1t-ErbB4t chimera and transmembrane domain is further connected to a signal peptide (*e.g.*, GMCSFR α) which directs the polypeptide construct to the cell surface. In an embodiment, the polypeptide construct is encoded by a polynucleotide having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:98 (JM-a variant) and SEQ ID NO:102 (JM-b variant). In an embodiment, the polypeptide construct has an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:99 (JM-a variant) and SEQ ID NO:103 (JM-b variant).

[0166] A polypeptide construct comprising a HER1t polypeptide can comprise any signal peptide capable of directing the polypeptide construct to the cell surface. For example, a cell surface polypeptide comprising a HER1t polypeptide (*e.g.*, comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:200, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216 and SEQ ID NO:217) can be fused to a signal peptide comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:2 (GMCSFR α), SEQ ID NO:4 (Ig Kappa), SEQ ID NO:6 (Immunoglobulin E), SEQ ID NO:8 (CD8 α), SEQ ID NO:10 (TVB2), SEQ ID NO:12 (CD52) or SEQ ID NO:14 (LNFGR).

[0167] A polypeptide construct comprising a HER1t polypeptide can comprise any transmembrane domain, including a transmembrane domain that does not comprise a

dimerization domain. For example, a cell surface polypeptide comprising a HER1t polypeptide (*e.g.*, comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:200, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216 and SEQ ID NO:217) can be linked to a transmembrane domain comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:26 (glycophorin A E91-R116), SEQ ID NO:28 (glycophorin A I92-I114), SEQ ID NO:30 (glycophorin A(I92-L109).integrin β 3 (A737-W741), SEQ ID NO:32 (CD3 zeta chain), SEQ ID NO: 34 (CD8 α), SEQ ID NO:36 (CD28), SEQ ID NO:38 (CTLA4) and SEQ ID NO:40 (LNGFR).

[0168] A polypeptide construct comprising a HER1t polypeptide can comprise any peptide linker (or in some embodiments no peptide linker). For example, a cell surface polypeptide comprising HER1t (*e.g.*, comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:200, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216 and SEQ ID NO:217) can be fused to a peptide linker comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:16 (GSG), SEQ ID NO:18 (SGSG), SEQ ID NO:20 ((G4S)₃), SEQ ID NO:22 ((G4S)₄) and SEQ ID NO:24 (Whitlow).

[0169] A cell surface polypeptide can incorporate a truncated CD polypeptide. For example, the cell surface polypeptide can include a truncated CD20 polypeptide (herein designated CD20t). The natural CD20 polypeptide is a multi-pass transmembrane protein encoded by a membrane-spanning 4-domains subfamily A member 1 (MS4A1) gene. In certain embodiments full-length CD20 can be encoded by a polynucleotide comprising the nucleotide sequence of SEQ ID NO:106, and full-length CD20 amino acid sequence can correspond to the amino acid sequence of SEQ ID NO:107. In some embodiments, CD20 comprises 4 transmembrane domain passes encompassing amino acids 57-78, 85-105, 121-141, and 189-209. In some embodiments, CD20 comprises 2 extracellular domains encompassing amino acids 79-84 and 142-188. In some embodiments, CD20 comprises 3 cytoplasmic domains encompassing amino acids 1-56, 106-120 and 210-297.

[0170] Provided herein are polypeptide constructs comprising CD20 polypeptides which are truncated for any amino acids, domains or fragments of endogenous CD20. Herein a CD20 polypeptide can comprise a CD20t polypeptide. In some embodiments, a CD20 polypeptide consists of or consists essentially of a CD20t polypeptide. In other embodiments, a CD20 polypeptide can comprise a CD20t polypeptide in addition to another CD20 domain or portion thereof (*e.g.* a CD20 transmembrane domain and/or cytoplasmic domain). For example, a CD20 polypeptide can be truncated for an intracellular cytoplasmic (*e.g.* signaling) domain or portion thereof, a transmembrane (*e.g.* helical) domain or portion thereof, and/or an extracellular domain or portion thereof. In some embodiments, a CD20 polypeptide can be missing multiple domains or multiple portions of a domain relative to the wildtype polypeptide. In an embodiment, a CD20 polypeptide comprises M1-E263 of endogenous CD20 (SEQ ID NO:109; CD20t1), M117-N214 of endogenous CD20 (SEQ ID NO:111 (CD20t2), M1-N214 of endogenous CD20 (SEQ ID NO:115; CD20t4), V82-N214 of endogenous CD20 (SEQ ID NO:117; CD20t5), or V82-I186 of endogenous CD20 (SEQ ID NO:119, CD20t6).

[0171] In an embodiment, a CD20t polypeptide can comprise an extracellular domain or fragment thereof. In an embodiment, a CD20t polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:218, SEQ ID NO:219 and SEQ ID NO:220. In some embodiments, a CD20t polypeptide can be linked to a transmembrane domain or fragment thereof. In an embodiment, a polypeptide construct comprises a CD20t polypeptide linked to a CD20 transmembrane domain. In some embodiments, a polypeptide construct comprising a CD20t polypeptide linked to a CD20 transmembrane domain is encoded by a polynucleotide comprising a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:108 (CD20t1 encoding M1-E263); SEQ ID NO:110 (CD20t2 encoding M117-N214); SEQ ID NO:114 (CD20t4 encoding M1-N214); SEQ ID NO:116 (CD20t5 encoding V82-N214); SEQ ID NO:118 (CD20t6 encoding V82-I186); SEQ ID NO:132 (CD20t13 encoding M1-A54 and C111-P297); SEQ ID NO:134 (CD20t14 encoding M1-A54 and C111-E281); SEQ ID NO:136 (CD20t15 encoding M1-A54 and C111-E263); SEQ ID NO:138 (CD20t16 encoding M1-A54 and C111-V228); and SEQ ID NO:140 (CD20t17 encoding M1-V8 and C111-P297). In an embodiment, a polypeptide construct comprising a CD20t polypeptide linked to a CD20 transmembrane domain can comprise an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:109 (CD20t1: M1-E263); SEQ ID

NO:111 (CD20t2: M117-N214); SEQ ID NO:115 (CD20t4: M1-N214); SEQ ID NO:117 (CD20t5: V82-N214); SEQ ID NO:119 (CD20t6: V82-I186); SEQ ID NO:133 (CD20t13: M1-A54 and C111-P297); SEQ ID NO:135 (CD20t14: M1-A54 and C111-E281); SEQ ID NO:137 (CD20t15: M1-A54 and C111-E263); SEQ ID NO:139 (CD20t16: M1-A54 and C111-V228); and SEQ ID NO:141 (CD20t17: M1-V8 and C111-P297).

[0172] In some embodiments, a CD20t polypeptide can retain at least one copy of a rituximab-binding mimotope of endogenous CD20, as described in Philip *et al.*, (2014), “A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy,” *Blood*: 124: 1277-1287. In some embodiments, one or more copies of a rituximab-binding epitope of CD20t can be fused to one or more CD-34-derived amino acid sequences, such as the amino-terminal 40 amino acids of CD34 which facilitate binding of an anti-CD34 monoclonal antibody. In some embodiments, a CD20t polypeptide can have multiple domains removed, or a portion of multiple domains removed.

[0173] A cell surface polypeptide incorporating a CD20t polypeptide can include an epitope that can be recognized by an exogenously introduced antibody or binding partner. For example, a CD20t polypeptide included in the cell surface polypeptide can incorporate a rituximab-binding domain in order to facilitate targeted depletion of cells expressing a polypeptide construct described herein (*e.g.*, via CDC and/or antibody-dependent cellular cytotoxicity ADCC). Non-limiting examples of antibodies which can be used to bind to an epitope of a cell surface polypeptide comprising a CD20t polypeptide include rituximab, hOUBM3/6, afutuzumab, blontuvetmab, obinutuzumab, ibritumomab tiuxetan, tositumomab, ofatumumab, ocaratuzumab, ocrelizumab, TRU-015 (Trubion) and veltuzumab (IMMU-106). In various embodiments, the antibody can be a monoclonal antibody, scFv, scFab, diabody, or camelid antibody. In other embodiments, the antibody can be conjugated to a drug or a toxin. In some embodiments, the CD20t polypeptide includes an epitope found in an extracellular domain of endogenous CD20. In some embodiments, an epitope of the CD20t polypeptide includes amino acids 170-185 of endogenous CD20. In some embodiments, an epitope of the CD20t polypeptide includes amino acids 170-173 and 182-185 of endogenous CD20.

[0174] In further embodiments, a cell surface polypeptide comprising a CD20t polypeptide is chimeric for a truncated variant of one or more additional polypeptides. For example, a chimeric cell surface polypeptide can comprise a CD20t polypeptide and a truncated CD8 α (CD8 α t) polypeptide.

[0175] A cell surface polypeptide can further comprise multiple CD20t linked sequences together as a concatemer. For example, a cell surface polypeptide can comprise the same CD20t amino acid sequence repeated in succession, or different CD20t variants connected together. In some embodiments, CD20t amino acid sequences are linked together in the cell surface polypeptide by a peptide linker. In an embodiment, an SGS or SG4S linker (SEQ ID NO: 223) can be used to link together repeating CD20 amino acid sequences in a cell surface polypeptide (*e.g.*, see SEQ ID NO:123 (SGS linker) and SEQ ID NO:129 (SG4S linker (SEQ ID NO: 223))), which further comprise the cell surface polypeptide linked to a CD28 transmembrane domain by an SG4S linker (SEQ ID NO: 223).

[0176] A polypeptide construct described herein can comprise any combination of signal peptide, cell surface polypeptide comprising a CD20t polypeptide (*e.g.*, comprising only CD20t or a CD20t chimera), transmembrane domain and optionally a linker. For example, a polypeptide construct can comprise an SG4S linker (SEQ ID NO: 223) which connects or fuses a cell surface polypeptide comprising a CD20t polypeptide to a transmembrane domain. In certain embodiments, a transmembrane domain is derived from or homologous to a transmembrane domain or fragment thereof from CD20, CD28 or CD8 α . In an embodiment, a polypeptide construct comprising CD20t is encoded by a polynucleotide comprising a nucleotide sequence selected from the list consisting of SEQ ID NO:112 (CD20t3 encoding CD20t (K142-S188) and CD8 α (I183-T203) transmembrane domain); SEQ ID NO:120 (CD20t7 encoding CD20t (P160-Q187), an SG4S linker (SEQ ID NO: 223) and CD28 (I96-D172) transmembrane domain); SEQ ID NO:122 (CD20t8 encoding a CD20t-concatemer (P160-Q187 separated by an SGS linker), SG4S linker (SEQ ID NO: 223) and CD28 (I96-D172) transmembrane domain); SEQ ID NO:124 (CD20t9 encoding CD20t (P160-Q187), an SG4S linker (SEQ ID NO: 223) and a CD8 α (P120-V201) transmembrane domain); SEQ ID NO:126 (CD20t10 encoding CD20t (C167-C183), an SG4S linker (SEQ ID NO: 223) and a CD28 (I96-D172) transmembrane domain; SEQ ID NO: 128 (CD20t11 encoding a CD20 concatemer (C167-C183 separated by an SG4S linker (SEQ ID NO: 223))), an SG4S linker (SEQ ID NO: 223) and a CD28 (I96-D172) transmembrane domain; and SEQ ID NO: 130 (CD20t12 encoding CD20t (C167-C183), an SG4S linker (SEQ ID NO: 223) and a CD8 α (P120-V201) transmembrane domain). In an embodiment, a polypeptide construct comprising CD20t comprises an amino acid sequence selected from the list consisting of SEQ ID NO:113 (CD20t3; CD20t (K142-S188) and CD8 α (I183-T203) transmembrane domain); SEQ ID NO:121 (CD20t7 encoding CD20t (P160-Q187), an SG4S linker (SEQ ID NO: 223) and CD28 (I96-D172) transmembrane domain); SEQ ID NO:123 (CD20t8 encoding a

CD20t-concatemer (P160-Q187 separated by an SGS linker), SG4S linker (SEQ ID NO: 223) and CD28 (I96-D172) transmembrane domain); SEQ ID NO:125 (CD20t9 encoding CD20t (P160-Q187), an SG4S linker (SEQ ID NO: 223) and a CD8 α (P120-V201) transmembrane domain); SEQ ID NO:127 (CD20t10 encoding CD20t (C167-C183), an SG4S linker (SEQ ID NO: 223) and a CD28 (I96-D172) transmembrane domain); SEQ ID NO: 129 (CD20t11 encoding a CD20 concatemer (C167-C183 separated by an SG4S linker (SEQ ID NO: 223)), an SG4S linker (SEQ ID NO: 223) and a CD28 (I96-D172) transmembrane domain; and SEQ ID NO:131 (CD20t12 encoding CD20t (C167-C183), an SG4S linker (SEQ ID NO: 223) and a CD8 α (P120-V201) transmembrane domain).

[0177] A polypeptide construct comprising a CD20t polypeptide can comprise any signal peptide capable of directing the polypeptide construct to the cell surface. For example, a polypeptide construct comprising a CD20t polypeptide (*e.g.*, a polypeptide which comprises an amino acid sequence selected from the list consisting of SEQ ID NO:218, SEQ ID NO:219 and SEQ ID NO:220) can be fused to a signal peptide comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:2 (GMCSF α), SEQ ID NO:4 (IG Kappa), SEQ ID NO:6 (Immunoglobulin E), SEQ ID NO:8 (CD8 α), SEQ ID NO:10 (TVB2), SEQ ID NO:12 (CD52) or SEQ ID NO:14 (LNFGR).

[0178] A polypeptide construct comprising a CD20t polypeptide can comprise any transmembrane domain, including a transmembrane domain that comprises a dimerization domain or does not comprise a dimerization domain. For example, a polypeptide construct comprising a CD20t polypeptide (*e.g.*, a polypeptide which comprises an amino acid sequence selected from the list consisting of SEQ ID NO:218, SEQ ID NO:219 and SEQ ID NO:220) can be fused to a transmembrane domain comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:26 (glycophorin A E91-R116), SEQ ID NO:28 (glycophorin A I92-I114), SEQ ID NO:30 (glycophorin A (I92-L109).integrin β 3 (A737-W741), SEQ ID NO:32 (CD3 zeta chain), SEQ ID NO: 34 (CD8 α), SEQ ID NO:36 (CD28), SEQ ID NO:38 (CTLA4) and SEQ ID NO:40 (LNGFR). Polypeptide constructs comprising CD20t can further comprise transmembrane domains derived from or homologous to CD28 and/or CD8 α .

[0179] A polypeptide construct comprising a CD20t polypeptide can comprise any peptide linker (or in some embodiments no peptide linker). For example, a polypeptide construct comprising a CD20t polypeptide (*e.g.*, a polypeptide which comprises an amino acid sequence

selected from the list consisting of SEQ ID NO:218, SEQ ID NO:219 and SEQ ID NO:220) can be fused to a peptide linker comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:16 (GSG), SEQ ID NO:18 (SGSG), SEQ ID NO:20 ((G4S)₃), SEQ ID NO:22 ((G4S)₄) and SEQ ID NO:24 (Whitlow).

[0180] Another example of a CD polypeptide which can be truncated and incorporated into a cell tag described herein is CD52. CD52 occurs endogenously in humans as a peptide of 12 amino acids linked at its C-terminus to a glycosylphosphatidylinositol (GPI) anchor. In some embodiments, glycosylphosphatidylinositol (GPI) can be used to anchor the polypeptides described herein to the cell surface.

[0181] Provided herein are polypeptide constructs comprising CD52 polypeptides which are truncated for any amino acids, domains or fragments of endogenous CD52. Herein a CD52 polypeptide can comprise a truncated CD52 (CD52t) polypeptide. In some embodiments, a CD52 polypeptide consists of or consists essentially of a cell surface polypeptide comprising a CD52t polypeptide. In other embodiments, a CD52 polypeptide can comprise a cell surface polypeptide comprising a CD52t polypeptide in addition to other CD52 domains (*e.g.* a CD52 signal peptide).

[0182] Herein are provided polypeptide constructs which comprise a cell surface polypeptide comprising a truncated CD52t polypeptide. In some embodiments, a CD52t polypeptide is linked to a CD52 signal peptide for directing the truncated variant to the cell surface. In some embodiments, a cell surface polypeptide comprising a CD52t polypeptide can incorporate one or more epitopes that can be recognized by an exogenously introduced antibody or binding partner. For example, a CD52t polypeptide can incorporate one or more alemtuzumab-binding domains and thereby facilitate targeted depletion of cells expressing a polypeptide construct described herein. In some embodiments, targeted depletion can result from alemtuzumab-mediated CDC and/or ADCC, or another cellular mechanism which mediates the cytotoxic effects of alemtuzumab recognition. Non-limiting examples of anti-CD52 molecules which can recognize a cell surface polypeptide comprising a CD52t polypeptide include alemtuzumab, ANT1034, HI 186(Bio Rad), YTH34.5 (Bio Rad) and YTH66.9HL (Bio-Rad). In various embodiments, the antibody can be a monoclonal antibody, scFv, scFab, diabody, or camelid antibody. In an embodiment, a polynucleotide sequence encoding a CD52 epitope comprises a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the nucleotide sequence of SEQ ID NO:142. In an embodiment, a CD52 epitope has at least 70%,

75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:143.

[0183] A polypeptide construct described herein can have multiple epitopes which can be recognized by an antibody or binding partner. For example, in the case of a CD52t polypeptide, a polypeptide construct comprising a CD52t polypeptide can comprise multiple epitopes specific for a binding partner (*e.g.*, alemtuzumab). In an embodiment, a CD52t polypeptide comprises multiple copies (*e.g.*, at least two copies, at least three copies, at least four copies, at least five copies, at least six copies, or at least ten copies) of the amino acid sequence shown in SEQ ID NO:143. Each copy or repeat of the amino acid sequence can be separated in a polypeptide construct by a linker (*e.g.*, Whitlow linker). In an embodiment, a polypeptide construct comprises a CD52 signal peptide linked to one or more copies of a CD52t polypeptide fused to a Whitlow linker, which is linked (*e.g.* via one or more copies of a (G4S) linker (SEQ ID NO: 221)) to a transmembrane domain (*e.g.*, CD28 transmembrane domain or a fragment thereof). In an embodiment, a polypeptide construct comprising a CD52t polypeptide is encoded by a polynucleotide which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:144 (CD52t1; encoding one copy of an epitope/linker;), SEQ ID NO:146 (CD52t2; encoding two copies of an epitope/linker), and SEQ ID NO:148 (CD52t3; encoding three copies of an epitope/linker). In an embodiment, a polypeptide comprising a CD52t polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:145 (CD52t1; encoding one copy of an epitope/linker;), SEQ ID NO:147 (CD52t2; encoding two copies of an epitope/linker), and SEQ ID NO:149 (CD52t3; encoding three copies of an epitope/linker)

[0184] A polypeptide construct comprising a CD52t polypeptide can comprise any transmembrane domain, including a transmembrane domain that comprises a dimerization domain or does not comprise a dimerization domain. For example, a cell surface polypeptide comprising a CD52t polypeptide can be fused via a linker (*e.g.* 3xGS linker (SEQ ID NO: 224)) to a transmembrane domain comprising a transmembrane dimerization domain (*e.g.* derived from or homologous to a transmembrane domain of glycoporphin A or glycoporphin A-integrin β 3). In an embodiment, a polypeptide construct comprising a CD52t polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:150 (CD52t4; CD52 signal peptide, 3xGS peptide linker (SEQ ID NO: 224) and glycoporphin A transmembrane domain), SEQ ID NO:151 (CD52t5; CD52 signal

peptide, 3xGS peptide linker (SEQ ID NO: 224) and glycoporphin A transmembrane domain), and SEQ ID NO: 152 (CD52t6; CD52 signal peptide, 3xGS linker (SEQ ID NO: 224) and glycoporphin A-integrin β 3 transmembrane domain).

[0185] In embodiments, a polypeptide construct comprising a CD52t polypeptide (*e.g.*, SEQ ID NO:143, which can be linked to a CD52 signal peptide to give rise to an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:145, SEQ ID NO:147, and SEQ ID NO:149) can be linked to a transmembrane domain comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:26 (glycoporphin A E91-R116), SEQ ID NO:28 (glycoporphin A I92-I114), SEQ ID NO:30 (glycoporphin A(I92-L109).integrin β 3 (A737-W741), SEQ ID NO:32 (CD3 zeta chain), SEQ ID NO: 34 (CD8 α), SEQ ID NO:36 (CD28), SEQ ID NO:38 (CTLA4) and SEQ ID NO:40 (LNGFR).

[0186] A polypeptide construct comprising a CD52t polypeptide can comprise any signal peptide capable of directing the polypeptide construct to the cell surface. In an embodiment, a CD52t polypeptide is linked to a signal peptide of CD52 (*e.g.*, the polypeptide construct comprises an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the amino acid sequence selected from the list consisting of SEQ ID NO:145, SEQ ID NO:147, and SEQ ID NO:149). In some embodiments, a polypeptide construct comprises a CD52t polypeptide (*e.g.*, SEQ ID NO:143) linked to a signal peptide comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:2 (GMCSFR α), SEQ ID NO:4 (IG Kappa), SEQ ID NO:6 (Immunoglobulin E), SEQ ID NO:8 (CD8 α), SEQ ID NO:10 (TVB2), SEQ ID NO:12 (CD52) or SEQ ID NO:14 (LNFGR).

[0187] A polypeptide construct comprising a CD52t polypeptide can comprise any peptide linker (or in some embodiments no peptide linker). For example, a cell surface polypeptide comprising CD52t (*e.g.*, comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:143) can be fused to a peptide linker comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:16 (GSG), SEQ ID NO:18 (SGSG), SEQ ID NO:20 ((G4S)₃), SEQ ID NO:22 ((G4S)₄) and SEQ ID NO:24 (Whitlow).

[0188] In other embodiments, the cell surface polypeptide can include a truncated version of a polypeptide from the tumor necrosis factor (TNF) receptor superfamily. For example, LNGFR is a single-pass type I transmembrane glycoprotein having an extracellular domain exhibiting a folded structure due in part to disulfide bond formation between cysteine residues of the protein. In an embodiment, a polynucleotide encoding LNGFR or a portion thereof comprises a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:153, SEQ ID NO: 155 (encoding K29-N250 of the LNGFR extracellular domain), SEQ ID NO: 157 (encoding E65-N250 including cysteine residues 2,3,4 capable of forming disulfide bonds), and SEQ ID NO: 159 (encoding R108-N250 including cysteine residues 3,4 capable of forming disulfide bonds). In an embodiment, LNGFR has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:154, SEQ ID NO: 156 (comprising K29-N250 of the LNGFR extracellular domain), SEQ ID NO: 158 (comprising E65-N250 including cysteine residues 2,3,4 capable of forming disulfide bonds), and SEQ ID NO: 160 (comprising R108-N250 including cysteine residues 3,4 capable of forming disulfide bonds).

[0189] Provided herein are polypeptide constructs comprising LNGFR polypeptides which are truncated for any amino acids, domains or fragments of endogenous LNGFR. Herein an LNGFR polypeptide can comprise an LNGFRt polypeptide. In some embodiments, an LNGFR polypeptide consists of or consists essentially of a cell surface polypeptide comprising an LNGFRt polypeptide. In other embodiments, an LNGFR polypeptide can comprise a cell surface polypeptide comprising an LNGFRt polypeptide in addition to other LNGFR domains (*e.g.* an LNGFR transmembrane domain).

[0190] A polypeptide construct can comprise a truncated LNGFR (herein LNGFRt) polypeptide with any domain or fragment thereof truncated relative to the wildtype protein. For example, an LNGFRt polypeptide can be truncated for one or more of the transmembrane domain or a portion thereof, the intracellular domain or a portion thereof, or the extracellular domain or a portion thereof. In some embodiments, an LNGFRt polypeptide can be truncated for one or more TNFR-Cys repeats that form a natural binding domain for its ligands (*e.g.*, NGF, BDNF, NTF3 and NTF4). In an embodiment, a polypeptide construct comprises an LNGFRt polypeptide comprising the entire extracellular domain (SEQ ID NO:156). In an embodiment, a polypeptide construct comprising an LNGFRt polypeptide is fused to an LNGFR transmembrane domain. In an embodiment, a polynucleotide encoding an LNGFRt polypeptide linked to an LNGFR transmembrane domain comprises a nucleotide sequence having at least 70%, 75%,

80%, 85%, 90%, 95%, 99%, or 100% identity to the nucleotide sequence of SEQ ID NO:161 (LNGFRt1). In an embodiment, an LNGFRt polypeptide linked to an LNGFR transmembrane domain has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:162 (LNGFRt1).

[0191] A polypeptide construct comprising an LNGFRt polypeptide can comprise any transmembrane domain, including a transmembrane domain that comprises a dimerization domain or does not comprise a dimerization domain. For example, a polypeptide construct can comprise an LNGFRt polypeptide linked to an LNGFR transmembrane domain or a fragment thereof. In other embodiments, a LNGFRt polypeptide can be fused (*e.g.*, via a linker) to a transmembrane domain or fragment thereof derived from a different polypeptide, including a transmembrane domain capable of dimerization. In an embodiment, a polypeptide construct comprising an LNGFRt polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:163 (LNGFRt2; entire LNGFR extracellular domain; GS linker and CD28 transmembrane domain); SEQ ID NO:164 (LNGFRt3; fragment of LNGFR extracellular domain including cysteine residues 2-4, a GS peptide linker and a CD28 transmembrane domain), SEQ ID NO: 165 (LNGFRt3; fragment of LNGFR extracellular domain including cysteine residues 3-4, a GS peptide linker and a CD28 transmembrane domain); SEQ ID NO:166 (LNGFRt5; fragment of LNGFR extracellular domain including cysteine residues 3-4, GS linker and glycoporphin A transmembrane domain), SEQ ID NO: 167 (LNGFRt6; fragment of LNGFR extracellular domain including cysteine residues 3-4, GS linker and glycoporphin A transmembrane domain); and SEQ ID NO: 168 (LNGFRt7; fragment of LNGFR extracellular domain comprising cysteine residues 3-4, GS linker and glycoporphin A-integrin β 3 transmembrane domain).

[0192] In some embodiments, a polypeptide construct comprising an LNGFRt polypeptide can be fused to a transmembrane domain comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:26 (glycoporphin A E91-R116), SEQ ID NO:28 (glycoporphin A I92-I114), SEQ ID NO:30 (glycoporphin A(I92-L109).integrin β 3 (A737-W741), SEQ ID NO:32 (CD3 zeta chain), SEQ ID NO: 34 (CD8 α), SEQ ID NO:36 (CD28), SEQ ID NO:38 (CTLA4) and SEQ ID NO:40 (LNGFR).

[0193] A polypeptide construct comprising an LNGFRt polypeptide can comprise any signal peptide capable of directing the polypeptide construct to the cell surface. For example, a cell surface polypeptide comprising an LNGFRt polypeptide can be fused to a signal peptide

comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:2 (GMCSFR α), SEQ ID NO:4 (IG Kappa), SEQ ID NO:6 (Immunoglobulin E), SEQ ID NO:8 (CD8 α), SEQ ID NO:10 (TVB2), SEQ ID NO:12 (CD52) or SEQ ID NO:14 (LNFGR).

[0194] A polypeptide construct comprising an LNGFRt polypeptide can comprise any peptide linker (or in some embodiments no peptide linker). For example, a cell surface polypeptide comprising an LNGFRt polypeptide can be fused to a peptide linker comprising an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:16 (GSG), SEQ ID NO:18 (SGSG), SEQ ID NO:20 ((G4S)³), SEQ ID NO:22 ((G4S)⁴) and SEQ ID NO:24 (Whitlow).

Polynucleotide Constructs

Vector

[0195] The polypeptide constructs described herein can be encoded by one or more polynucleotides incorporated into an engineered cell via a vector. Herein an “expression vector” or “vector” is any genetic element, *e.g.*, a plasmid, chromosome, virus, transposon, behaving either as an autonomous unit of polynucleotide replication within a cell. (*i.e.* capable of replication under its own control) or being rendered capable of replication by insertion into a host cell chromosome, having attached to it another polynucleotide segment, so as to bring about the replication and/or expression of the attached segment. Suitable vectors include, but are not limited to, plasmids, transposons, bacteriophages and cosmids. Vectors may contain polynucleotide sequences which are necessary to effect ligation or insertion of the vector into a desired host cell and to effect the expression of the attached segment. Such sequences differ depending on the host organism; they include promoter sequences to effect transcription, enhancer sequences to increase transcription, ribosomal binding site sequences and transcription and translation termination sequences. Alternatively, expression vectors may be capable of directly expressing nucleic acid sequence products encoded therein without ligation or integration of the vector into host cell DNA sequences.

[0196] A vector also can comprise a “selectable marker gene.” The term “selectable marker gene,” as used herein, refers to a nucleic acid sequence that allows cells expressing the nucleic acid sequence to be specifically selected for or against, in the presence of a corresponding selective agent. Suitable selectable marker genes are known in the art and described in, *e.g.*, International Patent Application Publications WO 1992/08796 and WO 1994/28143; Wigler et

al., Proc. Natl. Acad. Sci. USA, 77: 3567 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA, 78: 1527 (1981); Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78: 2072 (1981); Colberre-Garapin et al., J. Mol. Biol., 150:1 (1981); Santerre et al., Gene, 30: 147 (1984); Kent et al., Science, 237: 901-903 (1987); Wigler et al., Cell, 11: 223 (1977); Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48: 2026 (1962); Lowy et al., Cell, 22: 817 (1980); and U.S. Pat. Nos. 5,122,464 and 5,770,359.

[0197] In some embodiments, the vector is an “episomal expression vector” or “episome,” which is able to replicate in a host cell, and persists as an extrachromosomal segment of DNA within the host cell in the presence of appropriate selective pressure (see, *e.g.*, Conese et al., Gene Therapy, 11:1735-1742 (2004)). Representative commercially available episomal expression vectors include, but are not limited to, episomal plasmids that utilize Epstein Barr Nuclear Antigen 1 (EBNA1) and the Epstein Barr Virus (EBV) origin of replication (oriP). The vectors pREP4, pCEP4, pREP7, and pcDNA3.1 from Invitrogen (Carlsbad, Calif.) and pBK-CMV from Stratagene (La Jolla, Calif.) represent non-limiting examples of an episomal vector that uses T-antigen and the SV40 origin of replication in lieu of EBNA1 and oriP.

[0198] Provided herein is a polypeptide construct which can comprise a signal peptide, a transmembrane domain, a cell surface polypeptide comprising a truncated variant of a natural polypeptide, and optionally a peptide linker connecting the transmembrane domain to the cell surface polypeptide. For example, FIG. 4A illustrates an embodiment of a polypeptide construct having cell tag functionality. The truncated variant extends into the extracellular matrix via a peptide linker connecting to the transmembrane domain. The truncated variant can include one or more epitopes for an anti-truncated variant antibody (*e.g.*, exogenously added) which can recognize and bind to the truncated variant/cell tag. In some embodiments, binding of the antibody to the truncated variant can result in cell depletion (*e.g.*, via ADCC), which can be beneficial for example during adoptive cell therapy where the cell has been engineered to express one or more additional molecules such as a cytokine, TCR and/or CAR. In some embodiments, different polypeptide constructs comprise a constant transmembrane domain and signal peptide, but vary in the identity of the truncated variant incorporated into the polypeptide construct. For example, different polypeptide constructs can comprise different truncated variants of the same natural polypeptide. Where two polypeptide constructs incorporate different truncated variants of the same natural polypeptide, the polypeptide constructs may further differ based on the presence/absence of a peptide linker in the polypeptide construct or the length of the peptide linker. In some embodiments, the peptide linker of each polypeptide construct is sized to

maintain a relatively constant distance between the distal end of the particular truncated variant and the cell surface.

[0199] Provided herein are polynucleotides and methods for using the polynucleotides to facilitate the construction of polypeptide constructs for use during immunotherapy. In certain embodiments, a polynucleotide can comprise a vector comprising a sequence encoding a signal peptide and a transmembrane domain (*e.g.* either comprising or lacking a transmembrane dimerization domain). The vector can provide for the cloning of an insert between the signal peptide and the transmembrane domain, such that the insert comprises a nucleotide sequence encoding a particular truncated variant and optionally a peptide linker. Alternatively, vectors can be provided that comprise a polynucleotide encoding a signal peptide, a particular truncated variant and optionally a linker, and provide for the insertion of a nucleotide sequence encoding a transmembrane domain adjacent to the coding sequence for the truncated variant or linker. By providing for a series of vectors that maintain as constant a particular domain or domains in a resultant polypeptide construct, but allow for the swapping in and out of a domain that may be variable between polypeptide constructs, the present disclosure facilitates the production of polypeptide constructs comprising any combination of signal peptide, truncated variant, transmembrane domain and linker.

Vector Modifications

[0200] A polynucleotide vector useful for the methods and compositions described herein can be a good manufacturing practices (GMP) compatible vector. For example, a GMP vector may be purer than a non-GMP vector. In some cases, purity can be measured by bioburden. For example, bioburden can be the presence or absence of aerobes, anaerobes, sporeformers, fungi, or combinations thereof in a vector composition. In some cases, a pure vector can be endotoxin low or endotoxin free. Purity can also be measured by double-stranded primer-walking sequencing. Plasmid identity can be a source of determining purity of a vector. A GMP vector of the invention can be from 10% to 99% more pure than a non-GMP vector. A GMP vector can be from 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% more pure than a non-GMP vector as measured by the presence of bioburden, endotoxin, sequencing, or combinations thereof.

[0201] In some cases, a terminator sequence at the end of the first gene program is used. A terminator sequence can ensure that a transcript is terminating prior to initiating a second gene program. For example, an expression vectors may contain sequences necessary for the

termination of transcription and for stabilizing an mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions can contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA. Cells comprising the expression vector are grown under conditions that provide for expression of the desired polypeptide, either *in vivo* or *in vitro*.

[0202] In some cases, a spacer sequence can be used at the end of a first polypeptide encoded by a polynucleotide in a vector. In other cases, a spacer sequence can be used at the end of a second gene in a vector. A spacer sequence can also be used following a first gene and a second gene in a vector.

[0203] These vectors can be used to express a polypeptide encoded by a gene, or portion of a gene of interest. A gene or portion of a gene can be inserted by using any method, viral or non-viral. For example, a method can be a non-viral based technique.

Additional Features Encoded by Constructs

[0204] The polynucleotides disclosed herein can encode one or more proteins in addition to or alongside the polynucleotide constructs described above. For example, in some embodiments the polypeptide constructs can be linked to a chimeric antigen receptor (CAR), a T-cell receptor (TCR) and/or a cytokine.

Chimeric Receptors

[0205] Some embodiments described herein include a polynucleotide which encodes a chimeric receptor expressed on the surface of the cell. In some instances, the chimeric receptor comprises an antigen binding region that enables recognition and binding to an antigen, for instance, a tumor antigen such as a tumor-associated antigen or a tumor-specific antigen. In some instances, the antigen binding region comprises an antibody or binding fragment, for example, an Fab, an Fab', an F(ab')₂, an F(ab')₃, an scFv, an sc(Fv)₂, a dsFv, a diabody, a minibody, and a nanobody or binding fragments thereof. In some cases, the antigen binding region comprises an scFv. In some cases, the chimeric receptor comprises an scFv (*e.g.*, a chimeric antigen receptor (CAR)). In some instances, the chimeric antigen receptor comprises a pattern-recognition receptor. In other cases, the chimeric receptor comprises an engineered T-cell receptor (TCR).

Chimeric Antigen Receptors (CARs)

[0206] In some embodiments, a cell expressing a polypeptide construct described herein also expresses one or more chimeric antigen receptors (CARs).

[0207] A chimeric antigen receptor (CAR) as described herein, is an engineered receptor which grafts an exogenous specificity onto an immune effector cell. In some instances, a CAR comprises an extracellular domain (ectodomain) that comprises an antigen binding domain, a stalk region, a transmembrane domain and an intracellular (endodomain) domain. In some instances, the intracellular domain further comprises one or more intracellular signaling domains. In some instances, a CAR described herein comprises an antigen binding domain, a stalk region, a transmembrane domain, one or more costimulatory domains, and a signaling domain for T-cell activation.

[0208] In embodiments, the CAR of the present disclosure comprises a target-specific binding element otherwise referred to as an antigen-binding moiety. In embodiments, the CAR of the present disclosure is engineered to target a tumor antigen of interest by way of engineering a desired antigen-binding moiety that specifically binds to a predetermined antigen on a tumor cell. In the context of the present disclosure, "tumor antigen" or "hyperproliferative disorder antigen" or "antigen associated with a hyperproliferative disorder," refers to antigens that are common to specific hyperproliferative disorders such as cancer.

[0209] An antigen binding domain can comprise complementary determining regions of a monoclonal antibody, variable regions of a monoclonal antibody, and/or antigen binding fragments thereof. A complementarity determining region (CDR) is a short amino acid sequence found in the variable domains of antigen receptor (*e.g.*, immunoglobulin and T-cell receptor) proteins that assumes a structure that complements the structure of an antigen and therefore provides the receptor with its specificity for that particular antigen. Each polypeptide chain of an antigen receptor can contain three CDRs (CDR1, CDR2, and CDR3). In some instances, an antigen binding domain comprises F(ab')₂, Fab', Fab, Fv, or scFv. In some cases, an antigen binding domain is a scFv. In some cases, an antigen binding domain is a Fab. In some cases, an antigen binding domain is a Fab'. In some cases, an antigen binding domain is F(ab')₂. In some cases, an antigen binding domain is a Fv.

[0210] In some embodiments, a CAR described herein comprises an antigen binding domain that binds to an epitope on CD19, CD20, CD33, CD44, BCMA, CD123, EGFRvIII, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72 or VEGF-R2. In some embodiments, a CAR described herein comprises

an antigen binding domain that binds to an epitope on CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2. In some embodiments, a CAR described herein comprises an antigen binding domain that binds to an epitope on CD19 or CD33. In some instances, a CAR described herein comprises an antigen binding domain that binds to an epitope on CD19. In some cases, a CAR described herein comprises an antigen binding domain that binds to an epitope on CD33. In further embodiments, a CAR or a chimeric receptor or antigen binding polypeptide described herein comprises an autoantigen or an antigen binding region that binds to an epitope on HLA-A2, myelin oligodendrocyte glycoprotein (MOG), factor VIII (FVIII), MAdCAM1, SDF1, or collagen type II.

[0211] In some embodiments, the polynucleotides, polypeptides and methods described herein can be used for the treatment of a hyperproliferative disease, such as a cancer, an autoimmune disease or for the treatment of an infection, such as a viral, bacterial or parasitic infection. In some aspects, the antigen is an antigen that is elevated in cancer cells, in autoimmune cells or in cells that are infected by a virus, bacteria or parasite. Pathogens that may be targeted include, without limitation, Plasmodium, trypanosome, Aspergillus, Candida, Hepatitis A, Hepatitis B, Hepatitis C, HSV, HPV, RSV, EBV, CMV, JC virus, BK virus, or Ebola pathogens.

Autoimmune diseases can include graft-versus-host disease, rheumatoid arthritis, lupus, celiac disease, Crohn's disease, Sjogren Syndrome, polymyalgia rheumatic, multiple sclerosis, neuromyelitis optica, ankylosing spondylitis, Type 1 diabetes, alopecia areata, vasculitis, temporal arteritis, bullous pemphigoid, psoriasis, pemphigus vulgaris, or autoimmune uveitis.

[0212] The pathogen recognized by a CAR may be essentially any kind of pathogen, but in some embodiments the pathogen is a fungus, bacteria, or virus. Exemplary viral pathogens include those of the families of Adenoviridae, Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Respiratory Syncytial Virus (RSV), JC virus, BK virus, HPV, HSV, HHV family of viruses, Hepatitis family of viruses, *Picornaviridae*, *Herpesviridae*, *Hepadnaviridae*, *Flaviviridae*, *Retroviridae*, *Orthomyxoviridae*, *Paramyxoviridae*, *Papovaviridae*, *Polyomavirus*, *Rhabdoviridae*, and *Togaviridae*. Exemplary pathogenic viruses cause smallpox, influenza, mumps, measles, chickenpox, ebola, and rubella. Exemplary pathogenic fungi include *Candida*, *Aspergillus*, *Cryptococcus*, *Histoplasma*, *Pneumocystis*, and *Stachybotrys*. Exemplary pathogenic bacteria include *Streptococcus*, *Pseudomonas*, *Shigella*, *Campylobacter*, *Staphylococcus*, *Helicobacter*, *E. coli*, *Rickettsia*, *Bacillus*, *Bordetella*, *Chlamydia*, *Spirochetes*,

and *Salmonella*. In some embodiments the pathogen receptor Dectin-1 may be used to generate a CAR that recognizes the carbohydrate structure on the cell wall of fungi such as *Aspergillus*. In another embodiment, CARs can be made based on an antibody recognizing viral determinants (*e.g.*, the glycoproteins from CMV and Ebola) to interrupt viral infections and pathology.

[0213] In some embodiments, a “stalk” region, or a “spacer” or “hinge” region, is used to link the antigen-binding domain to the transmembrane domain. In some instances, a “stalk domain” or “stalk region” comprise any oligonucleotide- or polypeptide that functions to link the transmembrane domain to, either the extracellular domain or, the cytoplasmic domain in the polypeptide chain. In some embodiments, it is flexible enough to allow the antigen-binding domain to orient in different directions to facilitate antigen recognition. In some instances, the stalk region comprises the hinge region from IgG1. In alternative instances, the stalk region comprises the CH2CH3 region of immunoglobulin and optionally portions of CD3. In some cases, the stalk region comprises a CD8 α hinge region, an IgG4-Fc 12 amino acid hinge region (ESKYGPPCPPCP (SEQ ID NO: 225)) or IgG4 hinge regions as described in WO/2016/073755.

[0214] The transmembrane domain can be derived from either a natural or a synthetic source. Where the source is natural, the domain can be derived from any membrane-bound or transmembrane protein. Suitable transmembrane domains can include the transmembrane region(s) of alpha, beta or zeta chain of the T-cell receptor; or a transmembrane region from CD28, CD3 epsilon, CD3 ζ , CD45, CD4, CD5, CD8 α , CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 or CD154. Alternatively the transmembrane domain can be synthetic, and can comprise hydrophobic residues such as leucine and valine. In some embodiments, a triplet of phenylalanine, tryptophan and valine is found at one or both termini of a synthetic transmembrane domain. Optionally, a short oligonucleotide or polypeptide linker, in some embodiments, between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic signaling domain of a CAR. In some embodiments, the linker is a glycine-serine linker. In some embodiments, the transmembrane domain comprises a CD8 α transmembrane domain or a CD3 ζ transmembrane domain. In some embodiments, the transmembrane domain comprises a CD8 α transmembrane domain. In other embodiments, the transmembrane domain comprises a CD3 ζ transmembrane domain. In still other embodiments, the transmembrane domain comprises a transmembrane dimerization domain.

[0215] The intracellular domain can comprise one or more costimulatory domains. Exemplary costimulatory domains include, but are not limited to, CD8, CD27, CD28, 4-1BB (CD137),

ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof. In some instances, a CAR described herein comprises one or more, or two or more of costimulatory domains selected from CD8, CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof. In some instances, a CAR described herein comprises one or more, or two or more of costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, OX40 (CD134) or fragment or combination thereof. In some instances, a CAR described herein comprises one or more, or two or more of costimulatory domains selected from CD8, CD28, 4-1BB (CD137), or fragment or combination thereof. In some instances, a CAR described herein comprises one or more, or two or more of costimulatory domains selected from CD28, 4-1BB (CD137), or fragment or combination thereof. In some instances, a CAR described herein comprises costimulatory domains CD28 and 4-1BB (CD137) or their respective fragments thereof. In some instances, a CAR described herein comprises costimulatory domains CD28 and OX40 (CD134) or their respective fragments thereof. In some instances, a CAR described herein comprises costimulatory domains CD8 and CD28 or their respective fragments thereof. In some instances, a CAR described herein comprises costimulatory domains CD28 or a fragment thereof. In some instances, a CAR described herein comprises costimulatory domains 4-1BB (CD137) or a fragment thereof. In some instances, a CAR described herein comprises costimulatory domains OX40 (CD134) or a fragment thereof. In some instances, a CAR described herein comprises costimulatory domains CD8 or a fragment thereof.

[0216] The intracellular signaling domain, also known as cytoplasmic domain, of the CAR of the present disclosure, is responsible for activation of at least one of the normal effector functions of the immune cell in which the CAR has been placed. The term "effector function" refers to a specialized function of a cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines. Thus the term "intracellular signaling domain" refers to the portion of a protein which transduces the effector function signal and directs the cell to perform a specialized function. While usually the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such truncated portion may be used in place of the intact chain as long as it transduces the effector function signal. The term intracellular signaling domain is thus meant to include any truncated portion of the intracellular signaling domain sufficient to transduce the effector function signal. In some embodiments, the intracellular domain further comprises a signaling domain for T-cell activation. In some instances, the signaling domain for T-cell activation comprises a domain derived from

TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b or CD66d. In some cases, the signaling domain for T-cell activation comprises a domain derived from CD3 ζ .

[0217] The term “functional portion,” when used in reference to a CAR, refers to any part or fragment of the CAR of the present disclosure, which part or fragment retains the biological activity of the CAR of which it is a part (the parent CAR). In reference to a nucleic acid sequence encoding the parent CAR, a nucleic acid sequence encoding a functional portion of the CAR can encode a protein comprising, for example, about 10%, 25%, 30%, 50%, 68%, 80%, 90%, 95%, or more, of the parent CAR.

[0218] The term “functional variant,” as used herein, refers to a polypeptide, or a protein having substantial or significant sequence identity or similarity to the reference polypeptide, and retains the biological activity of the reference polypeptide of which it is a variant. Functional variants encompass, for example, those variants of the CAR described herein (the parent CAR) that retain the ability to recognize target cells to a similar extent, the same extent, or to a higher extent, as the parent CAR. In reference to a nucleic acid sequence encoding the parent CAR, a nucleic acid sequence encoding a functional variant of the CAR can be for example, about 10% identical, about 25% identical, about 30% identical, about 50% identical, about 65% identical, about 80% identical, about 90% identical, about 95% identical, or about 99% identical to the nucleic acid sequence encoding the parent CAR.

[0219] The polynucleotide constructs disclosed herein can be co-expressed in an engineered cell with a CAR. In some embodiments, a polypeptide construct and CAR can be encoded by a single transcript. An advantage of encoding a polypeptide construct comprising a truncated variant and a CAR in the same transcript is that an engineered cell manufacturing the CAR protein is also likely to have also manufactured the polypeptide construct. Accordingly, where intervention is required during immunotherapy to diminish CAR expression (*e.g.*, to mitigate side effects of therapy), an engineered cell co-expressing the polypeptide constructs with the CAR can be primed to respond in a relatively short time frame to the administration of exogenous antibodies that target the cell tags conferred by the truncated variants disclosed herein.

CD19-Specific CARs

[0220] CD19 is a cell surface glycoprotein of the immunoglobulin superfamily. In some instances, CD19 has been detected in solid tumors such as pancreatic cancer, liver cancer, and prostate cancer.

[0221] In some embodiments, the antigen binding moiety of a CAR described herein, is specific to CD19. A CD19-specific CAR, when expressed on the cell surface, may redirect the specificity of T cells to human CD19. In embodiments, the antigen binding domain comprises a single chain antibody fragment (scFv) comprising a variable domain light chain (VL) and variable domain heavy chain (VH) of a target antigen specific monoclonal anti-CD19 antibody joined by a flexible linker, such as a glycine-serine linker or a Whitlow linker. In embodiments, the scFv are SJ25C1 and/or FMC63. In embodiments, the scFv is humanized. In some embodiments, the antigen binding moiety may comprise VH and VL that are directionally linked, for example, from N to C terminus, VH-linker-VL or VL-linker-VH.

[0222] In some embodiments, described herein include a CD19-specific CAR, in which the antigen binding domain comprises a scFv that binds CD19. In some instances, the antigen binding domain recognizes an epitope on CD19.

[0223] In some embodiments, the antigen binding domain recognizes an epitope on CD19 that is also recognized by JCAR014, JCAR015, JCAR017, or 19-28z CAR (Juno Therapeutics). In some embodiments, described herein include a CD19-specific CAR-T cell, in which the antigen binding domain recognizes an epitope on CD19 that is also recognized by JCAR014, JCAR015, JCAR017, or 19-28z CAR (Juno Therapeutics). In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3ζ.

[0224] In some embodiments, described herein include a CD19-specific CAR-T cell comprises a scFv antigen binding domain, and the antigen binding domain recognizes an epitope on CD19 that is also recognized by JCAR014, JCAR015, JCAR017, or 19-28z CAR (Juno Therapeutics). In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3ζ.

[0225] In some embodiments, a CD19-specific CAR-T cell described herein comprises an anti-CD19 antibody described in US20160152723.

[0226] In some embodiments, the antigen binding domain recognizes an epitope on CD19 that is also recognized by KTE-C19 (Kite Pharma, Inc.). In some embodiments, described herein include a CD19-specific CAR-T cell, in which the antigen binding domain recognizes an epitope

on CD19 that is also recognized by KTE-C19. In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3ζ.

[0227] In some embodiments, described herein include a CD19-specific CAR-T cell comprises a scFv antigen binding domain, and the antigen binding domain recognizes an epitope on CD19 that is also recognized by KTE-C19. In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3ζ.

[0228] In some embodiments, a CD19-specific CAR-T cell described herein comprises an anti-CD19 antibody described in WO2015187528 or fragment or derivative thereof.

[0229] In some embodiments, the antigen binding domain recognizes an epitope on CD19 that is also recognized by CTL019 (Novartis). In some embodiments, described herein include a CD19-specific CAR-T cell, in which the antigen binding domain recognizes an epitope on CD19 that is also recognized by CTL019. In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3ζ.

[0230] In some embodiments, described herein include a CD19-specific CAR-T cell comprises a scFv antigen binding domain, and the antigen binding domain recognizes an epitope on CD19 that is also recognized by CTL019. In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3ζ. In some embodiments, the antigen binding domain recognizes an epitope on CD19 that is also recognized by UCART19 (Cellestis). In some embodiments, described herein include a CD19-specific CAR-T cell, in which the antigen binding domain recognizes an epitope on CD19 that is also recognized by UCART19. In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha

transmembrane domain or a CD3 ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3 ζ .

[0231] In some embodiments, described herein include a CD19-specific CAR-T cell comprises a scFv antigen binding domain, and the antigen binding domain recognizes an epitope on CD19 that is also recognized by UCART19. In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3 ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3 ζ .

[0232] In some embodiments, the antigen binding domain recognizes an epitope on CD19 that is also recognized by BPX-401 (Bellicum). In some embodiments, described herein include a CD19-specific CAR-T cell, in which the antigen binding domain recognizes an epitope on CD19 that is also recognized by BPX-401. In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3 ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3 ζ .

[0233] In some embodiments, described herein include a CD19-specific CAR-T cell comprises a scFv antigen binding domain, and the antigen binding domain recognizes an epitope on CD19 that is also recognized by BPX-401. In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3 ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3 ζ .

[0234] In some cases, the antigen binding domain recognizes an epitope on CD19 that is also recognized by blinatumomab (Amgen), coltuximabravtansine (ImmunoGen Inc./Sanofi-aventis), MOR208 (Morphosys AG/Xencor Inc.), MEDI-551 (Medimmune), denintuzumabmafodotin (Seattle Genetics), B4 (or DI-B4) (Merck Serono), taplitumomabpaptox (National Cancer Institute), XmAb 5871 (Amgen/Xencor, Inc.), MDX-1342 (Medarex) or AFM11 (Affimed). In some instances, the CD19-specific CAR further comprises a transmembrane domain selected from a CD8alpha transmembrane domain or a CD3 ζ transmembrane domain; one or more

costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3 ζ .

[0235] Some embodiments described herein include a CD19-specific CAR-T cell, in which the antigen binding domain comprises a F(ab')₂, Fab', Fab, Fv, or scFv. In some instances, the antigen binding domain recognizes an epitope on CD19. In some cases, the antigen binding domain recognizes an epitope on CD19 that is also recognized by blinatumomab (Amgen), coltuximabravtansine (ImmunoGen Inc./Sanofi-aventis), MOR208 (Morphosys AG/Xencor Inc.), MEDI-551 (Medimmune), denintuzumabmafodotin (Seattle Genetics), B4 (or DI-B4) (Merck Serono), taplitumomabpaptox (National Cancer Institute), XmAb 5871 (Amgen/Xencor, Inc.), MDX-1342 (Medarex) or AFM11 (Affimed). In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8 α transmembrane domain or a CD3 ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3 ζ .

[0236] In some cases, a CD19-specific CAR-T cell described herein comprise a scFv antigen binding domain, and the antigen binding domain recognizes an epitope on CD19 that is also recognized by blinatumomab (Amgen), coltuximabravtansine (ImmunoGen Inc./Sanofi-aventis), MOR208 (Morphosys AG/Xencor Inc.), MEDI-551 (Medimmune), denintuzumabmafodotin (Seattle Genetics), B4 (or DI-B4) (Merck Serono), taplitumomabpaptox (National Cancer Institute), XmAb 5871 (Amgen/Xencor, Inc.), MDX-1342 (Medarex) or AFM11 (Affimed). In some instances, the CD19-specific CAR-T cell further comprises a transmembrane domain selected from a CD8 α transmembrane domain or a CD3 ζ transmembrane domain; one or more costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134) or fragment or combination thereof; and a signaling domain from CD3 ζ .

[0237] In an embodiment, a polynucleotide encoding a CAR comprises a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:169 (encoding CD19-CD3 ζ CAR), SEQ ID NO: 171 (encoding CD19-CD137-CD3 ζ CAR), SEQ ID NO: 173 (encoding CD19-CD28-CD3 ζ CAR), and SEQ ID NO:175 (encoding CD19-CD28-CD ζ CAR further comprising an IgG4 Fc spacer). In an embodiment, an amino acid sequence comprising a CAR has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:170 (CD19-CD3 ζ CAR), SEQ ID NO: 172 (CD19-

CD137-CD3 ζ CAR), SEQ ID NO: 174 (CD19-CD28-CD3 ζ CAR), and SEQ ID NO:176 (CD19-CD28-CD3 ζ CAR further comprising an IgG4 Fc spacer).

[0238] In some embodiments, a polynucleotide disclosed herein can comprise a codon-optimized cDNA sequence encoding an anti-CD19 CAR and a cleavable T2A linker connecting to a cell surface polypeptide (*e.g.* HER1t). For example a cytotoxic T lymphocyte can be engineered to express a CD19-specific chimeric antigen receptor (CAR) that signals via a cytoplasmic costimulatory (CD28) domain fused to the cytoplasmic CD3- ζ domain. This polypeptide can further incorporate a C-terminal 2A cleavable linker followed by for example an extracellular cell tag comprising, in some embodiments, truncated human HER1 (HER1t), truncated CD20 (CD20t), truncated CD52 (CD52t), or truncated LNGFR (LNGFRt). In other embodiments, a polypeptide can comprise a polypeptide construct comprising a truncated variant preceding a CD19-specific CAR (*e.g.* via a P2A cleavable linker).

[0239] The present disclosure provides for polynucleotides and polypeptides encoding a CAR and any polypeptide construct described herein. In an embodiment, a polypeptide construct incorporating an anti-CD19 CAR, cleavable T2A linker and cell surface polypeptide is encoded by a polynucleotide comprising a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to a nucleotide sequence selected from the list consisting of SEQ ID NO:181 (CD19-CD28-CD3 ζ CAR.P2A.Ig Kappa signal peptide.HER1t1 from SEQ ID NO: 56) and SEQ ID NO:185 (CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t7 from SEQ ID NO:68).

[0240] In an embodiment, a polypeptide construct incorporating an anti-CD19 CAR, cleavable T2A linker and cell surface polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from the list consisting of SEQ ID NO:179 (CD19-CD137-CD3 ζ CAR.T2A.Ig Kappa signal peptide.HER1t from SEQ ID NO:55), SEQ ID NO:180 (CD19-CD137-CD3 ζ CAR.T2A.Ig Kappa signal peptide.HER1t from SEQ ID NO:55), SEQ ID NO:182 (CD19-CD28-CD3 ζ CAR.P2A.Ig Kappa signal peptide.HER1t1 from SEQ ID NO: 57), SEQ ID NO:183 (Ig Kappa signal peptide.HER1t1.P2A.CD8 α signal peptide.CD19-CD28-CD3 ζ CAR, where the HER1t1 is from SEQ ID NO:57), SEQ ID NO:184 (CD19-CD28-CD3 ζ CAR.Furin-T2A.Ig Kappa signal peptide.HER1t1 from SEQ ID NO:57), SEQ ID NO:186 (CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t7 from SEQ ID NO:69), SEQ ID NO:187 (CD19-CD28-CD3 ζ CAR.Furin-T2A.Ig Kappa signal peptide.HER1t8 from SEQ ID NO:73), SEQ ID NO:188 (CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t8 from SEQ ID NO:73), SEQ ID NO:189 (CD19-CD28-CD3 ζ CAR.Furin-T2A.Ig Kappa signal

peptide.HER1t9 from SEQ ID NO:77), SEQ ID NO:190 (CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t9 from SEQ ID NO:77), SEQ ID NO:191 (CD19-CD28-CD3 ζ CAR.Furin-T2A.Ig Kappa signal peptide.HER1t10 from SEQ ID NO:81), SEQ ID NO:192 (CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t10 from SEQ ID NO:81), SEQ ID NO:194 (CD19-CD28-CD3 ζ CAR.P2A.CD20), SEQ ID NO:195 (CD19-CD28-CD3 ζ CAR.P2A.CD20t1 from SEQ ID NO:109), SEQ ID NO:196 (CD19-CD28-CD3 ζ CAR.P2A.CD20t4 from SEQ ID NO:115), SEQ ID NO:197 (CD52t3.P2A.CD8 α signal peptide.CD19-CD28-CD3 ζ CAR, where CD52t3 is from SEQ ID NO:149), and SEQ ID NO:198 (Ig Kappa signal peptide.LNGFRt4.P2A.CD8 α signal peptide.CD19-CD28-CD3 ζ CAR, where LNGFRt4 is from SEQ ID NO:165).

Engineered T-cell Receptor (TCR)

[0241] In some embodiments, the chimeric receptor encoded by a polynucleotide described herein, comprises an engineered T-cell receptor. The T cell receptor (TCR) is composed of two chains ($\alpha\beta$ or $\gamma\delta$) that pair on the surface of the T cell to form a heterodimeric receptor. In some instances, the $\alpha\beta$ TCR is expressed on most T cells in the body and is known to be involved in the recognition of specific MHC-restricted antigens. Each α and β chain are composed of two domains: a constant domain (C) which anchors the protein to the cell membrane and is associated with invariant subunits of the CD3 signaling apparatus; and a variable domain (V) that confers antigen recognition through six loops, referred to as complementarity determining regions (CDRs). In some instances, each of the V domains comprises three CDRs; *e.g.*, CDR1, CDR2 and CDR3 with CDR3 as the hypervariable region. These CDRs interact with a complex formed between an antigenic peptide bound to a protein encoded by the major histocompatibility complex (pMHC) (*e.g.*, HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, or HLA-DRB1 complex). In some instances, the constant domain further comprises a joining region that connects the constant domain to the variable domain. In some cases, the beta chain further comprises a short diversity region which makes up part of the joining region.

[0242] In some cases, such TCR are reactive to specific tumor antigen, *e.g.* NY-ESO, Mage A3, Titin. In other cases, such TCR are reactive to specific neoantigens expressed within a patient's tumor (*i.e.* patient-specific, somatic, non-synonymous mutations expressed by tumors). In some cases, engineered TCRs can be affinity-enhanced.

[0243] In some embodiments, a TCR is described using the International Immunogenetics (IMGT) TCR nomenclature, and links to the IMGT public database of TCR sequences. For example, there can be several types of alpha chain variable ($V\alpha$) regions and several types of beta chain variable ($V\beta$) regions distinguished by their framework, CDR1, CDR2, and CDR3 sequences. As such, a $V\alpha$ type can be referred to in IMGT nomenclature by a unique TRAV number. For example, “TRAV21” defines a TCR $V\alpha$ region having unique framework and CDR1 and CDR2 sequences, and a CDR3 sequence which is partly defined by an amino acid sequence which is preserved from TCR to TCR but which also includes an amino acid sequence which varies from TCR to TCR. Similarly, “TRBV5-1” defines a TCR $V\beta$ region having unique framework and CDR1 and CDR2 sequences, but with only a partly defined CDR3 sequence.

[0244] In some cases, the beta chain diversity region is referred to in IMGT nomenclature by the abbreviation TRBD.

[0245] In some instances, the unique sequences defined by the IMGT nomenclature are widely known and accessible to those working in the TCR field. For example, they can be found in the IMGT public database and in “T cell Receptor Factsbook”, (2001) LeFranc and LeFranc, Academic Press, ISBN 0-12-441352-8.

[0246] In some embodiments, an $\alpha\beta$ heterodimeric TCR is, for example, transfected as full length chains having both cytoplasmic and transmembrane domains. In some cases, the TCRs contain an introduced disulfide bond between residues of the respective constant domains, as described, for example, in WO 2006/000830.

[0247] In some instances, TCRs described herein are in single chain format, for example see WO 2004/033685. Single chain formats include $\alpha\beta$ TCR polypeptides of the $V\alpha$ -L- $V\beta$, $V\beta$ -L- $V\alpha$, $V\alpha$ -C α -L- $V\beta$, $V\alpha$ -L- $V\beta$ -C β , $V\alpha$ -C α -L- $V\beta$ -C β types, wherein $V\alpha$ and $V\beta$ are TCR α and β variable regions respectively, C α and C β are TCR α and β constant regions respectively, and L is a linker sequence. In certain embodiments single chain TCRs of the present disclosure may have an introduced disulfide bond between residues of the respective constant domains, as described in WO 2004/033685.

[0248] The TCR described herein may be associated with a detectable label, a therapeutic agent or a PK modifying moiety.

[0249] Exemplary detectable labels for diagnostic purposes include, but are not limited to, fluorescent labels, radiolabels, enzymes, nucleic acid probes and contrast reagents.

[0250] The present disclosure provides for polynucleotides and polypeptides encoding a TCR and any polypeptide construct described herein. In some embodiments, a polynucleotide

disclosed herein can comprise a codon-optimized cDNA sequence encoding a TCR and a cleavable T2A linker connecting to a cell surface polypeptide (*e.g.* HER1t). For example a cytotoxic T lymphocyte can be engineered to express a TCR polypeptide that further incorporates a C-terminal 2A cleavable linker followed by for example an extracellular cell tag comprising, in some embodiments, truncated human HER1 (HER1t), truncated CD20 (CD20t), truncated CD52 (CD52t), or truncated LNGFR (LNGFRt). In other embodiments, a polypeptide can comprise a polypeptide construct comprising a truncated variant preceding a TCR (*e.g.* linked via a P2A cleavable linker).

Cytokines

[0251] Provided herein are polynucleotides encoding polypeptide cell tags and a cytokine, or variant or derivative thereof, and methods and systems incorporating the same. Cytokine is a category of small proteins between about 5-20 kDa that are involved in cell signaling. In some embodiments, the cytokines can be membrane bound or secreted. In other embodiments, the cytokines can be intracellular. In some instances, cytokines include chemokines, interferons, interleukins, colony-stimulating factors or tumor necrosis factors. In some embodiments, chemokines play a role as a chemoattractant to guide the migration of cells, and is classified into four subfamilies: CXC, CC, CX3C, and XC. Non-limiting exemplary chemokines include chemokines from the CC subfamily: CCL1, CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9 (or CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, and CCL28; the CXC subfamily: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, and CXCL17; the XC subfamily: XCL1 and XCL2; and the CX3C subfamily CX3CL1.

[0252] Interferons (IFNs) comprise interferon type I (*e.g.* IFN- α , IFN- β , IFN- ϵ , IFN- κ , and IFN- ω), interferon type II (*e.g.* IFN- γ), and interferon type III. In some embodiments, IFN- α is further classified into about 13 subtypes including IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, and IFNA21.

[0253] Interleukins are expressed by leukocytes or white blood cells and they promote the development and differentiation of T and B lymphocytes and hematopoietic cells. Exemplary interleukines include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-35, and IL-36.

[0254] In some embodiments, an interleukin comprises mbIL-15. In some embodiments, a mbIL-15 is a membrane-bound chimeric IL-15 which can be co-expressed with a modified effector cell described herein. In some embodiments, the mbIL-15 comprises a full-length IL-15 (*e.g.*, a native IL-15 polypeptide) or fragment or variant thereof, fused in frame with a full length IL-15R α , functional fragment or variant thereof. In some cases, the IL-15 is indirectly linked to the IL-15R α through a linker. In some instances, the mbIL-15 is as described in Hurton et al., “Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells,” PNAS 2016. In an embodiment, mbIL-15 is encoded by a polynucleotide comprising a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the nucleotide sequence of SEQ ID NO:177. In an embodiment, mbIL-15 has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:178.

[0255] In another aspect, the interleukin can comprise IL-12. In some embodiments, the IL-12 is a single chain IL-12 (scIL-12), protease sensitive IL-12, destabilized IL-12, membrane bound IL-12, intercalated IL-12. In some instances, the IL-12 variants are as described in WO2015/095249, WO2016/048903, WO2017/062953, all of which is incorporated by reference in their entireties.

[0256] Tumor necrosis factors (TNFs) are a group of cytokines that modulate apoptosis. In some instances, there are about 19 members within the TNF family, including, not limited to, TNF α , lymphotoxin-alpha (LT-alpha), lymphotoxin-beta (LT-beta), T cell antigen gp39 (CD40L), CD27L, CD30L, FASL, 4-1BBL, OX40L, and TNF-related apoptosis inducing ligand (TRAIL).

[0257] Colony-stimulating factors (CSFs) are secreted glycoproteins that interact with receptor proteins on the surface of hemopoietic stem cells, which subsequently modulates cell proliferation and differentiation into specific kind of blood cells. In some instances, a CSF comprises macrophage colony-stimulating factor, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) or promegapoietin.

[0258] In some embodiments, the cytokine is a membrane-bound cytokine, which is co-expressed with a chimeric antigen receptor and/or a TCR described herein.

[0259] In some embodiments, one or more methods described herein further comprise administration of a cytokine. In some instances, the cytokine comprises a chemokine, an interferon, an interleukin, a colony-stimulating factor or a tumor necrosis factor. In some instances, one or more methods described herein further comprise administration of a cytokine

selected from a chemokine, an interferon, an interleukin, a colony-stimulating factor or a tumor necrosis factor. In some instances, one or more methods described herein further comprise administration of a cytokine selected from IL2, IL7, IL12, IL15, IL21, IFN γ or TNF- α .

[0260] In some embodiments, a polynucleotide disclosed herein can comprise a codon-optimized cDNA sequence encoding a cytokine and a cleavable T2A linker connecting to a cell surface polypeptide (*e.g.* HER1t). For example a cytotoxic T lymphocyte can be engineered to express a polypeptide comprising a cytokine and further incorporating a 2A cleavable linker followed by for example an extracellular cell tag comprising, in some embodiments, truncated human HER1 (HER1t), truncated CD20 (CD20t), truncated CD52 (CD52t), or truncated LNGFR (LNGFRt). In other embodiments, a polypeptide can comprise a polypeptide construct comprising a truncated variant preceding a cytokine (*e.g.* linked via a P2A cleavable linker).

[0261] The present disclosure provides for polynucleotides and polypeptides encoding a cytokine and any polypeptide construct described herein. In an embodiment, a polypeptide construct incorporating a cytokine, cleavable T2A linker and cell surface polypeptide is has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:193 (membrane bound IL-15.T2A.HER1t1 from SEQ ID NO:57).

IRES and Linkers

[0262] Also disclosed are constructs comprising linkers and IRES elements to facilitate the expression and functionality of the polynucleotides and polypeptides described herein.

IRES Elements

[0263] The term “internal ribosome entry site (IRES)” as used herein can be intended to mean internal ribosomal entry site. In a vector comprising an IRES sequence, a first gene can be translated by a cap-dependent, ribosome scanning, mechanism with its own 5'-UTR, whereas translation of a subsequent gene can be accomplished by direct recruitment of a ribosome to an IRES in a cap-independent manner. An IRES sequence can allow eukaryotic ribosomes to bind and begin translation without binding to a 5' capped end. An IRES sequence can allow expression of multiple genes from one transcript (Mountford and Smith 1995).

[0264] The term “CAP” or “cap” as used herein refers to a modified nucleotide, generally a 7-methyl guanosine, linked 3' to 5' (7meG-ppp-G), to the 5' end of a eukaryotic mRNA, that serves as a required element in the normal translation initiation pathway during expression of protein from that mRNA.

[0265] In certain cases, an IRES region can be derived from a virus, such as picornavirus, encephalomyocarditis virus, hepatitis C virus IRES sequence. In other cases, an IRES sequence can be derived from an encephalomyocarditis virus. The term “EMCV” or “encephalomyocarditis virus” as used herein refers to any member isolate or strain of the encephalomyocarditis virus species of the genus of the family Picornaviridae. Examples are: EMCV-R (Rueckert) strain virus, Columbia-SK virus. In some cases, a cellular IRES element, such as eukaryotic initiation factor 4G, immunoglobulin heavy chain binding protein, c-myc proto-oncogene, vascular endothelial growth factor, fibroblast growth factor-1 IRES, or any combination or modification thereof can be used. In some cases, a cellular IRES can have increased gene expression when compared to a viral IRES.

[0266] An IRES sequence of viral, cellular or a combination thereof can be utilized in a vector. An IRES can be from encephalomyocarditis (EMCV) or poliovirus (PV). In some cases, an IRES element is selected from a group consisting of Poliovirus (PV), Encephalomyelitis virus (EMCV), Foot-and-mouth disease virus (FMDV), Porcine teschovirus-1 (PTV-1), Aichivirus (AiV), Seneca Valley virus (SVV), Hepatitis C virus (HCV), Classical swine fever virus (CSFV), Human immunodeficiency virus-2 (HIV-2), Human immunodeficiency virus-1 (HIV-1), Moloney murine leukemia virus (MoMLV), Feline immunodeficiency virus (FIV), Mouse mammary tumor virus (MMTV), Human cytomegalovirus latency (pUL138), Epstein-Barr virus (EBNA-1), Herpes virus Marek’s disease (MDV RLORF9), SV40 polycistronic 19S (SV40 19S), Rhopalosiphum padi virus (RhPV), Cricket paralysis virus (CrPV), Ectropis obliqua picorna-like virus (EoPV), Plautia stali intestine virus (PSIV), Triatoma virus (TrV), Bee paralysis dicistrovirus (IAPV, KBV), Black currant reversion virus (BRV), Pelargonium flower break virus (PFBV), Hibiscus chlorotic ringspot virus (HCRSV), Crucifer-infecting tobamovirus (CrTMV), Potato leaf roll polerovirus (PLRV), Tobacco etch virus (TEV), Giardiavirus (GLV), Leishmania RNA virus-1 (LRV-1), and combinations or modifications thereof. In some cases, an IRES is selected from a group consisting of Apaf-1, XIAP, HIAP2/c-IAP1, DAP5, Bcl-2, c-myc, CAT-1, INR, Differentiation LEF-1, PDGF2, HIF-1a, VEGF, FGF2, BiP, BAG-1, CIRP, p53, SHMT1, PITSLREp58, CDK1, Rpr, hid, hsp70, grim, skl, Antennapedia, dFoxO, dInR, Adh-Adhr, HSP101, ADH, URE-2, GPR1, NCE102, YMR181a, MSN1, BOI1, FLO8, GIC1, and any combination or modification thereof.

[0267] In certain embodiments, a IRES is an EMCV IRES comprising a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5% or 100% identity with the nucleotide sequence of SEQ ID NO:49.

[0268] When an IRES element is included between two open reading frames (ORFs), initiation of translation can occur by a canonical 5'-m7GpppN cap-dependent mechanism in a first ORF and a cap-independent mechanism in a second ORF downstream of the IRES element.

[0269] In some cases, genes can be linked by an internal ribosomal entry site (IRES). An IRES can allow simultaneous expression of multiple genes. For example, an IRES sequence can permit production of multiple proteins from a single mRNA transcript. A ribosomes can bind to an IRES in a 5'-cap independent manner and initiate translation.

[0270] In some cases, an IRES sequence can be or can be about 500 base pairs. An IRES sequence can be from 300 base pairs to 1000 base pairs. For example, an IRES can be 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 base pairs long.

[0271] In some cases, expression of a downstream gene within a vector comprising an IRES sequence can be reduced. For example, a gene following an IRES sequence can have reduced expression over a gene preceding an IRES sequence. Reduced expression can be from 1% to 99% reduction over a preceding gene.

Linkers

[0272] In some embodiments, a polynucleotide linker can be utilized in a polynucleotide described herein. A polynucleotide linker can be a double-stranded segment of DNA containing desired restriction sites that may be added to create end structures that are compatible with a vector comprising a polynucleotide described herein. In some cases, a polynucleotide linker can be useful for modifying vectors comprising polynucleotides described herein. For example, a vector modification comprising a polynucleotide linker can be a change in a multiple cloning site, or the addition of a poly-histidine tail. Polynucleotide linkers can also be used to adapt the ends of blunt insert DNA for cloning into a vector cleaved with a restriction enzyme with cohesive end termini. The use of polynucleotide linkers can be more efficient than a blunt ligation into a vector and can provide a method of releasing an insert from a vector in downstream applications. In some cases an insert can be a polynucleotide sequence encoding polypeptides useful for therapeutic applications.

[0273] A polynucleotide linker can be an oligomer. A polynucleotide linker can be a DNA double strand, single strand, or a combination thereof. In some cases, a linker can be RNA. A polynucleotide linker can be ligated into a vector comprising a polynucleotide described herein by a T4 ligase in some cases. To facilitate a ligation an excess of polynucleotide linkers can be added to a composition comprising an insert and a vector. In some cases, an insert and vector are

pre-treated before a linker is introduced. For example, pre-treatment with a methylase can prevent unwanted cleavage of insert DNA.

[0274] In embodiments, a polynucleotide linker comprises a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5% or 100% identity with the nucleotide sequence of porcine teschovirus-1 2A region (P2A) (SEQ ID NO:41); equine rhinitis A virus 2A region (E2A) (SEQ ID NO:43); Thosea asigna virus 2A region (T2A) (SEQ ID NO:45); or foot-and-mouth disease virus 2A region (F2A) (SEQ ID NO:47).

[0275] In certain embodiments, two or more polypeptides encoded by a polynucleotide described herein can be separated by an intervening sequence encoding an intervening linker polypeptide. Herein the term “intervening linker polypeptide” referring to an amino acid sequence separating two or more polypeptides encoded by a polynucleotide is distinguished from the term “peptide linker” which refers to the sequence of amino acids which is optionally included in a polypeptide construct disclosed herein to connect the transmembrane domain to the cell surface polypeptide (*e.g.* comprising a truncated variant of a natural polypeptide). In certain cases, the intervening linker polypeptide is a cleavage-susceptible intervening linker polypeptide. In some embodiments, polypeptides of interest are expressed as fusion proteins linked by a cleavage-susceptible intervening linker polypeptide. In certain embodiments, cleavage-susceptible intervening linker polypeptide(s) can be any one or more of: F/T2A, T2A, p2A, 2A, GSG-p2A, GSG linker (SEQ ID NO: 16), and furin link variants.

[0276] In embodiments, an intervening linker polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5% or 100% identity with the amino acid sequence of porcine teschovirus-1 2A region (P2A) (SEQ ID NO:41); equine rhinitis A virus 2A region (E2A) (SEQ ID NO:44); Thosea asigna virus 2A region (T2A) (SEQ ID NO:46); or foot-and-mouth disease virus 2A region (F2A) (SEQ ID NO:48).

[0277] In some cases, a viral 2A sequence can be used. 2A elements can be shorter than IRES, having from 5 to 100 base pairs. In some cases, a 2A sequence can have 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 100 nucleotides in length. 2A linked genes can be expressed in one single open reading frame and “self-cleavage” can occur co-translationally between the last two amino acids, GP, at the C-terminus of the 2A polypeptide, giving rise to equal amounts of co-expressed proteins.

[0278] A viral 2A sequence can be about 20 amino acids. In some cases, a viral 2A sequence can contain a consensus motif Asp-Val/Ile-Glu-X-Asn-Pro-Gly-Pro (SEQ ID NO: 229). A consensus motif sequence can act co-translationally. For example, formation of a normal peptide bond between a glycine and proline residue can be prevented, which can result in ribosomal skipping and cleavage of a nascent polypeptide. This effect can produce multiple genes at equimolar levels.

[0279] A 2A peptide can allow translation of multiple proteins in a single open reading frame into a polypeptide that can be subsequently cleaved into individual polypeptide through a ribosome-skipping mechanism (Funston, Kallioinen et al. 2008). In some embodiments, a 2A sequence can include: F/T2A, T2A, p2A, 2A, T2A, E2A, F2A, and BmCPV2A, BmIFV2A, and any combination thereof.

[0280] In some cases, a vector can comprise an IRES sequence and a 2A polynucleotide linker sequence. In other cases, expression of multiple genes linked with 2A peptides can be facilitated by a spacer sequence (GSG (SEQ ID NO: 16)) ahead of the 2A peptides. In some cases, constructs can combine a spacers, linkers, adaptors, promoters, or combinations thereof. For example, a construct can have a spacer (SGSG (SEQ ID NO: 18) or GSG (SEQ ID NO: 16)) and furin intervening polypeptide linker (R-A-K-R (SEQ ID NO: 230)) cleavage site with different 2A peptides. A spacer can be an I-CeuI. In some cases, a linker can be engineered. For example, a linker can be designed to comprise chemical characteristics such as hydrophobicity. In some cases, at least two linker sequences can produce the same protein. In other cases, multiple linkers can be used in a vector.

[0281] In certain cases, an intervening linker polypeptide can comprise an amino acid sequence “RAKR (SEQ ID NO: 230)”. In certain cases, a Furin intervening linker polypeptide can be encoded by a polynucleotide sequence comprising “AGAGCTAAGAGG (SEQ ID NO: 231).”

[0282] In certain cases, **an intervening linker polypeptide** can be a linker comprising a sequence disclosed in the table below:

Table 1. Linker amino acid sequences

SEQ ID No.	Linker Name	Sequence (N- to C- terminus)
230	Furinlink1	RAKR
233	Fmdv	RAKRAPVKQTLNFDLLKLAGDVESNPGP
42	p2a	ATNFSLLKQAGDVEENPGP
235	GSG-p2a	GSGATNFSLLKQAGDVEENPGP
237	fp2a	RAKRAPVKQGSGATNFSLLKQAGDVEENPGP

SEQ ID No.	Linker Name	Sequence (N- to C- terminus)
16	GSG linker	GSG
18	SGSG linker	SGSG
24	Whitlow	GSTSGSGKPGSGEGSTKG
226	Linker	SGGGSGGGGSGGGGSGGGGSGGGSLQ
227	Furin-GSG-T2A	RAKRSGEGRGSLTTCGDVEENPGP
228	Furin-SGSG-T2A	RAKRSGSGEGRGSLTTCGDVEENPGP
42	Porcine teschovirus-1 2A region (P2A)	ATNFSLLKQAGDVEENPGP
44	Equine rhinitis A virus 2A region (E2A)	QCTNYALLKLAGDVESNPGP
48	Foot-and-mouth disease virus 2A region (F2A)	VKQTLNFDLLKLAGDVESNPGP

[0283] In some embodiments, a linker can be utilized in a polynucleotide described herein. A linker can be a flexible linker, a rigid linker, an *in vivo* cleavable linker, or any combination thereof. In some cases, a linker may link functional domains together (as in flexible and rigid linkers) or releasing free functional domain *in vivo* as in *in vivo* cleavable linkers.

[0284] In some embodiments, polynucleotide linkers and intervening linker polypeptides can improve biological activity, increase expression yield, and achieve desirable pharmacokinetic profiles.

[0285] In some cases, an intervening linker polypeptide sequence described herein can include a flexible linker. Flexible linkers can be applied when a joined domain requires a certain degree of movement or interaction. Flexible linkers can be composed of small, non-polar (*e.g.*, Gly) or polar (*e.g.*, Ser or Thr) amino acids. A flexible linker can have sequences consisting primarily of stretches of Gly and Ser residues (“GS” linker). An example of a flexible linker can have the sequence of (Gly-Gly-Gly-Gly-Ser)_n (SEQ ID NO: 221; *e.g.*, SEQ ID NO: 20 or 22). By adjusting the copy number “n”, the length of this exemplary GS linker can be optimized to achieve appropriate separation of functional domains, or to maintain necessary inter-domain interactions. Besides GS linkers, other flexible linkers can be utilized for recombinant fusion proteins. In some cases, flexible linkers can also be rich in small or polar amino acids such as Gly and Ser, but can contain additional amino acids such as Thr and Ala to maintain flexibility. In other cases, polar amino acids such as Lys and Glu can be used to improve solubility.

[0286] Flexible linkers included in linker sequences described herein, can be rich in small or polar amino acids such as Gly and Ser to provide good flexibility and solubility. Flexible linkers

can be suitable choices when certain movements or interactions are desired for fusion protein domains. In addition, although flexible linkers may not have rigid structures, they can serve as a passive linker to keep a distance between functional domains. The length of a flexible linker can be adjusted to allow for proper folding or to achieve optimal biological activity of the fusion proteins.

[0287] An intervening linker polypeptide described herein can further include a rigid linker in some cases. A rigid linker can be utilized to maintain a fixed distance between domains of a polypeptide. Examples of rigid linkers can be: Alpha helix-forming linkers, Pro-rich sequence, (XP)_n, X-Pro backbone (SEQ ID NO: 239), A(EAAAK)_nA (SEQ ID NO: 240) (n = 2-5), to name a few. Rigid linkers can exhibit relatively stiff structures by adopting α -helical structures or by containing multiple Pro residues in some cases.

[0288] An intervening linker polypeptide described herein can be cleavable in some cases. In other cases an intervening linker polypeptide is not cleavable. Linkers that are not cleavable may covalently join functional domains together to act as one molecule throughout an *in vivo* process or an *ex vivo* process. An intervening linker polypeptide can also be cleavable *in vivo*. A cleavable intervening linker polypeptide can for example be introduced to release free functional domains *in vivo*. An intervening linker polypeptide can be cleaved by for example the presence of reducing reagents and proteases. For example, a reduction of a disulfide bond may be utilized to produce a cleavable intervening linker polypeptide. In the case of a disulfide intervening linker polypeptide, a cleavage event through disulfide exchange with a thiol, such as glutathione, could produce a cleavage. In other cases, an *in vivo* cleavage of a intervening linker polypeptide in a recombinant fusion protein may also be carried out by proteases that can be expressed *in vivo* under pathological conditions (*e.g.* cancer or inflammation), in specific cells or tissues, or constrained within certain cellular compartments. In some cases, a cleavable intervening linker polypeptide may allow for targeted cleavage. For example, the specificity of many proteases can offer slower cleavage of a intervening linker polypeptide in constrained compartments. A cleavable intervening linker polypeptide can also comprise hydrazone, peptides, disulfide, or thioether. For example, a hydrazone can confer serum stability. In other cases, a hydrazone can allow for cleavage in an acidic compartment. An acidic compartment can have a pH up to about 7. A linker can also include a thioether. A thioether can be nonreducible and/or can be designed for intracellular proteolytic degradation.

[0289] A linker can be an engineered linker. Methods of designing linkers can be computational. In some cases, computational methods can include graphic techniques.

Computation methods can be used to search for suitable peptides from libraries of three-dimensional peptide structures derived from databases. For example, a Brookhaven Protein Data Bank (PDB) can be used to span the distance in space between selected amino acids of a linker.

[0290] In some embodiments are polynucleotides encoding a polypeptide construct comprising a furin polypeptide and a 2A polypeptide, wherein the furin polypeptide and the 2A polypeptide are connected by an intervening linker polypeptide comprising at least three hydrophobic amino acids. In some cases, at least three hydrophobic amino acids are selected from the list consisting of glycine (Gly)(G), alanine (Ala)(A), valine (Val)(V), leucine (Leu)(L), isoleucine (Ile)(I), proline (Pro)(P), phenylalanine (Phe)(F), methionine (Met)(M), tryptophan (Trp)(W).

Expression of Polypeptide Constructs

[0291] In some embodiments, the polynucleotides and polypeptides described herein can be constitutively expressed, for example using the constitutive promoters of viral and non-viral delivery systems (see below). In other embodiments, the polypeptide constructs, polynucleotides and methods provided herein can be implemented in a gene switch system. The term “gene switch” refers to the combination of a response element associated with a promoter, and for instance, an EcR based system which, in the presence of one or more ligands, modulates the expression of a gene into which the response element and promoter are incorporated. Tightly regulated inducible gene expression systems or gene switches are useful for various applications such as gene therapy, large scale production of proteins in cells, cell based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals. Such inducible gene expression systems may include ligand inducible heterologous gene expression systems.

[0292] An early version of EcR-based gene switch used *Drosophila melanogaster* EcR (DmEcR) and *Mus musculus* RXR (MmRXR) polypeptides and showed that these receptors in the presence of steroid, ponasteroneA, transactivate reporter genes in mammalian cell lines and transgenic mice (Christopherson et al., 1992; No et al., 1996). Later, Suhr et al., 1998 showed that non-steroidal ecdysone agonist, tebufenozide, induced high level of transactivation of reporter genes in mammalian cells through *Bombyx mori* EcR (BmEcR) in the absence of exogenous heterodimer partner.

[0293] International Patent Applications No. PCT/US97/05330 (WO 97/38117) and PCT/US99/08381 (WO99/58155) disclose methods for modulating the expression of an exogenous gene in which a DNA construct comprising the exogenous gene and an ecdysone

response element is activated by a second DNA construct comprising an ecdysone receptor that, in the presence of a ligand therefor, and optionally in the presence of a receptor capable of acting as a silent partner, binds to the ecdysone response element to induce gene expression. In this example, the ecdysone receptor was isolated from *Drosophila melanogaster*. Typically, such systems require the presence of the silent partner, preferably retinoid X receptor (RXR), in order to provide optimum activation. In mammalian cells, insect ecdysone receptor (EcR) is capable of heterodimerizing with mammalian retinoid X receptor (RXR) and, thereby, be used to regulate expression of target genes or heterologous genes in a ligand dependent manner. International Patent Application No. PCT/US98/14215 (WO 99/02683) discloses that the ecdysone receptor isolated from the silk moth *Bombyx mori* is functional in mammalian systems without the need for an exogenous dimer partner.

[0294] U.S. Pat. No. 6,265,173 discloses that various members of the steroid/thyroid superfamily of receptors can combine with *Drosophila melanogaster* ultraspiracle receptor (USP) or fragments thereof comprising at least the dimerization domain of USP for use in a gene expression system. U.S. Pat. No. 5,880,333 discloses a *Drosophila melanogaster* EcR and ultraspiracle (USP) heterodimer system used in plants in which the transactivation domain and the DNA binding domain are positioned on two different hybrid proteins. In each of these cases, the transactivation domain and the DNA binding domain (either as native EcR as in International Patent Application No. PCT/US98/14215 or as modified EcR as in International Patent Application No. PCT/US97/05330) were incorporated into a single molecule and the other heterodimeric partners, either USP or RXR, were used in their native state.

[0295] International Patent Application No. PCT/US01/0905 discloses an ecdysone receptor-based inducible gene expression system in which the transactivation and DNA binding domains are separated from each other by placing them on two different proteins results in greatly reduced background activity in the absence of a ligand and significantly increased activity over background in the presence of a ligand. This two-hybrid system is a significantly improved inducible gene expression modulation system compared to the two systems disclosed in applications PCT/US97/05330 and PCT/US98/14215. The two-hybrid system is believed to exploit the ability of a pair of interacting proteins to bring the transcription activation domain into a more favorable position relative to the DNA binding domain such that when the DNA binding domain binds to the DNA binding site on the gene, the transactivation domain more effectively activates the promoter (see, for example, U.S. Pat. No. 5,283,173). The two-hybrid gene expression system comprises two gene expression cassettes; the first encoding a DNA

binding domain fused to a nuclear receptor polypeptide, and the second encoding a transactivation domain fused to a different nuclear receptor polypeptide. In the presence of ligand, it is believed that a conformational change is induced which promotes interaction of the first polypeptide with the second polypeptide thereby resulting in dimerization of the DNA binding domain and the transactivation domain. Since the DNA binding and transactivation domains reside on two different molecules, the background activity in the absence of ligand is greatly reduced.

[0296] The ecdysone receptor (EcR) is a member of the nuclear receptor superfamily and is classified into subfamily 1, group H (referred to herein as “Group H nuclear receptors”). The members of each group share 40-60% amino acid identity in the E (ligand binding) domain (Laudet et al., A Unified Nomenclature System for the Nuclear Receptor Subfamily, 1999; Cell 97: 161-163). In addition to the ecdysone receptor, other members of this nuclear receptor subfamily 1, group H include: ubiquitous receptor (UR), Orphan receptor 1 (OR-1), steroid hormone nuclear receptor 1 (NER-1), RXR interacting protein-15 (RIP-15), liver x receptor β (LXR β), steroid hormone receptor like protein (RLD-1), liver x receptor (LXR), liver x receptor α (LXR α), farnesoid x receptor (FXR), receptor interacting protein 14 (RIP-14), and farnesol receptor (HRR-1).

[0297] In some cases, an inducible promoter can be a small molecule ligand-inducible two polypeptide ecdysone receptor-based gene switch, such as Intrexon Corporation's RHEOSWITCH[®] gene switch. In some cases, a gene switch can be selected from ecdysone-based receptor components as described in, but without limitation to, any of the systems described in: PCT/US2001/009050 (WO 2001/070816); U.S. Pat. Nos. 7,091,038; 7,776,587; 7,807,417; 8,202,718; PCT/US2001/030608 (WO 2002/029075); U.S. Pat. Nos. 8,105,825; 8,168,426; PCT/1J52002/005235 (WO 2002/066613); U.S. App. No. 10/468,200 (U.S. Pub. No. 20120167239); PCT/US2002/005706 (WO 2002/066614); U.S. Pat. Nos. 7,531,326; 8,236,556; 8,598,409; PCT/U52002/005090 (WO 2002/066612); U.S. Pat. No. 8,715,959 (U.S. Pub. No. 20060100416); PCT/US2002/005234 (WO 2003/027266); U.S. Pat. Nos. 7,601,508; 7,829,676; 7,919,269; 8,030,067; PCT/U52002/005708 (WO 2002/066615); U.S. App. No. 10/468,192 (U.S. Pub. No. 20110212528); PCT/US2002/005026 (WO 2003/027289); U.S. Pat. Nos. 7,563,879; 8,021,878; 8,497,093; PCT/US2005/015089 (WO 2005/108617); U.S. Pat. No. 7,935,510; 8,076,454; PCT/U52008/011270 (WO 2009/045370); U.S. App. No. 12/241,018 (U.S. Pub. No. 20090136465); PCT/US2008/011563 (WO 2009/048560); U.S. App. No. 12/247,738 (U.S. Pub. No. 20090123441); PCT/US2009/005510 (WO 2010/042189); U.S. App.

No. 13/123,129 (U.S. Pub. No. 20110268766); PCT/US2011/029682 (WO 2011/119773); U.S. App. No. 13/636,473 (U.S. Pub. No. 20130195800); PCT/US2012/027515 (WO 2012/122025); and, U.S. Pat. No. 9,402,919 each of which is incorporated by reference in its entirety.

Modified Effector Cells

[0298] Provided are effector cells modified to express one or more polypeptide constructs capable of functioning in the effector cells as cell tags.

[0299] “T cell” or “T lymphocyte” as used herein is a type of lymphocyte that plays a central role in cell-mediated immunity. They may be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface.

[0300] In some embodiments, modified effector cells are modified immune cells that comprise T cells and/or natural killer cells. T cells or T lymphocytes are a subtype of white blood cells that are involved in cell-mediated immunity. Exemplary T cells include T helper cells, cytotoxic T cells, TH17 cells, stem memory T cells (TSCM), naïve T cells, memory T cells, effector T cells, regulatory T cells, or natural killer T cells.

[0301] T helper cells (TH cells) assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. In some instances, TH cells are known as CD4⁺ T cells due to expression of the CD4 glycoprotein on the cell surfaces. Helper T cells become activated when they are presented with peptide antigens by MHC class II molecules, which are expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response. These cells can differentiate into one of several subtypes, including TH1, TH2, TH3, TH17, Th9, or TFH, which secrete different cytokines to facilitate different types of immune responses. Signaling from the APC directs T cells into particular subtypes. In some embodiments herein, secreted cytokines can be recombinant.

[0302] Cytotoxic T cells (TC cells or CTLs) destroy virus-infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8⁺ T cells since they express the CD8 glycoprotein on their surfaces. These cells recognize their targets by binding to antigen associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, the CD8⁺ cells can be inactivated to an anergic state, which prevents autoimmune diseases.

[0303] Memory T cells are a subset of antigen-specific T cells that persist long-term after an infection has resolved. They quickly expand to large numbers of effector T cells upon re-exposure to their cognate antigen, thus providing the immune system with “memory” against past infections. Memory T cells comprise subtypes: stem memory T cells (TSCM), central memory T cells (TCM cells) and two types of effector memory T cells (TEM cells and TEMRA cells). Memory cells may be either CD4⁺ or CD8⁺. Memory T cells may express the cell surface proteins CD45RO, CD45RA and/or CCR7.

[0304] Regulatory T cells (Treg cells), formerly known as suppressor T cells, play a role in the maintenance of immunological tolerance. Their major role is to shut down T cell-mediated immunity toward the end of an immune reaction and to suppress autoreactive T cells that escaped the process of negative selection in the thymus.

[0305] Natural killer T cells (NKT cells) bridge the adaptive immune system with the innate immune system. Unlike conventional T cells that recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigen presented by a molecule called CD1d. Once activated, these cells can perform functions ascribed to both Th and Tc cells (*i.e.*, cytokine production and release of cytolytic/cell killing molecules). They are also able to recognize and eliminate some tumor cells and cells infected with herpes viruses.

[0306] Natural killer (NK) cells are a type of cytotoxic lymphocyte of the innate immune system. In some instances, NK cells provide a first line defense against viral infections and/or tumor formation. NK cells can detect MHC presented on infected or cancerous cells, triggering cytokine release, and subsequently induce lysis and apoptosis. NK cells can further detect stressed cells in the absence of antibodies and/or MHC, thereby allowing a rapid immune response.

Viral Based Delivery Systems

[0307] The present disclosure also provides delivery systems, such as viral-based systems, in which a nucleic acid described herein is inserted. Representative viral expression vectors include, but are not limited to, adeno-associated viral vectors, adenovirus-based vectors (*e.g.*, the adenovirus-based Per.C6 system available from Crucell, Inc. (Leiden, The Netherlands)), lentivirus-based vectors (*e.g.*, the lentiviral-based pLPI from Life Technologies (Carlsbad, Calif.)), retroviral vectors (*e.g.*, the pFB-ERV plus pCFB-EGSH), and herpes virus-based vectors. In an embodiment, the viral vector is a lentivirus vector. Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they

allow long-term, stable integration of a transgene and its propagation in daughter cells. Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity. In an additional embodiment, the viral vector is an adeno-associated viral vector. In a further embodiment, the viral vector is a retroviral vector. In general, and in embodiments, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers, (*e.g.*, WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).

[0308] Additional suitable vectors include integrating expression vectors, which may randomly integrate into the host cell's DNA, or may include a recombination site to enable the specific recombination between the expression vector and the host cell's chromosome. Such integrating expression vectors may utilize the endogenous expression control sequences of the host cell's chromosomes to effect expression of the desired protein. Examples of vectors that integrate in a site specific manner include, for example, components of the flp-in system from Invitrogen (Carlsbad, Calif.) (*e.g.*, pcDNATM5/FRT), or the cre-lox system, such as can be found in the pExchange-6 Core Vectors from Stratagene (La Jolla, Calif.). Examples of vectors that randomly integrate into host cell chromosomes include, for example, pcDNA3.1 (when introduced in the absence of T-antigen) from Invitrogen (Carlsbad, Calif.), and pCI or pFN10A (ACT) FLEXITM from Promega (Madison, Wis.). Additional promoter elements, *e.g.*, enhancers, regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription.

[0309] One example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto.

[0310] Another example of a suitable promoter is human elongation growth factor 1 alpha 1 (hEF1a1). In embodiments, the vector construct comprising the CARs and/or TCRs of the present disclosure comprises hEF1a1 functional variants.

[0311] However, other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter. Further, the present disclosure should not be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the present disclosure. The use of an inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to a metallothionein promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.

[0312] In order to assess the expression of a CAR or TCR polypeptide or portions thereof, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors. In other aspects, the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers include, for example, antibiotic-resistance genes, such as neomycin resistance gene (neo) and ampicillin resistance gene and the like. In some embodiments, a truncated epidermal growth factor receptor (HER1t) tag may be used as a selectable marker gene.

[0313] Reporter genes can be used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences. In general, a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, *e.g.*, enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells. Suitable reporter genes may include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green

fluorescent protein gene (*e.g.*, Ui-Tei et al., FEBS Letters 479: 79-82 (2000)). Suitable expression systems are well known and may be prepared using known techniques or obtained commercially. In general, the construct with the minimal 5' flanking region showing the highest level of expression of reporter gene is identified as the promoter. Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription.

[0314] In some embodiments, the vectors comprise a hEF1a1 promoter to drive expression of transgenes, a bovine growth hormone polyA sequence to enhance transcription, a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), as well as LTR sequences derived from the pFUGW plasmid.

[0315] Methods of introducing and expressing genes into a cell are known in the art. In the context of an expression vector, the vector can be readily introduced into a host cell, *e.g.*, mammalian, bacterial, yeast, or insect cell by any method in the art. For example, the expression vector can be transferred into a host cell by physical, chemical, or biological means.

[0316] Physical methods for introducing a polynucleotide into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example, Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (2001)). In embodiments, a method for the introduction of a polynucleotide into a host cell is calcium phosphate transfection or polyethylenimine (PEI) Transfection.

[0317] Biological methods for introducing a polynucleotide of interest into a host cell include the use of DNA and RNA vectors. Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, *e.g.*, human cells. Other viral vectors can be derived from lentivirus, poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like. See, for example, U.S. Pat. Nos. 5,350,674 and 5,585,362.

[0318] Chemical means for introducing a polynucleotide into a host cell include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (*e.g.*, an artificial membrane vesicle).

[0319] In the case where a viral delivery system is utilized, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of the nucleic acids

into a host cell (*in vitro*, *ex vivo* or *in vivo*). In another aspect, the nucleic acid may be associated with a lipid. The nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or with a "collapsed" structure. They may also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which may be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.

[0320] Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be obtained from Sigma, St. Louis, Mo.; dicetyl phosphate ("DCP") can be obtained from K & K Laboratories (Plainview, N.Y.); cholesterol ("Choi") can be obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol ("DMPG") and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, Ala.). Stock solutions of lipids in chloroform or chloroform/methanol can be stored at about -20°C. Chloroform is used as the only solvent since it is more readily evaporated than methanol. "Liposome" is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes can be characterized as having vesicular structures with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh et al., *Glycobiology* 5: 505-10 (1991)). However, compositions that have different structures in solution than the normal vesicular structure are also encompassed. For example, the lipids may assume a micellar structure or merely exist as non-uniform aggregates of lipid molecules. Also contemplated are lipofectamine-nucleic acid complexes.

Non-Viral Based Delivery Systems

[0321] In some instances, polynucleotides encoding cell tags described herein can also be introduced into T cells using non-viral based delivery systems, such as the “Sleeping Beauty (SB) Transposon System,” which refers a synthetic DNA transposon system for introducing DNA sequences into the chromosomes of vertebrates. Some exemplary embodiments of the system are described, for example, in U.S. Pat. Nos. 6,489,458 and 8,227,432. The Sleeping Beauty transposon system is composed of a Sleeping Beauty (SB) transposase and a SB transposon. In embodiments, the Sleeping Beauty transposon system can include the SB11 transposon system, the SB100X transposon system, or the SB110 transposon system.

[0322] DNA transposons translocate from one DNA site to another in a simple, cut-and-paste manner. Transposition is a precise process in which a defined DNA segment is excised from one DNA molecule and moved to another site in the same or different DNA molecule or genome. As do other Tc1/mariner-type transposases, SB transposase inserts a transposon into a TA dinucleotide base pair in a recipient DNA sequence. The insertion site can be elsewhere in the same DNA molecule, or in another DNA molecule (or chromosome). In mammalian genomes, including humans, there are approximately 200 million TA sites. The TA insertion site is duplicated in the process of transposon integration. This duplication of the TA sequence is a hallmark of transposition and used to ascertain the mechanism in some experiments. The transposase can be encoded either within the transposon or the transposase can be supplied by another source, for instance a DNA or mRNA source, in which case the transposon becomes a non-autonomous element. Non-autonomous transposons are most useful as genetic tools because after insertion they cannot independently continue to excise and re-insert. SB transposons envisaged to be used as non-viral vectors for introduction of genes into genomes of vertebrate animals and for gene therapy. Briefly, the Sleeping Beauty (SB) system (Hackett et al., *Mol Ther* 18:674-83, (2010)) was adapted to genetically modify the T cells (Cooper et al., *Blood* 105:1622-31, (2005)). This involved two steps: (i) the electro-transfer of DNA plasmids expressing a SB transposon [*i.e.*, chimeric antigen receptor (CAR) to redirect T-cell specificity (Jin et al., *Gene Ther* 18:849-56, (2011); Kebriaei et al., *Hum Gene Ther* 23:444-50, (2012)) and SB transposase and (ii) the propagation and expansion of T cells stably expressing integrants on designer artificial antigen-presenting cells (AaPC) derived from the K562 cell line (also known as AaPCs (Activating and Propagating Cells). In one embodiment, the SB transposon system includes coding sequence encoding membrane bound IL-15 and/or a chimeric antigen receptor. Such systems are described for example in Singh et al., *Cancer Res* (8):68 (2008). April 15, 2008 and Maiti et al., *J Immunother.* 36(2): 112–123 (2013), incorporated herein by reference in their

entireties. In certain embodiments, the DNA plasmid expressing a SB transposon comprising a CAR or TCR and a cytokine and polypeptide cell tag are electroporated into an effector cell which is then infused into a patient without further propagation and expansion.

[0323] In some embodiments, a polynucleotide encoding a CAR or a TCR or a cytokine and one or more polypeptide cell tag(s) in a modified effector cell described herein is encoded in one or more transposon DNA plasmid vectors, and the SB transposase is encoded in a separate vector. In embodiments, the polypeptide cell tag is encoded in a transposon DNA plasmid vector, a CAR or TCR or cytokine is encoded in a second transposon DNA plasmid vector, and the SB transposase is encoded in a third DNA plasmid vector. In some embodiments, the CAR or TCR and cytokine and polypeptide cell tag is encoded in a single transposon.

[0324] In some embodiments, the polypeptides described herein provides a safety mechanism by allowing for depletion of infused CAR-T cells through administering FDA approved antibodies or any antibody that recognizes a polypeptide construct to induce a cell depletion pathway. In some embodiments, HER1t variants described herein provide a safety mechanism by binding to introduced cetuximab and allowing for cell depletion. In some embodiments, CD20t variants also provide a safety mechanism by allowing for depletion of infused CAR-T cells through administering FDA-approved rituximab therapy.

[0325] Regardless of the method used to introduce exogenous nucleic acids into a host cell or otherwise expose a cell to the inhibitor of the present disclosure, in order to confirm the presence of the recombinant DNA sequence in the host cell, a variety of assays may be performed. Such assays include, for example, molecular assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; "biochemical" assays, such as detecting the presence or absence of a particular peptide, *e.g.*, by immunological means (ELISAs and Western blots) or by assays described herein to identify agents falling within the scope of the present disclosure.

[0326] In embodiments, a modified effector cell described herein and other genetic elements are delivered to a cell using the SB11 transposon system, the SB100X transposon system, the SB110 transposon system, the piggyBac transposon system (see, *e.g.*, Wilson et al, "PiggyBac Transposon-mediated Gene Transfer in Human Cells," *Molecular Therapy* 15:139-145 (2007), incorporated herein by reference in its entirety) and/or the piggyBac transposon system (see, *e.g.*, Mitra et al., "Functional characterization of piggyBac from the bat *Myotis lucifugus* unveils an active mammalian DNA transposon," *Proc. Natl. Acad. Sci USA* 110:234-239 (2013).

Additional transposases and transposon systems are provided in U.S. Patent Nos.; 6,489,458;

6,613,752, 7,148,203; 7,985,739; 8,227,432; 9,228,180; U.S. Patent Publn. No. 2011/0117072; Mates et al., Nat Genet, 41(6):753-61 (2009). doi: 10.1038/ng.343. Epub 2009 May 3, Gene Ther., 18(9):849-56 (2011). doi: 10.1038/gt.2011.40. Epub 2011 Mar 31 and in Ivics et al., Cell. 91(4):501-10, (1997), each of which is incorporated herein by reference in their entirety.

Additional suitable non-viral systems can include integrating expression vectors, which may randomly integrate into the host cell's DNA, or may include a recombination site to enable the specific recombination between the expression vector and the host cell's chromosome. Targeted integration of transgenes into predefined genetic loci is a desirable goal for many applications. First, a first recombination site for a site-specific recombinase is inserted at a genomic site, either at a random or at a predetermined location. Subsequently, the cells are transfected with a plasmid carrying the gene or DNA of interest and the second recombination site and a source for recombinase (expression plasmid, RNA, protein, or virus-expressing recombinase).

Recombination between the first and second recombination sites leads to integration of plasmid DNA.

[0327] Such integrating expression vectors may utilize the endogenous expression control sequences of the host cell's chromosomes to effect expression of the desired protein. In some embodiments, targeted integration is promoted by the presence of sequences on the donor polynucleotide that are homologous to sequences flanking the integration site. For example, targeted integration using the donor polynucleotides described herein may be achieved following conventional transfection techniques, *e.g.* techniques used to create gene knockouts or knockins by homologous recombination. In other embodiments, targeted integration is promoted both by the presence of sequences on the donor polynucleotide that are homologous to sequences flanking the integration site, and by contacting the cells with donor polynucleotide in the presence of a site-specific recombinase. By a site-specific recombinase, or simply a recombinase, it is meant is a polypeptide that catalyzes conservative site-specific recombination between its compatible recombination sites. As used herein, a site-specific recombinase includes native polypeptides as well as derivatives, variants and/or fragments that retain activity, and native polynucleotides, derivatives, variants, and/or fragments that encode a recombinase that retains activity.

[0328] Also provided herein is a system for integrating heterologous genes in a host cell, said system comprising one or more gene expression cassettes. In some instances, the system includes a first gene expression cassette comprising a first polynucleotide encoding a first polypeptide construct. In other instances, the system can include a second gene expression

cassette comprising a second polynucleotide encoding a second polypeptide construct. In yet other instances, the system can include a third gene expression cassette. In one embodiment, the system includes recombinant attachment sites; and a serine recombinase; such that upon contacting said host cell with at least said first gene expression cassette, in the presence of said serine recombinase, said heterologous genes are integrated in said host cell.

[0329] In some instances, the system further comprises a ligand; such that upon contacting said host cell, in the presence of said ligand, said heterologous gene are expressed in said host cell. In one instance, the system also includes recombinant attachment sites. In some instances, one recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB). In one instance, the host cell is an eukaryotic cell. In another instance, the host cell is a human cell. In further instances, the host cell is a T cell or NK cell.

[0330] In one embodiment, the heterologous gene in the system described above comprises a CAR. In some embodiments, the CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2.

[0331] In another embodiment, the system includes a heterologous gene comprising a cytokine. In some instances, the cytokine comprises at least one of IL-15, IL-2, IL-12, IL-21, and a fusion of IL-15 and IL-15R α . In some embodiments, the system includes a heterologous gene comprising at least one cell tag described herein. In some embodiments, said cell tag comprises at least one of a HER1 polypeptide, a LNGFR polypeptide, a CD20 polypeptide and a CD52 polypeptide. In some embodiments, the mbIL-15 is encoded with a cell tag. Examples of cell tags can include truncated: HER1 polypeptide, LNGFR polypeptide, CD20 polypeptide, CD52 polypeptide or any other appropriate cell tags for use as a depletion or kill switch, or enrichment marker.

[0332] In further embodiments, said system is contained in one or more vectors. In one instance, the system is contained in one vector. In one instance, the first gene expression cassette, the second gene expression cassette, and the recombinant attachment sites are contained in one vector. In one instance, the first gene expression cassette, the second gene expression cassette, the third gene expression cassette and the recombinant attachment sites are contained in one vector. In another instance, the serine recombinase is SF370. In other instances, the serine recombinase is in a separate vector.

[0333] The recombinases can be introduced into a target cell before, concurrently with, or after the introduction of a targeting vector. The recombinase can be directly introduced into a cell as a protein, for example, using liposomes, coated particles, or microinjection. Alternately, a polynucleotide, either DNA or messenger RNA, encoding the recombinase can be introduced into the cell using a suitable expression vector. The targeting vector components described above are useful in the construction of expression cassettes containing sequences encoding a recombinase of interest. However, expression of the recombinase can be regulated in other ways, for example, by placing the expression of the recombinase under the control of a regulatable promoter (*i.e.*, a promoter whose expression can be selectively induced or repressed).

[0334] Recombinases for use in the practice of the present invention can be produced recombinantly or purified as previously described. Polypeptides having the desired recombinase activity can be purified to a desired degree of purity by methods known in the art of protein ammonium sulfate precipitation, purification, including, but not limited to, size fractionation, affinity chromatography, HPLC, ion exchange chromatography, heparin agarose affinity chromatography (*e.g.*, Thorpe & Smith, Proc. Nat. Acad. Sci. 95:5505-5510, 1998.)

[0335] In one embodiment, the recombinases can be introduced into the eukaryotic cells that contain the recombination attachment sites at which recombination is desired by any suitable method. Methods of introducing functional proteins, *e.g.*, by microinjection or other methods, into cells are well known in the art. Introduction of purified recombinase protein ensures a transient presence of the protein and its function, which is often a preferred embodiment. Alternatively, a gene encoding the recombinase can be included in an expression vector used to transform the cell, in which the recombinase-encoding polynucleotide is operably linked to a promoter which mediates expression of the polynucleotide in the eukaryotic cell. The recombinase polypeptide can also be introduced into the eukaryotic cell by messenger RNA that encodes the recombinase polypeptide. It is generally preferred that the recombinase be present for only such time as is necessary for insertion of the nucleic acid fragments into the genome being modified. Thus, the lack of permanence associated with most expression vectors is not expected to be detrimental. One can introduce the recombinase gene into the cell before, after, or simultaneously with, the introduction of the exogenous polynucleotide of interest. In one embodiment, the recombinase gene is present within the vector that carries the polynucleotide that is to be inserted; the recombinase gene can even be included within the polynucleotide. In other embodiments, the recombinase gene is introduced into a transgenic eukaryotic organism. Transgenic cells or animals can be made that express a recombinase constitutively or under cell-

specific, tissue-specific, developmental-specific, organelle-specific, or small molecule-inducible or repressible promoters. The recombinases can be also expressed as a fusion protein with other peptides, proteins, nuclear localizing signal peptides, signal peptides, or organelle-specific signal peptides (*e.g.*, mitochondrial or chloroplast transit peptides to facilitate recombination in mitochondria or chloroplast).

[0336] For example, a recombinase may be from the Integrase or Resolvase families. The Integrase family of recombinases has over one hundred members and includes, for example, FLP, Cre, and lambda integrase. The Integrase family, also referred to as the tyrosine family or the lambda integrase family, uses the catalytic tyrosine's hydroxyl group for a nucleophilic attack on the phosphodiester bond of the DNA. Typically, members of the tyrosine family initially nick the DNA, which later forms a double strand break. Examples of tyrosine family integrases include Cre, FLP, SSV1, and lambda (λ) integrase. In the resolvase family, also known as the serine recombinase family, a conserved serine residue forms a covalent link to the DNA target site (Grindley, et al., (2006) *Ann Rev Biochem* 16:16).

[0337] In one embodiment, the recombinase is an isolated polynucleotide sequence comprising a nucleic acid sequence that encodes a recombinase selecting from the group consisting of a SP β c2 recombinase, a SF370.1 recombinase, a Bxb1 recombinase, an A118 recombinase and a ϕ Rv1 recombinase. Examples of serine recombinases are described in detail in U.S. Patent No. 9,034,652, hereby incorporated by reference in its entirety.

[0338] In one embodiment, a method for site-specific recombination comprises providing a first recombination site and a second recombination site; contacting the first and second recombination sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination sites, the first recombination site is attP or attB, the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a *Listeria monocytogenes* phage recombinase, a *Streptococcus pyogenes* phage recombinase, a *Bacillus subtilis* phage recombinase, a *Mycobacterium tuberculosis* phage recombinase and a *Mycobacterium smegmatis* phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP, and when the first recombination attachment site is attP, the second recombination attachment site is attB. Further embodiments provide for the introduction of a site-specific recombinase into a cell whose genome is to be modified. One embodiment relates to a method for obtaining site-specific recombination in an eukaryotic cell comprises providing a eukaryotic cell that comprises a first

recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination attachment site is attB or attP, and the recombinase is selected from the group consisting of a *Listeria monocytogenes* phage recombinase, a *Streptococcus pyogenes* phage recombinase, a *Bacillus subtilis* phage recombinase, a *Mycobacterium tuberculosis* phage recombinase and a *Mycobacterium smegmatis* phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP, and when the first recombination attachment site is attP, the second recombination attachment site is attB. In an embodiment the recombinase is selected from the group consisting of an A118 recombinase, a SF370.1 recombinase, a SP β c2 recombinase, a ϕ Rv1 recombinase, and a Bxb1 recombinase. In one embodiment the recombination results in integration.

Immune Effector Cell Sources

[0339] In certain aspects, the embodiments described herein include methods of making and/or expanding the antigen-specific redirected immune effector cells (*e.g.*, T-cells, NK-cell or NK T-cells) that comprises transfecting the cells with an expression vector containing a DNA (or RNA) construct encoding the polypeptide construct, then, optionally, stimulating the cells with feeder cells, recombinant antigen, or an antibody to the receptor to cause the cells to proliferate. In certain aspects, the cell (or cell population) engineered to express a CAR or TCR is a stem cell, iPS cell, immune effector cell or a precursor of these cells.

[0340] Sources of immune effector cells can include both allogeneic and autologous sources. In some cases immune effector cells may be differentiated from stem cells or induced pluripotent stem cells (iPSCs). Thus, cell for engineering according to the embodiments can be isolated from umbilical cord blood, peripheral blood, human embryonic stem cells, or iPSCs. For example, allogeneic T cells can be modified to include a chimeric antigen receptor (and optionally, to lack functional TCR). In some aspects, the immune effector cells are primary human T cells such as T cells derived from human peripheral blood mononuclear cells (PBMC). PBMCs can be collected from the peripheral blood or after stimulation with G-CSF (Granulocyte colony stimulating factor) from the bone marrow, or umbilical cord blood. Following

transfection or transduction (*e.g.*, with a CAR expression construct), the cells may be immediately infused or may be cryo-preserved. In certain aspects, following transfection, the cells may be propagated for days, weeks, or months *ex vivo* as a bulk population within about 1, 2, 3, 4, 5 days or more following gene transfer into cells. In a further aspect, following transfection, the transfectants are cloned and a clone demonstrating presence of a single integrated or episomally maintained expression cassette or plasmid, and expression of the chimeric antigen receptor is expanded *ex vivo*. The clone selected for expansion demonstrates the capacity to specifically recognize and lyse antigen-expressing target cells. The recombinant T cells may be expanded by stimulation with IL-2, or other cytokines that bind the common gamma-chain (*e.g.*, IL-7, IL-12, IL-15, IL-21, and others). The recombinant T cells may be expanded by stimulation with artificial antigen presenting cells. The recombinant T cells may be expanded on artificial antigen presenting cell or with an antibody, such as OKT3, which cross links CD3 on the T cell surface. Subsets of the recombinant T cells may be further selected with the use of magnetic bead based isolation methods and/or fluorescence activated cell sorting technology and further cultured with the AaPCs. In a further aspect, the genetically modified cells may be cryopreserved.

[0341] T cells can also be obtained from a number of sources, including peripheral blood, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumor (tumor-infiltrating lymphocytes). In certain embodiments of the present disclosure, any number of T cell lines available in the art, may be used. In certain embodiments of the present disclosure, T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as Ficoll® separation. In embodiments, cells from the circulating blood of an individual are obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one embodiment, the cells collected by apheresis may be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps. In one embodiment of the present disclosure, the cells are washed with phosphate buffered saline (PBS). In an alternative embodiment, the wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations. Initial activation steps in the absence of calcium lead to magnified activation. As those of ordinary skill in the art would readily appreciate a washing step may be accomplished by methods known to those in the art, such as by using a semi-automated "flow-through" centrifuge (for example, the Cobe 2991 cell processor, the Baxter

CytoMate, or the Haemonetics Cell Saver 5) according to the manufacturer's instructions. After washing, the cells may be resuspended in a variety of biocompatible buffers, such as, for example, Ca²⁺-free, Mg²⁺-free PBS, PlasmaLyte A, or other saline solution with or without buffer. Alternatively, the undesirable components of the apheresis sample may be removed and the cells directly resuspended in culture media.

[0342] In another embodiment, T cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLL® gradient or by counterflow centrifugal elutriation. A specific subpopulation of T cells, such as CD3⁺, CD28⁺, CD4⁺, CD8⁺, CD45RA⁺, and CD45RO⁺ T cells, can be further isolated by positive or negative selection techniques. In another embodiment, CD14⁺ cells are depleted from the T-cell population. For example, in one embodiment, T cells are isolated by incubation with anti-CD3/anti-CD28 (*i.e.*, 3x28)-conjugated beads, such as DYNABEADS® M-450 CD3/CD28 T, for a time period sufficient for positive selection of the desired T cells. In one embodiment, the time period is about 30 minutes. In a further embodiment, the time period ranges from 30 minutes to 36 hours or longer and all integer values there between. In a further embodiment, the time period is at least 1, 2, 3, 4, 5, or 6 hours. In yet another embodiment, the time period is 10 to 24 hours. In one embodiment, the incubation time period is 24 hours. For isolation of T cells from patients with leukemia, use of longer incubation times, such as 24 hours, can increase cell yield. Longer incubation times may be used to isolate T cells in any situation where there are few T cells as compared to other cell types, such in isolating tumor infiltrating lymphocytes (TIL) from tumor tissue or from immune-compromised individuals. Further, use of longer incubation times can increase the efficiency of capture of CD8⁺ T cells. Thus, by simply shortening or lengthening the time T cells are allowed to bind to the CD3/CD28 beads and/or by increasing or decreasing the ratio of beads to T cells (as described further herein), subpopulations of T cells can be preferentially selected for or against at culture initiation or at other time points during the process. Additionally, by increasing or decreasing the ratio of anti-CD3 and/or anti-CD28 antibodies on the beads or other surface, subpopulations of T cells can be preferentially selected for or against at culture initiation or at other desired time points. The skilled artisan would recognize that multiple rounds of selection can also be used in the context of this disclosure. In certain embodiments, it may be desirable to perform the selection procedure and use the "unselected" cells in the activation and expansion process. "Unselected" cells can also be subjected to further rounds of selection.

[0343] Enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method is cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4⁺ cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In certain embodiments, it may be desirable to enrich for or positively select for regulatory T cells which typically express CD4⁺, CD25⁺, CD62Lhi, GITR⁺, and FoxP3⁺. Alternatively, in certain embodiments, T regulatory cells are depleted by anti-CD25 conjugated beads or other similar method of selection.

[0344] For isolation of a desired population of cells by positive or negative selection, the concentration of cells and surface (*e.g.*, particles such as beads) can be varied. In certain embodiments, it may be desirable to significantly decrease the volume in which beads and cells are mixed together (*i.e.*, increase the concentration of cells), to ensure maximum contact of cells and beads. For example, in one embodiment, a concentration of 2 billion cells/ml is used. In one embodiment, a concentration of 1 billion cells/ml is used. In a further embodiment, greater than 100 million cells/ml is used. In a further embodiment, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet another embodiment, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further embodiments, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells, or from samples where there are many tumor cells present (*i.e.*, leukemic blood, tumor tissue, etc.). Such populations of cells may have therapeutic value and would be desirable to obtain. For example, using high concentration of cells allows more efficient selection of CD8⁺ T cells that normally have weaker CD28 expression.

[0345] In a related embodiment, it may be desirable to use lower concentrations of cells. By significantly diluting the mixture of T cells and surface (*e.g.*, particles such as beads), interactions between the particles and cells is minimized. This selects for cells that express high amounts of desired antigens to be bound to the particles. For example, CD4⁺ T cells express higher levels of CD28 and are more efficiently captured than CD8⁺ T cells in dilute concentrations. In one embodiment, the concentration of cells used is 5x10⁶/ml. In other

embodiments, the concentration used can be from about $1 \times 10^5/\text{ml}$ to $1 \times 10^6/\text{ml}$, and any integer value in between.

[0346] In other embodiments, the cells may be incubated on a rotator for varying lengths of time at varying speeds at either 2-10°C or at room temperature.

[0347] T cells for stimulation can also be frozen after a washing step. After the washing step that removes plasma and platelets, the cells may be suspended in a freezing solution. While many freezing solutions and parameters are known in the art and will be useful in this context, one method involves using PBS containing 20% DMSO and 8% human serum albumin, or culture media containing 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin and 7.5% DMSO, or 31.25% Plasmalyte-A, 31.25% Dextrose 5%, 0.45% NaCl, 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin, and 7.5% DMSO or other suitable cell freezing media containing for example, Hespan and PlasmaLyte A, the cells then are frozen to -80°C at a rate of 1°C per minute and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing may be used as well as uncontrolled freezing immediately at -20°C or in liquid nitrogen.

[0348] In certain embodiments, cryopreserved cells are thawed and washed as described herein and allowed to rest for one hour at room temperature prior to activation using the methods of the present disclosure.

[0349] Also contemplated in the context of the present disclosure is the collection of blood samples or apheresis product from a subject at a time period prior to when the expanded cells as described herein might be needed. As such, the source of the cells to be expanded can be collected at any time point necessary, and desired cells, such as T cells, isolated and frozen for later use in T cell therapy for any number of diseases or conditions that would benefit from T cell therapy, such as those described herein. In one embodiment a blood sample or an apheresis is taken from a generally healthy subject. In certain embodiments, a blood sample or an apheresis is taken from a generally healthy subject who is at risk of developing a disease, but who has not yet developed a disease, and the cells of interest are isolated and frozen for later use. In certain embodiments, the T cells may be expanded, frozen, and used at a later time. In certain embodiments, samples are collected from a patient shortly after diagnosis of a particular disease as described herein but prior to any treatments. In a further embodiment, the cells are isolated from a blood sample or an apheresis from a subject prior to any number of relevant treatment modalities, including but not limited to treatment with agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, radiation, immunosuppressive agents, such as cyclosporin,

azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies, cytoxan, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and irradiation. These drugs inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin) (Liu et al., Cell 66:807-815, (1991); Henderson et al., Immun 73:316-321, (1991); Bierer et al., Curr. Opin. Immun 5:763-773, (1993)). In a further embodiment, the cells are isolated for a patient and frozen for later use in conjunction with (*e.g.*, before, simultaneously or following) bone marrow or stem cell transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the cells are isolated prior to and can be frozen for later use for treatment following B-cell ablative therapy such as agents that react with CD20, *e.g.*, Rituxan.

[0350] In a further embodiment of the present disclosure, T cells are obtained from a patient directly following treatment. In this regard, it has been observed that following certain cancer treatments, in particular treatments with drugs that damage the immune system, shortly after treatment during the period when patients would normally be recovering from the treatment, the quality of T cells obtained may be optimal or improved for their ability to expand *ex vivo*. Likewise, following *ex vivo* manipulation using the methods described herein, these cells may be in a preferred state for enhanced engraftment and *in vivo* expansion. Thus, it is contemplated within the context of the present disclosure to collect blood cells, including T cells, dendritic cells, or other cells of the hematopoietic lineage, during this recovery phase. Further, in certain embodiments, mobilization (for example, mobilization with GM-CSF) and conditioning regimens can be used to create a condition in a subject wherein repopulation, recirculation, regeneration, and/or expansion of particular cell types is favored, especially during a defined window of time following therapy. Illustrative cell types include T cells, B cells, dendritic cells, and other cells of the immune system.

Activation and Expansion of T Cells

[0351] In certain embodiments T cells comprising polynucleotides and polypeptides described herein can optionally, be activated and expanded generally using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466;

6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005.

[0352] “Adoptive T cell transfer” refers to the isolation and ex vivo expansion of tumor specific T cells to achieve greater number of T cells than what could be obtained by vaccination alone or the patient’s natural tumor response. The tumor specific T cells are then infused into patients with cancer in an attempt to give their immune system the ability to overwhelm remaining tumor via T cells which can attack and kill cancer. There are many forms of adoptive T cell therapy being used for cancer treatment; culturing tumor infiltrating lymphocytes or TIL, isolating and expanding one particular T cell or clone, and even using T cells that have been engineered to potentially recognize and attack tumors.

[0353] In some cases, T cells described herein are expanded by contact with a surface having attached thereto an agent that stimulates a CD3/TCR complex associated signal and a ligand that stimulates a co-stimulatory molecule on the surface of the T cells. In particular, T cell populations may be stimulated as described herein, such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (*e.g.*, bryostatin) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a ligand that binds the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. To stimulate proliferation of either CD4⁺ T cells or CD8⁺ T cells, an anti-CD3 antibody and an anti-CD28 antibody. Examples of an anti-CD28 antibody include 9.3, B-T3, XR-CD28 (Diaclone, Besancon, France) can be used as can other methods commonly known in the art (Berg et al., Transplant Proc. 30(8):3975-3977, (1998); Haanen et al., J. Exp. Med. 190(9):1319-1328, (1999); Garland et al., J. Immunol Meth. 227(1-2):53-63, (1999)).

[0354] In certain embodiments, the primary stimulatory signal and the co-stimulatory signal for the T cell may be provided by different protocols. For example, the agents providing each signal may be in solution or coupled to a surface. When coupled to a surface, the agents may be coupled to the same surface (*i.e.*, in “cis” formation) or to separate surfaces (*i.e.*, in “trans” formation). Alternatively, one agent may be coupled to a surface and the other agent in solution. In one embodiment, the agent providing the co-stimulatory signal is bound to a cell surface and the agent providing the primary activation signal is in solution or coupled to a surface. In certain embodiments, both agents can be in solution. In another embodiment, the agents may be in

soluble form, and then cross-linked to a surface, such as a cell expressing Fc receptors or an antibody or other binding agent which will bind to the agents. In this regard, see for example, U.S. Patent Application Publication Nos. 20040101519 and 20060034810 for artificial antigen presenting cells (aAPCs) that are contemplated for use in activating and expanding T cells in the present disclosure.

[0355] In one embodiment, the two agents are immobilized on beads, either on the same bead, *i.e.*, "cis," or to separate beads, *i.e.*, "trans." By way of example, the agent providing the primary activation signal is an anti-CD3 antibody or an antigen-binding fragment thereof and the agent providing the co-stimulatory signal is an anti-CD28 antibody or antigen-binding fragment thereof; and both agents are co-immobilized to the same bead in equivalent molecular amounts. In one embodiment, a 1:1 ratio of each antibody bound to the beads for CD4⁺ T cell expansion and T cell growth is used. In certain aspects of the present disclosure, a ratio of anti CD3:CD28 antibodies bound to the beads is used such that an increase in T cell expansion is observed as compared to the expansion observed using a ratio of 1:1. In one particular embodiment an increase of from about 1 to about 3 fold is observed as compared to the expansion observed using a ratio of 1:1. In one embodiment, the ratio of CD3:CD28 antibody bound to the beads ranges from 100:1 to 1:100 and all integer values there between. In one aspect of the present disclosure, more anti-CD28 antibody is bound to the particles than anti-CD3 antibody, *i.e.*, the ratio of CD3:CD28 is less than one. In certain embodiments of the present disclosure, the ratio of anti CD28 antibody to anti CD3 antibody bound to the beads is greater than 2:1. In one particular embodiment, a 1:100 CD3:CD28 ratio of antibody bound to beads is used. In another embodiment, a 1:75 CD3:CD28 ratio of antibody bound to beads is used. In a further embodiment, a 1:50 CD3:CD28 ratio of antibody bound to beads is used. In another embodiment, a 1:30 CD3:CD28 ratio of antibody bound to beads is used. In embodiments, a 1:10 CD3:CD28 ratio of antibody bound to beads is used. In another embodiment, a 1:3 CD3:CD28 ratio of antibody bound to the beads is used. In yet another embodiment, a 3:1 CD3:CD28 ratio of antibody bound to the beads is used.

[0356] Ratios of particles to cells from 1:500 to 500:1 and any integer values in between may be used to stimulate T cells or other target cells. As those of ordinary skill in the art can readily appreciate, the ratio of particles to cells may depend on particle size relative to the target cell. For example, small sized beads could only bind a few cells, while larger beads could bind many. In certain embodiments the ratio of cells to particles ranges from 1:100 to 100:1 and any integer values in-between and in further embodiments the ratio comprises 1:9 to 9:1 and any integer

values in between, can also be used to stimulate T cells. The ratio of anti-CD3- and anti-CD28-coupled particles to T cells that result in T cell stimulation can vary as noted above, however certain values include 1:100, 1:50, 1:40, 1:30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, and 15:1 with one ratio being at least 1:1 particles per T cell. In one embodiment, a ratio of particles to cells of 1:1 or less is used. In one particular embodiment, the particle:cell ratio is 1:5. In further embodiments, the ratio of particles to cells can be varied depending on the day of stimulation. For example, in one embodiment, the ratio of particles to cells is from 1:1 to 10:1 on the first day and additional particles are added to the cells every day or every other day thereafter for up to 10 days, at final ratios of from 1:1 to 1:10 (based on cell counts on the day of addition). In one particular embodiment, the ratio of particles to cells is 1:1 on the first day of stimulation and adjusted to 1:5 on the third and fifth days of stimulation. In another embodiment, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:5 on the third and fifth days of stimulation. In another embodiment, the ratio of particles to cells is 2:1 on the first day of stimulation and adjusted to 1:10 on the third and fifth days of stimulation. In another embodiment, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:10 on the third and fifth days of stimulation. One of skill in the art will appreciate that a variety of other ratios may be suitable for use in the present disclosure. In particular, ratios will vary depending on particle size and on cell size and type.

[0357] In further embodiments of the present disclosure, the cells, such as T cells, are combined with agent-coated beads, the beads and the cells are subsequently separated, and then the cells are cultured. In an alternative embodiment, prior to culture, the agent-coated beads and cells are not separated but are cultured together. In a further embodiment, the beads and cells are first concentrated by application of a force, such as a magnetic force, resulting in increased ligation of cell surface markers, thereby inducing cell stimulation.

[0358] By way of example, cell surface proteins may be ligated by allowing paramagnetic beads to which anti-CD3 and anti-CD28 are attached (3x28 beads) to contact the T cells. In one embodiment the cells (for example, 10⁴ to 10⁹ T cells) and beads (for example, DYNABEADS® M-450 CD3/CD28 T paramagnetic beads at a ratio of 1:1, or MACS® MicroBeads from Miltenyi Biotec) are combined in a buffer, for example, PBS (without divalent cations such as, calcium and magnesium). Again, those of ordinary skill in the art can readily appreciate any cell concentration may be used. For example, the target cell may be very rare in the sample and comprise only 0.01% of the sample or the entire sample (*i.e.*, 100%) may comprise the target cell

of interest. Accordingly, any cell number is within the context of the present disclosure. In certain embodiments, it may be desirable to significantly decrease the volume in which particles and cells are mixed together (*i.e.*, increase the concentration of cells), to ensure maximum contact of cells and particles. For example, in one embodiment, a concentration of about 2 billion cells/ml is used. In another embodiment, greater than 100 million cells/ml is used. In a further embodiment, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet another embodiment, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further embodiments, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells. Such populations of cells may have therapeutic value and would be desirable to obtain in certain embodiments. For example, using high concentration of cells allows more efficient selection of CD8⁺ T cells that normally have weaker CD28 expression.

[0359] In one embodiment of the present disclosure, the mixture may be cultured for several hours (about 3 hours) to about 14 days or any hourly integer value in between. In another embodiment, the mixture may be cultured for 21 days. In one embodiment of the invention the beads and the T cells are cultured together for about eight days. In another embodiment, the beads and T cells are cultured together for 2-3 days. Several cycles of stimulation may also be desired such that culture time of T cells can be 60 days or more. Conditions appropriate for T cell culture include an appropriate media (*e.g.*, Minimal Essential Media or RPMI Media 1640 or, X-vivo 15, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (*e.g.*, fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN- γ , IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGF β , and TNF- α or any other additives for the growth of cells known to the skilled artisan. Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI 1640, AIM-V, DMEM, MEM, alpha-MEM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, *e.g.*, penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under

conditions necessary to support growth, for example, an appropriate temperature (*e.g.*, 37°C) and atmosphere (*e.g.*, air plus 5% CO₂).

[0360] T cells that have been exposed to varied stimulation times may exhibit different characteristics. For example, typical blood or apheresed peripheral blood mononuclear cell products have a helper T cell population (TH, CD4+) that is greater than the cytotoxic or suppressor T cell population (TC, CD8+). Ex vivo expansion of T cells by stimulating CD3 and CD28 receptors produces a population of T cells that prior to about days 8-9 consists predominately of TH cells, while after about days 8-9, the population of T cells comprises an increasingly greater population of TC cells. Accordingly, depending on the purpose of treatment, infusing a subject with a T cell population comprising predominately of TH cells may be advantageous. Similarly, if an antigen-specific subset of TC cells has been isolated it may be beneficial to expand this subset to a greater degree.

[0361] Further, in addition to CD4 and CD8 markers, other phenotypic markers vary significantly, but in large part, reproducibly during the course of the cell expansion process. Thus, such reproducibility enables the ability to tailor an activated T cell product for specific purposes.

[0362] In some cases, immune effector cells of the embodiments (*e.g.*, T-cells) are co-cultured with activating and propagating cells (AaPCs), to aid in cell expansion. AaPCs can also be referred to as artificial Antigen Presenting cells (aAPCs). For example, antigen presenting cells (APCs) are useful in preparing therapeutic compositions and cell therapy products of the embodiments. In one aspect, the AaPCs may be genetically modified K562 cells. For general guidance regarding the preparation and use of antigen-presenting systems, see, *e.g.*, U.S. Pat. Nos. 6,225,042, 6,355,479, 6,362,001 and 6,790,662; U.S. Patent Application Publication Nos. 2009/0017000 and 2009/0004142; and International Publication No. WO2007/103009, each of which is incorporated by reference. In yet a further aspect of the embodiments, culturing the genetically modified CAR cells comprises culturing the genetically modified CAR cells in the presence of dendritic cells or activating and propagating cells (AaPCs) that stimulate expansion of the CAR-expressing immune effector cells. In still further aspects, the AaPCs comprise a CAR-binding antibody or fragment thereof expressed on the surface of the AaPCs. The AaPCs may comprise additional molecules that activate or co-stimulate T-cells in some cases. The additional molecules may, in some cases, comprise membrane-bound C γ cytokines. In yet still further aspects, the AaPCs are inactivated or irradiated, or have been tested for and confirmed to be free of infectious material. In still further aspects, culturing the transgenic CAR cells in the

presence of AaPCs comprises culturing the transgenic CAR cells in a medium comprising soluble cytokines, such as IL-15, IL-21 and/or IL-2. The cells may be cultured at a ratio of about 10:1 to about 1:10; about 3:1 to about 1:5; about 1:1 to about 1:3 (immune effector cells to AaPCs); or any range derivable therein. For example, the co-culture of T cells and AaPCs can be at a ratio of about 1:1, about 1:2 or about 1:3.

[0363] In one aspect, the AaPCs may express CD137L. In some aspects, the AaPCs can further express the antigen that is targeted by the CAR cell. In other aspects, the AaPCs may further express CD19, CD64, CD86, or mIL15. In certain aspects, the AaPCs may express at least one anti-CD3 antibody clone, such as, for example, OKT3 and/or UCHT1. In one aspect, the AaPCs may be treated (*e.g.* irradiated or mytomycin C) to eliminate their growth potential. In one aspect, the AaPCs may have been tested for and confirmed to be free of infectious material. Methods for producing such AaPCs are known in the art. In one aspect, culturing the CAR-modified T cell population with AaPCs may comprise culturing the cells at a ratio of about 10:1 to about 1:10; about 3:1 to about 1:5; about 1:1 to about 1:3 (T cells to AaPCs); or any range derivable therein. For example, the co-culture of T cells and AaPCs can be at a ratio of about 1:1, about 1:2 or about 1:3. In one aspect, the culturing step may further comprise culturing with an aminobisphosphonate (*e.g.*, zoledronic acid).

[0364] In a further aspect, the population of CAR-T cells is cultured and/or stimulated for no more than 7, 14, 21, 28, 35, 42 days, 49, 56, 63 or 70 days. In some embodiments, the population of CAR-T cells is cultured and/or stimulated for at least 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or more days. In some embodiments, the population of CAR-T cells is cultured and/or stimulated for at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or more days. In some embodiments, the population of CAR-T cells is cultured and/or stimulated for at least 7, 14, 21, 28, 35, 42, 49, 56, 63 or more days. In other embodiments, a stimulation includes the co-culture of the CAR-T cells with AaPCs to promote the growth of CAR positive T cells. In another aspect, the population of genetically modified CAR cells is stimulated for not more than: 1X stimulation, 2X stimulation, 3X stimulation, 4X stimulation, 5X stimulation, 5X stimulation, 6X stimulation, 7X stimulation, 8X stimulation, 9X stimulation or 10X stimulation. In some instances, the genetically modified cells are not cultured *ex vivo* in the presence of AaPCs. In some specific instances, the method of the embodiment further comprises enriching the cell population for CAR-expressing immune effector cells (*e.g.*, T-cells) after the transfection and/or culturing step. The enriching may comprise fluorescence-activated cell sorting (FACS) and sorting for CAR-expressing cells. In a further aspect, the sorting for CAR-expressing cells

comprises use of a CAR-binding antibody. The enriching may also comprise depletion of CD56+ cells. In yet still a further aspect of the embodiment, the method further comprises cryopreserving a sample of the population of genetically modified CAR cells.

[0365] In some cases, AaPCs are incubated with a peptide of an optimal length that allows for direct binding of the peptide to the MHC molecule without additional processing. Alternatively, the cells can express an antigen of interest (*i.e.*, in the case of MHC-independent antigen recognition). Furthermore, in some cases, APCs can express an antibody that binds to either a specific CAR polypeptide or to CAR polypeptides in general (*e.g.*, a universal activating and propagating cell (uAPC)). Such methods are disclosed in WO/2014/190273, which is incorporated herein by reference. In addition to peptide-MHC molecules or antigens of interest, the AaPC systems may also comprise at least one exogenous assisting molecule. Any suitable number and combination of assisting molecules may be employed. The assisting molecule may be selected from assisting molecules such as co-stimulatory molecules and adhesion molecules. Exemplary co-stimulatory molecules include CD70 and B7.1 (B7.1 was previously known as B7 and also known as CD80), which among other things, bind to CD28 and/or CTLA-4 molecules on the surface of T cells, thereby affecting, for example, T-cell expansion, Th1 differentiation, short-term T-cell survival, and cytokine secretion such as interleukin (IL)-2. Adhesion molecules can include carbohydrate-binding glycoproteins such as selectins, transmembrane binding glycoproteins such as integrins, calcium-dependent proteins such as cadherins, and single-pass transmembrane immunoglobulin (Ig) superfamily proteins, such as intercellular adhesion molecules (ICAMs), that promote, for example, cell-to-cell or cell-to-matrix contact. Exemplary adhesion molecules include LFA-3 and ICAMs, such as ICAM-1. Techniques, methods, and reagents useful for selection, cloning, preparation, and expression of exemplary assisting molecules, including co-stimulatory molecules and adhesion molecules, are exemplified in, *e.g.*, U.S. Pat. Nos. 6,225,042, 6,355,479, and 6,362,001, incorporated herein by reference.

[0366] Cells selected to become AaPCs, preferably have deficiencies in intracellular antigen-processing, intracellular peptide trafficking, and/or intracellular MHC Class I or Class II molecule-peptide loading, or are poikilothermic (*i.e.*, less sensitive to temperature challenge than mammalian cell lines), or possess both deficiencies and poikilothermic properties. Preferably, cells selected to become AaPCs also lack the ability to express at least one endogenous counterpart (*e.g.*, endogenous MHC Class I or Class II molecule and/or endogenous assisting molecules as described above) to the exogenous MHC Class I or Class II molecule and assisting molecule components that are introduced into the cells. Furthermore, AaPCs preferably retain the

deficiencies and poikilothermic properties that were possessed by the cells prior to their modification to generate the AaPCs. Exemplary AaPCs either constitute or are derived from a transporter associated with antigen processing (TAP)-deficient cell line, such as an insect cell line. An exemplary poikilothermic insect cells line is a *Drosophila* cell line, such as a Schneider 2 cell line (see, *e.g.*, Schneider 1972 Illustrative methods for the preparation, growth, and culture of Schneider 2 cells, are provided in U.S. Pat. Nos. 6,225,042, 6,355,479, and 6,362,001.

[0367] In one embodiment, AaPCs are also subjected to a freeze-thaw cycle. In an exemplary freeze-thaw cycle, the AaPCs may be frozen by contacting a suitable receptacle containing the AaPCs with an appropriate amount of liquid nitrogen, solid carbon dioxide (*i.e.*, dry ice), or similar low-temperature material, such that freezing occurs rapidly. The frozen APCs are then thawed, either by removal of the AaPCs from the low-temperature material and exposure to ambient room temperature conditions, or by a facilitated thawing process in which a lukewarm water bath or warm hand is employed to facilitate a shorter thawing time. Additionally, AaPCs may be frozen and stored for an extended period of time prior to thawing. Frozen AaPCs may also be thawed and then lyophilized before further use. Preferably, preservatives that might detrimentally impact the freeze-thaw procedures, such as dimethyl sulfoxide (DMSO), polyethylene glycols (PEGs), and other preservatives, are absent from media containing AaPCs that undergo the freeze-thaw cycle, or are essentially removed, such as by transfer of AaPCs to media that is essentially devoid of such preservatives.

[0368] In further embodiments, xenogenic nucleic acid and nucleic acid endogenous to the AaPCs, may be inactivated by crosslinking, so that essentially no cell growth, replication or expression of nucleic acid occurs after the inactivation. In one embodiment, AaPCs are inactivated at a point subsequent to the expression of exogenous MHC and assisting molecules, presentation of such molecules on the surface of the AaPCs, and loading of presented MHC molecules with selected peptide or peptides. Accordingly, such inactivated and selected peptide loaded AaPCs, while rendered essentially incapable of proliferating or replicating, retain selected peptide presentation function. Preferably, the crosslinking also yields AaPCs that are essentially free of contaminating microorganisms, such as bacteria and viruses, without substantially decreasing the antigen-presenting cell function of the AaPCs. Thus crosslinking maintains the important AaPC functions of while helping to alleviate concerns about safety of a cell therapy product developed using the AaPCs. For methods related to crosslinking and AaPCs, see for example, U.S. Patent Application Publication No. 20090017000, which is incorporated herein by reference.

[0369] In certain embodiments there are further provided an engineered antigen presenting cell (APC). Such cells may be used, for example, as described above, to propagate immune effector cells *ex vivo*. In further aspects, engineered APCs may, themselves be administered to a patient and thereby stimulate expansion of immune effector cells *in vivo*. Engineered APCs of the embodiments may, themselves, be used as a therapeutic agent. In other embodiments, the engineered APCs can be used as a therapeutic agent that can stimulate activation of endogenous immune effector cells specific for a target antigen and/or to increase the activity or persistence of adoptively transferred immune effector cells specific to a target antigen.

[0370] As used herein the term “engineered APC” refers to cell(s) that comprises at least a first transgene, wherein the first transgene encodes a HLA. Such engineered APCs may further comprise a second transgene for expression of an antigen, such that the antigen is presented at the surface on the APC in complex with the HLA. In some aspects, the engineered APC can be a cell type that presented antigens (*e.g.*, a dendritic cell). In further aspects, engineered APC can be produced from a cell type that does not normally present antigens, such as a T-cell or T-cell progenitor (referred to as “T-APC”). Thus, in some aspects, an engineered APC of the embodiments comprises a first transgene encoding a target antigen and a second transgene encoding a human leukocyte antigen (HLA), such that the HLA is expressed on the surface of the engineered APC in complex with an epitope of the target antigen. In certain specific aspects, the HLA expressed in the engineered APC is HLA-A2.

[0371] In some aspects, an engineered APC of the embodiments may further comprise at least a third transgene encoding co-stimulatory molecule. The co-stimulatory molecule may be a co-stimulatory cytokine that may be a membrane-bound $C\gamma$ cytokine. In certain aspects, the co-stimulatory cytokine is IL-15, such as membrane-bound IL-15. In some further aspects, an engineered APC may comprise an edited (or deleted) gene. For example, an inhibitory gene, such as PD-1, LIM-3, CTLA-4 or a TCR, can be edited to reduce or eliminate expression of the gene. An engineered APC of the embodiments may further comprise a transgene encoding any target antigen of interest. For example, the target antigen can be an infectious disease antigen or a tumor-associated antigen (TAA).

Point-of-Care

[0372] In one embodiment of the present disclosure, the immune effector cells described herein are modified at a point-of-care site. In some cases, the point-of-care site is at a hospital or at a facility (*e.g.*, a medical facility) near a subject in need of treatment. The subject undergoes

apheresis and peripheral blood mononuclear cells (PBMCs) or a sub population of PBMC can be enriched for example, by elutriation or Ficoll separation. Enriched PBMC or a subpopulation of PBMC can be cryopreserved in any appropriate cryopreservation solution prior to further processing. In one instance, the elutriation process is performed using a buffer solution containing human serum albumin. Immune effector cells, such as T cells can be isolated by selection methods described herein. In one instance, the selection method for T cells includes beads specific for CD3 and CD8 on T cells. In one case, the beads can be paramagnetic beads. The harvested immune effector cells can be cryopreserved in any appropriate cryopreservation solution prior to modification. The immune effector cells can be thawed up to 24 hours, 36 hours, 48 hours, 72 hours or 96 hours ahead of infusion. The thawed cells can be placed in cell culture buffer, for example in cell culture buffer (*e.g.* RPMI) supplemented with fetal bovine serum (FBS) or placed in a buffer that includes cytokines such as IL-2 and IL-21, prior to modification. In another aspect, the harvested immune effector cells can be modified immediately without the need for cryopreservation.

[0373] In some cases, the immune effector cells are modified by engineering/introducing a chimeric receptor, one or more cell tag(s) described herein, and/or cytokine into the immune effector cells and then rapidly infused into a subject. In some cases, the sources of immune effector cells can include both allogeneic and autologous sources. In one case, the immune effector cells can be T cells or NK cells. In one case, the chimeric receptor can be a CD19 CAR. In another case, the chimeric receptor can be a CD33CAR. In a further case, the chimeric receptor can be a MUC16 CAR. In another case, the cytokine can be mbIL-15. In one case, the mbIL-15 is of SEQ ID NO: 178, or variant or fragment thereof. In one case, the cell tag can be SEQ ID NO: 57. In yet another case, expression of mbIL-15 is modulated by ligand inducible gene-switch expression systems described herein. For example, a ligand such as veledimex can be delivered to the subject to modulate the expression of mbIL-15. In another aspect, veledimex is provided at 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg or 100 mg. In a further aspect, lower doses of veledimex are provided, for example, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg or 20 mg. In one embodiment, veledimex is administered to the subject 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days prior to infusion of the modified immune effector cells. In a further embodiment, veledimex is administered about once every 12 hours, about once every 24 hours, about once every 36 hours or about once every 48 hours, for an effective period of time to a subject post infusion of the modified immune effector cells. In one embodiment, an effective period of time for veledimex administration is about: 7, 8,

9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 days. In other embodiments, vedimex can be re-administered after a rest period, after a drug holiday or when the subject experiences a relapse.

[0374] In certain cases, where an adverse effect on a subject is observed or when treatment is not needed, the cell tag can be activated, for example via cetuximab, for conditional *in vivo* ablation of modified immune effector cells comprising cell tags such as truncated epidermal growth factor receptor tags (HER1t variants) as described herein.

[0375] In some embodiments, such immune effectors cells are modified by the constructs through electroporation. In one instance, electroporation is performed with electroporators such as Lonza's Nucleofector™ electroporators. In other embodiments, the vector comprising the above-mentioned constructs is a non-viral or viral vector. In one case, the non-viral vector includes a Sleeping Beauty transposon-transposase system. In one instance, the immune effector cells are electroporated using a specific sequence. For example, the immune effector cells can be electroporated with one transposon followed by the DNA encoding the transposase followed by a second transposon. In another instance, the immune effector cells can be electroporated with all transposons and transposase at the same time. In another instance, the immune effector cells can be electroporated with a transposase followed by both transposons or one transposon at a time. While undergoing sequential electroporation, the immune effector cells may be rested for a period of time prior to the next electroporation step.

[0376] In some cases, the modified immune effector cells do not undergo a propagation and activation step. In some cases, the modified immune effector cells do not undergo an incubation or culturing step (*e.g. ex vivo* propagation). In certain cases, the modified immune effector cells are placed in a buffer that includes IL-2 and IL21 prior to infusion. In other instances, the modified immune effector cells are placed or rested in cell culture buffer, for example in cell culture buffer (*e.g.* RPMI) supplemented with fetal bovine serum (FBS) prior to infusion. Prior to infusion, the modified immune effector cells can be harvested, washed and formulated in saline buffer in preparation for infusion into the subject.

[0377] In one instance, the subject has been lymphodepleted prior to infusion. In other instances, lymphodepletion is not required and the modified immune effector cells are rapidly infused into the subject. Exemplary lymphodepletion regimens are listed in **Tables 2 and 3** below:

Table 2. Regimen 1

D-6	Admit / IV Hydration
D-5	Fludarabine 25 mg/m ² , Cyclophosphamide 250 mg/m ²
D-4	Fludarabine 25 mg/m ² , Cyclophosphamide 250 mg/m ²
D-3	Fludarabine 25 mg/m ² IV, Cyclophosphamide 250 mg/m ²
D-2	REST
D-1	REST
D-0	T-cell infusion

Table 3. Regimen 2

D-6	Admit / IV Hydration
D-5	Fludarabine 30 mg/m ² , Cyclophosphamide 500 mg/m ²
D-4	Fludarabine 30 mg/m ² , Cyclophosphamide 500 mg/m ²
D-3	Fludarabine 30 mg/m ² IV, Cyclophosphamide 500 mg/m ²
D-2	REST
D-1	REST
D-0	T-cell infusion

[0378] In a further instance, the subject undergoes minimal lymphodepletion. Minimal lymphodepletion herein refers to a reduced lymphodepletion protocol such that the subject can be infused within 1 day, 2 days or 3 days following the lymphodepletion regimen. In one instance, a reduced lymphodepletion protocol can include lower doses of fludarabine and/or cyclophosphamide. In another instance, a reduced lymphodepletion protocol can include a shortened period of lymphodepletion, for example 1 day or 2 days.

[0379] In one embodiment, the immune effector cells are modified by engineering/introducing a chimeric receptor and a cytokine into said immune effector cells and then rapidly infused into a subject. In other cases, the immune effector cells are modified by engineering/introducing a chimeric receptor and a cytokine into said cells and then infused within at least: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 hours into a subject. In other cases, immune effector cells are modified by engineering/introducing a chimeric receptor

and a cytokine into the immune effector cells and then infused in 0 days, <1 day, <2 days, <3 days, <4 days, <5 days, <6 days or <7 days into a subject.

[0380] In some embodiments, an amount of modified effector cells is administered to a subject in need thereof and the amount is determined based on the efficacy and the potential of inducing a cytokine-associated toxicity. In another embodiment, the modified effector cells are CAR⁺ and CD3⁺ cells. In some cases, an amount of modified effector cells comprises about 10⁴ to about 10⁹ modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10⁴ to about 10⁵ modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10⁵ to about 10⁶ modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10⁶ to about 10⁷ modified effector cells/kg. In some cases, an amount of modified effector cells comprises >10⁴ but ≤ 10⁵ modified effector cells/kg. In some cases, an amount of modified effector cells comprises >10⁵ but ≤ 10⁶ modified effector cells/kg. In some cases, an amount of modified effector cells comprises >10⁶ but ≤ 10⁷ modified effector cells/kg. In one embodiment, a lower dose >10² but ≤ 10⁴ modified effector cells/kg may be infused.

[0381] In one embodiment, the modified immune effector cells are targeted to the cancer via regional delivery directly to the tumor tissue. For example, in ovarian cancer, the modified immune effector cells can be delivered intraperitoneally (IP) to the abdomen or peritoneal cavity. Such IP delivery can be performed via a port or pre-existing port placed for delivery of chemotherapy drugs. Other methods of regional delivery of modified immune effector cells can include catheter infusion into resection cavity, ultrasound guided intratumoral injection, hepatic artery infusion or intrapleural delivery.

[0382] In one embodiment, a subject in need thereof, can begin therapy with a first dose of modified immune effector cells delivered via IP followed by a second dose of modified immune effector cells delivered via IV. In a further embodiment, the second dose of modified immune effector cells can be followed by subsequent doses which can be delivered via IV or IP. In one embodiment, the duration between the first and second or further subsequent dose can be about: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 days. In one embodiment, the duration between the first and second or further subsequent dose can be about: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 months. In another embodiment, the duration between the first and second or further subsequent dose can be about: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 years.

[0383] In another embodiment, a catheter can be placed at the tumor or metastasis site for further administration of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 doses of modified immune effector cells. In some cases, doses of modified effector cells can comprise about 10^2 to about 10^9 modified effector cells/kg. In cases where toxicity is observed, doses of modified effector cells can comprise about 10^2 to about 10^5 modified effector cells/kg. In some cases, doses of modified effector cells can start at about 10^2 modified effector cells/kg and subsequent doses can be increased to about: 10^4 , 10^5 , 10^6 , 10^7 , 10^8 or 10^9 modified effector cells/kg.

[0384] In other embodiments, a method of stimulating the proliferation and/or survival of engineered cells comprises obtaining a sample of cells from a subject, and transfecting cells of the sample of cells with one or more polynucleotides that comprise one or more transposons. In one embodiment, the transposons encode a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, and a transposase effective to integrate said one or more polynucleotides into the genome of said cells, to provide a population of engineered cells. In an embodiment, the transposons encode a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, gene switch polypeptides for ligand-inducible control of the cytokine and a transposase effective to integrate said one or more polynucleotides into the genome of said cells, to provide a population of engineered cells. In an embodiment, the gene switch polypeptides comprise i) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain, and ii) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain. In some embodiments, the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker. In one instance, lymphodepletion is not required prior to administration of the engineered cells to a subject.

In one instance, a method of *in vivo* propagation of engineered cells comprises obtaining a sample of cells from a subject, and transfecting cells of the sample of cells with one or more polynucleotides that comprise one or more transposons. In one embodiment, the transposon(s) comprising a chimeric antigen receptor (CAR), a cytokine, one or more cell tags; and a transposase effective to integrate said one or more polynucleotides into the genome of said cells are electroporated into the sample of cells, to provide a population of engineered cells. In a further embodiment, the transposons encode a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, gene switch polypeptides for ligand-inducible control of the cytokine and a transposase effective to integrate said one or more polynucleotides into the genome of said cells, to provide a population of engineered cells. In an embodiment, the gene switch polypeptides

comprise i) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain, and ii) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain. In some embodiments, the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker. In another embodiment, a single transposon can comprise a chimeric antigen receptor (CAR), a cytokine, one or more cell tags such as HER1t or any variants described herein. In one instance, lymphodepletion is not required prior to administration of the engineered cells to a subject.

[0385] In another embodiment, a method of enhancing *in vivo* persistence of engineered cells in a subject in need thereof comprises obtaining a sample of cells from a subject, and transfecting cells of the sample of cells with one or more polynucleotides that comprise one or more transposons. In one embodiment, the transposon(s) comprising a chimeric antigen receptor (CAR), a cytokine, one or more cell tags; and a transposase effective to integrate said one or more polynucleotides into the genome of said cells are electroporated into the sample of cells, to provide a population of engineered cells. In another embodiment, a single transposon can comprise a chimeric antigen receptor (CAR), a cytokine, one or more cell tags such as HER1t or any variants described herein. In some cases, one or more transposons encode a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, gene switch polypeptides for ligand-inducible control of the cytokine and a transposase effective to integrate the DNA into the genome of said cells, to provide a population of engineered cells. In some cases, the gene switch polypeptides comprise i) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain, and ii) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain, wherein the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker. In one instance, lymphodepletion is not required prior to administration of the engineered cells to a subject.

[0386] In another embodiment, a method of treating a subject with a solid tumor comprises obtaining a sample of cells from a subject, transfecting cells of the sample with one or more polynucleotides that comprise one or more transposons, and administering the population of engineered cells to the subject. In one instance, lymphodepletion is not required prior to administration of the engineered cells to a subject. In some cases, the one or more transposons encode a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, and a transposase effective to integrate the DNA into the genome of the cells. In some cases, the one or more

transposons encode a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, gene switch polypeptides for ligand-inducible control of the cytokine and a transposase effective to integrate the DNA into the genome of the cells. In some cases, the gene switch polypeptides comprise: i) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain, and ii) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain, wherein the first gene switch polypeptide and second gene switch polypeptide are connected by a linker. In some cases, the cells are transfected via electroporation. In some cases, the polynucleotides encoding the gene switch polypeptides are modulated by a promoter. In some cases, the promoter is a tissue-specific promoter or an EF1A promoter or functional variant thereof. In some cases, the tissue-specific promoter comprises a T cell specific response element or an NFAT response element. In some cases, the cytokine comprises at least one of IL-1, IL-2, IL-15, IL-12, IL-21, a fusion of IL-15, IL-15R or an IL-15 variant. In some cases, the cytokine is in secreted form. In some cases, the cytokine is in membrane-bound form. In some cases, the cells are NK cells, NKT cells, T-cells or T-cell progenitor cells. In some cases, the cells are administered to a subject (*e.g.* by infusing the subject with the engineered cells). In some cases, the method further comprises administering an effective amount of a ligand (*e.g.* vedolimex) to induce expression of the cytokine. In some cases, the CAR is capable of binding at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, MUC-16, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2. In some cases, the transposase is salmonid-type Tc1-like transposase. In some cases, the transposase is SB11 or SB100x transposase. In other cases, the transposase is PiggyBac. In some cases, the cell tag comprise at least one of a HER1t1.

Indications

[0387] In some embodiments, disclosed herein are methods of administering a modified effector cell encoding a polynucleotide described herein to a subject having a disorder, for instance cancer or an infectious disease. In some cases, the cancer is a cancer associated with an expression of CD19, CD20, CD33, CD44, BCMA, CD123, EGFRvIII, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72 or VEGF-R2.

[0388] In some embodiments, disclosed herein are methods of administering a polynucleotide, polypeptide or a modified effector cell encoding a polynucleotide described herein, to a subject having a cancer associated with an overexpression of CD19. In some embodiments, disclosed herein are methods of administering a modified effector cell to a subject having a cancer associated with an overexpression of CD33. In some embodiments, disclosed herein are methods of administering a modified effector cell to a subject having a cancer associated with an overexpression of CD44, BCMA, CD123, EGFRvIII, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72 or VEGF-R2. In some cases, the cancer is a metastatic cancer. In other cases, the cancer is a relapsed or refractory cancer.

[0389] In some cases, a cancer is a solid tumor or a hematologic malignancy. In some instances, the cancer is a solid tumor. In other instances, the cancer is a hematologic malignancy. In some cases, the cancer is a metastatic cancer. In some cases, the cancer is a relapsed or refractory cancer.

[0390] In some instances, the cancer is a solid tumor. Exemplary solid tumors include, but are not limited to, anal cancer; appendix cancer; bile duct cancer (*i.e.*, cholangiocarcinoma); bladder cancer; brain tumor; breast cancer; cervical cancer; colon cancer; cancer of Unknown Primary (CUP); esophageal cancer; eye cancer; fallopian tube cancer; gastroenterological cancer; kidney cancer; liver cancer; lung cancer; medulloblastoma; melanoma; oral cancer; ovarian cancer; pancreatic cancer; parathyroid disease; penile cancer; pituitary tumor; prostate cancer; rectal cancer; skin cancer; stomach cancer; testicular cancer; throat cancer; thyroid cancer; uterine cancer; vaginal cancer; or vulvar cancer.

[0391] In some instances, the cancer is a hematologic malignancy. In some cases, a hematologic malignancy comprises a lymphoma, a leukemia, a myeloma, or a B-cell malignancy. In some cases, a hematologic malignancy comprises a lymphoma, a leukemia or a myeloma. In some instances, exemplary hematologic malignancies include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, non-CLL/SLL lymphoma, prolymphocytic leukemia (PLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma,

B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis. In some embodiments, the hematologic malignancy comprises a myeloid leukemia. In some embodiments, the hematologic malignancy comprises acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).

[0392] In some instances, disclosed herein are methods of administering to a subject having a hematologic malignancy selected from chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, non-CLL/SLL lymphoma, prolymphocytic leukemia (PLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis a modified effector cell described herein. In some instances, disclosed herein are methods of administering to a subject having a hematologic malignancy selected from AML or CML a modified effector cell to the subject.

[0393] In other cases, disclosed herein are methods of administering to a subject having an infection due to an infectious disease. An infectious disease can be a disease resulting from a bacterial, viral or fungi infection. In other instances, exemplary viral pathogens include those of the families of Adenoviridae, Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Respiratory Syncytial Virus (RSV), JC virus, BK virus, HSV, HHV family of viruses, Picornaviridae, Herpesviridae, Hepadnaviridae, Flaviviridae, Retroviridae, Orthomyxoviridae, Paramyxoviridae, Papovaviridae, Polyomavirus, Rhabdoviridae, and Togaviridae. Exemplary pathogenic viruses cause smallpox, influenza, mumps, measles, chickenpox, ebola, and rubella. Exemplary pathogenic fungi include Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocystis, and Stachybotrys. Exemplary pathogenic bacteria include Streptococcus, Pseudomonas, Shigella, Campylobacter, Staphylococcus, Helicobacter, E. coli, Rickettsia, Bacillus, Bordetella, Chlamydia, Spirochetes, and Salmonella.

Modified Effector Cell Doses

[0394] In some embodiments, an amount of modified effector cells is administered to a subject in need thereof and the amount is determined based on the efficacy and the potential of inducing a cytokine-associated toxicity. In some cases, an amount of modified immune effector cells comprises about 10^2 to about 10^9 modified immune effector cells/kg. In some cases, an amount of modified immune effector cells comprises about 10^3 to about 10^9 modified immune effector cells/kg. In some cases, an amount of modified immune effector cells comprises about 10^4 to about 10^9 modified immune effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^5 to about 10^9 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^5 to about 10^8 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^5 to about 10^7 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^6 to about 10^9 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^6 to about 10^8 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^7 to about 10^9 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^5 to about 10^6 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^6 to about 10^7 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^7 to about 10^8 modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10^8 to about 10^9 modified effector cells/kg. In some instances, an amount of modified effector cells comprises about 10^9 modified effector cells/kg. In some instances, an amount of modified effector cells comprises about 10^8 modified effector cells/kg. In some instances, an amount of modified effector cells comprises about 10^7 modified effector cells/kg. In some instances, an amount of modified effector cells comprises about 10^6 modified effector cells/kg. In some instances, an amount of modified effector cells comprises about 10^5 modified effector cells/kg.

[0395] In some embodiments, the modified effector cells are modified T cells. In some instances, the modified T cells are CAR-T cells. In some cases, an amount of CAR-T cells comprises about 10^2 to about 10^4 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^5 to about 10^9 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^5 to about 10^8 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^5 to about 10^7 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^6 to about 10^9 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^6 to about 10^8 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^7 to about 10^9 CAR-T cells/kg. In some cases, an amount of CAR-T cells

comprises about 10^5 to about 10^6 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^6 to about 10^7 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^7 to about 10^8 CAR-T cells/kg. In some cases, an amount of CAR-T cells comprises about 10^8 to about 10^9 CAR-T cells/kg. In some instances, an amount of CAR-T cells comprises about 10^9 CAR-T cells/kg. In some instances, an amount of CAR-T cells comprises about 10^8 CAR-T cells/kg. In some instances, an amount of CAR-T cells comprises about 10^7 CAR-T cells/kg. In some instances, an amount of CAR-T cells comprises about 10^6 CAR-T cells/kg. In some instances, an amount of CAR-T cells comprises about 10^5 CAR-T cells/kg.

[0396] In some embodiments, the CAR-T cells are CD19-specific CAR-T cells. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^2 to about 10^9 CAR-T cells/kg. In some embodiments, the CAR-T cells are CD19-specific CAR-T cells. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^3 to about 10^9 CAR-T cells/kg. In some embodiments, the CAR-T cells are CD19-specific CAR-T cells. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^4 to about 10^9 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^5 to about 10^9 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^5 to about 10^8 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^5 to about 10^7 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^6 to about 10^9 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^6 to about 10^8 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^7 to about 10^9 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^5 to about 10^6 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^6 to about 10^7 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^7 to about 10^8 CAR-T cells/kg. In some cases, an amount of CD19-specific CAR-T cells comprises about 10^8 to about 10^9 CAR-T cells/kg. In some instances, an amount of CD19-specific CAR-T cells comprises about 10^9 CAR-T cells/kg. In some instances, an amount of CD19-specific CAR-T cells comprises about 10^8 CAR-T cells/kg. In some instances, an amount of CD19-specific CAR-T cells comprises about 10^7 CAR-T cells/kg. In some instances, an amount of CD19-specific CAR-T cells comprises about 10^6 CAR-T cells/kg. In some instances, an amount of CD19-specific CAR-T cells comprises about 10^5 CAR-T cells/kg. In some instances, an amount of CD19-specific CAR-T cells comprises about 10^4 CAR-T cells/kg. In some instances, an amount of

CD19-specific CAR-T cells comprises about 10^3 CAR-T cells/kg. In some instances, an amount of CD19-specific CAR-T cells comprises about 10^2 CAR-T cells/kg.

[0397] In some embodiments, the modified T cells are engineered TCR T-cells. In some cases, an amount of engineered TCR T- cells comprises about 10^2 to about 10^9 TCR cells/kg. In some cases, an amount of engineered TCR T- cells comprises about 10^3 to about 10^9 TCR cells/kg. In some cases, an amount of engineered TCR T- cells comprises about 10^4 to about 10^9 TCR cells/kg. In some cases, an amount of engineered TCR T- cells comprises about 10^5 to about 10^9 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^5 to about 10^8 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^5 to about 10^7 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^6 to about 10^9 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^6 to about 10^8 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^7 to about 10^9 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^5 to about 10^6 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^6 to about 10^7 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^7 to about 10^8 TCR cells/kg. In some cases, an amount of engineered TCR cells comprises about 10^8 to about 10^9 TCR cells/kg. In some instances, an amount of engineered TCR cells comprises about 10^9 TCR cells/kg. In some instances, an amount of engineered TCR cells comprises about 10^8 TCR cells/kg. In some instances, an amount of engineered TCR cells comprises about 10^7 TCR cells/kg. In some instances, an amount of engineered TCR cells comprises about 10^6 TCR cells/kg. In some instances, an amount of engineered TCR cells comprises about 10^5 TCR cells/kg. In some instances, an amount of engineered TCR cells comprises about 10^4 TCR cells/kg. In some instances, an amount of engineered TCR cells comprises about 10^3 TCR cells/kg. In some instances, an amount of engineered TCR cells comprises about 10^2 TCR cells/kg.

Pharmaceutical Compositions and Dosage Forms

[0398] In some embodiments, disclosed herein are compositions comprising a polynucleotide or polypeptide disclosed herein for administration in a subject. In some instances, are modified effector cell compositions encoding a polynucleotide or polypeptide disclosed herein, and optionally containing a cytokine and/or an additional therapeutic agent. In some instances, also included herein are vectors encoding polypeptide constructs for expressing cell tags for modification of an effector cell.

[0399] In some instances, pharmaceutical compositions of a modified effector cell or a vector encoding polypeptide constructs and a chimeric antigen receptor are formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).

[0400] Pharmaceutical compositions are optionally manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

[0401] In certain embodiments, compositions may also include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.

[0402] In other embodiments, compositions may also include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.

[0403] The pharmaceutical compositions described herein are administered by any suitable administration route, including but not limited to, oral, parenteral (*e.g.*, intravenous, subcutaneous, intramuscular, intracerebral, intracerebroventricular, intra-articular, intraperitoneal, or intracranial), intranasal, buccal, sublingual, or rectal administration routes. In some instances, the pharmaceutical composition is formulated for parenteral (*e.g.*, intravenous, subcutaneous, intramuscular, intracerebral, intracerebroventricular, intra-articular, intraperitoneal, or intracranial) administration.

[0404] The pharmaceutical compositions described herein are formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral ingestion by an individual to be treated, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations. In some embodiments, the pharmaceutical compositions are formulated into capsules. In some embodiments, the pharmaceutical compositions are formulated into solutions (for example, for IV administration). In some cases, the pharmaceutical composition is formulated as an infusion. In some cases, the pharmaceutical composition is formulated as an injection.

[0405] The pharmaceutical solid dosage forms described herein optionally include a compound described herein and one or more pharmaceutically acceptable additives such as a compatible carrier, binder, filling agent, suspending agent, flavoring agent, sweetening agent, disintegrating agent, dispersing agent, surfactant, lubricant, colorant, diluent, solubilizer, moistening agent, plasticizer, stabilizer, penetration enhancer, wetting agent, anti-foaming agent, antioxidant, preservative, or one or more combination thereof.

[0406] In still other aspects, using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000), a film coating is provided around the compositions. In some embodiments, the compositions are formulated into particles (for example for administration by capsule) and some or all of the particles are coated. In some embodiments, the compositions are formulated into particles (for example for administration by capsule) and some or all of the particles are microencapsulated. In some embodiments, the compositions are formulated into particles (for example for administration by capsule) and some or all of the particles are not microencapsulated and are uncoated.

[0407] In certain embodiments, compositions provided herein may also include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.

[0408] "Proliferative disease" as referred to herein means a unifying concept that excessive proliferation of cells and turnover of cellular matrix contribute significantly to the pathogenesis of several diseases, including cancer is presented.

[0409] “Patient” as used herein refers to a mammalian subject diagnosed with or suspected of having or developing a physiological condition, for instance a cancer or an autoimmune condition or an infection. In some embodiments, the term “patient” refers to a mammalian subject with a higher than average likelihood of developing cancer. Exemplary patients may be humans, apes, dogs, pigs, cattle, cats, horses, goats, sheep, rodents and other mammals that can benefit from the therapies disclosed herein. Exemplary human patients can be male and/or female.

[0410] “Administering” is referred to herein as providing the compositions of the present disclosure to a patient. By way of example and not limitation, composition administration, *e.g.*, injection, may be performed by intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, or intramuscular (i.m.) injection. One or more such routes may be employed. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time. Alternatively, or concurrently, administration may be by the oral route. Additionally, administration may also be by surgical deposition of a bolus or pellet of cells, or positioning of a medical device.

[0411] “A patient in need thereof” or “subject in need thereof” is referred to herein as a patient or subject diagnosed with or suspected of having a disease or disorder, for instance, but not restricted to a proliferative disorder such as cancer. In one embodiment, the patient or subject has or is likely to develop solid tumors or leukemia. In some embodiments leukemia can be, for instance, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML).

[0412] The compositions of the present disclosure may comprises host cells expressing the inventive nucleic acid sequences, or a vector comprising the inventive nucleic acid sequence, in an amount that is effective to treat or prevent proliferative disorders. As used herein, the terms “treatment,” “treating,” and the like refer to obtaining a desired pharmacologic and/or physiologic effect. In embodiments, the effect is therapeutic, *i.e.*, the effect partially or completely cures a disease and/or adverse symptom attributable to the disease. To this end, the inventive method comprises administering a “therapeutically effective amount” of the composition comprising the host cells expressing the inventive nucleic acid sequence, or a vector comprising the inventive nucleic acid sequences.

[0413] A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the

individual, and the ability of the inventive nucleic acid sequences to elicit a desired response in the individual.

[0414] Alternatively, the pharmacologic and/or physiologic effect may be “prophylactic,” *i.e.*, the effect completely or partially prevents a disease or symptom thereof.

[0415] A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result (*e.g.*, prevention of disease onset).

[0416] “Antifoaming agents” reduce foaming during processing which can result in coagulation of aqueous dispersions, bubbles in the finished film, or generally impair processing. Exemplary anti-foaming agents include silicon emulsions or sorbitan sesquoleate.

[0417] “Antioxidants” include, for example, butylated hydroxytoluene (BHT), sodium ascorbate, ascorbic acid, sodium metabisulfite and tocopherol. In certain embodiments, antioxidants enhance chemical stability where required.

[0418] Formulations described herein may benefit from antioxidants, metal chelating agents, thiol containing compounds and other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.

[0419] “Binders” impart cohesive qualities and include, *e.g.*, alginic acid and salts thereof; cellulose derivatives such as carboxymethylcellulose, methylcellulose (*e.g.*, Methocel®), hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (*e.g.*, Klucel®), ethylcellulose (*e.g.*, Ethocel®), and microcrystalline cellulose (*e.g.*, Avicel®); microcrystalline dextrose; amylose; magnesium aluminum silicate; polysaccharide acids; bentonites; gelatin; polyvinylpyrrolidone/vinyl acetate copolymer; crospovidone; povidone; starch; pregelatinized starch; tragacanth, dextrin, a sugar, such as sucrose (*e.g.*, Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (*e.g.*, Xylitab®), and lactose; a natural or synthetic gum such as acacia, tragacanth, ghatti gum, mucilage of isapol husks, polyvinylpyrrolidone (*e.g.*, Polyvidone® CL, Kollidon® CL, Polyplasdone® XL-10), larch arabogalactan, Veegum®, polyethylene glycol, waxes, sodium alginate, and the like.

[0420] A “carrier” or “carrier materials” include any commonly used excipients in pharmaceuticals and should be selected on the basis of compatibility with compounds disclosed herein, such as, compounds of ibrutinib and an anticancer agent, and the release profile properties of the desired dosage form. Exemplary carrier materials include, *e.g.*, binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like. “Pharmaceutically compatible carrier materials” may include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, polyvinylpyrrolidone (PVP), cholesterol, cholesterol esters, sodium caseinate, soy lecithin, taurocholic acid, phosphatidylcholine, sodium chloride, tricalcium phosphate, dipotassium phosphate, cellulose and cellulose conjugates, sugars sodium stearyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, and the like. See, *e.g.*, Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).

[0421] “Dispersing agents,” and/or “viscosity modulating agents” include materials that control the diffusion and homogeneity of a drug through liquid media or a granulation method or blend method. In some embodiments, these agents also facilitate the effectiveness of a coating or eroding matrix. Exemplary diffusion facilitators/dispersing agents include, *e.g.*, hydrophilic polymers, electrolytes, Tween ® 60 or 80, PEG, polyvinylpyrrolidone (PVP; commercially known as Plasdane®), and the carbohydrate-based dispersing agents such as, for example, hydroxypropyl celluloses (*e.g.*, HPC, HPC-SL, and HPC-L), hydroxypropyl methylcelluloses (*e.g.*, HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M), carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinyl pyrrolidone/vinyl acetate copolymer (S630), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (*e.g.*, Pluronic F68®, F88®, and F108®, which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (*e.g.*, Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Corporation, Parsippany, N.J.)),

polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyvinylpyrrolidone/vinyl acetate copolymer (S-630), polyethylene glycol, *e.g.*, the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, sodium carboxymethylcellulose, methylcellulose, polysorbate-80, sodium alginate, gums, such as, *e.g.*, gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, cellulosics, such as, *e.g.*, sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, polysorbate-80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone, carbomers, polyvinyl alcohol (PVA), alginates, chitosans and combinations thereof. Plasticizers such as cellulose or triethyl cellulose can also be used as dispersing agents. Dispersing agents particularly useful in liposomal dispersions and self-emulsifying dispersions are dimyristoyl phosphatidyl choline, natural phosphatidyl choline from eggs, natural phosphatidyl glycerol from eggs, cholesterol and isopropyl myristate.

[0422] Combinations of one or more erosion facilitator with one or more diffusion facilitator can also be used in the present compositions.

[0423] The term “diluent” refers to chemical compounds that are used to dilute the compound of interest prior to delivery. Diluents can also be used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions (which also can provide pH control or maintenance) are utilized as diluents in the art, including, but not limited to a phosphate buffered saline solution. In certain embodiments, diluents increase bulk of the composition to facilitate compression or create sufficient bulk for homogenous blend for capsule filling. Such compounds include *e.g.*, lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel®; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac® (Amstar); mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose-based diluents, confectioner’s sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; mannitol, sodium chloride; inositol, bentonite, and the like.

[0424] “Filling agents” include compounds such as lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose

powder, dextrose, dextrans, dextran, starches, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.

[0425] “Lubricants” and “glidants” are compounds that prevent, reduce or inhibit adhesion or friction of materials. Exemplary lubricants include, *e.g.*, stearic acid, calcium hydroxide, talc, sodium stearyl fumarate, a hydrocarbon such as mineral oil, or hydrogenated vegetable oil such as hydrogenated soybean oil (Sterotex®), higher fatty acids and their alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, glycerol, talc, waxes, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol (*e.g.*, PEG-4000) or a methoxypolyethylene glycol such as Carbowax™, sodium oleate, sodium benzoate, glyceryl behenate, polyethylene glycol, magnesium or sodium lauryl sulfate, colloidal silica such as Syloid™, Cab-O-Sil®, a starch such as corn starch, silicone oil, a surfactant, and the like.

[0426] “Plasticizers” are compounds used to soften the microencapsulation material or film coatings to make them less brittle. Suitable plasticizers include, *e.g.*, polyethylene glycols such as PEG 300, PEG 400, PEG 600, PEG 1450, PEG 3350, and PEG 800, stearic acid, propylene glycol, oleic acid, triethyl cellulose and triacetin. In some embodiments, plasticizers can also function as dispersing agents or wetting agents.

[0427] “Solubilizers” include compounds such as triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate, sodium docusate, vitamin E TPGS, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, hydroxypropyl cyclodextrins, ethanol, n-butanol, isopropyl alcohol, cholesterol, bile salts, polyethylene glycol 200-600, glycofurol, transcitol, propylene glycol, and dimethyl isosorbide and the like.

[0428] “Stabilizers” include compounds such as any antioxidation agents, buffers, acids, preservatives and the like.

[0429] “Suspending agents” include compounds such as polyvinylpyrrolidone, *e.g.*, polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, vinyl pyrrolidone/vinyl acetate copolymer (S630), polyethylene glycol, *e.g.*, the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose acetate stearate, polysorbate-80, hydroxyethylcellulose, sodium alginate, gums, such as, *e.g.*, gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, celluloses, such as, *e.g.*,

sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, polysorbate-80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone and the like.

[0430] “Surfactants” include compounds such as sodium lauryl sulfate, sodium docusate, Tween 60 or 80, triacetin, vitamin E TPGS, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, *e.g.*, Pluronic® (BASF), and the like. Some other surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, *e.g.*, polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, *e.g.*, octoxynol 10, octoxynol 40. In some embodiments, surfactants may be included to enhance physical stability or for other purposes.

[0431] “Viscosity enhancing agents” include, *e.g.*, methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose acetate stearate, hydroxypropylmethyl cellulose phthalate, carbomer, polyvinyl alcohol, alginates, acacia, chitosans and combinations thereof.

[0432] “Wetting agents” include compounds such as oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium docusate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, Tween 80, vitamin E TPGS, ammonium salts and the like.

Kits/Article of Manufacture

[0433] Disclosed herein, in certain embodiments, are kits and articles of manufacture for use with one or more methods described herein. Such kits include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. In one embodiment, the containers are formed from a variety of materials such as glass or plastic.

[0434] The articles of manufacture provided herein contain packaging materials. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, bags, containers, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.

[0435] For example, the container(s) include cells encoding polypeptide constructs expressing one or more of the truncated non-immunogenic polypeptides described herein (*e.g.*, CD20 or CD52). Optionally, the cells may additionally contain one or more heterologous genes, for example a gene encoding a CAR, T-cell receptor and/or a cytokine. Such kits optionally include an identifying description or label or instructions relating to its use in the methods described herein.

[0436] A kit typically includes labels listing contents and/or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.

[0437] In some embodiments, a label is on or associated with the container. In one embodiment, a label is on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label is associated with a container when it is present within a receptacle or carrier that also holds the container, *e.g.*, as a package insert. In one embodiment, a label is used to indicate that the contents are to be used for a specific therapeutic application. The label also indicates directions for use of the contents, such as in the methods described herein.

SEQUENCES

[0438] Provided below is a representative list of certain sequences included in embodiments provided herein.

Sequence Name	SEQ ID NO	Sequence
GMCSFR alpha signal peptide (nt)	1	atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatccca
GMCSFR alpha signal peptide (aa)	2	MLLLVTSLLLCELPHPAFLLIP
Ig Kappa signal peptide (nt)	3	atgaggctccctgctcagctcctggggctgctaatactctgggtcccaggatccagtggg
Ig Kappa signal peptide (aa)	4	MRLPAQLLGLLMLWVPGSSG
Immunoglobulin E signal peptide (nt)	5	atggattggacctggattctgtttctgggtggccgctgccacaagagtgcacagc
Immunoglobulin E signal peptide (aa)	6	MDWTWILFLVAAATRVHS
CD8 α signal peptide (nt)	7	atggcgctgcccgtgaccgccttgctcctgccgctggccttgctgctccacgccgcag gccg
CD8 α signal peptide (aa)	8	MALPVTALLLPLALLLHAARP

TVB2(T21A) signal peptide (nt)	9	atgggacaccagcctcctctgctggatggccctgtgtctcctgggggcagatcacgcagagtgt
TVB2(T21A) signal peptide (aa)	10	MGTSLLCWMALCLLGADHADA
CD52 signal peptide (nt)	11	atgaagcgcttcctcttctcctactcaccatcagcctcctggttatggtacagataca aactggactctca
CD52 signal peptide (aa)	12	MKRFLFLLLTISLLVMVQIQTGLS
Low-affinity nerve growth factor receptor (LNGFR, TNFRSF16) signal peptide (nt)	13	atggggggcaggtgccaccggccgcgccatggacggggccgcgcctgctgctgttgctgct tctgggggtgtcccttggagggtgcc
Low-affinity nerve growth factor receptor (LNGFR, TNFRSF16) signal peptide (aa)	14	MGAGATGRAMDGPRLLLLLLLGVSLGGA
GSG linker (nt)	15	ggaagcgga
GSG linker (aa)	16	GSG
SGSG linker (nt)	17	agtggcagcggc
SGSG linker (aa)	18	SGSG
(G4S)3 Linker (nt)	19	ggcggaggcggaagcggaggcggaggctccggcggaggcggaagc
(G4S)3 Linker (aa)	20	GGGSGGGSGGGGS
(G4S)4 Linker (nt)	21	Ggtggcgggtggctcgggcgggtgggtgggtcgggtggcggcgatctggtggcgggtggctc g
(G4S)4 Linker (aa)	22	GGGSGGGSGGGSGGGGS
Whitlow Linker (nt)	23	ggcagcacctccggcagcggcaagcctggcagcggcgagggcagcaccaagggc
Whitlow Linker (aa)	24	GSTSGSGKPGSGEGSTKG
Glycophorin A (E91-R116) (nt)	25	gagataacactcattatTTTTGGGGTgatggctggtgttattggaacgatcctcttaattt ttcttacgggtattcgccga
Glycophorin A (E91-R116) (aa)	26	EITLIIFGV MAGVIGTILLISYGI
Glycophorin A (I92-I114) (nt)	27	ataacactcattatTTTTGGGGTgatggctggtgttattggaacgatcctcttaatttc ttacggtatt
Glycophorin A (I92-I114) (aa)	28	ITLIIFGV MAGVIGTILLISYGI
Glycophorin A (I92- L109).Integrin β 3(A737-W741) chimera (nt)	29	ataacactcattatTTTTGGGGTgatggctggtgttattggaacgatcctcttagccct gctcatctgg
Glycophorin A (I92- L109).Integrin β 3(A737-W741)	30	ITLIIFGV MAGVIGTILLALLIW

chimera (aa)		
CD3 zeta (CD247) transmembrane domain (nt)	31	ctctgctacctgctggatggaatcctcttcatctatggtgtcattctcactgccttggtcctg
CD3 zeta (CD247) transmembrane domain (aa)	32	LCYLLDGILFIYGVILTALFL
CD8 α transmembrane domain (nt)	33	atctacatctgggccccctctggccggcacctgtggcgtgctgctgctgagcctggcatcacctgtactgcaaccaccggaat
CD8 α transmembrane domain (aa)	34	IYIWAPLAGTCGVLLLSLVITLYCNHRN
CD28 transmembrane domain (nt)	35	ttttgggtgctggtggtggttggtggagtcctggcttgctatagcttgctagtaacaggcctttattattttctgggtg
CD28 transmembrane domain (aa)	36	FWVLVVGGVLACYSLLVTVAFIIFWV
Cytotoxic T-lymphocyte protein 4 transmembrane domain (nt)	37	ttcctcctctggatccttgcagcagttagttcgggggtgtttttttatagctttctcctcaca
Cytotoxic T-lymphocyte protein 4 transmembrane domain (aa)	38	FLLWILAAVSSGLFFYSFLLT
Low-affinity nerve growth factor receptor (LNGFR, TNFRSF16) transmembrane domain (nt)	39	ctcatccctgtctattgctccatcctggctgctgtggttggtggccttggtggcctacatagccttc
Low-affinity nerve growth factor receptor (LNGFR, TNFRSF16) transmembrane domain (aa)	40	LIPVYCSILAAVVVGLVAYIAF
Porcine teschovirus-1 2A region (P2A) (nt)	41	gcaacgaacttctctctcctaaaacaggctggtgatgtggaggagaatcctggtcca
Porcine teschovirus-1 2A region (P2A) (aa)	42	ATNFSLLKQAGDVEENPGP
Equine rhinitis A virus 2A region (E2A) (nt)	43	cagtgtactaattatgctctcttgaaattggctggagatgttgagagcaaccctggacct
Equine rhinitis A virus 2A	44	QCTNYALLKLAGDVESNPGP

region (E2A) (aa)		
Thosea asigna virus 2A region (T2A) (nt)	45	gagggcagaggaagtctgctaacatgcggtgacgtcgaggagaatcctggacct
Thosea asigna virus 2A region (T2A) (aa)	46	EGRGSLLTCDVEENPGP
Foot-and-mouth disease virus 2A region (F2A) (nt)	47	gtcaaacagaccctaactttgatctgctaaaactggccggggatgtggaaagtaatcc cggcccc
Foot-and-mouth disease virus 2A region (F2A) (aa)	48	VKQTLNFDLLKLAGDVESNPGP
EMCV IRES (nt)	49	ccccctctccctccccccccctaactgttactggccgaagccgcttgggaataaggccgg tgtgcgtttgtctatatgttattttccaccatattgccgtcttttggcaatgtgagggc ccggaaacctggccctgtcttcttgacgagcattcctaggggtctttccctctcgcca aaggaatgcaaggtctgttgatgtcgtgaaggaagcagttcctctggaagcttctga agacaaacaacgtctgtagcgaccctttgcaggcagcggaacccccacctggcgacag gtgcctctgcgggccaaaagccacgtgtataagatacacctgcaaggcggcacacccc agtgccacgttgtgagttggatagttgtggaaagagtcaaatggctctcctcaagcgta ttcaacaaggggctgaaggatgccagaaggtacccattgtatgggatctgatctggg gcctcggtgcacatgctttacatgtgttttagtcgaggttaaaaaacgtctaggcccccc gaaccacggggacgtgggttttcctttgaaaaacacgatac
Epidermal growth factor receptor (EGFR) isoform a precursor (aa)	50	MRPSGTAGAALLALLAALCPASRALEEKVCQGTSNKLTQLGTFEDHFLSLQRMFNCE VVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIANTVERIPLNLQIIRGNMYENSYA LAVLSNYDANKTGLKELPMRNLQEIHLGAVRFSNNPALCNVESIQWRDIVSSDFLSNMS MDFQNLHGSCQKCDPSPNGSCWAGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQ AAGCTGPRESDCLVCRKFRDEATCKDTCPLMLYNPTTYQMDVNPEGKYSFGATCVKKC PRNYVVDHGSVCVRACGADSYEMEEDGVRKCKCEGPCRKVCNGIGIGEFKDSLSINAT NIKHFKNCTISISGLHILPVAFRGDSFTHTPPLDPQELDILKTVEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNCYA NTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGEPRDCVSCRNVSR GRECVDKCNLLEGEPRFVENSECICHPCECLPQAMNITCTGRGPDNCIQAHYIDGPH CVKTCPAGVMGENNTLVWKYADAGHVCHLHPNCTYGTGPGLGECPTNGPKIPSIATG MVGALLLLLVVALGIGLFMRRRHIVKRTRLRRLQERELVEPLTPSGEAPNQALLRLK ETEFKKIKVLGSGAFGTVYKGLWIPEGEKVIPVAIKELREATSPKANKEILDEAYVMA SVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIQSQYLLNWCQVIAKGMN YLEDRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEKEYHAEGGKVPIKWMALLES ILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVY MIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMD EEDMDDVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNLQSCPIKE DSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSR DPHYQDPHSTAVGNPEYLNVTQPTCVNSTFDSPAHWAKGSHQISLDNPDYQQDFFPKE AKPNGIFKGSTAENAEYLRVAPQSSEFIGA
Receptor tyrosine-protein kinase ErbB2 (HER2) isoform a precursor (aa)	51	MELAAALCRWGLLLALLPPGAASTQVCTGTDMLRLPASPETHLDMLRHLVYQGCQVVQGN LELTYLPTNASLSFLQDIQEVQGYVLIHNVQRVQVPLQRLRIVRGTLQFEDNYALAVLD NGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNN QLALTIDTNRSRACHPCSPMCKGSRWGESSEDCQSLTRTVACAGGCARCKGPLPTDCC HEQCAAGCTGPKHSDCLACLFHNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASC VTACPYNLYLSTDVGSCTLVCPHNLQEVTAEDGTQRCEKCKSPCARVCYGLGMEHLREVR AVTSANIQEFAGCKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYIS AWPDSLPLDSVFQNLQVIRGRILHNGAYSLTQGLGISWLGLRSLRELGSGLALIHNT HLCFVHTVPWDQLFRNPQALLHTANRPEDECVGELACHQLCARGHCWGPQTQCVNC SQFLRGQECVEECRVLQGLPREYVNAHCLPCHPECQPQNGSVTCFGPEADQCVACAHY KDPPFCVARCPGSKVLPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRAS

		PLTSIISAVVGILLVVVLGVVFGILIKRRQKIRKYTMRRLLQETELVEPLTPSGAMPN QAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEI LDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRRGLSGDLLNWC MQIAKGMSYLEVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVP IKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQP PICTIDVYMIMVKCWMIDSECRPRFRELVEFSRMARDPQRFVVIQNEGLGPASPLDST FYRSLLEDDEMDGLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRSSSTRSGGGDLTLG LEPSEEEAPRSLAPSEGAGSDVFDGDLGMGAAGLQSLPTHDPSPQLQRYSEDPTVPL PSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLAARPAGATLERPKTLPSPGKNG VVKDVFAGGAVENPEYLTQGGGAAPQPHPPAFSPAFDNLYYWDQDPPERGAPPSTFK GTPTAENPEYLGLDVPV
Receptor tyrosine-protein kinase ErbB3 (HER3) isoform 1 precursor (aa)	52	MRANDALQVLGLLFLSLARGSEVGNQAVCPGTNLGLSVTGAENQYQTYLYKERCEVV MGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIF VMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVK DNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGNPNQCCHDECAGGCS GPQDTCFACRHFNDSGACVPRCPQLVYNKLTQLEPNPHTKYQYGGVCVASCPHNFV VDQTSVCRACPPDKMEVDKNGLKMCPCGGLCPKACEGTGSGSRFQTVDSNIDGFVNC TKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFVSFS NLTTIGGRSLYNRGFSLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSNLNWK VLRGPTEERLDIKHNRPRRDCVAEGKVCDDLCSGGCGWGPQGLSCRNYSRGGVCVT HCNFLNGEPREFAEAECSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPCHVSSCP HGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTALTVI AGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVL ARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVEDKSGRQSFQAVTDH MLAIGSLDHAHIVRLGLCPGSSLQLVTQYLPGLSLLDHVRQHRGALGPQLLLNWGVQI AKGMYLLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKW MALESIHFGKYTHQSDVWSYGVTVWELMTFGAEPYAGRLAEVPDLLLEKGERLAQPQIC TIDVYMMVKCWMIDENIRPTFKELANEFTRMARDPPRYLVIKRESGPGIAPGPEPHGL TNKKLEEEVELEPELDLDLDEAEEDNLATTLGSALSLPVGTNLNRPRGSQSLSP SSGYMPMNQGNLGESECSAVSGSSERCPRPVSLHMPRGCLASESSEGHVTDGSEAELO EKVSMCRSRSRSPRPGDSAYHSQRHSLLTPTVTLSPPGLEEEDVNGYVMPDTHLKG TPSSREGTLSSVGLSSVLGTEEDEDEEYEMNRRRHSPHPPRPPSSLEELGYEYMDV GSDLASLSTQSCPLHPVPIMPTAGTTPDEDEYEMNRQRDGGGPGDYAAMGACPAE QGYEEMRAFQGGPHQAPHVHYARLKTLSLEATDSAFDNPDYWHSRLFPKANAQRT
Receptor tyrosine-protein kinase ErbB4 (HER4) isoform JM-a/CVT-1 precursor (aa)	53	MKPATGLWVWSLLVAAGTVQPSDSQSVACGTENKLSSLSDLQEQYRALRKYENCEVV MGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGKLYEDRYALA IFLNYRKDGNFGLQELGLKNLTELNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTL VSTNGSSGGRCHKSCGTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPVSDCCHRECAG GCSGPKDTCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNKYTYGAFVKKCPH NFVVDSSSCVRACPSSKMEVEENGIMCKPCTDICPKACDGIGTGLMSAQTVDS SNIDKFINCTKINGNLIFLVTGIHGDYPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPP NMTDFSVFSLNLTIGGRVLYSGLSLLILKQQGITSLSLQFQSLKEISAGNIYITDNSLCY YHTINWTTLFSTINQIRIVIRDNKAENCTAEGMVCNHLCSGCGWGPDPQCLSCRRES RGRICIESCNLYDGEFREFENGSIQVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDG PNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLP QHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIIKKRALRRFLETLEVEPLTP SGTAPNQAQLRILKETELRKVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGP KANVEFMDEALIMASMDPHPLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQ LLLNWCQVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLLEGDEKEYNA DGGKMPIKWMALCIEHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKG ERLPQPPICTIDVYMMVKCWMIDADSRPKFKELAAEFMRMARDPQRYLVIQGGDRMKL PSPNDSKFFQNLDEEDLEDMDMAEEYLVPQAFNIPPIYTSRARIDSNRSEIGH SPPPAYTPMSGNQFVYRDGGFAAEQGVSVPYRAPSTIPEAPVAQGATAEIFDDSCCNG TLRKPVAPHVQEDSSTQRYSDPTVFAPERSPRGELDEEGYMPMRDKPKQEYLNPEVE NPFVSRRKNGDLQALDNPEYHNASNGPPKAEDYVNEPLYLNTFANTLGKAEYLNKNNIL SMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLS EFSLKPGTVLPPPPYRHRNTVV
Receptor	54	MKPATGLWVWSLLVAAGTVQPSDSQSVACGTENKLSSLSDLQEQYRALRKYENCEVV

tyrosine-protein kinase ErbB4 (HER4) isoform JM-b (isoform X7) precursor (aa)		MGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIRGTKLYEDRYALAIFLNRYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLT LVSTNGSSGCGRCHKSC TGR CWGPTENHCQT LTRTVCAEQDCGR CYGPVSDCCHRECAGGCSGPKD TDCFACMNFND SGACVTQCPQTFVYNPTTFQLEHNFN AKYTYGAFVCVKKCPHNFVVDSSSCVRACPSSKMEVEENG IKMCKPCTD ICPKACDGIGTGS LMSAQTV DSSNIDKF INCTKINGNLIFLVTGIHGD PYNAIEAIDPEKLN VFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSLLILKQQGITS LQFQSLKEISAGNIYITDNSNLCYHYTI NWTTLFSTINQRIVIRDNRKAENCTAEGMVCNHL CSSDGCWGPGPDQCLSCRRFSRGRI CIESCNLYDGEFREFENG SICVECDPQCEK MEDGLLTCHGPGPDNCTKCSHF KDGPNCV EKCPDGLQGAN SFIFKYADPDRECHPCHP NCTQGCIGSSIEDCIGLMDRTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRALRRFLET ELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGT VYKGIWPEGETVKIPVAIKILNETTGPKANVEFMD EALIMASMDH PHLVRL LGVCLSP TIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEE RRLVHRDLAARNVLKSPNHVKITDFGLARLLEGEDEKEYNADGGKMPIKWMAL ECIHYRKFTHQSDVWSYGV TIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMMV KCWMIDADSRPKFKELAAEF SRMARDPQRYLV IQGDDRMKLPSPNDSKFFQNLDEEDL EDMMDAEEYLVPQAFNIPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSPYRAP TSTIPEAPVAQGATAE IFDDSCCNGTLRKP VAPHVQEDSSTQRY SADPTVFAPERSPRGELDEEGYMT PMRD PKQ EYLN PVEENPFVSR RNKGD LQALDNPEYHNASNGPPKADEYVNEPLYLNTFANTLGKAEY LKNNILSMPEKAKKAFDNP DYWNHSLPP RSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV
Truncated EGFR (huEGFRt) (Her1t) (aa)	55	RKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFTH TPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGR TKQH GQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGR ECVDKCNLLEGEPRFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCA HYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGTGPGL EGCP TNGPKIPSIATGMVGALLLLLVLVALGIGLFM
EGFR truncated design 1 (Her1 truncated design 1) (HER1t1) (nt)	56	Cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggccttgccctga aacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatttgctga tgcaaatacaataaaactggaaaaaactgtttgggacctccggctcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggctgctccatgccttgctgc tccccgagggtgctgctggggcccgaggccaggactgcgtctctggtggcggtggctc gggcggtggtgggtcggtggcgggcggtatctggtggcggtggctcggtttgggtgctgg tgggtggtggtggagtcctggcttgctatagcttgctagtaacagtggtgcctttattatt ttctgggtgaggagtaagaggagc
EGFR truncated design 1 (Her1 truncated design 1) (HER1t1) (aa)	57	RKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFTH TPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGR TKQH GQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSGGGGSGGG GSGGGGSGGGGSFWLVVVVGGVLACYSLLVTVAFIIFWVRSKRS
EGFR truncated design 2 (Her1 truncated design 2) (HER1t2) (nt)	58	Cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggccttgccctga aacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatttgctga tgcaaatacaataaaactggaaaaaactgtttgggacctccggctcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggctgctccatgccttgctgc tccccgagggtgctgctggggcccgaggccaggactgcgtctcttgccggaatgtcag ccgaggcagggaatgctggacaagggtggcggtggctcgggcgggtggtgggtcggttg gggcggtatctggtggcggtggctcggtttgggtgctggtggtggtggtggagtcctg

		gcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagag gagc
EGFR truncated design 2 (Her1 truncated design 2) (HER1t2) (aa)	59	RKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFHTPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRKQHGQFSLAVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGRECVDKGGGSGGGGSGGGGSGGGGFWVLV VVGVLACYSLLVTVAFIIFWVRSKRS
EGFR truncated design 3 (Her1 truncated design 3) (HER1t3) (nt)	60	cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggccttgccctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaaacaaaaatttgtgcta tgcaatacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgccatgccttgtgc tccccgagggctgctggggcccggagcccagggaactgcgtctcttgcggaatgtcag ccgaggcaggggaatgcgtggacaagtgcacaccttctggagggtgagccaagggagttg tggaagaactctgagtcatacagggtggcgggtggctcgggcggtgggtgggtgggtggc ggcggatctggtggcgggtggctcgttttgggtgctggtgggtgggtgggtggagtcctggc ttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggag gc
EGFR truncated design 3 (Her1 truncated design 3) (HER1t3) (aa)	61	RKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFHTPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRKQHGQFSLAVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQGGGSGG GGGSGGGGSGGGGFWVLVVGVLACYSLLVTVAFIIFWVRSKRS
EGFR truncated design 4 (Her1 truncated design 4) (HER1t4) (nt)	62	cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggccttgccctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaaacaaaaatttgtgcta tgcaatacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgccatgccttgtgc tccccgagggctgctggggcccggagcccagggaactgcgtctcttgcggaatgtcag ccgaggcaggggaatgcgtggacaagtgcacaccttctggagggtgagccaagggagttg tggaagaactctgagtcatacagtgccaccagagtgctgcctcaggccatgaacatc acctgcacaggacggggaccagacaactgtatccaggggcggaggcgggaagcggaggcgg aggctccggcggaggcgggaagcttttgggtgctggtgggtgggtgggtggagtcctggctt gctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggagc
EGFR truncated design 4 (Her1 truncated design 4) (HER1t4) (aa)	63	RKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFHTPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRKQHGQFSLAVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQGGGSGGGGSGGGGFWVLVVGVLACYSLL VTVAFIIFWVRSKRS
EGFR truncated design 5 (Her1 truncated design 5) (HER1t5) (nt)	64	cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggccttgccctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaaacaaaaatttgtgcta

		tgcaaatacaataaaactggaaaaaactgtttgggacctccggtcagaaaaccaaataa taagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgc tccccgagggctgctggggcccggagcccagggaactgcgtctcttggcgaatgtcag ccgaggcaggggaatgctgggacaagtgaacaccttctggagggtgagccaaggagtttg tggagaactctgagtgcatagctgcccaccagagtgccctgacctcaggccatgaacatc acctgcacaggacggggaccagacaactgtatccagtgtgcccactacattgacggccc ccactgctcaagaccggcggaggcggaagcggaggcgaggctccggcggaggcggaag gcttttgggtgctggtggtggttggtagtcttgcttagcttagtaaca gtggcctttattattttctgggtgaggagtaagaggagc
EGFR truncated design 5 (Her1 truncated design 5) (HER1t5) (aa)	65	RKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEDRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKTTGGGSGGGSGGGSGFWVL VVVGGVLACYSLLVTVAFIIFWVRSKRS
EGFR truncated design 6 (Her1 truncated design 6) (HER1t6) (nt)	66	cgaaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgccgatctccacatcctgc cgggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataaagtgtgagatgtgataatttcaggaaacaaaaatttgtgcta tgcaaatacaataaaactggaaaaaactgtttgggacctccggtcagaaaaccaaataa taagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgc tccccgagggctgctggggcccggagcccagggaactgcgtctcttggcgaatgtcag ccgaggcaggggaatgctgggacaagtgaacaccttctggagggtgagccaaggagtttg tggagaactctgagtgcatagctgcccaccagagtgccctgacctcaggccatgaacatc acctgcacaggacggggaccagacaactgtatccagtgtgcccactacattgacggccc ccactgctcaagacctgcccggcaggagtcagtgaggagaaacaacaccttggtctgga agtacgcagacgccggccatgtgtgccacctggggcggaggcggaagcggaggcgaggc tccttttgggtgctggtggtggttggtagtcttgcttagcttagtaaac agtggcctttattattttctgggtgaggagtaagaggagc
EGFR truncated design 6 (Her1 truncated design 6) (HER1t6) (aa)	67	RKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEDRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKTPAGVMGENNTLVWKYADA GHVCHLGGGSGGGSGFWLVVVGGVLACYSLLVTVAFIIFWVRSKRS
EGFR truncated design 7 (Her1 truncated design 7) (HER1t7) (nt)	68	cgaaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgccgatctccacatcctgc cgggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataaagtgtgagatgtgataatttcaggaaacaaaaatttgtgcta tgcaaatacaataaaactggaaaaaactgtttgggacctccggtcagaaaaccaaataa taagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgc tccccgagggctgctggggcccggagcccagggaactgcgtctcttggcgaatgtcag ccgaggcaggggaatgctgggacaagtgaacaccttctggagggtgagccaaggagtttg tggagaactctgagtgcatagctgcccaccagagtgccctgacctcaggccatgaacatc acctgcacaggacggggaccagacaactgtatccagtgtgcccactacattgacggccc ccactgctcaagacctgcccggcaggagtcagtgaggagaaacaacaccttggtctgga agtacgcagacgccggccatgtgtgccacctgtgccatccaaactgcacctacggatgc actgggcccaggcttgaaggctgtccagggtggcgggtggcgggatctttttgggtgct ggtggtggttggtagtcttgcttagcttagtaaacagtggcctttatta tttctgggtgaggagtaagaggagctaa

EGFR truncated design 7 (Her1 truncated design 7) (HER1t7) (aa)	69	RKVCNGIGIGEFKDSLSINATNIKHFKNCT SISGDLHLIPVAFRGDSFHTPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPPEPRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCAPAGVMGENNTLVWKYADA GHVCHLCHPNCTYGTGPGLEGCPGGGGGGSFWVLVVVGGVLACYSLLVT VAFIIFWVRSKRS*
EGFR truncated design 8 (Her1 truncated design 8) (HER1t8) Ig Kappa Signal Peptide (nt)	70	atgaggctccctgctcagctcctggggctgctaatactctgggtcccaggatccagtgg gcgcaaagtgtgtaacggaataggtatttggtgaatttaaagactcactctccataaatg ctacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctg ccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaact ggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctg aaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaag caacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacg ctccctcaaggagataagtgtgagatgtgataatttcaggaacaaaaatttgtgct atgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatt ataagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgcatgccttggtg ctccccgagggtgctggtggggcccgagccagggactgcgtctctggtggcggtggct cgggcgggtggtgggtcgggtggcgggcggtatctggtggcggtggctcggagataacactc attatttttggggtgatggctggtgttatttgaacgatcctcttaatttcttacggtat tcgccgaggaggtggaagc
EGFR truncated design 8 (Her1 truncated design 8) (HER1t8) Ig Kappa Signal Peptide (aa)	71	MRLPAQLLGLLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNIKHFKNCT SISGDLHLIPVAFRGDSFHTPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPPEPRDCVSGGGGSGGGGSGGGGSGGGGSEITLIIFGVMAGVIGTIL LISYGIRRRGGGS
EGFR truncated design 8 (Her1 truncated design 8) (HER1t8) (nt)	72	cgaaagtgtgtaacggaataggtatttggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgtgagatgtgataatttcaggaacaaaaatttgtgcta tgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgcatgccttggtgc tccccgagggtgctggtggggcccgagccagggactgcgtctctggtggcggtggctc gggcgggtggtgggtcgggtggcgggcggtatctggtggcggtggctcggagataacactca ttatttttggggtgatggctggtgttatttgaacgatcctcttaatttcttacggtatt cgccgaggaggtggaagc
EGFR truncated design 8 (Her1 truncated design 8) (HER1t8) (aa)	73	RKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHLIPVAFRGDSFHTPLDPQEL DILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLR SLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALC SPEGCWGPPEPRDCVSGGGGSGGGGSGGGGSGGGGSEITLIIFGVMAGVIGTILLISYGI RRGGGS
EGFR truncated design 9 (Her1 truncated design 9) (HER1t9) with Ig Kappa Signal Peptide (nt)	74	atgaggctccctgctcagctcctggggctgctaatactctgggtcccaggatccagtgg gcgcaaagtgtgtaacggaataggtatttggtgaatttaaagactcactctccataaatg ctacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctg ccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaact ggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctg aaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaag caacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacg ctccctcaaggagataagtgtgagatgtgataatttcaggaacaaaaatttgtgct atgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatt ataagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgcatgccttggtg ctccccgagggtgctggtggggcccgagccagggactgcgtctctggtggcggtggct

		cgggcgggtgggtgggtcggggtggcggcgatctgggtggcgggtggctcgataaacactcatt atTTTTgggtgatggctgggtgttattggaacgatcctcttaatttcttacggtattgg aggtggaagc
EGFR truncated design 9 (Her1 truncated design 9) (HER1t9) with Ig Kappa Signal Peptide (aa)	75	MRLPAQLLGLLMLWVPSSGRKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFHTPLDPQELDILKTVEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSGGGGSGGGGSGGGGSGGGGSITLIIFGV MAGVIGTILL ISYIGIGGS
EGFR truncated design 9 (Her1 truncated design 9) (HER1t9) (nt)	76	cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatttgtgcta tgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgccatgccttgtgc tccccgagggctgctggggcccggagcccagggaactgcgtctctgggtggcgggtggctc gggcgggtgggtgggtcggggtggcggcgatctgggtggcgggtggctcgataaacactcatta tttttggggtgatggctgggtgttattggaacgatcctcttaatttcttacggtattgga ggtggaagc
EGFR truncated design 9 (Her1 truncated design 9) (HER1t9) (aa)	77	RKVCNGIGIGEFKDSLSINATNIKHFNCTSISGDLHILPVAFRGDSFHTPLDPQEL DILKTVEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLR SLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALC SPEGCWGPEPRDCVSGGGGSGGGGSGGGGSGGGGSITLIIFGV MAGVIGTILLISYIGIG GGS
EGFR truncated design 10 (Her1 truncated design 10) (HER1t10) with Ig Kappa Signal Peptide (nt)	78	atgaggctccctgctcagctcctggggctgctaattgctctgggtcccaggatccagtgg gcgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatg ctacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctg ccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaact ggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctg aaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaag caacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacg ctccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatttgtgct atgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatt ataagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgccattgtg ctccccgagggctgctggggcccggagcccagggaactgcgtctctgggtggcgggtggct cgggcgggtgggtgggtcggggtggcggcgatctgggtggcgggtggctcgataaacactcatt atTTTTggggtgatggctgggtgttattggaacgatcctcttagccctgctcatctgggg aggtggaagc
EGFR truncated design 10 (Her1 truncated design 10) (HER1t10) with Ig Kappa Signal Peptide (aa)	79	MRLPAQLLGLLMLWVPSSGRKVCNGIGIGEFKDSLSINATNIKHFNCT SISGDLHILPVAFRGDSFHTPLDPQELDILKTVEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSGGGGSGGGGSGGGGSGGGGSITLIIFGV MAGVIGTILL ALLIWGGGS
EGFR truncated design 10 (Her1 truncated design 10) (HER1t10) (nt)	80	cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatttgtgcta tgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgccatgccttgtgc tccccgagggctgctggggcccggagcccagggaactgcgtctctgggtggcgggtggctc

		gggcgggtgggtgggtcgggtggcggcggatctggtggcgggtggctcgataaacactcatta tttttggggatgatggctgggtgttattggaacgatcctcttagccctgctcatctgggga ggtggaagc
EGFR truncated design 10 (Her1 truncated design 10) (HER1t10) (aa)	81	RKVCNGIGIGEFKDSLSINATNIKHFKNCTISGDLHILPVAFRGDSFTHTPPLDPQEL DILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRKQHQGFSLAVVSLNITSLGLR SLKEISDGDVVISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALC SPEGCWGPEPRDCVSGGGGSGGGGSGGGGSGGGGSITLIIFGVMAGVIGTILLALLIWG GGS
EGFR truncated design 11 (Her1 truncated design 11) (HER1t11) with Ig Kappa Signal Peptide (nt)	82	atgaggctccctgctcagctcctggggctgctaagtctctgggtcccaggatccagtgg gcgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatg ctacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctg ccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaact ggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctg aaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaag caacatgggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacg ctccctcaaggagataagtgtgagatgtgataatttcaggaaacaaaaatttgtgct atgcaaatacaataaactggaaaaaactgtttgggacctccgggtcagaaaacaaaaatt ataagcaacagaggtgaaaacagctgcaaggccacaggccagggtctgccatgccttgtg ctccccgagggctgctggggcccgagccagggactgcgtctctgggtggcgggtggct cgggcgggtgggtgggtcgggtggcggcggatctggtggcgggtggctcgctctgctacctg ctggatggaatcctcttcatctatggtgtcattctcactgccttgttctctgggaggtgg aagc
EGFR truncated design 11 (Her1 truncated design 11) (HER1t11) with Ig Kappa Signal Peptide (aa)	83	MRLPAQLLGLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNIKHFKNCTISGDLHIL PVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRK QHQGFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNLCYANTINWKKLFGTSGQKTKI ISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSGGGGSGGGGSGGGGSGGGGSLCYL LDGILFIYGVILTALFLGGGS
EGFR truncated design 11 (Her1 truncated design 11) (HER1t11) (nt)	84	cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatgggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgtgagatgtgataatttcaggaaacaaaaatttgtgcta tgcaaatacaataaactggaaaaaactgtttgggacctccgggtcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggctctgccatgccttgtgc tccccgagggctgctggggcccgagccagggactgcgtctctgggtggcgggtggctc gggcgggtgggtgggtcgggtggcggcggatctggtggcgggtggctcgctctgctacctgc tggtatggaatcctcttcatctatggtgtcattctcactgccttgttctctgggaggtgga agc
EGFR truncated design 11 (Her1 truncated design 11) (HER1t11) (aa)	85	RKVCNGIGIGEFKDSLSINATNIKHFKNCTISGDLHILPVAFRGDSFTHTPPLDPQEL DILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRKQHQGFSLAVVSLNITSLGLR SLKEISDGDVVISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALC SPEGCWGPEPRDCVSGGGGSGGGGSGGGGSGGGGSLCYLLDGILFIYGVILTALFLGGG S
Truncated EGFR- HER2 Chimera with GMCSFR alpha signal peptide (nt)	86	atgcttctcctgggtgacaagccttctgctctgtgagttaccacaccagcattcctcct gatccacgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctcca taaatgctacgaatattaaacacttcaaaaactgcacctccatcagtgggcgatctccac atcctgccggtggcatttaggggtgactccttcacacatactcctcctctggatccaca ggaactggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggctt ggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcagg accaagcaacatgggtcagttttctcttgagtcgtcagcctgaacataacatccttggg attacgctccctcaaggagataagtgtgagatgtgataatttcaggaaacaaaaatt tgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccgggtcagaaaacc

		aaaattataagcaacagaggtgaaaacagctgcaaggccacaggccaggcctgccacca gctgtgcgcccaggggcactgctgggggtccaggggccaccagtggtgtaactgcagcc agttccttcggggccaggagtgctggaggaatgccgagtactgcaggggctccccagg gtagtatgtgaatgccaggcactgtttgccgtgccaccctgagtgtagccccagaatgg ctcagtgacctgttttggaccggaggctgaccagtggtgtggcctgtgcccactataagg accctcccttctgctggcccgcctgccccagcgggtgtgaaacctgacctctctacatg cccatctggaagtttccagatgaggagggcgcatgccagccttccccatcaactgcac ccactcctgtgtggacctggatgacaagggctgccccgccgagcagagagccagccctc tgacgtccatcatctctgcggtgggtggcattctgctggctggtgcttgggggtggtc tttgggatcctcatc
Truncated EGFR- HER2 Chimera with GMCSFR alpha signal peptide (aa)	87	MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKN CTSISGDLHLIPVAFRGDSFTHTPPLDPQELDILKTVEITGFLLIQAWP ENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDV IISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQACHQLCA RGHCVGPPTQCVNCSQFLRGQECVEECRVLQGLPREYVNRHCLPCHPE CQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPGSKVPDLSYMPIWKF PDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVV LGVVFGLI
Truncated EGFR- HER2 Chimera (nt)	88	cgaaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgccgatctccacatcctgc cgggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggccttgccctga aacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataaagtgatggagatgtgataatttcaggaaacaaaaatttgtgcta tgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaaccaaataa taagcaacagaggtgaaaacagctgcaaggccacaggccaggcctgccaccagctgtgc gccgagggcactgctgggggtccaggggccaccagtggtgtaactgcagccagttcct tcggggccaggagtgctggaggaatgccgagtactgcaggggctcccaggaggatg tgaatgccaggcactgtttgccgtgccaccctgagtgtagccccagaatggctcagtg acctgttttggaccggaggctgaccagtggtgtggcctgtgcccactataaggacctcc ctctgctggcccgcctgccccagcgggtgtgaaacctgacctctctacatgcccactc ggaagtttccagatgaggagggcgcatgccagccttggcccatcaactgcaccactcc tgtgtggacctggatgacaagggctgccccgccgagcagagagccagccctctgacgtc catcatctctgcggtgggtggcattctgctggctggtgcttgggggtggctcttggga tcctcatc
Truncated EGFR- HER2 Chimera (aa)	89	RKVCNGIGIGEFKDSLSINATNIKHFKN CTSISGDLHLIPVAFRGDSFTHTPPLDPQELDILKTVEITGFLLIQAWP ENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDV IISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQACHQLCA RGHCVGPPTQCVNCSQFLRGQECVEECRVLQGLPREYVNRHCLPCHPE CQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPGSKVPDLSYMPIWKF PDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVV LGVVFGLI
Truncated EGFR- HER2 (delta 16) Chimera with GMCSFR alpha signal peptide (nt)	90	atgcttctcctgggtgacaagccttctgctctgtgagttaccacaccagcattcctcct gatcccacgaaaagtgtgtaacggaataggtattggtgaatttaaagactcactctcca taaatgctacgaatattaaacacttcaaaaactgcacctccatcagtgccgatctccac atcctgccggtggcatttaggggtgactccttcacacatactcctcctctggatccaca ggaactggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcctt ggctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcagg accaagcaacatggtcagttttctcttgagtcgtcagcctgaacataacatccttggg attacgtctccctcaaggagataaagtgatggagatgtgataatttcaggaaacaaaaatt tgtgctatgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaacc aaaattataagcaacagaggtgaaaacagctgcaaggccacaggccaggcctgccacca gctgtgcgcccaggggcactgctgggggtccaggggccaccagtggtgtaactgcagcc agttccttcggggccaggagtgctggaggaatgccgagtactgcaggggctccccagg gtagtatgtgaatgccaggcactgtttgccgtgccaccctgagtgtagccccagaatgg ctgagtgacctgttttggaccggaggctgaccagtggtgtggcctgtgcccactataagg

		accctcccttctgctggtggcccgctgccccagcggtgtgaaacctgacctctcctacatg cccatctggaagtttccagatgaggaggcgcatgccagccttgccccatcaactgcac ccactccctctgacgtccatcatctctgcggtggttggtcattctgctggtcgtggtctt tgggggtggtctttgggatcctcatc
Truncated EGFR- HER2 (delta 16) Chimera with GMCSFR alpha signal peptide (aa)	91	MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKN CTISGDLHLIPVAFRGDSFHTPLDPQELDILKTVEITGFLLIQAWP ENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDV IISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQACHQLCA RGHCWGPPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPE CQPQNGSVTCFGPEADQCVACAHYKDPFVCARCPSGVKPDLSPYMPIWKF PDEEGACQPCPINCTHSPLTSIISAVVGILLVVLGVVFGILI
Truncated EGFR- HER2 (delta 16) (nt)	92	cgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtggtgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttcagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgtgagatgtgataatttcaggaaacaaaaatttgtgcta tgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaaacaaaaatta taagcaacagaggtgaaaaacagctgcaaggccacaggccaggcctgccaccagctgtgc gcccagggcactgctggggtccaggggccaccagtggtgtcaactgcagccagttcct tcggggccaggagtgctgggaggaatgccagtgactgcaggggctcccaggagtgatg tgaatgccaggcactgtttgccgtgccaccctgagtgctcagccccagaatggctcagtg acctgttttgaccggaggctgaccagtggtgtggcctgtgcccactataaggacctcc cttctgctggcccgctgccccagcggtgtgaaacctgacctctcctacatgccatct ggaagtttccagatgaggaggggcgcatgccagccttgccccatcaactgcaccactcc cctctgacgtccatcatctctgcggtggttggtcattctgctggtcgtggtcttgggggt ggtctttgggatcctcatc
Truncated EGFR- HER2 (delta 16) (aa)	93	RKVCNGIGIGEFKDSLSINATNIKHFKN CTISGDLHLIPVAFRGDSFHTPLDPQELDILKTVEITGFLLIQAWP ENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDV IISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQACHQLCA RGHCWGPPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPE CQPQNGSVTCFGPEADQCVACAHYKDPFVCARCPSGVKPDLSPYMPIWKF PDEEGACQPCPINCTHSPLTSIISAVVGILLVVLGVVFGILI
Truncated EGFR- ErbB3 Chimera with GMCSFR alpha signal peptide (nt)	94	atgcttctcctggtgacaagccttctgctctgtgagttaccacaccagcattcctcct gatcccacgcaaagtgtgtaacggaataggtattggtgaatttaaagactcactctcca taaatgctacgaatattaaacacttcaaaaactgcacctccatcagtggtgatctccac atcctgccggtggcatttaggggtgactccttcacacatactcctcctctggatccaca ggaactggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggctt ggcctgaaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcagg accaagcaacatggtcagttttctcttcagtcgtcagcctgaacataacatccttggg attacgctccctcaaggagataagtgtgagatgtgataatttcaggaaacaaaaatt tgtgctatgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaacc aaaattataagcaacagaggtgaaaaacagctgcaaggccacaggccagggtgtgtgacc actgtgctcctctgggggatgctggggccaggccctggctcagtgcttctgtcgtcga attatagccgaggaggtgtctgtgtgaccactgcaactttctgaatggggagcctcga gaatttgccatgaggccgaatgcttctcctgccaccgggaatgccaaccatggaggg cactgccacatgcaatggctcgggctctgatacttgtgctcaatgtgcccattttcag atgggccccactgtgtgagcagctgcccccatggagtcctagtgccaaggggccaatc tacaagtaccagatgttcagaatgaatgtcgccctgccatgagaactgcaccagggg gtgtaaaggaccagagcttcaagactgttaggacaaacactgggtgctgatcgga cccatctgacaatggctttgacagtgatagcaggatttgtagtatttcatgatgctg ggcggcacttttctctac
Truncated EGFR- ErbB3 Chimera with GMCSFR alpha signal	95	MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKN CTISGDLHLIPVAFRGDSFHTPLDPQELDILKTVEITGFLLIQAWP ENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDV IISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCDPLCS

peptide (aa)		SGGCWGP GPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPE CQPMEGTATCNGSGSDTCAQCAHFRDGPVSSCPHGVLAGKGP IYKYPD VQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVI FMMLGGTFLY
Truncated EGFR- ErbB3 Chimera (nt)	96	cgcaaagtgtgtaacggaatagggtattgggtgaatttaaagactcactctccataaatgc tacgaatattaaacacttcaaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggccttgccctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatttgtgcta tgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaacaaaaatta taagcaacagagggtgaaaacagctgcaaggccacaggccagggtgtgtgacccactgtgc tcctctgggggatgctggggcccaggccctggtcagtgcttgcctgtcgaattatag ccgaggagggtgtctgtgtgacccactgcaactttctgaatggggagcctcgagaatttg cccatgaggccgaatgcttctcctgccaccgggaatgccaaccatggaggggcactgcc acatgcaatggctcgggctctgatacttgtgtcgaatgtgcccattttcgagatggggc ccactgtgtgagcagctgccccatggagtccttaggtgccaaggggccaatctacaagt accagatgttcagaatgaatgtcggccctgccatgagaactgacccagggggtgtaaa ggaccagagcttcaagactgtttaggacaaacactgggtgctgatcggcaaaacctatct gacaatggctttgacagtgatagcaggattggtagtgattttcatgatgctggcgcca cttttctctac
Truncated EGFR- ErbB3 Chimera (aa)	97	RKVCNGIGIGEFKDSLSINATNIKHFKN CTISISGLHLIPVAFRGDSFHTPLDPQELDILKTVKEITGFLLIQAWP ENRTDLHAFENLEIIRGRKQHGQFSLAVVSLNITSLGLRSLKEISDGDV IISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCDPLCS SGGCWGP GPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPE CQPMEGTATCNGSGSDTCAQCAHFRDGPVSSCPHGVLAGKGP IYKYPD VQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVI FMMLGGTFLY
Truncated EGFR- ErbB4 (JM-a) Chimera with GMCSFR alpha signal peptide (nt)	98	atgcttctcctgggtgacaagccttctgctctgtgagttaccacacccagcattcctct gatccacgcgcaaagtgtgtaacggaatagggtattgggtgaatttaaagactcactctcca taaatgctacgaatattaaacacttcaaaaaactgcacctccatcagtgggcgatctccac atcctgccgggtggcatttaggggtgactccttcacacatactcctcctctggatccaca ggaactggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggctt ggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcagg accaagcaacatggtcagttttctcttgagtcgtcagcctgaacataacatccttggg attacgctccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatt tgtgctatgcaataacaataaactggaaaaaactgtttgggacctccggtcagaaaacc aaaattataagcaacagagggtgaaaacagctgcaaggccacaggccagggtgtgcaacca tctgtgttccagtgatggctgttggggacctggggccagaccaatgtctgtcgtgtcggc gcttcagtagaggaaggatctgcatagagtcttgtaacctctatgatgggtgaatttcgg gagtttgagaatggctccatctgtgtggagtgtagcccccagtgtagaagatggaaga tggcctcctcacatgccatggaccgggtcctgacaactgtacaaagtgtctctatttta aagatggcccaaactgtgtggaataatgtccagatggcttacagggggcaaacagtttc attttcaagtatgctgatccagatcgggagtgccacctatgccatccaaactgcaccca agggtgtaacggtcccactagtcagtgactgcatttactacctatggacggggcattcca ctttaccacaacatgctagaactcccctgattgcagctggagtaattgggtgggctcttc attctgggtcattgtgggtctgacatttgcgtgttatgtt
Truncated EGFR- ErbB4 (JM-a) Chimera with GMCSFR alpha signal peptide (aa)	99	MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTISISGLH ILPVAFRGDSFTH TPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRKQH GQFSLAVVSLNITSLGLRSLKEISDGDV IISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSCKATGQVCHLCS SDGCWGP GPDQCLSCRFFSRGR ICIESCNLYDGEFREFENGSI CVECDPQCEKMEDGLLTCHGPGPDNCTKC SHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQCNGPTS HDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYV
Truncated EGFR-	100	cgcaaagtgtgtaacggaatagggtattgggtgaatttaaagactcactctccataaatgc

ErbB4 (JM-a) Chimera (nt)		tacgaatattaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatttgtgcta tgcaataacaataaactggaaaaaactgttgggacctccggtcagaaaacaaaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccagggtgtgcaaccatctgtgt tccagtgatggctgttggggacctgggcccagaccaatgtctgtcgtgtcgcgcttcag tagaggaaggatctgcatagagtccttgtaacctctatgatggtgaatttcgggagtttg agaatggctccatctgtgtggagtgtagccccagtggtgagaagatggaagatggcctc ctcacatgccatggaccgggtcctgacaactgtacaaagtgtctcatttttaagatgg ccaaactgtgtggaaaaatgtccagatggcttacagggggcacaacagtttcattttca agtatgctgatccagatcgggagtgccaccatgccatccaaactgcacccaagggtgt aacgggtcccactagtcagtgactgcatttactaccatggacgggcccattccactttacc acaacatgctagaactcccctgattgcagctggagtaattggtgggctcttcattctgg tcattgtgggtctgacatttgcgttttatgtt
Truncated EGFR- ErbB4 (JM-a) Chimera (aa)	101	RKVCNGIGIGEFKDSLSINATNIKHFNKNTSISGDLHILPVAFRGDSFTH TPPLDPQELDILKTVEITGFLLIQAWPENRTDLHAFENLEIIRGRKQKQ GQFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSCKATGQVCNHLCS SDGCWGPDPDQCLSCRRFSRGR ICIESCNLYDGEFREFENGSI CEVCDPQCEKMEDGLLTCHGPGPDNCTKC SHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTS HDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYV
Truncated EGFR- ErbB4 (JM-b) Chimera with GMCSFR alpha signal peptide (nt)	102	atgcttctcctgggtgacaagccttctgctctgtgagttaccacaccagcattcctcct gatcccacgcaaagtgtgtaacggaataggtattgggtgaatttaaagactcactctcca taaatgctacgaatattaacacttcaaaaactgcacctccatcagtgggcgatctccac atcctgccggtggcatttaggggtgactccttcacacatactcctcctctggatccaca ggaactggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggctt ggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcagg accaagcaacatggtcagttttctcttgagtcgtcagcctgaacataacatccttggg attacgctccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatt tgtgctatgcaataacaataaactggaaaaaactgttgggacctccggtcagaaaacc aaaattataagcaacagaggtgaaaacagctgcaaggccacaggccagggtgtgcaacca tctgtgttccagtgatggctgttggggacctgggcccagaccaatgtctgtcgtcgtcc gcttcagtagaggaaggatctgcatagagtccttgtaacctctatgatggtgaatttcgg gagtttgagaatggctccatctgtgtggagtgtagccccagtggtgagaagatggaaga tggcctcctcacatgccatggaccgggtcctgacaactgtacaaagtgtctcatttta aagatggcccaactgtgtggaaaaatgtccagatggcttacagggggcacaacagtttc attttcaagtatgctgatccagatcgggagtgccaccatgccatccaaactgcaccca agggtgcataggctcaagtattgaagactgcatcgccctgatggatagaactcccctga ttgcagctggagtaattggtgggctcttcattctggtcattgtgggtctgacatttgct gtttatgtt
Truncated EGFR- ErbB4 (JM-b) Chimera with GMCSFR alpha signal peptide (aa)	103	MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFNKNTSISGDLH ILPVAFRGDSFTH TPPLDPQELDILKTVEITGFLLIQAWPENRTDLHAFENLEIIRGRKQKQ GQFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSCKATGQVCNHLCS SDGCWGPDPDQCLSCRRFSRGR ICIESCNLYDGEFREFENGSI CEVCDPQCEKMEDGLLTCHGPGPDNCTKC SHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCIGSSI EDCIGLMDRTPLIAAGVIGGLFILVIVGLTFAVYV
Truncated EGFR- ErbB4 (JM-b) Chimera (nt)	104	Cgaaagtgtgtaacggaataggtattgggtgaatttaaagactcactctccataaatgc tacgaatattaacacttcaaaaactgcacctccatcagtgggcgatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggtcagttttctcttgagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaacaaaaatttgtgcta

		tgcaaatacaataaaactggaaaaaactgtttgggacctccggtcagaaaaccaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccaggtgtgcaaccatctgtgt tccagtgtggctgttggggacctggggccagaccaatgtctgtcgtgtcgccgcttcag tagaggaaggatctgcatagagtcttgaacctctatgatggtgaatttcgggagtttg agaatggctccatctgtgtggagtgtgaccccgagtgtgagaagatggaagatggcctc ctcacatgccatggaccgggtcctgacaactgtacaaagtgtctctcattttaaagatgg cccaaactgtgtggaaaaatgtccagatggcttacagggggcaaacagtttcttttca agtatgtctgatccagatcgggagtgccaccatgccatccaaactgcacccaagggtgc ataggctcaagtattgaagactgcacatcgccctgatggatagaactcccctgattgcagc tggagtaattgggtgggtccttcttctgtggtcattgtgggtctgacatttctgtttatg tt
Truncated EGFR- ErbB4 (JM-b) Chimera (aa)	105	RKVCNGIGIGEFKDSLSINATNIKHFNKNTSISGDLHILPVAFRGDSFTH TPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRKQH GQFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSKATGQVCNHLCSDDGCGWPGPDQCLSCRRFSRGR ICIESCNLYDGEFREFENGSI CVECDPQCEKMEDGLLTCHGPGPDNCTKC SHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCIGSSI EDCIGLMDRTPLIAAGVIGGLFILVIVGLTFAVYV
Full length CD20 (nt)	106	Atgacaacaccagaaattcagtaaatgggactttccgggcagagccaatgaaaggccc tattgtctatgcaatctgggtccaaaaccactcttcaggaggatgtcttcactgggtgggcc ccacgcaaagcttcttcatgagggaatctaagactttgggggctgtccagattatgaat gggctcttccacattgccctgggggggtcttctgatgatccagcagggatctatgcacc catctgtgtgactgtgtggtaccctctctggggaggcattatgtatattatttccggat cactcctggcagcaacggagaaaaactccaggaagtgtttgggtcaaaggaataatgata atgaattcattgagcctcttctgtgccatttctggaatgattcttcaatcatggacat acttaatatataaaatttccatttttttaaaaatggagagtctgaattttattagagctc acacaccatatattaacatatataaactgtgaaccagctaattccctctgagaaaaactcc ccatctacccaatactgttacagcatacaatctctgttcttgggcattttgtcagtgtat gctgatctttgccttcttccaggaacttgtaatagctggcatcgttgagaatgaatgga aaagaacgtgctccagaccaaatctaacaatagttctctctgcagcagaagaaaaaaa gaacagactattgaaataaaagaagaagtgggtgggctaactgaaacatcttcccaacc aaagaatgaagaagacattgaaattattccaatccaagaagaggaagaagaagaacag agacgaactttccagaacctcccccaagatcaggaatcctcaccaatagaaaaatgacagc tctcct
Full length CD20 (aa)	107	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRMSSLVGPQTQSFMRRESK TLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTWYPLWGGIMYIISGSL LAATEKNSRKCLVKGMIMNSLSLFAAISGMILSIMDILNIKISHFLKME SLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIF AFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLT ETSSQPKNEEDIEIPIQEEEEETETNFPPEPPQDQESSPIENDSSP
Truncated CD20 design 1 (CD20t1) [CD20(M1-E263)] (nt)	108	atgaccacaccacggaactctgtgaatggcaccttccagcagagccaatgaaggggacc aatcgcaatgcagagcggaccgaagcctctgtttcggagaatgagctccctgggtgggcc caaccagctccttctttatgagagagtctaagacactgggcgcgctgcagatcatgaac ggactgttccacatcgccctgggaggactgctgatgatccagccggcatctacgcccc tatctgcgtgaccgtgtgtggtaccctctgtggggcgccatcatgtatatcatctcggct ctctgtggcgccacagagaagaacagcaggaagtgtctggtgaagggaagatgatc atgaatagcctgtccctgtttgccgcatctctggcatgatcctgagcatcatggacat cctgaacatcaagatcagccacttctgaagatggagagcctgaacttcatcagagccc acacccttacatcaacatctataattgcgagcctgccacccatccgagaagaattct ccaagcacacagtactgttattccatccagtctctgttcttgggcacctgtctgtgat gctgatctttgccttcttccaggagctgggtcatcgccggcatcgtggagaacgagtgga agaggacctgcagccgccccaaagtccaatctgtgctgtgtcgcggaggagaagaag gagcagacaatcgagatcaaggaggaggtgggtgggcctgaccgagacatctagccagcc taagaatgaggaggatctcgag
Truncated CD20 design 1 (CD20t1) [CD20(M1-E263)]	109	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRMSSLVGPQTQSFMRRESK TLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTWYPLWGGIMYIISGSL LAATEKNSRKCLVKGMIMNSLSLFAAISGMILSIMDILNIKISHFLKME SLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIF

(aa)		AFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLT ETSSQPKNEEDIE
Truncated CD20 design 2 (CD20t2) CD20(M117- N214)(nt)	110	atgataatgaattcattgagcctcttttctgctgccatttctggaatgattctttcaatcat ggacatacttaatatataaaatttccatttttttaaaaatggagagtctgaattttatta gagctcacacaccatatattaacatatacaactgtgaaccagctaattccctctgagaaa aactccccatctaccaatactgttacagcatacaatctctgttcttgggcattttgtc agtgatgctgatcctttgccttcttccaggaacttgtaatagctggcatcgttgagaat
Truncated CD20 design 2 (CD20t2) CD20(M117-N214) (aa)	111	MIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYN CEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVEN
Truncated CD20 design 3 (CD20t3)CD20(K14 2- S188).CD8a(I183- T203) (nt)	112	atggccttaccagtgaccgccttgctcctgccgtggccttgctgctccacgccgccag gccgaaaatttccatttttttaaaaatggagagtctgaattttattagagctcacacac catatattaacatatacaactgtgaaccagctaattccctctgagaaaaactccccatct accaatactgttacagcatacaatctatctacatctgggcgcccttggcgggacttg tggggctccttctcctgtcactggttatcacc
Truncated CD20 design 3 (CD20t3)CD20(K14 2- S188).CD8a(I183- T203) (aa)	113	MALPVTALLLPLALLLHAARPKISHFLKMESLNFIRAHTPYINIYNCEPA NPSEKNSPSTQYCYSIQSIYIWAPLAGTCGVLLLSLVIT
Truncated CD20 design 4 (CD20t4) CD20(M1-N214) (nt)	114	atgacaacaccagaaattcagtaaattgggactttccggcagagccaatgaaaggccc tattgctatgcaatctgggtccaaaaccactcttcaggaggatgtcttcactgggtgggccc cacgcaaagcttctcatgagggaatctaagactttgggggctgtccagattatgaat gggctcttccacattgccctggggggtcttctgatgatccagcagggatctatgcacc catctgtgtgactgtgtgtgtaccctctctggggaggcattatgtatattatttccggat cactcctggcagcaaccggagaaaaactccaggaagtgtttgggtcaaaggaaaaatgata atgaattcattgagcctctttgctgccatttctggaatgattctttcaatcatggacat acttaatatataaaatttccatttttttaaaaatggagagtctgaattttattagagctc acacaccatatattaacatatacaactgtgaaccagctaattccctctgagaaaaactcc catctaccaatactgttacagcatacaatctctgttcttgggcattttgtcagtgat gctgatcctttgccttcttccaggaacttgtaatagctggcatcgttgagaat
Truncated CD20 design 4 (CD20t4) CD20(M1-N214) (aa)	115	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRMSSLVGPTQSFPMRESK TLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTWYPLWGGIMYIISGSL LAATEKNSRKCLVKGMIMNSLSLFAAISGMILSIMDILNIKISHFLKME SLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIF AFFQELVIAGIVEN
Truncated CD20 design 5 (CD20t5) CD20(V82-N214) (nt)	116	gtgactgtgtgtgtaccctctctggggaggcattatgtatattatttccggatcactcct ggcagcaacggagaaaaactccaggaagtgtttgggtcaaaggaaaaatgataatgaatt cattgagcctctttgctgccatttctggaatgattctttcaatcatggacatacttaatt attaaaaatttccatttttttaaaaatggagagtctgaattttattagagctcacacacc atatattaacatatacaactgtgaaccagctaattccctctgagaaaaactccccatcta ccaataactgttacagcatacaatctctgttcttgggcattttgtcagtgatgctgatc tttgccttcttccaggaacttgtaatagctggcatcgttgagaat
Truncated CD20 design 5 (CD20t5) CD20(V82-N214) (aa)	117	VTWYPLWGGIMYIISGSLLAATEKNSRKCLVKGMIMNSLSLFAAISGM ILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPSTQ YCYSIQSLFLGILSVMLIFAFFQELVIAGIVEN
Truncated CD20 design 6 (CD20t6)	118	Gtgactgtgtgtgtgtaccctctctggggaggcattatgtatattatttccggatcactcct ggcagcaacggagaaaaactccaggaagtgtttgggtcaaaggaaaaatgataatgaatt cattgagcctctttgctgccatttctggaatgattctttcaatcatggacatacttaatt

CD20(V82-I186) (nt)		attaaaaatttcccatTTTTTAAAAATGGAGAGTCTGAATTTTATTAGAGCTCACACACC atatattaacatatatacaactgtgaaccagctaataccctctgagaaaaactccccatcta cccaataactgttacagcata
Truncated CD20 design 6 (CD20t6) CD20(V82-I186) (aa)	119	VTWYPLWGGIMYIISGSLAATEKNSRKCLVKGMIMNSLSLFAAISGM ILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPSTQ YCYSIQSLFLGILSVMLIFAFFQELVIAGIVEN
Truncated CD20 design 7 (CD20t7) CD20(P160- Q187).SG4S linker.CD28(I96- D172) (nt)	120	ccatatattaacatatatacaactgtgaaccagctaataccctctgagaaaaactccccatc taccaataactgttacagcatacaaatcgggtggcggcgatctattgaagttatgtatc ctctccttacctagacaatgagaagagcaatggaaccattatccatgtgaaagggaaa cacctttgtccaagtcacctatttcccgaccttctaagcccttttgggtgctgggtggt ggttgggtggagtcctggcttgctatagcttgctagtaacagtggcctttattattttct gggtgaggagtaagaggagcaggctcctgcacagtgc
Truncated CD20 design 7 (CD20t7) CD20(P160- Q187).SG4S linker.CD28(I96- D172) (aa)	121	PYINIYNCEPANPSEKNSPSTQYCYSIQSGGGGSIEVMYPPPYLDNEKSNGTIIHVKGK HLCPSPLFPGPSKPFWVLVWGGVLACYSLLVTVAFIIFWVRSKRSRLLHSD
Truncated CD20 design 8 (CD20t8) CD20(P160- Q187).SGS linker.hCD20(P16 0-Q187).SG4S linker.CD28(I96- D172) (nt)	122	ccatatattaacatatatacaactgtgaaccagctaataccctctgagaaaaactccccatc taccaataactgttacagcatacaaatcgggtggcggcgatctccatatattaacatat acaactgtgaaccagctaataccctctgagaaaaactccccatctaccaataactgttac agcatacaaatcgggtggcggcgatctattgaagttatgtatcctcctccttacctaga caatgagaagagcaatggaaccattatccatgtgaaagggaaacacctttgtccaagtc ccctatttcccgaccttctaagcccttttgggtgctgggtgggtgggtgggtggagtcctg gcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagag gagcaggctcctgcacagtgc
Truncated CD20 design 8 (CD20t8) CD20(P160- Q187).SGS linker.hCD20(P16 0-Q187).SG4S linker.CD28(I96- D172) (aa)	123	PYINIYNCEPANPSEKNSPSTQYCYSIQSGGGGSPYINIYNCEPANPSEKNSPSTQYCY SIQSGGGGSIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPPLFPGPSKPFWVLVWGGVL ACYSLLVTVAFIIFWVRSKRSRLLHSD
Truncated CD20 design 9 (CD20t9) CD20(P160- Q187).SG4S linker.CD8a(P120 -V201) (nt)	124	ccatatattaacatatatacaactgtgaaccagctaataccctctgagaaaaactccccatc taccaataactgttacagcatacaaatcgggtggcggcgatctccagcgccgcgaccac caacaccggcgcccaccatcgctcgagccctgtccctgcgcccagaggcggtgccgg ccagcggcgggggcgagtgacacgagggggctggacttcgctgtgatattctacat ctgggcgccccttgccgggacttggtgggtccttctcctgtcactgggttatcacccttt actgcaaccacaggaaccgaagacgtgtttgcaaatgtccccggcctgtggtc
Truncated CD20 design 9 (CD20t9) CD20(P160- Q187).SG4S linker.CD8a(P120 -V201) (aa)	125	PYINIYNCEPANPSEKNSPSTQYCYSIQSGGGGSPAPRPPTPAPTIASQPLSLRPEACR PAAGGAVHTRGLDFACDIYIWAFLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVV

Truncated CD20 design 10 (CD20t10) CD20(C167-C183).SG4S linker.CD28(I96-D172) (nt)	126	tgtgaaccagctaataccctctgagaaaaactccccatctacccaatactgttcgggtggcggcgatctattgaagttatgtatcctcctcttacctagacaatgagaagagcaatggaaccattatccatgtgaaagggaaacacctttgtccaagtccccctatttccggaccttctaagcccttttgggtgctgggtgggtgggtggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggagcaggctcctgcacagtac
Truncated CD20 design 10 (CD20t10) CD20(C167-C183).SG4S linker.CD28(I96-D172) (aa)	127	CEPANPSEKNSPSTQYCSGGGGSIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPGPSKPFWVLVWVGVLACYSLLVTVAFIIFWVRSKRSRLLHSD
Truncated CD20 design 11 (CD20t11) CD20(C167-C183).SG4S linker.CD20(C167-C183).SG4S linker.CD28(I96-D172) (nt)	128	tgtgaaccagctaataccctctgagaaaaactccccatctacccaatactgttcgggtggcggcgatcttgtgaaccagctaataccctctgagaaaaactccccatctacccaatactgttcgggtggcggcgatctattgaagttatgtatcctcctcttacctagacaatgagaagagcaatggaaccattatccatgtgaaagggaaacacctttgtccaagtccccctatttccggaccttctaagcccttttgggtgctgggtgggtgggtggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggagcaggctcctgcacagtac
Truncated CD20 design 11 (CD20t11) CD20(C167-C183).SG4S linker.CD20(C167-C183).SG4S linker.CD28(I96-D172) (aa)	129	CEPANPSEKNSPSTQYCSGGGGSCEPANPSEKNSPSTQYCSGGGGSIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPGPSKPFWVLVWVGVLACYSLLVTVAFIIFWVRSKRSRLLHSD
Truncated CD20 design 12 (CD20t12) CD20(C167-C183).SG4S linker.CD8a(P120-V201) (nt)	130	tgtgaaccagctaataccctctgagaaaaactccccatctacccaatactgttcgggtggcggcgatctccagcgcgcgaccaccaacaccggcgcccaccatcgctgcagccccgtgccctgcgcccagaggcgtgcccggccagcggcggggggagtcacacagaggggctggacttcgcctgtgatatctacatctgggcgcccttggccgggacttggtggggtccttctcctgtcactggttatcaccctttactgcaaccacaggaaccgaagacgtgtttgcaaatgtccccggcctgtggtc
Truncated CD20 design 12 (CD20t12) CD20(C167-C183).SG4S linker.CD8a(P120-V201) (aa)	131	CEPANPSEKNSPSTQYCSGGGGSAPRPPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVV
Truncated CD20 design 13 (CD20t13) CD20v1 [CD20(M1-A54).CD20(C111-P297)] (nt)	132	atgaccacaccccggaactccgtgaatggcaccttcctgccgagccaatgaagggccctatcgccatgcagtctggcccaaagcccctgttcggagaatgagctccctgggtgggccacccagagcttctttatgagggagtcgaagacactgggcgcctgcctggtgaagggcaagatgatcatgaactctctgagcctgttcgccgccatctccggcatgatcctgtctatcatggacatcctgaacatcaagatctctcacttctgaagatggagagcctgaacttcatccggggccacacccatacatcaacatctataattgcgagcccgcaaccctagcgagaagaattccccctctacacagtactgttatagcatccagtcctgttcctgggcatcctgtccgtgatgctgatctttgccttctttcaggagctgggtcatcgccggcatcgtggaga

		acgagtggaagaggacctgttctcgccctaagagcaatatcgtgctgctgagcgccgag gagaagaaggagcagacaatcgagatcaaggaggaggtggtgggcctgaccgagacatc tagccagcctaagaatgaggaggatcgcgagatcatcccaatccaggaggaggaggagg aggagaccgagacaaactttccagagccccctcaggaccaggagtcctctccaatcgag aatgatagctccccctgataa
Truncated CD20 design 13 (CD20t13) CD20v1 [CD20(M1- A54).CD20(C111- P297)] (aa)	133	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRMSSLVGPTQSFFMRESKTLGACLVKG KMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSE KNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAE EKKEQTIEIKEEVVGLTETSSQPKNEEDIEIPIQEEEEETETNFPPEPPQDQESSPIE NDSS
Truncated CD20 design 14 (CD20t14) CD20v1 (delta 281-297 / wildtype) [CD20(M1- A54).CD20(C111- E281)] (nt)	134	atgaccacaccacggaacagcgtgaatggcaccttcccagcagagccaatgaagggacc aatcgcaatgcagtcgggacccaagcctctgtttcggagaatgagctccctggtggggcc ccaccagctctttctttatgaggaggagcaagacactgggcgctgcctggtgaaggggc aagatgatcatgaactcctgtctctgttcgccgccatcagcggcatgatcctgtccat catggacatcctgaacatcaagatctcccacttctgaagatggagagcctgaacttca tccggggccacacccccttatcatcaacatctataattgcgagcctgccaacccatctgag aagaatagcccatccacacagtactgttattctatccagagcctgttcctgggcatcct gtccgtgatgctgatctttgccttctttcaggagctggtcatcgccggcatcgtggaga acgagtggaagaggacctgttcccgcccaagtctaatactgctgctgctgagcgccgag gagaagaaggagcagacaatcgagatcaaggaggaggtggtgggcctgaccgagacatc tagccagcccaagaacgaggaggatcgcgagatcatccctatccaggaggaggaggagg aggagaccgagacaaattttcctgagtgataa
Truncated CD20 design 14 (CD20t14) CD20v1 (delta 281-297 / wildtype) [CD20(M1- A54).CD20(C111- E281)] (aa)	135	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRMSSLVGPTQSFFMRESKTLGACLVKG KMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSE KNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAE EKKEQTIEIKEEVVGLTETSSQPKNEEDIEIPIQEEEEETETNFPPE
Truncated CD20 design 15 (CD20t15) CD20v1 (delta 263-297 / wildtype)_2 [CD20(M1- A54).CD20(C111- E263)] (nt)	136	atgaccacaccccggaacagcgtgaatggcaccttcccagccgagcccatgaaggggccc tatcgccatgcagtcgggcccccaagcctctgtttcggagaatgagctccctggtggggcc ccaccagctctttctttatgaggaggagcaagacactgggcgctgcctggtgaaggggc aagatgatcatgaactcctgtctctgttcgccgccatcagcggcatgatcctgtccat catggacatcctgaacatcaagatctcccacttctgaagatggagagcctgaacttca tccggggccacaccccatacatcaacatctataattgcgagcctgccaacccatctgag aagaatagccccctccacacagtactgttattctatccagagcctgttcctgggcatcct gtccgtgatgctgatctttgccttctttcaggagctggtcatcgccggcatcgtggaga acgagtggaagaggacctgttcccgccctaagtctaatactgctgctgctgagcgccgag gagaagaaggagcagacaatcgagatcaaggaggaggtggtgggcctgaccgagacatc tagccagccaaagaatgaggaggatcgcgagtgataa
Truncated CD20 design 15 (CD20t15) CD20v1 (delta 263-297 / wildtype)_2 [CD20(M1- A54).CD20(C111- E263)] (aa)	137	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRMSSLVGPTQSFFMRESKTLGACLVKG KMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSE KNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAE EKKEQTIEIKEEVVGLTETSSQPKNEEDIE
Truncated CD20 design 16 (CD20t16) CD20v1 (delta 245-297 / wildtype) [CD20(M1- A54).CD20(C111- V228)] (nt)	138	atgaccacaccccggaactcctggaatggcaccttcccagccgagcccatgaaggggccc tatcgccatgcagtcgtggcccccaagcctctgtttcggagaatgagctccctggtggggcc ctaccagagcttctttatgaggaggagtccaagacactgggcgctgcctggtgaaggggc aagatgatcatgaactctctgagcctgttcgccgccatctccggcatgatcctgtctat catggacatcctgaacatcaagatctctcacttctgaagatggagagcctgaacttca tccggggccacaccccatacatcaacatctataattgcgagcctgccaacccaagcgag aagaattccccctctacacagtactgttatagcatccagtcctgttcctgggcatcct gtccgtgatgctgatctttgccttctttcaggagctggtcatcgccggcatcgtggaga

		acgagtggaagaggacatgttctcgccccaagagcaatatcgtgtgataa
Truncated CD20 design 16 (CD20t16) CD20v1 (delta 245-297 / wildtype) [CD20(M1-A54).CD20(C111-V228)] (aa)	139	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRMSSLVGPTQSFFMRESKTLGACLVKG KMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSE KNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIV
Truncated CD20 design 17 (CD20t17) CD20v2 [CD20(M1-V8).CD20(C111-P297)] (nt)	140	atgaccacacccaggaacagcgtgtgcctgggtgaagggcaagatgatcatgaatagcct gtccctgttcgccgccatctctggcatgatcctgagcatcatggacatcctgaacatca agatctcccacttcctgaagatggagagcctgaacttcacccgggcccacacccatac atcaacatctataattgcgagccagccaacccagcgagaagaattctcccagcacaca gtactgttattccatccagtcctctgttcctgggcatcctgtccgtgatgctgatctttg cttctttcaggagctgggtcatcgccggcatcgtggagaacgagtgggaagcggacctgt agcagacctaagtccaatatcgtgctgctgtccgccgaggagaagaaggagcagacaat cgagatcaaggaggaggtgggtgggcctgaccgagacaagctcccagcccagaacgagg aggatatcgagatcatccctatccaggaggaggaggaggaggagaccgagacaaacttt ccagagccccctcaggaccaggagtctagccctatcgagaatgattcctctcatgata a
Truncated CD20 design 17 (CD20t17) CD20v2 [CD20(M1-V8).CD20(C111-P297)] (aa)	141	MTTPRNSVCLVKGMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPY INIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTC SRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIEIPIQEEEEETETNF PEPPQDQESSPIENDSSP
CD52 (G25-S36) (CAMPATH-1 antigen) (nt)	142	ggacaaaacgacaccagccaaaccagcagccccctca
CD52 (G25-S36) (CAMPATH-1 antigen) (aa)	143	GQNDSQTSSPS
Truncated CD52 Design 1 (CD52t1) with CD52 signal peptide (nt)	144	atgaagcgcttcctcttctcctactcaccatcagcctcctgggttatggtacagataca aactggactctcaggacaaaacgacaccagccaaaccagcagccccctcaggcagcacct ccggcagcggcaagcctggcagcggcgagggcagcaccaagggcggcgaggcggaagc ggaggcggaggctccaagcccttctgggtgctggtcgtggcggcggagtgtggcctg ttacagcctgctggtcaccgtggccttcacatccttttgggtc
Truncated CD52 Design 1 (CD52t1) with CD52 signal peptide (aa)	145	MKRFLFLLLTISLLVMVQIQTGLSGQNDTSQTSSPSGSTSGSGKPGSGEG STKGGGGGSGGGGSKPFWLVVVGVLACYSLLVTVAFIIFWV
Truncated CD52 Design 2 (CD52t2) with CD52 signal peptide (nt)	146	atgaagcgcttcctcttctcctactcaccatcagcctcctgggttatggtacagataca aactggactctcaggacaaaacgacaccagccaaaccagcagccccctcaggcagcacct ccggcagcggcaagcctggcagcggcgagggcagcaccaagggcggcgaggatgataca tctcagacttcacatctcctagcggatccacttctgggttcggtaaacagggttctgggga aggtagtacaaaaggaggcggaggcgggaagcggaggcggaggctccaagcccttctggg tgctggctgctggcggcggagtgtggcctgttacagcctgctggtcaccgtggccttc atcatcttttgggtc
Truncated CD52 Design 2 (CD52t2) with CD52 signal peptide (aa)	147	MKRFLFLLLTISLLVMVQIQTGLSGQNDTSQTSSPSGSTSGSGKPGSGEG STKGGQNDTSQTSSPSGSTSGSGKPGSGEGSTKGGGGGSGGGGSKPFWLV VVGVLACYSLLVTVAFIIFWV
Truncated CD52	148	atgaagcgcttcctcttctcctactcaccatcagcctcctgggttatggtacagataca

Design 3 (CD52t3) with CD52 signal peptide (nt)		aactggactctcaggacaaaacgacaccagccaaccagcagccccctcaggcagcacct ccggcagcggcgaagcctggcagcggcgaggcagcaccaagggcggccagaatgataca tctcagacttcatctcctagcggatccacttctggttccggtaaaccaggttctgggga aggtagtacaaaaggaggtcagaacgacacttcacagacatctagtcacccggcagta caagcgggaagtggaaagcccggaagtggtaggggatcaactaaggggtggcggaggcggga agcggaggcggaggctccaagcccttctgggtgctggctggtcggcggagtgctggc ctgttacagcctgctggtcaccgtggccttcacatcttttgggtc
Truncated CD52 Design 3 (CD52t3) with CD52 signal peptide (aa)	149	MKRFLFLLLTISLLVMVQIQTGLSGQNDSQTSSPSGSTSGSGKPGSGEG STKGGQNDSQTSSPSGSTSGSGKPGSGEGSTKGGQNDSQTSSPSGSTS GSGKPGSGEGSTKGGGGSGGGGSKPFWLVVVGVLACYSLLVTVAFII FWV
Truncated CD52 Design 4 (CD52t4) with CD52 signal peptide (aa)	150	MKRFLFLLLTISLLVMVQIQTGLSGQNDSQTSSPSGSTSGSGKPGSGEG STKGGQNDSQTSSPSGSTSGSGKPGSGEGSTKGGQNDSQTSSPSGSTS GSGKPGSGEGSTKGGGGSGGGGSGGGGSEITLIIFGVMAGVIGTII LLISYGIIRRGGS
Truncated CD52 Design 5 (CD52t5) with CD52 signal peptide (aa)	151	MKRFLFLLLTISLLVMVQIQTGLSGQNDSQTSSPSGSTSGSGKPGSGEG STKGGQNDSQTSSPSGSTSGSGKPGSGEGSTKGGQNDSQTSSPSGSTS GSGKPGSGEGSTKGGGGSGGGGSGGGGSGGGGSEITLIIFGVMAGVIGTIL LALLIWGGGS
Truncated CD52 Design 6 (CD52t6) with CD52 signal peptide (aa)	152	MKRFLFLLLTISLLVMVQIQTGLSGQNDSQTSSPSGSTSGSGKPGSGEG STKGGQNDSQTSSPSGSTSGSGKPGSGEGSTKGGQNDSQTSSPSGSTS GSGKPGSGEGSTKGGGGSGGGGSGGGGSGGGGSEITLIIFGVMAGVIGTIL LALLIWGGGS
Low-affinity nerve growth factor receptor (LNGFR, TNFRSF16) (nt)	153	atgggggaggtgccaccggccgcgcatggacgggcccgcgctgctgctgttctgct tctgggggtgtcccttggagggtgccaaaggagcatgccccacaggcctgtacacacaca gcggtgagtgctgcaaacctgcaacctgggcgagggtgtggcccagccttgtggagcc aaccagaccgtgtgtgagccctgcctggacagcgtgacgttctccgacgtggtgagcgc gaccgagccgtgcaagccgtgcaccgagtgctggtgggctccagagcatgtcggcgcctg gcgtggaggccgacgacgcctgtgctgctgcgcctacggctactaccaggtgagacg actgggctgctgcaggcgtgcccgtgtgctgagggcgggctcgggctcgtgttctcctg ccaggacaagcagaacaccgtgtgctgagagtgccccgacggcacgtattccgacagg ccaaccacgtggaccctgacctgacctgcacgtgtgctgaggaacaccgagcgcagctc cgcgagtgacacgctgggcccagcgcagtgctgagggagatccctggccttggattac acggtccacaccccagagggtctggacagcacagccccagcaccagggagcctgagg cacctccagaacaagacctatagccagcacgggtggcaggtgtggtgaccacagtgatg ggcagctcccagcccgtggtgacctgagggcaccacagcaacctcatcctgtctattg ctccatcctggctgctgtgtgtgtggccttgtggcctacatagccttcaagaggtgga acagctgcaagcagaacaagcaaggagccaacagccggccagtgaaccagacgccccca ccagaggggagaaaaactccacagcgacagtggcatctccgtggacagccagagcctgca tgaccagcagccccacagcagacagcctcgggccaggccctcaagggtgacggaggcc tctacagcagcctgccccagccaagcgggaggaggtggagaagcttctcaacggctct gcgggggacacctggcgccacctggcgggcgagctgggctaccagcccagcacataga ctcctttaccatgaggcctgccccgttcgcgctgcttgcaagctgggcccaccagg acagcgccacactggacgcccctcctggccgctgctgcccagcagcagcgcacctc gtggagagtctgtgagtgagtgacctgcccacatccccgggtgtga
Low-affinity nerve growth factor receptor (LNGFR, TNFRSF16) (aa)	154	MGAGATGRAMDGPRLLLLLLLGVSLGGAKEACPTGLYTHSGECKACNLGEGVAQPCGA NQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAVGYQDET TGRCEACRVCEAGSLVFSQDKQNTVCEECPDGTYSDEANHVDPLCTVCEDETERQL RECTRWADAEEIEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVTTVM GSSQPVVTRGTTDNLIPVYCSILAADVVLVAYIAFKRWNSCKQNKQGANSRPNQTPP PEGEKLHSDSGISVDSQS LHDQPHQTASGQALKGDGGLYSSLPPAKREEVEKLLNGS AGDTRHRLAGELGYQPEHIDSFTHEACPVRALLASWATQDSATLDALLAALRRIQRADL VESLCSESTATSPV
LNGFR	155	aaggaggcatgccccacaggcctgtacacacacagcggtagtgctgcaagcctgcaa

Extracellular Domain (K29-N250) (nt)		cctgggcgagggtgtggcccagccttgtggagccaaccagaccgtgtgtgagccctgcc tggacagcgtgacgttctccgacgtggtgagcgcgaccgagccgtgcaagccgtgcacc gagtgcgtggggctccagagcatgtcggcgccgtgctgaggagccgacgacgccgtgtg ccgtgcgccctacggctactaccaggatgagacgactgggcgctgagggcgtgccgcg tgtgagggcgggctcgggcctcgtgttctcctgccaggacaagcagaacaccgtgtgc gaggagtgtcccgacggcacgtattccgacgaggccaaccacgtggaccctgtcctgcc ctgcaccgtgtgagggacaccgagcgccagctccgcgagtgacacgctggggccgacg ccgagtgcgaggagatccctggccgttgattacacggtccacacccccagagggctcg gacagcacagccccagcaccaggagcctgaggcacctccagaacaagacctcatagc cagcacggtggcaggtgtggtgaccacagtgtgaggcagctcccagcccgtggtgacc gaggcaccaccgacaac
LNGFR Extracellular Domain (K29-N250) (aa)	156	KEACPTGLYTHSGECKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVS ATEPCKPCTECVGLQSMSAPCVEADDAVCRCAAYGYQDETTGRCEACRV EAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLR ECTRWADEECIEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTV AGVVTTVMGSSQPVVTRGTTDN
LNGFR Cys 2,3,4 (E65-N250) (nt)	157	Gagccctgcctggacagcgtgacgttctccgacgtggtgagcgcgaccgagccgtgcaa gccgtgcaccgagtgctgtggggctccagagcatgtcggcgccgtgctgaggagccgacg acgccgtgtgcccgtgcgcctacggctactaccaggatgagacgactgggcgctgcgag gcgtgccgcgtgtgagggcgggctcgggcctcgtgttctcctgccaggacaagcagaa caccgtgtgagggagtgtcccgacggcacgtattccgacgaggccaaccacgtggacc cgtgcctgccctgcaccgtgtgagggacaccgagcgccagctccgcgagtgacacgc tggggccgacgcccagtgagggagatccctggccgttgattacacggtccacaccccc agagggctcggacagcacagccccagcaccaggagcctgaggcacctccagaacaag acctcatagccagcacggtggcaggtgtggtgaccacagtgtgaggcagctcccagccc gtggtgacccgaggcaccaccgacaac
LNGFR Cys 2,3,4 (E65-N250) (aa)	158	EPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAAYGY QDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDP LPCTVCEDTERQLRECTRWADAECIEIPGRWITRSTPPEGSDSTAPSTQE PEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDN
LNGFR Cys3,4 (R108-N250) (nt)	159	cgctgcgccctacggctactaccaggatgagacgactgggcgctgagggcgtgccgcgt gtgcgaggcgggctcgggcctcgtgttctcctgccaggacaagcagaacaccgtgtgcg aggagtgtcccgacggcacgtattccgacgaggccaaccacgtggaccctgtgcctgcc tgaccgtgtgagggacaccgagcgccagctccgcgagtgacacgctggggccgacgc cgagtgcgaggagatccctggccgttgattacacggtccacacccccagagggctcgg acagcacagccccagcaccaggagcctgaggcacctccagaacaagacctcatagcc agcacggtggcaggtgtggtgaccacagtgtgaggcagctcccagcccgtggtgacccg aggcaccaccgacaac
LNGFR Cys3,4 (R108-N250) (aa)	160	RCAYGYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDE ANHVDPCLPCTVCEDTERQLRECTRWADAECIEIPGRWITRSTPPEGSDS TAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDN
Truncated LNGFR design 1 (LNGFRt1) (nt)	161	aaggaggcatgtcccccagggcctgtacacacagcggtgagtgctgcaagcctgcaa cctgggcgagggtgtggcccagccttgtggagccaaccagaccgtgtgtgagccctgcc tggacagcgtgacgttctccgacgtggtgagcgcgaccgagccgtgcaagccgtgcacc gagtgcgtggggctccagagcatgtcggcgccgtgctgaggagccgacgacgccgtgtg ccgtgcgccctacggctactaccaggatgagacgactgggcgctgagggcgtgccgcg tgtgagggcgggctcgggcctcgtgttctcctgccaggacaagcagaacaccgtgtgc gaggagtgtcccgacggcacgtattccgacgaggccaaccacgtggaccctgtcctgcc ctgcaccgtgtgagggacaccgagcgccagctccgcgagtgacacgctggggccgacg ccgagtgcgaggagatccctggccgttgattacacggtccacacccccagagggctcg gacagcacagccccagcaccaggagcctgaggcacctccagaacaagacctcatagc cagcacggtggcaggtgtggtgaccacagtgtgaggcagctcccagcccgtggtgaccc gaggcaccaccgacaacctcatccctgtctattgtctcatcctggctgctgtggtgtg ggccttgtggcctacatagccttc
Truncated LNGFR design 1 (LNGFRt1) (aa)	162	KEACPTGLYTHSGECKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVS ATEPCKPCTECVGLQSMSAPCVEADDAVCRCAAYGYQDETTGRCEACRV EAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLR ECTRWADEECIEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTV

		AGVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAF
Truncated LNGFR design 2 (LNGFRt2) (aa)	163	KEACPTGLYTHSGECKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVS ATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLR ECTRWADECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTV AGVTTVMGSSQPVVTRGTTDNGGGSGGGSGGGSGGGGSFWLVVVG GVLACYSLLVTVAFIIFWVRSKRS
Truncated LNGFR design 3 (LNGFRt3) (aa)	164	EPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYY QDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCL LPCTVCEDTERQLRECTRWADAEEIPGRWITRSTPPEGSDSTAPSTQE PEAPPEQDLIASTVAGVTTVMGSSQPVVTRGTTDNGGGSGGGSGGGG SGGGGSFWLVVVGVLACYSLLVTVAFIIFWVRSKRS
Truncated LNGFR design 4 (LNGFRt4) (aa)	165	RCAYGYQDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDE ANHVDPCLPCTVCEDTERQLRECTRWADAEEIPGRWITRSTPPEGSDS TAPSTQEPEAPPEQDLIASTVAGVTTVMGSSQPVVTRGTTDNGGGSGG GGSGGGSGGGGSFWLVVVGVLACYSLLVTVAFIIFWVRSKRS
Truncated LNGFR design 5 (LNGFRt5) (aa)	166	RCAYGYQDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDE ANHVDPCLPCTVCEDTERQLRECTRWADAEEIPGRWITRSTPPEGSDS TAPSTQEPEAPPEQDLIASTVAGVTTVMGSSQPVVTRGTTDNGGGSGG GGSGGGSGGGGSEITLIIFGVMAGVIGTILLISYGIIRGGGS
Truncated LNGFR design 6 (LNGFRt6) (aa)	167	RCAYGYQDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDE ANHVDPCLPCTVCEDTERQLRECTRWADAEEIPGRWITRSTPPEGSDS TAPSTQEPEAPPEQDLIASTVAGVTTVMGSSQPVVTRGTTDNGGGSGG GGSGGGSGGGGSITLIIFGVMAGVIGTILLALLIWGGGS
Truncated LNGFR design 7 (LNGFRt7) (aa)	168	RCAYGYQDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDE ANHVDPCLPCTVCEDTERQLRECTRWADAEEIPGRWITRSTPPEGSDS TAPSTQEPEAPPEQDLIASTVAGVTTVMGSSQPVVTRGTTDNGGGSGG GGSGGGSGGGGSITLIIFGVMAGVIGTILLALLIWGGGS
CD19-CD3 ζ CAR (nt)	169	atggcgctgcccgtgaccgccttgcctcctgcccgtggccttgctgctccacgccgccaag gccggacatccagatgacacagactacatcctccctgtcgtcctcctgggagacagag tcaccatcagttgcagggaagtcaggacattagtaaatatttaaattggtatcagcag aaaccagatggaactgttaaaactcctgatctaccatacatcaagattacactcaggagt cccatcaaggttcagtggcagtggtctggaacagattattctctcaccattagcaatt tggagcaggaagatattgccacttacttttccaacagggtataacgcttcctacacg ttcggaggggggaccaagctggagatcacaggtggcgggtggctcgggcgggtgggtc gggtggcggcggtatctgaggtgaaactgcaggagtcaggacctggcctgggtggcgccct cacagagcctgtccgtcacatgcactgtctcaggggtctcattaccgactatggtgta agctggattcgcagcctccacgaaagggtctggagtggtcgggagtaatatggggtag tgaaccacatactataattcagctctcaaatccagactgaccatcatcaaggacaact ccaagagccaagttttcttaaaaaatgaacagctctgcaaacctgatgacacagccattac tactgtgccaacattattactacgggtggttagctatgctatggactactggggccaagg aacctcagtcaccgtctcctcaaccacgacgccagcgccgcgaccaccaacaccggcgc ccaccatcgctcgagccccgtgctccctgcgccagaggcgtgtagaccggctgcaggt ggagcagtgacacaggggggctggacttcgcctgtgatattacatctgggcgcctt ggccgggacttggtggggtccttctcctgtcactgggttatcacctttactgccgcgtca agttcagcaggagcgacagcgccccgcgtacaagcaggggccagaaccagctctataac gagctcaatctaggacgaagagaggagtagatgttttggacaagagacgtggccggga ccctgagatggggggaaagccgagaaggagaaccctcaggaaggcctgtacaatgaac tgcagaaagataagatggcggaggcctacagttagattgggatgaaaggcagcgccgg aggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacaccta cgacgcccttcacatgcaggccctgccccctcgc
CD19-CD3 ζ CAR (aa)	170	MALPVTALLPLALLHAARPDIQMTQTSSLSASLGDRVTISCRASQDI SKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLE QEDIATYFCQQGNTLPYTFGGGKLEITGGGGSGGGSGGGGSEVKLQES GPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVWIGSETT YYNSALKSRLTIKDNSKSQVFLKMNSLQDDTAIYYCAKHYYGGSYAM DYWGQGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT

		RGLDFACDIYIWAPLAGTCGVLLLLSLVITLYCRVKFSRSADAPAYKQGQN QLYNELNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA EAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
CD19-CD137-CD3 ζ CAR (nt)	171	atggccttaccagtgaccgccttgctcctgccgtggccttgctgctccacgccgccag gccggacatccagatgacacagactacatcctccctgtctgctcctctgggagacagag tcaccatcagttgcagggcaagtcaggacattagtaaatatttaaattggtatcagcag aaaccagatggaactgttaaactcctgatctaccatacatcaagattacactcaggagt cccatcaaggttcagtggcagtggtctggaacagattattctctcaccattagcaacc tgagcaagaagatattgccacttacttttccaacagggtaatagccttcgtacacg ttcggaggggggaccaagctggagatcacaggcagcacctccggcagcggcaagcctgg cagcggcgagggcagcaccaaggcgaggtgaaactgcaggagtcaggacctggcctgg tgccgcccctcacagagcctgtccgtcacatgcactgtctcaggggtctcattaccgcac tatggtgtaagctggattcgccagcctccacgaaagggtctggagtggctgggagtaaat atggggtagtgaaaccacatactataattcagctctcaaatccagactgaccatcatca aggacaactccaagagccaagttttcttaaaaatgaacagctctgcaaactgatgacaca gccatttactactgtgccaacattattactacgggtggtagctatgctatggactactg gggccaaggaacctcagtcaccgtctcctcaaccacgacgccagcgccgcgaccacca caccggcgccaccatcgctgcagccccctgtccctgcgcccagaggcgtgccggcca gcggcgggggggcagtgacacagagggggctggacttcgctgtgatattctacatctg ggcgcccttgccgggacttggtggggtccttctcctgtcactgggtatcaccccttact gcaaacggggcagaaagaaactcctgtatatattcaacaaccatttatgagaccagta caaactactcaagaggaagatggctgtagctgccgattttccagaagaagaaggagg atgtgaactgagagtgaagttcagcaggagcgagacgccccgcgtacaagcaggggc agaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttgga aagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaacctcagga aggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgtgattggga tgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtaca gccaccaaggacacctacgacgcccccttcacatgcaggccctgccccctcgc
CD19-CD137-CD3 ζ CAR (aa)	172	MALPVTALLPLALLHAARPDIQMTQTSSLSASLGDRVTISCRASQDI SKYLNWYQKPDGTVKLLIYHSTRLHSGVPSRFSGSGSGTDYSLTISNLE QEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGSGEGSTKGEVKL QESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLVGIWGS ETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDITAIYYCAKHYYYGGS YAMDYWGQGSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACHPAAGGA VHTRGLDFACDIYIWAPLAGTCGVLLLLSLVITLYCKRGRKLLYIFKQPF MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNE LNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSE IGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
CD19-CD28-CD3 ζ CAR (nt)	173	atggcgctgcccgtgaccgccttgctcctgccgtggccttgctgctccacgccgccag gccggacatccagatgacacagactacatcctccctgtctgctcctctgggagacagag tcaccatcagttgcagggcaagtcaggacattagtaaatatttaaattggtatcagcag aaaccagatggaactgttaaactcctgatctaccatacatcaagattacactcaggagt cccatcaaggttcagtggcagtggtctggaacagattattctctcaccattagcaatt tgagcaggaagatattgccacttacttttccaacagggtaatagccttcgtacacg ttcggaggggggaccaagctggagatcacagggtggcggtggctcgggcggtgggtgggtc gggtggcgcgatctgaggtgaaactgcaggagtcaggacctggcctgggtggcgccct cacagagcctgtccgtcacatgcactgtctcaggggtctcattaccgactatggtgta agctggattcgccagcctccacgaaagggtctggagtggctgggagtaatatggggtag tgaaaccacatactataattcagctctcaaatccagactgaccatcatcaaggacaact ccaagagccaagttttcttaaaaatgaacagctctgcaaactgatgacacagccatttac tactgtgccaacattattactacgggtggtagctatgctatggactactggggccaagg aacctcagtcaccgtctcctcaaccacgacgccagcgccgcgaccaccaacaccggcgc ccaccatcgctgcagccccctgtccctgcgcccagaggcgtgtagaccggctgcagggt ggagcagtgacacaggggggctggacttcgctgtgatattctacatctgggcgcccctt ggcgggacttggtggggtccttctcctgtcactgggtatcaccccttactgcaggagta agaggagcaggctcctgcacagtgactacatgaacatgactccccgcgccccggggccc accgcaagcattaccagccctatgccccaccacgcgacttcgcagcctatcgctccc

		cgtcaagttcagcaggagcgcagacgcccccggtacaagcaggccagaaccagctct ataacgagctcaatctaggacgaagagaggagtacgatgttttgacaagagacgtggc cgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaa tgaactgcagaaagataagatggcggaggcctacagttagattgggatgaaaggcgagc gccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggac acctacgacgccccttcacatgcaggccctgccccctgc
CD19-CD28-CD3 ζ CAR (aa)	174	MALPVTALLLPLALLLHAARPDIQMTQTSSLSASLGDRVTISCRASQDI SKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLE QEDIATYFCQQGNTLPYTFGGGKLEITGGGSGGGGSGGGSEVKLQES GPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVWGETT YYNSALKSRLTIIKDNSKSQVFLKMNSLQDDTAIYYCAKHYYGGSYAM DYWGQTSVTVSSTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT RGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRSKRSRLHSDYMNMTPR RPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGGQNQLYNEINLG RREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMK GERRRGKGGHDGLYQGLSTATKDTYDALHMQALPPR
CD19-CD28-CD3 ζ CAR (nt)	175	atgctgctgctgggtgaccagcctgctgctgtgtgagctgccccacccgcctttctgct gatccccgacatccagatgacccagaccacctccagcctgagcgccagcctggcgacc gggtgaccatcagctgccgggagccagcaggacatcagcaagtacctgaactggtatcag cagaagcccgacggcaccgtcaagctgctgatctaccacaccagccggctgcacagcgg cgtgcccagccgggttagcggcagcggctccggcaccgactacagcctgaccatctcca acctggagcaggaggacatcgccacctacttttgccagcagggaacacactgccctac acctttggcggcggaacaaagctggagatcacccggcagcacctccggcagcggcaagcc tggcagcggcgagggcagcaccgaagggcgaggtgaagctgcaggagagcggccctggcc tgggtggccccagccagagcctgagcgtgacctgtacctgtccggcgtgtccctgccc gactacggcgtgtcctggatccggcagccccctaggaagggcctggagtggctggcggt gatctggggcagcagaccacctactacaacagcgccctgaagagccggctgaccatca tcaaggacaacagcaagagccaggtgttctgaagatgaacagcctgcagaccgacgac accgccatctactactgtgccaagcactactactacggcggcagctacgccatggacta ctggggccaggggcaccagcgtgacctgttcagcagagagcaagtacggccctccctgcc ccccttgccctgccccgagttcctggcgaggccagcgtgttctgttcccccccaag ccaaggacacccctgatgatcagcggaccccgagggtgacctgtgtggtggtggacgt gtcccaggaggaccccgagggtcagttcaactgggtacgtggagcggcgtggaggtgcaca acgccaagaccgaagcccgaggagcaggtcaatgacacctaccgggtggtgtcctgtg ctgacctgtgtgcaccaggactggctgaacggcaaggaatacaggtgaaggtgtccaa caagggcctgcccagcagcatcgagaaaaccatcagcaaggccaagggccagcctcggg agccccaggtgtacacctgccccctagccaagaggagatgaccaagaatcaggtgtcc ctgacctgcctggtgaagggtcttctaccccagcgacatcgccgtggagtgggagagcaa cggccagcccgagaacaactacaagaccacccccctgtgctggacagcgacggcagct tcttctgtacagcaggtgacctgggacaagagcgggtggcaggagggaacgtcttt agctgtcctgtgatgcagaggccctgcacaaccactacaccagaagagcctgtccct gagcctgggcaagatgttctgggtgctggtcgtggtgggtggcgtgtggcctgtaca gcctgtggtgacagtggccttcatcatcttttgggtgaggagcaagcggagcagaggc ggccacagcgactacatgaacatgacccccggaggcctggccccaccgggaagcacta ccagccctacgccccctccagggaacttcgcccctaccggagcgggtgaagttcagcc ggagcggcgacgccccctgcctaccagcaggggcagaaccagctgtacaacgagctgaac ctgggcccggaggaggagtagcagctgctggacaagcggagagggccgggacctgagat ggcgggcaagccccggagaaagaaccctcaggagggcctgtataacgaactgcagaaag acaagatggccgaggcctacagcgagatcgcatgaagggcgagcggcgagggggcaag ggccacgacggcctgtaccagggcctgagcaccgccaccaaggatacctacgacgccct gcacatgcaggccctgccccccaga
CD19-CD28-CD3 ζ CAR (aa)	176	MLLVTSLLLCELPHPAFLIPDIQMTQTSSLSASLGDRVTISCRASQD ISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNL EQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGSGEGSTKGEVK LQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVWIG SETTYNSALKSRLTIIKDNSKSQVFLKMNSLQDDTAIYYCAKHYYGG SYAMDYWGQTSVTVSSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTL

		MISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTL PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDS GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKMFV LVVVGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKH YQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVL DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG HDGLYQGLSTATKDTYDALHMQALPPR
Membrane bound Interleukin-15 (IL- 15.Linker.IL- 15R α) (nt)	177	aactgggtgaatgtgatcagcgacctgaagaagatcaggatctgatccagagcatgca cattgatgccaccctgtacacagaatctgatgtgcaccctagctgtaaagtgaccgcca tgaagtgttttctgctggagctgcaggtgatttctctggaaagcggagatgcctctatc cacgacacagtggagaatctgatcatcctggccaacaatagcctgagcagcaatggcaa tgtgacagagtctggctgtaaggagtgtgaggagctggaggagaagaacatcaaggagt ttctgacagagctttgtgcacatcgtgcagatgttcatcaatacaagctctggcggaggga tctggaggaggcggatctggaggaggaggcagtgaggaggcggaggatctggcggaggatc tctgcagattacatgccctcctccaatgtctgtggagcagcgccgatatttgggtgaagt cctacagcctgtacagcagagagagatacatctgcaacagcggctttaagagaaaggcc ggcacctcttctctgacagagtgcgtgctgaataaggccacaatgtggcccactggac aacacctagcctgaagtgcattagagatcctgccctggctccaccagaggcctgccctc catctacagtgcacaacagccggagtgcacacctcagcctgaatctctgagcccttctgga aaagaacctgccgccagctctcctagctctaataataaccgccccacaacagccgccat tgtgcctggatctcagctgatgcctagcaagtctcctagcacaggcacaacagagatca gcagccacgaatcttctcacggaacaccttctcagaccaccgccaagaattgggagctg acagcctctgcctctcaccagcctccaggagtgtatcctcaggggcactctgataaac agtggccatcagcacatctacagtgtctgtgtgtggactgtctgccgtgtctctgtgg cctgttacctgaagtctagacagacacctcctctggcctctgtggagatggaggccatg gaagccctgcctgtgacatggggaacaagcagcagagatgaggacctggagaattgttc tcaccacctg
Membrane bound Interleukin-15 (IL- 15.Linker.IL- 15R α) (aa)	178	NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELQVISLESGDASI HDTVENLIILANNSLSSNGNVTESGCKECELEEKNIKEFLQSFVHIVQMFINTSSGGG SGGGSGGGSGGGSGGGSLQITCPPPMSVEHADIWVKSYSLSRERYICNSGFKRA GTSSL TECVLNKATNVAHWTPSLKCI RDPALVHQRPAPPSTVTTAGVTPQPELSLSPSGKEPAA SSPSSNNTAATTA AIVPGSQLMPSKSPSTGTTEISSHESHGTPSQTTAKNWELTASAS HQPPGVYPQGHSDTTVAISTSTVLLCGLSAVSL LACYLKSRTPLASVEMEAMEALPV TWGTSSRDEDLENCSSHL
CD19-CD137-CD3 ζ CAR.T2A.Ig Kappa signal peptide.HER1t (aa)	179	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDTAIYYCAKHYYYGGSYAMDYWG QGTSTVTSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEG LYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPREGRG SLLTCGDVEENPGPMRLPAQLLGLLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNIKH FKNCTSIGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDL HAFENLEIIRGRTKHQHGFSLAVVSLNITSLGLRSLKEISGDVLIISGNKNLCYANTIN WKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGREG VDKCNLLEGEPREFVENSEICIQHCECLPQAMNITCTGRPDNCIQCAHYIDGPHCVKT CPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGTGPGLEGCTNGPKIPSIATGMVGA LLLLLVVALGIGLFM
CD19-CD137-CD3 ζ CAR.T2A.Ig Kappa signal peptide.HER1t (aa)	180	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDTAIYYCAKHYYYGGSYAMDYWG QGTSTVTSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEG

		LYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPREGRG SLLTCGDVEENPGPMRLPAQLLGLMLWVPSSGRKVCNGIGIGEFKDSLSINATNIKH FKNCTSIISGLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDL HAFENLEIIRGRKQHQFSLAVVSLNITSLGLRSLKEISGDVLIISGNKNLCYANTIN WKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEDCVSGGGGSGGGGS GGGGSGGGGSFWVLVVVGGVLACYSLLVTAFIIFWVRSKRS
CD19-CD28-CD3 ζ CAR.P2A.Ig Kappa signal peptide.HER1t1 (nt)	181	gacatccaaatgacacagacaaccagcagcctctctgccagctctgggagatcgtgtgac catcagttgttagagcctcacaagatatttcaaatacctaaactgggtatcagcaaaaac cagatgggtacagtgaagttactgatctaccatactagccgtcttcattccgggtgtgcct tctcgcttttagcgggtctggatcaggaacagattacagtctcaccatcagcaacctcga acaagaagatatagctacctattttctgccagcagggtaacactttgccatataccttcg gaggaggcacaaaactggagatcactgggtctaccagtgggaagcggcaagcctggctcc ggtgaagggaagtacaaaggcgaagtgaagctgaagagtcagggtccagggtttggtagc tcccagccaatccctatctgttacctgtacagtgtctgggtgtgtcacttccagattatg gcgtgtcatggataaggcagccccacgaaaaggcctgggaatgggtgggggtgatctgg ggatctgagaccactactacaacagcgccctgaaaagtcgggtcaccatcatcaaaga caactccaagtcacaagtgtttcttaagatgaactcacttcagaccgacgacacagcca tatactactgtgctaatactactactatggcggtagctatgccatggattactgggggt caaggtagctgtgacagtatcatctgaatcaaagtatggccaccctgcccccttg tcccgtcctgagttcctgggtgggtccctccgtattcctgtttccacctaagccaaaag aactctcatgatcagcagaacacctgaggtgacatgcgtcgtagttgatgttagccag gaggacccgaagtgaatttaactgggtacgtagacgggtgtggaagtgcataacgcaaa gaccaagccagtgaaagagcagtttaactccacctaccagagtggtgtctgtgtctcacag tcttacatcaagattggctgaacggaaaagagtataaatgtaaagtatccaataagggc cttccctctagcatcgaagaaactatctccaaagccaaggacagccacgcgaaccaca ggtgtatactttacctccttctcaagaagagatgaccaagaaccaagtatctctgacgt gtttgggtgaaggggttctacctctctgacatcgcagtggaatgggaatcaaagggtcaa cctgagaacaattacaaaaccacccacctgtgtctggatagcgacggcagcttcttct gtatagcaggctcacagtggataaaaagtcgggtggcaggaaggaacgtatttagttgca gtgtgatgcacgaggccctccataaccattataaccagaagtcactctcacttagtctg ggtaagatgttctgggtgtctgtgggtcgtaggtggagtgctggcttgcacttccctct agtgaccgtggcttttatcatcttctgggtacgttccaaaaggtcccgtgtgtggccatt cagattacatgaatatgacccccagacgaccaggcccaacaagggaagcattatcaacct tacgccccctccccgagattttgcagcttatcgaagtaggggtgaagttcagccggtctgc tgacgctcctgcataaccagcaaggtcagaatcagttatacaatgagctaaatctaggac gacgcgaagaatatgatgtgtctggacaaacgacgtggcagggaccctgaaatgggtggc aagccaagaaggaagaaccacaaagagggtctgtacaacgagttgcagaaagacaagat ggcagaggcctactccgagatcggaaatgaaaggagagaggcggaggggtaaaggacatg acgggtctttaccagggcctgagcacagctactaaagatacctacgacgccctccacatg caggctttgccccacgagctaccaatttttagtctgttgaaacaagctggagatgtcga ggaaaatccaggcccaatgcgacttctgtctcaactgctgggtctgtcatgtgtggg ttcctggaagcagtggtccgaaaggctctgcaacggcatcggtatcggcgaatttaaggat agtctatctatcaacgctaccaatatattaagcatttttaagaactgcagctctatttccgg cgacttgacatctctcctgttgcatcttcgggggtgatagtttcacccataccccctc tcgatccacaagaactggacattcttaaaaccgttaagaataaacagggttttctctc atccaggcatggcccagaataggacagatcttcacgcatttgaaaacctcgaatcat cagagggaggaccaaacagcatgggtcagtttagtctcgcagtggtgtctctgaacatca cttcttttagggcttcgatcacttaaggaaatctctgacgggtgatgtaatcatcagcgg aacaagaacctgtgtacgctaacacgatcaactggaagaagctgtttggcacaagcgg ccagaaaaccaagatcattagtaatagggcgagaatagctgtaaagcaaccgggcaag tgtgtcacgctctgtgttctcccaggggatgttggggacctgaaccaagagactgcgtt agtggaggggggggctctgggtggcggaggatctggcggaggcgggaagcggaggcggggg gagcttctgggtgtctgtgtcgttaggaggggtgctggcctgttactcttactctgtaa ctgttgctttcatcatattctgggtccgaagtaagcgtagc
CD19-CD28-CD3 ζ CAR.P2A.Ig Kappa	182	DIQMTQTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS

signal peptide.HER1t1 (aa)		GEGSTKGEVKLQESGPGVLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQDDTAIYYCAKHYYYGGSYAMDYWG QGTSVTVSSESKYGPPCPPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG LPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSGDSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GKMFVWL VVVGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYP YAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRATNFSLLKQAGDVEENPGPMRLPAQLLGLLMLWVPGSSGRKVCNGIGIGEFKD SLSINATNIKHFKNCTISGDLHLIPVAFRGDSFTHTPPLDPQELDILKTVKEITGFL LIQAWPENRTDLHAFENLEIIRGRTKQHGGQFSLAVVSLNITSLGLRSLKEISDGDVVISG NKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCV SGGGSGGGGSGGGGSGGGGSGFWVLVVVGVLACYSLLVTVAFIIFWVRSKRS
Ig Kappa signal peptide.HER1t1.P 2A.CD8α signal peptide.CD19-CD28-CD3ζ CAR (aa)	183	MRLPAQLLGLLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNIKHFKNCTISGDLHLIPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGGQFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSGGGSGGGGSGGGGSGGGGSGFWLVVVGVLACYSLLVTVAFIIFWVRSKRSATNFSLLKQAGDVEENPGPMALPVTALLPLALLHAARPDIMTQTTSLSASLGDRVTISCRASQDISKYLWYQQKPDGTVKLLIYH TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKEITGTS TSGSGKPGSGEGSTKGEVKLQESGPGVLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRK GLEWLGVWIGSETTYNSALKSRLTIKDNSKSQVFLKMNSLQDDTAIYYCAKHYYYG GSYAMDYWGQGTSVTVSSESKYGPPCPPAPEFLGGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTTPVLDSGDSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHY TQKSLSLSLGKMFVWL VVVGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR RGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT KDTYDALHMQALPPR
CD19-CD28-CD3ζ CAR.Furin-T2A.Ig Kappa signal peptide.HER1t1 (aa)	184	DIQMTQTTSLSASLGDRVTISCRASQDISKYLWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKEITGSTSGSGKPGS GEGSTKGEVKLQESGPGVLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQDDTAIYYCAKHYYYGGSYAMDYWG QGTSVTVSSKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCNHRNRSKRSRGGHSDYMNMTPRRPGPTRKHYPYAPPR DFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPP RRAKRSRSGEGRGSLLTCGDVEENPGPMRLPAQLLGLLMLWVPGSSGRKVCNGIGIGEF KDSLSINATNIKHFKNCTISGDLHLIPVAFRGDSFTHTPPLDPQELDILKTVKEITGFL LIQAWPENRTDLHAFENLEIIRGRTKQHGGQFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRD CVSGGGSGGGGSGGGGSGGGGSGFWLVVVGVLACYSLLVTVAFIIFWVRSKRS
CD19-CD137-CD3ζ CAR.E2A.Ig Kappa signal peptide.HER1t7 (nt)	185	gacatacagatgactcagacaacaagtagcttgctccgcatccctgggcgatagagtgcac catcagttgtcgagcatcccaagatatatccaagtacttaaactggatatcagcagaagc cagatggcaccgtcaagctgctaattaccacacaagtaggctccacagcggagtgacct agccgattctctggttctggttctggcacagactattccctaaccatcagcaacctgga gcaagaggacattgcaacatatTTTTTgcccagcagggaacacactgccatataacctttg gaggcgggaccaagctggaaatcaccggtagtagcagtggttctggaaaacctggttct gggaaggttagtactaaaggagaggtgaaacttcaagagagtggccctggcttggtggc cccttctcaaagtttgagcgtgacctgcacagtaagtggcgtcagcctgccagattacg gtagtcagttggattcgccagcctccaaggaaggcccttgatggctgggcgtaattctgg ggtccgaaaccacctattacaactccgacttaagagccgttaaccatcatcaaaga caacagcaagagtcaggtctttctcaaaatgaatagtctgcaaacggacgacaccgcta tctactattgtgccaaagcactactactatggtggctcctacgctatggattactgggga caaggaacaagcgtgacagtgtcaagtactaccacacctgctccccgtcctccaacccc cgctcctactattgcccagtcacacctgtctcttaggcccaggcatgtaggcccagcag

		caggcggggctgtgcatacccgaggtctcgacttcgctgcgacatatatatctgggccc cctctggctggcacttgtggggctctcctcctgagtcctgtgatcactctgtattgtaa acgtgggcgaaagaagctcctttacatcttcaagcaacccttcatgaggcctgtacaga ccacgcaggaggaggacgggtgtagttgccgattccccgaagaggaagaaggcggttgc gagcttcgagtgaattcagtaggagtgctgacgcaccagcatataagcagggccagaa ccaattatacaacgagctgaacctcggacgaagggaagagtatgatgtgctggataagc gcagaggccgtgatccagaaatgggcggaacctcgtcgaaaaatccacaagagggg ctatacaacgaattgcagaaagacaaaatggcagaggcctattctgaaatcggcatgaa gggcgaacgacgaagaggttaagggtcatgacggcctgtatcaaggctctcttaccgcca caaaggacacttacgatgctttacacatgcaggctctccctccagacaatgcaccaac tacgctctattgaagtggcaggagatgtggaatccaacccggctctatgcgtctacc tgccagctgcttgggctcctgatgctgtgggtccccggcagcagtggtagaaaagtat gtaacggcataggtatcggtgaatttaaggactcactaagcatcaacgccacaaacatc aagcactttaagaactgtacctctattagcggagacttacacatcctgccagtcgcatt tcgaggagacagtttaccacactccacctctcgatcctcaggaattagacattctta aaacagttaaggaaatcactggatttcttcttatccaggcctggccagaaaatagaaca gacctgcacgcttctcgagaaccttgaaataatacagggcaggaccaaacagcatggcca atttagtttgctgtagtctccttgaaatcacttcccttggcctaagggtctttgaagg aatcagtgacggagacgtgattatcagcgggaacaagaacctctgttacgcaaacaca atcaactggaagaagctcttggcaccagcggccagaagacaaagatcatttctaaccg aggagagaacagttgtaaggcaacaggacaagtgtgccacgcttgtgcagccccgagg gatgttggggtcctgagccacgtgattgtgtctcttggcgaacgtcagcagaggtaga gaatgtgtggataaagtgaacctcctggaaggggagcctcgtgagttcgtggagaactc cgaatgtatccagtgatccagaatgcctgccccaggccatgaacataacatgtacag gacgcggcccagacaactgcatacagtcgcccactacattgatggccccattgctga aagacttgtcctgtgagtgatgggcgaaaataaacacctggtgtggaagtacgccga cgctggccatgtatgtcatctgtgtcatcctaattgcacctatggctgcactggccccg gccttgaaggatgccccggcggtggaggaggaggctcttcttgggtcctcgtggtggtg ggaggcgtgtggcctgctattccttggctgggtcacggctgccttcattatcttgggtg gagatctaaaagaagc
CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t7 (aa)	186	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPS SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDITAIYYCAKHYYYGGSYAMDYWG QGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYKQGNQLYNELNLRREEYDVLDRRGRDPEMGGKPRRKNPQEG LYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDYDALHMQALPPRQCTN YALLKLAGDVESNPGPMRLPAQLLGLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNI KHFKNCTSIGDLHILPVAFRGDSFHTPPLDPQELDKTVKEITGFLLIQAWPENRT DLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANT INWKKLFGTSGQKTIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGR ECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCV KTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGTGPGLEGCPGGGGGGSFWLVVV GGVLACYSLLVTVAFIIFWVRSKRS
CD19-CD28-CD3 ζ CAR.Furin-T2A.Ig Kappa signal peptide.HER1t8 (aa)	187	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPS SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDITAIYYCAKHYYYGGSYAMDYWG QGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCNRNRSKRSRGGHSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQ NQLYNELNLRREEYDVLDRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDYDALHMQALPPRRAKRS GSGEGRGSLTCDGVEENPGPMRLPAQLLGLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNIKHFKNCTSIGDLHILPVAFRGDSFHTPPLDPQEL DILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGFSLAVVS

		LNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIIS NRGENSCKATGQVCHALCSPEGCGWPEPRDCVSGGGSGGGSGGGSGGG GGSEITLIIFGVMAGVIGTILLISYGIRRGGS
CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t8 (aa)	188	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQDDTAIYYCAKHHYYGGSYAMDYWG QGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYKQGQNLQLYNELNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEG LYNELQKDKMAEAYSEIGMKGERRRGKGDGLYQGLSTATKDTYDALHMQALPPRQCTN YALLKLAGDVESNPGPMRLPAQLLGLLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNI KHFKNCTISGDLHILPVAFRGDSFHTPPLDPQELDILKTVKEITGFLLIQAWPENRT DLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANT INWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCGWPEPRDCVSGGGSGGG GSGGGSGGGGSEITLIIFGVMAGVIGTILLISYGIRRGGS
CD19-CD28-CD3 ζ CAR.Furin-T2A.Ig Kappa signal peptide.HER1t9 (aa)	189	DIQMTQTTSSLSASLGDRVTISCRASQD ISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNL EQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGSGEGSTKGEVK LQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKLEWLGVW SETTYNSALKSRLTIKDNSKSQVFLKMNSLQDDTAIYYCAKHHYYGGSYAMDYWG QGTSVTVSSKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCNHRNRSKRSRGG HSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQ NQLYNELNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGDGLYQGLSTATKDTYDALHMQALPPRAKRS GSGEGRGSLTTCGDVEENPGPMRLPAQLLGLLMLWVPGSSGRKVCNGIGI GEFKDSLSINATNIKHFKNCTISGDLHILPVAFRGDSFHTPPLDPQEL DILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGFSLAVVS LNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIIS NRGENSCKATGQVCHALCSPEGCGWPEPRDCVSGGGSGGGSGGGSGGG GGITLIIFGVMAGVIGTILLISYGIGGS
CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t9 (aa)	190	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQDDTAIYYCAKHHYYGGSYAMDYWG QGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYKQGQNLQLYNELNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEG LYNELQKDKMAEAYSEIGMKGERRRGKGDGLYQGLSTATKDTYDALHMQALPPRQCTN YALLKLAGDVESNPGPMRLPAQLLGLLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNI KHFKNCTISGDLHILPVAFRGDSFHTPPLDPQELDILKTVKEITGFLLIQAWPENRT DLHAFENLEIIRGRTKQHGFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANT INWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCGWPEPRDCVSGGGSGGG GSGGGSGGGGSEITLIIFGVMAGVIGTILLISYGIGGS
CD19-CD28-CD3 ζ CAR.Furin-T2A.Ig Kappa signal peptide.HER1t10 (aa)	191	DIQMTQTTSSLSASLGDRVTISCRASQD ISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNL EQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGSGEGSTKGEVK LQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKLEWLGVW SETTYNSALKSRLTIKDNSKSQVFLKMNSLQDDTAIYYCAKHHYYGGSYAMDYWG QGTSVTVSSKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCNHRNRSKRSRGG HSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQ NQLYNELNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGDGLYQGLSTATKDTYDALHMQALPPRAKRS GSGEGRGSLTTCGDVEENPGPMRLPAQLLGLLMLWVPGSSGRKVCNGIGI GEFKDSLSINATNIKHFKNCTISGDLHILPVAFRGDSFHTPPLDPQEL DILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGFSLAVVS

		LNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIIS NRGENSCKATGQVCHALCSPEGCGWPEPRDCVSGGGGSGGGGSGGGGSGG GGSTITLIIFGVMAGVIGTILLALLIWGGGS
CD19-CD137-CD3 ζ CAR.E2A.Ig Kappa signal peptide.HER1t10 (aa)	192	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVW GSETTYNSALKSRLLTIKDNSKSQVFLKMNSLQTDDAIYYCAKHYYYGGSYAMDYWG QGTSTVTSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYKQGGNQLYNE LNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEG LYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRQCTN YALLKLAGDVESNPGPMRLPAQLLGLMLWVPGSSGRKVCNGIGIGEFKDSLSINATNI KHFKNCTISGDLHILPVAFRGDSFHTPPLDPQELDILKTVKEITGFLLIQAWPENRT DLHAFENLEIIRGRTKQHGGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANT INWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCGWPEPRDCVSGGGGSGGG GSGGGGSGGGGSITLIIFGVMAGVIGTILLALLIWGGGS*
Membrane bound IL-15.T2A.HER1t1 (aa)	193	NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELQVISLESGDASI HDTVENLIILANNSLSSNGNVTESGCKECEEELEEKNIKEFLQSFVHIVQMFINTSSGGG SGGGGSGGGGSGGGGSGGGSLQITCPPPMSVEHADIWVKSYSLSRERYICNSGFKRKA GTSSL TECVLNKATNVAHWTPSLKCIRDPALVHQRAPPSTVTTAGVTPQPELSPSGKEPAA SSPSSNNTAATTAIIVPGSQLMPSKSPSTGTTEISSHESHGTPSQTTAKNWELTASAS HQPPGVYPQGHSDTTVAISTSTVLLCGLSAVSLACYLKSRQTPPLASVEMEAMEALPV TWGTSSRDEDLENCSSHLRAKRGSGEGRGSLLTCGDVEENPGMRLPAQLLGLMLWV GSSGRKVCNGIGIGEFKDSLSINATNIKHFKNCTISGDLHILPVAFRGDSFHTPPLD PQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGGQFSLAVVSLNITS LGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVC HALCSPEGCGWPEPRDCVSGGGGSGGGGSGGGGSGGGGSGFVWLWVGGVLACYSLLVT VAFIIFWVRSKRS
CD19-CD28-CD3 ζ CAR.P2A.CD20 (aa)	194	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVW GSETTYNSALKSRLLTIKDNSKSQVFLKMNSLQTDDAIYYCAKHYYYGGSYAMDYWG QGTSTVTSSESKEYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG LPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSGDSFFLYSRLTVDKSRWQEGNVFSCSVMHREALHNYHTQKSLSL GKMFVWLWVGGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYP YAPPRDFAAYRSRVKFSRSADAPAYQQGQNL YNE LNLGRREEYDVLDRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRATNFSLLKQAGDVEENPGPMTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRM SSLVGPTQSFMRRESKTLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTWVYPLWGGIM YIISGSLAATEKNSRKCLVKGMIMNSLSLFAAISGMILSMDILNIKISHFLKMESL NFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGI VENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIEIPIQEE EEEEETETNFPEPPQDQESSPIENDSSP
CD19-CD28-CD3 ζ CAR.P2A.CD20t1 (aa)	195	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVW GSETTYNSALKSRLLTIKDNSKSQVFLKMNSLQTDDAIYYCAKHYYYGGSYAMDYWG QGTSTVTSSESKEYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG LPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSGDSFFLYSRLTVDKSRWQEGNVFSCSVMHREALHNYHTQKSLSL GKMFVWLWVGGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYP YAPPRDFAAYRSRVKFSRSADAPAYQQGQNL YNE LNLGRREEYDVLDRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRATNFSLLKQAGDVEENPGPMTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRM

		SSLVGPTQSFFMRESKTLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTWVYPLWGGIM YIISGSLAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESL NFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGI VENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIE
CD19-CD28-CD3 ζ CAR.P2A.CD20t4 (aa)	196	DIQMTQTSSLSASLGDRVTISCRASQDISKYLWYQQKPDGTVKLLIYHTSRLHSGVP SRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKEITGSTSGSGKPGS GEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDATAIYYCAKHHYYGGSYAMDYWG QGSTVTVSSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGL LPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMH EALHNHYTQKSLSLSL GKMFVWL VVVGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYP YAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNE LNLGRREEYDVL DKRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGGHGLYQGLSTATKDTYDALHM QALPPRATNFSLLKQAGDVEENPGPMTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRM SSLVGPTQSFFMRESKTLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTWVYPLWGGIM YIISGSLAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESL NFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGI VEN
CD52t3.P2A.CD8 α signal peptide.CD19- CD28-CD3 ζ CAR (aa)	197	MKRFLFLLLTISLLVMVQIQTGLSGQNDTSQTSSPSGSTSGSGKPGSGEGSTKGGQNDT SQTSSPSGSTSGSGKPGSGEGSTKGGQNDTSQTSSPSGSTSGSGKPGSGEGSTKGGGGG SGGGGSKPFVWL VVVGVLACYSLLVTVAFIIFWVATNFSLLKQAGDVEENPGMALPV TALLPLALLLHAARPDQMTQTSSLSASLGDRVTISCRASQDISKYLWYQQKPDGT VKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGT KLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSW IRQPPRKGLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDATAIYYC AKHHYYGGSYAMDYWGQGSTVTVSSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMH EALHNHYTQKSLSLSL GKMFVWL VVVGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYM NMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNE LNLGRREE YDVL DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGGHGLY QGLSTATKDTYDALHMQALPPR
Ig Kappa signal peptide.LNGFRt4. P2A.CD8 α signal peptide.CD19- CD28-CD3 ζ CAR (aa)	198	MR LPAQLLGLLMLWVPGSSGRCA YGYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVC EECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEG DSTAPSTQEPEAPPEQDLIASTVAGVTTVMGSSQPVVTRGTTDNGGGGSGGGGSGGGG SGGGGSFVWL VVVGVLACYSLLVTVAFIIFWVRSKRSATNFSLLKQAGDVEENPGPMA LPVTALLPLALLLHAARPDQMTQTSSLSASLGDRVTISCRASQDISKYLWYQQKPDG TVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFG GGTKEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGV SWIRQPPRKGLEWLGVW GSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDATAI YYCAKHHYYGGSYAMDYWGQGSTVTVSSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS VMHEALHNHYTQKSLSLSL GKMFVWL VVVGVLACYSLLVTVAFIIFWVRSKRSRGGHS DYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNE LNLGR REEYDVL DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGGH GLYQGLSTATKDTYDALHMQALPPR
Epidermal growth factor receptor (EGFR) Domain III [(R310-Q480) of mature protein OR (R334-Q504) of	199	cgaaagtgtgtaacggaataggtattggtgaatttaagactcactctccataaatgc tacgaatattaaacacttcaaaaactgcacctccatcagtgggcatctccacatcctgc cggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactg gatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggccttgccctga aaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagc aacatggctcagttttctcttcagtcgtcagcctgaacataacatccttgggattacgc tccctcaaggagataagtgatggagatgtgataatttcaggaaacaaaatttgtgcta

proprotein] (nt)		tgcaaatacaataaaactggaaaaaactgtttgggacctccggtcagaaaaccaaatta taagcaacagaggtgaaaacagctgcaaggccacaggccag
Epidermal growth factor receptor (EGFR) Domain III [(R310-Q480) of mature protein OR (R334-Q504) of proprotein] (aa)	200	RKVCNGIGIGIEFKDLSINATNIKHFNCTISGDLHILPVAFRGDSFTHTPPLDPQEL DILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRKQHQGQFSLAVVSLNITSLGLR SLKEISDGDVVISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQ
Epidermal growth factor receptor (EGFR) Domain IV [(V481-S621) of mature protein OR (V505-S645) of proprotein] (nt)	201	gtctgcatgccttgtgctccccgagggctgctggggcccgagcccagggaactgcgt ctcttgccggaatgtcagccgagggcaggggaatgctggacaagtgaaccttctggagg gtgagccaagggagtttgtggagaactctgagtgcatagtgccaccagagtgctg cctcaggccatgaacatcacctgcacaggacggggaccagacaactgtatccagtgctg ccactacattgacggccccactgctgcaagacctgcccggcaggagtcattgggagaaa acaacaccctggtctggaagtacgcagacgccggccatgtgtgccacctgtgccatcca aactgcacctacggatgcactggggccaggtcttgaaggctgtccaacgaatgggctaa gatcccgctcc
Epidermal growth factor receptor (EGFR) Domain IV [(V481-S621) of mature protein OR (V505-S645) of proprotein] (aa)	202	VCHALCSPEGCWGPEPRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHP NCTYGCTGPGLEGCPNTPKIPS
HER1t1 Domain IV	203	VCHALCSPEGCWGPEPRDCVS
HER1t2 Domain IV	204	VCHALCSPEGCWGPEPRDCVSCRNVSRGECVDK
HER1t3 Domain IV	205	VCHALCSPEGCWGPEPRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQ
HER1t4 Domain IV	206	VCHALCSPEGCWGPEPRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQ
HER1t5 Domain IV	207	VCHALCSPEGCWGPEPRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKT
HER1t6 Domain IV	208	VCHALCSPEGCWGPEPRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHL
HER1t7 Domain IV	209	VCHALCSPEGCWGPEPRDCVSCRNVSRGECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHP NCTYGCTGPGLEGCP
HER1t Domain III/IV	210	RKVCNGIGIGIEFKDLSINATNIKHFNCTISGDLHILPVAFRGDSFTH TPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRKQHQ GQFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGR ECVDKCNLLEGEPRFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCA HYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLE GCPTNTPKIPS
HER1t1 Domain III/IV	211	RKVCNGIGIGIEFKDLSINATNIKHFNCTISGDLHILPVAFRGDSFTH TPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRKQHQ GQFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVS
HER1t2 Domain III/IV	212	RKVCNGIGIGIEFKDLSINATNIKHFNCT SISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRKQHQGQFSLAVVSLNITSLGLRSLKEISDGDVII SGKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGECVDK
HER1t3 Domain III/IV	213	RKVCNGIGIGIEFKDLSINATNIKHFNCT SISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRKQHQGQFSLAVVSLNITSLGLRSLKEISDGDVII

		SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQ
HER1t4 Domain III/IV	214	RKVCNGIGIGEFKDSLSINATNIKHFKNCT SISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGGQFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQ
HER1t5 Domain III/IV	215	RKVCNGIGIGEFKDSLSINATNIKHFKNCT SISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGGQFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKT
HER1t6 Domain III/IV	216	RKVCNGIGIGEFKDSLSINATNIKHFKNCT SISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGGQFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADA GHVCHL
HER1t7 Domain III/IV	217	RKVCNGIGIGEFKDSLSINATNIKHFKNCT SISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPEN RTDLHAFENLEIIRGRTKQHGGQFSLAVVSLNITSLGLRSLKEISDGDVII SGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE GCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQCHPECL PQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADA GHVCHLCHPNCTYGCTGPGLEGCP
CD20t3 EC Domain 142-188	218	KISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQS
CD20t7 EC Domain P160-Q187	219	PYINIYNCEPANPSEKNSPSTQYCYSIQS
CD20t10 EC Domain C167-C183	220	CEPANPSEKNSPSTQYC
Linker	221	G4S linker
linker	222	(G4S) _n , wherein n = 0, 1, 2, 3, 4, 5
Linker	223	SG4S linker
Linker	224	3xGS linker
Linker	225	ESKYGPPCPPCP
Linker	226	SGGGSGGGSGGGSGGGSGGGSLQ
Furin-GSG-T2A	227	RAKRGSGEGRSLLTCGDVEENPGP
Furin-SGSG-T2A	228	RAKRGSGEGRSLLTCGDVEENPGP
Linker	229	Asp-Val/Ile-Glu-X-Asn-Pro-Gly-Pro
Furinlink1	230	RAKR
Linker	231	AGAGCTAAGAGG
Furinlink1	232	CGTGCAAAGCGT
Fmdv	233	RAKRAPVKQTLNFDLLKLAGDVESNPGP
Fmdv	234	AGAGCCAAGAGGGCACCGGTGAAACAGACTTTGAATTTTGACCTTCTGAAGTTGGCAGG AGACGTTGAGTCCAACCTGGGCC
GSG-p2a	235	GSGATNFSLLKQAGDVEENPGP
GSG-p2a	236	GGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCC TGGACCT
fp2a	237	RAKRAPVKQSGATNFSLLKQAGDVEENPGP
fp2a	238	CGTGCAAAGCGTGCACCGGTGAAACAGGGAAGCGGAGCTACTAACTTCAGCCTGCTGAA GCAGGCTGGAGACGTGGAGGAGAACCCTGGACCT
Linker	239	(XP) _n (n = 2-5)

linker	240	A(EAAAK) _n A (n = 2-5)
--------	-----	-----------------------------------

EXAMPLES

[0439] These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.

Example 1. Expression and activity of truncated CD20 (CD20t) polypeptide construct as a cell tag

[0440] HEK-293T cells were transfected with wild-type CD20, truncated CD20 cell tags as well as a positive control for anti-CD20 antibody rituximab. Expression was measured by flowcytometry using rituximab. As shown in **FIG. 1**, CD20 truncation variant CD20t1 (SEQ ID NO:109) exhibited robust expression when detected by rituximab relative to variant CD20t4 (SEQ ID NO:115). These data indicate that only specific truncations in the CD20 endogenous polypeptide may be compatible with the use of CD20t as a cell tag.

[0441] Human PBMCs were nucleofected using a Sleeping Beauty transposon coding for a CAR and CD20t1 cell tag as well as Sleeping Beauty transposase plasmid. Co-expression of CAR and CD20t was measured using flow cytometry. **FIG. 2** shows that CD20t1 (SEQ ID NO:109; y-axis) and CAR (x-axis) are co-expressed from a CAR-CD20t1 construct compared to non-transfected cells.

[0442] *Specific anti-CD20 antibody induced ADCC of truncated CD20 cell tags*

[0443] Jurkat reporter cell line was modified to stably express CD20t1 cell tag. Expression of CD20t1 was confirmed by rituximab staining using flow cytometry. Ability of rituximab to specifically eliminate CD20t1 expressing Jurkat target cells was measured in an *in vitro* cytotoxicity assay. **FIG. 3** shows rituximab induced ADCC activity of CD20t1 expressing cell line. In comparison, treatment with anti-EGFR cetuximab had no effect on ADCC activity.

Example 2. Expression of truncated HER1 (HER1t) polypeptide construct as a cell tag

Expression of chimeric cell tags

[0444] Novel chimeric cell tags were generated by using domain III of HER1 gene and domain IV of HER2, 3 or 4 genes. HER1-ErBB4 chimeric cell tags were expressed in human primary cells. Domain III of HER1 gene was genetically fused to a Domain IV of ErbB4 gene variant JM-a or a JM-b and TM domain of ErbB4 gene to generate chimeric cell tags. GMCSF alpha signal peptide was utilized as a signal peptide to direct chimeric cell tags to cell surface. HER1-

ErbB4 cell tags (truncated EGFR-ErbB4 (JM-a) corresponding to SEQ ID NO:101 and truncated EGFR-ErbB4 (JM-b) corresponding to SEQ ID NO:105) were cloned in pCDNA3.1 vector backbone along with control HER1t cell tag and transfected by electroporation into primary human PBMC. Expression of HER1-ErbB4 cell tags was confirmed in CD3+ T cells by flow cytometry using anti-HER1 specific antibody, cetuximab. As shown in Figure 4D, transduced T cells expressed high levels of chimeric cell tags post transfection. Isotype antibody staining as well as non-transfected mock cells showed specificity of cetuximab staining to cell tags.

Expression of truncated HER1t cell tags

[0445] Various truncated cell tags were constructed as depicted in the schematic shown in Fig. 4A. Truncated HER1t variants (HER1t1 corresponding to SEQ ID NO:57, HER1t2 corresponding to SEQ ID NO:59, HER1t3 corresponding to SEQ ID NO:61, HER1t4 corresponding to SEQ ID NO:63, HER1t5 corresponding to SEQ ID NO:65, HER1t6 corresponding to SEQ ID NO:67, and HER1t7 corresponding to SEQ ID NO:69) along with HER1t control cell tag were cloned in pCDNA3.1 vector backbone to test for expression. These expression vectors were transfected by electroporation in primary human PBMCs. Expression of truncated cell tags was confirmed in CD3+ T cells by flow cytometry using anti-HER1 specific antibody cetuximab. As shown in Figure 4E, T cells expressed high levels of cell tags post transfection. Isotype antibody staining as well as non-transfected mock cells showed specificity of cetuximab staining to cell tags.

[0446] Self-inactivating lentiviral vectors encoding for either CAR alone or CAR as well as truncated HER1t1 cell tag were generated to evaluate co-expression of both genes. Activated human pan T cells were transduced with lentiviral vectors and expression of both CAR and HER1t1 was measured post transduction by flow cytometry using CAR-specific antigen-Fc fusion protein and anti-HER1 antibody cetuximab respectively. As shown in right panel of FIG. 5A and FIG. 5B, transduced T cells co-expressed both CAR (x-axis) and HER1t (y-axis). Left panel of FIG. 5A showed minimum background staining observed in non-transduced T cells. Left panel of FIG. 5B demonstrated expression of CAR but not HER1t when T cells were transduced with a lentiviral vector encoding for CAR only. *Western blot analysis of truncated HER1t cell tag expressing cell lines*

[0447] SUP-T1 cell line was genetically modified to express HER1t1 (SUP-T1/HER1t1). SUP-T1/HER1t1 cell line was sorted by FACS for either high (High) or low (Low) levels of HER1t1 expression as measured by flow cytometry. Expression of truncated HER1t cell tag was confirmed in SUP-T1/HER1t1 (High) and SUP-T1/HER1t1 (Low) cell lines by Western blot

analysis. Anti-HER1 antibody cetuximab was incubated with SUP-T1/CAR/HER1t1 or control (Jurkat and A431) cell line extracts to enable antibody to bind to HER1 derived cell tag proteins. The antibody/antigen complex was then precipitated using protein A/G-coupled agarose beads. This sample was then separated by SDS-PAGE for western blot analysis using an anti-HER1 antibody. Western blot shown in FIG. 8 confirms expression of HER1t1 in SUP-T1/HER1t1 cell lines. Intensity of HER1t1 is lower in SUP-T1/HER1t1 (Low) cell line compared to SUP-T1/HER1t1 (High) cell line. Full length HER1 was detected in A431 positive control cell line. No expression of HER1 was detected in non-modified Jurkat cell line. Fig. 8: Lane 1: IP antibody only; Lane 2: Jurkat cells only; Lane 3: SUP-T1/HER1t1 (high levels of HER1t1); Lane 4: SUP-T1/HER1t1 (lower levels of HER1t1); Lane 5: A431 cells expressing full-length HER1; Lane 6: Marker. Bold arrow points to protein precipitated by cetuximab in lanes except lane 5 where it refers to full length HER1.

Example 3. ADCC and CDC of truncated HER1t cell tag expressing cells by anti-HER1 antibody

[0448] Functionality of HER1t1 cell tag in an ADCC assay was assessed using an NK cell line. A parental NK cell line was modified to express CD16 receptor variant to induce ADCC. CD16⁺ NK cell line was further modified to co-express a CAR and HER1t1 cell tag. Parental NK, CD16⁺ NK and CD16⁺/CAR⁺/HER1t1⁺ NK cell lines were analyzed for ADCC in presence of either anti-HER1 cetuximab or positive control alemtuzumab, capable of binding CD52 on NK cells. As shown in FIG. 6, ADCC was only observed when NK cells expressed CD16 as expected as binding of antibodies to CD16 induced effector function. Furthermore, alemtuzumab was able to induce ADCC of NK cells whether those cells expressed HER1t cell tag or not as long as CD16 was expressed. In contrast, cetuximab induced ADCC only when both HER1t1 and CD16 were expressed thus confirming specificity.

[0449] SUP-T1 (a human T lymphocyte cell line), reporter cell line was genetically modified to co-express a CAR and HER1t1 (SUP-T1/CAR/HER1t1). SUP-T1/CAR/HER1t1 cell line was sorted by FACS for either high (High) or medium (Med) levels of HER1t1 expression as measured by flow cytometry to evaluate effect of cell tag density on cell surface for ADCC using anti-HER1 antibody. FIG. 7A, shows expression levels of CAR and HER1t1 in sorted SUP-T1/CAR/HER1t1 populations. Left panel of FIG. 7A shows isotype antibody only staining, middle panel shows high HER1t expression and right panel shows medium HER1t expression by flow cytometry. Since CAR and HER1t1 genes are expressed from the same transcript, sorting

cells based on HER1t1 affected expression of CAR in similar manner as well. SUP-T1/CAR/HER1t1 High and Med cell lines were tested in an ADCC assay using cetuximab or non-specific rituximab as control. 5:1 effector (E) to HER1t1+ target (T) cell ratio was utilized for the assay. ADCC was quantified as fold induction of reporter gene expression. As shown in FIG. 7B, cetuximab specifically induced ADCC of HER1t1 expressing cell line in dose dependent manner. Furthermore, induction of ADCC was dependent on level of HER1t1 expression on cell surface.

[0450] Human donor PBMCs were transfected by electroporation with two Sleeping Beauty transposon vectors to express CD19 CAR and HER1t1 cell tag along with SB11 transposase to redirect T cell specificity. The day after transfection (day 1) cells were counted, and CAR expression was measured by flow cytometry. CAR T Cells were stimulated with either γ -irradiated (100 Gy) or mitomycin C treated AaPCs at a 1:1 ratio for 4 stimulation cycles. The AaPC cells used were K562-AaPC expressing CD19 antigen. Cultures were supplemented with IL-21 (30ng/ml) only for the first round of stimulation and subsequently with recombinant human IL-2 (50 IU/ml) and IL-21 (30 ng/ml) (Pepro Tech) for remaining stimulations. T cell cultures were phenotyped at the end of each stimulation cycle, which typically lasted 7 days. The cultures were phenotyped for CAR expression by multi-parameter flow cytometry utilizing either Protein L or anti-idiotypic antibody that recognizes CD19 CAR. Ability of cetuximab to specifically eliminate CD19 CAR+/HER1t1+ T cells *in vitro* was tested in ADCC and complement dependent cytotoxicity (CDC) assays. CFSE-labeled CD19 CAR+/HER1t1+ T target cells (T) (5e4 cells/well) were incubated with CD16+ NK effector cell line (E) (2.5e5 cells/well) at E:T ratio of 5:1 with 5 μ g/ml cetuximab or rituximab for 2-24 hours in triplicates. For CDC assay, 10% Rabbit serum with and without heat-inactivation (HI) as well as 30% human serum with and without heat-inactivation (HI) was utilized. Cells are stained with DAPI and data acquired with iQUE Screener plus instrument. Live cell counts were reported for each condition. As shown in FIG. 9 (left panel), cetuximab induced specific cytotoxicity of CD19 CAR+/HER1t1+ T cells as evident by low live cell counts in ADCC assay. As shown in FIG. 9 (right panel), cetuximab induced specific cytotoxicity of CD19 CAR+/HER1t1+ T cells as evident by low live cell counts in CDC assay when human or rabbit serum was not heat inactivated.

Example 4. Next-generation kill switch/cell tag constructs enhance ADCC and CDC

[0451] FIG. 10 is a schematic diagram comparing the design of first generation and next generation polypeptide constructs comprising truncated cell tags. First-generation truncated cell tags (top) comprise a truncated variant and a non-dimerizing transmembrane domain (TM) connected by an optional peptide linker. Next-generation truncated cell tags (bottom panel) include a multimerization domain to generate cell tags that are capable of multimerizing on cell surface. The example depicted in the bottom panel of FIG. 10, utilizes a transmembrane domain (TM-A) capable of homodimerizing to induce cell tag dimers on the cell surface. Although homo-dimerization of cell surface polypeptides is shown, formation of heterodimers at the cell surface is also possible if cells are engineered to co-express polypeptide constructs having different cell surface polypeptides. In both first generation and next-generation polypeptide constructs, anti-truncated variant antibody or another binding domain recognizes and binds to the truncated variant. For such next-generation constructs, dimerization of the cell surface polypeptides can increase the avidity and amplify a signaling effect induced by antibody binding beyond that of the first generation constructs, as well as improve purification and sorting of cells using the multimer cell tag.

[0452] Human donor PBMC were transfected (day 0) by electroporation with Sleeping Beauty transposon vectors designed to co-express CD19 CAR and first or next-generation HER1t cell tags along with SB11 transposase to redirect T cell specificity. The day after transfection (day 1) cells were counted, and CAR expression was measured by flow cytometry. CAR-T cells were stimulated with either γ -irradiated (100 Gy) or mitomycin C treated AaPCs at a 1:1 ratio for 4 stimulation cycles. The AaPC cells used were K562-AaPC expressing CD19 antigen. Cultures were supplemented with IL-21 (30ng/ml) only for the first round of stimulation and subsequently with recombinant human IL-2 (50 IU/ml) and IL-21 (30 ng/ml) (Pepro Tech) for remaining stimulations. T cell cultures were phenotyped at the end of each stimulation cycle, which typically lasted 7 days. The cultures were phenotyped for CAR expression by multi-parameter flow cytometry utilizing either Protein L or anti-idiotypic antibody that recognized CD19 CAR and anti-HER1 antibody cetuximab that recognized various truncated HER1t cells tags. **FIG. 11** demonstrates that CD19 CAR expression does not vary over time in next-generation polypeptide constructs comprising HER1t variants (for example, HER1t8 corresponding to SEQ ID NO:71, HER1t9 corresponding to SEQ ID NO:75, and Her1t10 corresponding to SEQ ID NO:79) compared to a first generation polypeptide construct (HER1t1 corresponding to SEQ ID NO:57)

and a control cell line which does not express HER1t. Percentage of CD3⁺ T cells expressing CD19 CAR in various cultures is shown in **Table 4**.

Table 4. Quantification of CD19 CAR expression in FIG. 11.

	Day1	Day14	Day21	Day28
CAR only	40.45	72.07	86.87	91.56
CAR/HER1t1	24.54	66.22	77.51	87.66
CAR/Her1t8	24.02	60.75	66.26	86.27
CAR/HER1t9	24.41	58.43	72.51	83.7
CAR/HER1t10	20.34	59.57	73.56	83.03

[0453] **FIG. 12** shows that cell lines expressing next generation polypeptide constructs comprising HER1t variants with a transmembrane dimerization domain (variants HER1t8 corresponding to SEQ ID NO:71, HER1t9 corresponding to SEQ ID NO:75, and Her1t10 corresponding to SEQ ID NO:79) have similar HER1t expression levels over time as a line expressing a first generation HER1t polypeptide construct (HER1t1 corresponding to SEQ ID NO:57). No HER1t expression was detected in culture transfected with CAR only transposon. **Table 5** shows percentage of CD3⁺ T cells expressing HER1t variants in various cultures, whereas **Table 6** shows the mean fluorescence intensity (MFI) of HER1t from FIG. 12 at days 14, 21 and 28.

Table 5. Quantification of HER1t expression in FIG. 12.

	Day1	Day14	Day21	Day28
CAR only	0.98	4.79	0.38	0.99
CAR/HER1t1	19.1	75.63	95	97.69
CAR/Her1t8	31.27	76.91	95.04	98.67
CAR/HER1t9	24.68	70.75	95.56	98.31
CAR/HER1t10	27.72	76.8	96.53	98.58

Table 6. Mean fluorescence intensity of HER1t variants at days 14, 21 and 28 from FIG. 12.

	Day14	Day21	Day28
CAR only	19,368	9,132	16,033
CAR/HER1t1	66,766	123,459	105,492
CAR/Her1t8	133,345	217,748	187,545
CAR/HER1t9	92,190	150,762	126,327
CAR/HER1t10	101,528	181,300	116,499

[0454] CD19 CAR-T cells expressing next generation HER1t variants were tested for cetuximab induced ADCC in an *in vitro* assay and compared with first generation HER1t design for efficacy. CD19 CAR-T target cells (T) were labeled with CFSE at 0.0005 μ M for CAR-T cells expressing HER1t variants and 0.01 μ M for CAR-T cells without HER1t. Target cells were suspended at 0.8×10^6 cells/ml, mixed at a 1:1 ratio and seeded at 4×10^4 cells/50 μ l/well (each at 2×10^4 cells/50 μ l/well). Next, CD16⁺ NK effector cells (E) were collected, washed and resuspended at 0.2×10^6 cells/ml. Cells were then seeded at 2×10^4 cells/100 μ l/well (E:T = 0.5:1). Rituximab or cetuximab antibodies were prepared at 0.4 μ g/ml along with a control solution lacking antibody, and solutions were added to wells as follows: (i) rituximab (anti-CD20) control: 50 μ l /well at a final concentration of 0.1 μ g/ml in each well; (ii) cetuximab (anti-HER1): 50 μ l/well at a final concentration of 0.1 μ g/ml in each well; (iii) control solution (no antibody): 50 μ l /well at a final concentration of 0 μ g/ml in each well. The final volume in each well was adjusted to 200 μ l. Solutions were mixed well and cultured for 4, 8, 16 and 24 hours. Following incubation cells were washed and stained with CD3-BV786 in the presence of Human Fc Block. Cells were then washed two times with FACS buffer, resuspended in 50 μ l of FACS buffer containing 7AAD for 10 minutes and then analyzed. **FIG. 13A-B** demonstrate that next-generation HER1t polypeptide constructs comprising potential dimerized HER1t variants on cell surface polypeptides (HER1t8, HER1t9 and HER1t10) mediate improved ADCC relative to polypeptide constructs comprising non-dimerizing transmembrane domain (HER1t control) in the presence of cetuximab.

[0455] *In vitro* studies were conducted to confirm the ability of cetuximab to induce ADCC against CD19CAR- mbIL15-T cells. CD19CAR- mbIL15-T cells were generated by electro-transfer of CD19 CAR and mbIL15-HER1t transposons and SB11 transposase. The genetically modified T cells were numerically expanded ex vivo on irradiated CD19⁺ feeder cells for ADCC assay. Due to the bicistronic design of mbIL15-HER1t transposon, CD19CAR- mbIL15-T cells

co-expressed HER1t1 when mbIL15 is expressed. Negative control CD19 CAR+mbIL15-HER1tneg T cells lacking expression of mbIL15-HER1t generated by transfection of CD19 CAR transposon and SB11 transposase were numerically expanded ex vivo using same CD19+ feeder cells. Expanded allogeneic NK cells which express endogenous FcR were used as effector cells and co-cultured overnight with labelled CAR+ T cells at 10:1 E: T ratio in the presence of 10 µg/mL cetuximab, or anti-CD20 antibody (rituximab) which serves as negative control. mbIL15-HER1t+ T cells remaining in culture post antibody treatment were determined by flow cytometry to calculate percent killing. Addition of cetuximab resulted in elimination of >90% mbIL15-HER1t+ population of CD19-mbIL15-CAR T cells (Figure 14). Rituximab showed a lower level of non-specific elimination of CD19-mbIL15-CAR-T cells. Cetuximab failed to exhibit significant level of lysis of CAR+mbIL15-HER1tneg T cells confirming HER1t- specific mechanism of action. 10 µg/mL concentration of cetuximab utilized in this experiment is within the range previously reported in patients dosed with cetuximab. These data support the use of cetuximab to deplete CD19CAR- mbIL15-T cells if needed due to the development of untoward clinical effects.

[0456] An *in vivo* study was conducted in NSG mice. On Day 0, 5E6 CAR-HER1t1 T cells and 5E6 KHYG-1-CD16high cells were injected intraperitoneally (IP) into each mice. On the same day, mice were randomized and treated with saline or cetuximab (0.5mg: IP). Peritoneal lavage was harvested on day 1 and flow cytometry assessment was performed to assess frequency of CAR-HER1t1 T cells from mice in both groups. Absolute cell counts of CAR-HER1t1 T cells from were also performed. Data (not shown) demonstrates ability of cetuximab to specifically eliminate CAR T cells expressing HER1t1 tag in contrast to saline treated mice.

[0457] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the present disclosure. It should be understood that various alternatives to the embodiments described herein, or combinations of one or more of these embodiments or aspects described therein may be employed in practicing the present disclosure. It is intended that the following claims define the scope of the present disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

CLAIMS

WHAT IS CLAIMED IS:

1. A polynucleotide encoding:
a truncated non-immunogenic HER1 polypeptide consisting of at least a HER1 Domain III or fragment thereof, and a truncated HER1 Domain IV, wherein said HER1 polypeptide binds an anti-HER1 antibody, and
wherein said HER1 polypeptide is expressed in an engineered cell.
2. The polynucleotide of claim 1, wherein said truncated HER1 Domain IV comprises a truncation of at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% of said HER1 Domain IV.
3. The polynucleotide of claim 1, wherein said truncated HER1 Domain IV comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NOs:203, 204, 205, 206, 207, 208 and 209.
4. The polynucleotide of claim 3, wherein said truncated HER1 Domain IV comprises a polypeptide sequence comprising a sequence shown in SEQ ID Nos:203, 204, 205, 206, 207, 208 and 209.
5. The polynucleotide of claim 1, wherein said HER1 Domain III or fragment thereof comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the sequence shown in SEQ ID NO:200.
6. The polynucleotide of claim 5, wherein said HER1 Domain III comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:200.
7. The polynucleotide of any one of claims 1 to 6, wherein said polynucleotide further encodes a CD28 trans-membrane domain and a peptide linker for coupling said HER1 polypeptide to said CD28 trans-membrane domain.
8. The polynucleotide of claim 7, wherein said polynucleotide encodes a polypeptide construct comprising a polypeptide sequence comprising the sequence shown in SEQ ID NO:57.
9. The polynucleotide of any one of claims 1-8, wherein said anti-HER1 antibody comprises at least one of rituximab, cetuximab, futuximab, depatuxizumab, imgatuzumab, laprituximab, matuzumab, necitumumab, nimotuzumab, panitumumab and zalutumumab.
10. A polynucleotide encoding:

a truncated non-immunogenic CD20 polypeptide that binds an anti-CD20 antibody, wherein said truncated non-immunogenic CD20 polypeptide does not bind an endogenous receptor.

11. The polynucleotide of claim 10, wherein said CD20 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the sequence shown in SEQ ID NO:109.

12. The polynucleotide of claim 10, wherein said CD20 polypeptide comprises a polypeptide sequence comprising the sequence of SEQ ID NO:109.

13. The polynucleotide of any one of claims 10-12, wherein said CD20 polypeptide binds said anti-CD20 antibody with at least 50%, 60%, 70%, 80% or 90% the binding efficiency as native CD20.

14. The polynucleotide of claim 13, wherein said anti-CD20 antibody comprises at least one of rituximab, tositumomab, veltuzumab, afutuzumab, blontuvetmab and obinutuzumab.

15. A polynucleotide encoding:
a truncated non-immunogenic CD52 polypeptide that binds an anti-CD52 antibody,
wherein said truncated non-immunogenic CD52 polypeptide does not bind an endogenous receptor, and
wherein said non-immunogenic CD52 polypeptide is expressed in an engineered cell.

16. The polynucleotide of claim 15, wherein said CD52 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the sequence shown in SEQ ID NO:143.

17. The polynucleotide of claim 16, wherein said CD52 polypeptide comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:143.

18. The polynucleotide of any one of claims 10-17, wherein said polynucleotide is expressed in a cell further comprising at least one sequence encoding at least one heterologous gene.

19. The polynucleotide of claim 18, wherein said at least one heterologous gene is modulated by an inducible promoter.

20. The polynucleotide of claim 18, wherein said at least one heterologous gene comprises at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR), and a cytokine.

21. The polynucleotide of claim 20, wherein said at least one heterologous gene comprises a CAR, and wherein said CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123, and VEGF-R2.
22. The polynucleotide of any one of claims 18-20, wherein said at least one heterologous gene comprises a cytokine.
23. The polynucleotide of claim 22, wherein said cytokine comprises at least one of IL-15, IL-2, IL-12, IL-21, and a fusion of IL-15 and IL-15R α .
24. The polynucleotide of claim 23, wherein said cytokine is in secreted form.
25. The polynucleotide of claim 23, wherein said cytokine is in membrane bound form.
26. A vector comprising the polynucleotide of any one of claims 10-25.
27. The vector of claim 26, wherein said vector is a lentivirus vector, a retroviral vector or a non-viral vector.
28. The vector of claim 27, wherein the non-viral vector is a Sleeping Beauty transposon.
29. The polynucleotide of any one of claims 10-25, wherein said polynucleotide is incorporated into an engineered cell by genome editing.
30. The polynucleotide of claim 29, wherein said genome editing comprises use of at least a site specific serine recombinase system.
31. An engineered cell comprising the polynucleotide of any one of claims 10-25 and 29-30.
32. The engineered cell of claim 31, which is a T cell or an NK cell.
33. A polypeptide construct comprising:
 - a cell surface polypeptide and a trans-membrane dimerization domain,
 - wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide, and
 - wherein said cell surface polypeptide binds a predetermined antibody or a variant or fragment thereof.

34. The polypeptide construct of claim 33, wherein said cell surface polypeptide comprises at least one of a HER1 polypeptide, a LNGFR polypeptide, a CD20 polypeptide, or a CD52 polypeptide.
35. The polypeptide construct of claim 34, wherein said cell surface polypeptide comprises a HER1 polypeptide, and wherein said HER 1 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NOs: 211, 212, 213, 214, 215, 216, or 217.
36. The polypeptide construct of claim 35, wherein said HER1 polypeptide comprises a polypeptide sequence comprising a sequence shown in SEQ ID NOs: 211, 212, 213, 214, 215, 216, or 217.
37. The polypeptide construct of claim 34, wherein said cell surface polypeptide comprises a CD20 polypeptide, and wherein said CD20 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:218, SEQ ID NO:219, or SEQ ID NO:220.
38. The polypeptide construct of claim 37, wherein said CD20 polypeptide comprises a polypeptide sequence comprising a sequence shown in SEQ ID NO:218, SEQ ID NO:219, or SEQ ID NO:220.
39. The polypeptide construct of claim 34, wherein said cell surface polypeptide comprises a LNGFR polypeptide, and wherein said LNGFR polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:156, SEQ ID NO:158, or SEQ ID NO:160.
40. The polypeptide construct of claim 34, wherein said cell surface polypeptide comprises a LNGFR polypeptide, and wherein said LNGFR polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:156, SEQ ID NO:158, or SEQ ID NO:160.
41. The polypeptide construct of any one of claims 33-40, wherein said cell surface polypeptide does not bind an endogenous receptor.
42. The polypeptide construct of any one of claims 33-41, wherein said trans-membrane dimerization domain can form either a homodimer or a heterodimer with a complementary dimerization domain.

43. The polypeptide construct of any one of claims 33-42, wherein said trans-membrane dimerization domain comprises at least one cysteine residue.
44. The polypeptide construct of any one of claims 33-43, wherein said trans-membrane dimerization domain comprises a glycoporphin A transmembrane domain or fragment or variant thereof, a glycoporphin A-integrin $\beta 3$ chimeric transmembrane domain or fragment or variant thereof, or a CD3 zeta transmembrane domain.
45. The polypeptide construct of claim 44, wherein said cell surface polypeptide comprises at least a HER1 polypeptide.
46. The polypeptide construct of any one of claims 33-45 wherein said polypeptide construct is expressed in an engineered cell.
47. The polypeptide construct of claim 46, wherein said engineered cell is an animal cell.
48. The polypeptide construct of claim 47, wherein said animal cell is a human cell.
49. The polypeptide construct of claim 48, wherein said human cell is a T cell or NK cell.
50. The polypeptide construct of any one of claims 46-49, wherein said engineered cell further comprises a Sleeping Beauty transposase.
51. The polypeptide construct of any one of claims 46-50, wherein said engineered cell further expresses at least one additional exogenous polypeptide.
52. The polypeptide construct of any one of claims 46-50, wherein said engineered cell further expresses at least one exogenous receptor polypeptide or fragment thereof.
53. The polypeptide construct of any one of claims 46-50, wherein said engineered cell further expresses at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR), and a cytokine.
54. The polypeptide construct of claim 53, wherein said engineered cell further expresses at least one CAR and wherein said CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2.
55. The polypeptide construct of any one of claims 52-53, wherein said engineered cell further expresses at least one recombinant cytokine.

56. The polypeptide construct of claim 55, wherein said recombinant cytokine is IL-15, mbIL-15, IL-2, IL-12 or IL-21.
57. The polypeptide construct of any one of claims 46-56, wherein said polypeptide construct is encoded by a polynucleotide incorporated into said engineered cell by genome editing.
58. The polypeptide construct of claim 57, wherein said genome editing comprises use of at least a site specific serine recombinase system.
59. The polypeptide construct of any one of claims 33-58, comprising a linker that fuses said cell surface polypeptide to said trans-membrane dimerization domain.
60. A polypeptide homo-dimer or heterodimer comprising the polypeptide construct of any one of claims 33-59.
61. A polynucleotide encoding a polypeptide construct comprising:
a non-immunogenic cell surface polypeptide fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide.
62. The polynucleotide of claim 61, wherein said cell surface polypeptide does not bind an endogenous receptor.
63. The polynucleotide of claim 61, wherein said cell surface polypeptide does not contain any endogenous signaling or trafficking functions.
64. The polynucleotide of any one of claims 61-63 expressed in a cell further comprising at least one sequence encoding at least one heterologous gene.
65. The polynucleotide of claim 64, wherein said at least one heterologous gene is modulated by an inducible promoter.
66. The polynucleotide of claim 64, wherein said at least one heterologous gene comprises at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR) and a cytokine.
67. The polynucleotide of claim 66, wherein said at least one heterologous gene comprises said CAR, and wherein said CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2.

68. The polynucleotide of any one of claims 66-67, wherein said at least one heterologous gene comprises a cytokine.
69. The polynucleotide of claim 68, wherein said cytokine comprises at least one of IL-15, IL-2, IL-12, IL-21, and a fusion of IL-15 and IL-15R α .
70. The polynucleotide of claim 68, wherein said cytokine is in secreted form.
71. The polynucleotide of claim 68, wherein said cytokine is in membrane bound form.
72. The polynucleotide of any one of claims 61-71, comprising at least one sequence encoding a polypeptide linker comprising 2A, GSG-2A, GSG linker (SEQ ID NO: 16), SGSG linker (SEQ ID NO: 18), furinlink variants and derivatives thereof.
73. The polynucleotide of claim 72, wherein said 2A linker is a p2A linker a T2A linker, F2A linker or E2A linker.
74. The polynucleotide of any one of claims 61-73, wherein said polypeptide construct acts as a tag to enrich cells, select cells, or induce cell death in cells expressing said cell surface polypeptide.
75. The polynucleotide of any one of claims 61-74, wherein said cell surface polypeptide comprises at least one of a HER1 polypeptide, a LNGFR polypeptide, a CD20 polypeptide and a CD52 polypeptide.
76. The polynucleotide of any one of claims 61-75, wherein said trans-membrane dimerization domain comprises a glycoporphin A transmembrane domain or fragment or variant thereof, a glycoporphin A-integrin β 3 chimeric transmembrane domain or fragment or variant thereof or a CD3 zeta transmembrane domain.
77. A vector comprising the polynucleotide of any one of claims 61-76.
78. The vector of claim 77, wherein said vector is a lentivirus vector, a retroviral vector, or a non-viral vector.
79. The vector of claim 78, wherein the non-viral vector is a Sleeping Beauty transposon.
80. The polynucleotide of any one of claims 61-76, wherein said polynucleotide is incorporated into an engineered cell by genome editing.
81. The polynucleotide of claim 80, wherein said genome editing comprises use of at least a site specific serine recombinase system.

82. A method of regulating activity of genetically engineered cells in a subject comprising:
providing to said subject an amount of genetically engineered cells encoding a polypeptide construct comprising a cell surface polypeptide fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide, and wherein said cell surface polypeptide binds a predetermined binding partner or a variant or fragment thereof; and
providing to said subject said predetermined binding partner in an amount sufficient to bind and thereby regulating activity of said genetically engineered cells.
83. The method of claim 82, wherein said cell surface polypeptide is a non-immunogenic polypeptide.
84. The method of any one of claims 82-83, wherein said cell surface polypeptide comprises at least one of a HER1 polypeptide, a LNGFR polypeptide, a CD20 polypeptide and a CD52 polypeptide.
85. The method of any one of claims 82-84, wherein said cell surface polypeptide does not bind an endogenous receptor.
86. The method any one of claims 82-85, wherein said trans-membrane dimerization domain can form either a homodimer or a heterodimer with a complementary dimerization domain.
87. The method any one of claims 82-85, wherein said trans-membrane dimerization domain comprises at least one cysteine residue.
88. The method any one of claims 82-85, wherein said trans-membrane dimerization domain comprises a glycoporphin A transmembrane domain or fragment or variant thereof, a glycoporphin A-integrin $\beta 3$ chimeric transmembrane domain or fragment or variant thereof or a CD3 zeta transmembrane domain.
89. The method of any one of claims 82-88, wherein said binding partner comprises an antibody, or cell surface polypeptide binding region thereof.
90. The method of claim 89, wherein said antibody comprises at least one of: monoclonal antibody, scFv, scFab, diabody, and camelid antibody.
91. The method of claim 89, wherein said antibody comprises at least one of rituximab, cetuximab, alemtuzumab, panitumumab and necitumumab.

92. The method of any one of claims 82-91, wherein said genetically engineered cells comprise at least one of: T cells and NK cells.
93. The method of any one of claims 82-92, wherein at least one of said genetically engineered cells further expresses at least one additional exogenous polypeptide.
94. The method of any one of claims 82-92, wherein at least one of said genetically engineered cells further expresses at least one of a chimeric antigen receptor (CAR), a T-cell receptor (TCR) and a cytokine.
95. The method of claim 94, wherein at least one of said genetically engineered cells further expresses at least one CAR and wherein said CAR binds at least one of CD19, CD33, BCMA, CD44, α -Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, MUC-1, MUC-16, MAGE-A1, h5T4, PSMA, TAG-72, EGFRvIII, CD123 and VEGF-R2.
96. The method of claim 94, wherein at least one of said genetically engineered cells further expresses at least one recombinant cytokine.
97. The method of claim 96, wherein said recombinant cytokine comprises at least one of IL-15, mbIL-15, IL-2, IL-12 and IL-21.
98. The method of any one of claims 82-97, wherein said predetermined binding partner is provided in an amount sufficient to cause a reduction in at least one symptom associated with a cytokine storm or a systemic inflammatory response.
99. The method of any one of claims 82-98, wherein said predetermined binding partner is provided in an amount sufficient to cause a reduction in at least one symptom associated with tumor lysis syndrome.
100. The method of any one of claims 82-99, wherein said polypeptide construct is encoded by a polynucleotide incorporated into said engineered cells by genome editing.
101. The method of claim 100, wherein said genome editing comprises use of at least a site specific serine recombinase system.
102. A polypeptide encoded by the polynucleotide of any one of claims 1-25, 29-30, 61-76, and 80-81.

103. A method of treating cancer comprising administering to a subject an effective amount of an engineered cell comprising a polynucleotide of any one of claims 1-25, 29-30, 61-76, and 80-81.
104. The method of claim 103, further comprising administering at least one binding partner capable of binding to a polypeptide expressed on said engineered cell.
105. The method of claim 104, wherein said binding partner is an antibody.
106. A method of regulating activity of genetically engineered cells in a subject comprising:
providing to said subject an amount of genetically engineered cells encoding a polypeptide construct comprising a cell surface polypeptide which is a chimeric polypeptide comprising a first truncated non-immunogenic polypeptide and a second truncated non-immunogenic polypeptide, and wherein said cell surface polypeptide binds at least one predetermined binding partner or a variant or fragment thereof; and
providing to said subject said predetermined binding partner in an amount sufficient to bind and thereby regulating activity of said genetically engineered cells.
107. The method of claim 106, wherein said first truncated non-immunogenic polypeptide comprises a fragment or derivative of a member of the EGFR family.
108. The method of claim 106 or 107, wherein said second truncated non-immunogenic polypeptide comprises a fragment or derivative of a member of the EGFR family.
109. The method of any one of claims 106-108, wherein said first truncated non-immunogenic polypeptide comprises a HER1 polypeptide.
110. The method of claim 109, wherein said HER1 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NOs:211, 212, 213, 214, 215, 216, or 217.
111. The method of claim 110, wherein said HER1 polypeptide comprises a polypeptide sequence comprising a sequence shown in SEQ ID NOs:211, 212, 213, 214, 215, 216, or 217.
112. The method of claim 111, wherein said HER1 polypeptide comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:211.
113. The method of any one of claims 109 to 112, wherein said second truncated non-immunogenic polypeptide comprises a HER2 polypeptide, an ErbB3 polypeptide, or an ErbB4 polypeptide.

114. The method of claim 113, wherein said polypeptide construct comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NOs:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:101, or SEQ ID NO:105.

115. The method of claim 109, wherein said at least one predetermined binding partner binds said HER1 polypeptide.

116. The method of claim 115, wherein said at least one predetermined binding partner comprises at least one of rituximab, cetuximab, futuximab, depatuxizumab, imgatuzumab, laprituximab, matuzumab, necitumumab, nimotuzumab, panitumumab and zalutumumab.

117. The method of claim 116, wherein said at least one predetermined binding partner further includes a second predetermined binding partner that binds said second truncated non-immunogenic polypeptide.

118. The method of claim 117, wherein said second truncated non-immunogenic polypeptide is a HER2 polypeptide, and said second predetermined binding partner is pertuzumab.

119. The method of claim 106, wherein said polypeptide construct further comprises a signal peptide.

120. The method of claim 106, wherein said polypeptide construct further comprises a trans-membrane domain.

121. The method of claim 120, wherein said trans-membrane domain comprises a trans-membrane dimerization domain.

122. The method of claim 121, wherein said trans-membrane dimerization domain comprises a glycoporphin A transmembrane domain, a glycoporphin A-integrin β 3 chimeric transmembrane domain or a CD3 zeta transmembrane domain.

123. The method of claim 121, wherein said trans-membrane dimerization domain comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30 or SEQ ID NO:32.

124. The method of claim 123, wherein said trans-membrane dimerization domain comprises a polypeptide sequence shown in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30 or SEQ ID NO:32.

125. The method of claim 106, wherein said first truncated non-immunogenic polypeptide comprises a CD20 polypeptide.

126. The method of claim 125, wherein said CD20 polypeptide comprises a polypeptide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to a sequence shown in SEQ ID NO:218, SEQ ID NO:219 or SEQ ID NO:220.

127. The method of claim 126, wherein said CD20 polypeptide comprises a polypeptide sequence comprising a sequence shown in SEQ ID NO:218, SEQ ID NO:219 or SEQ ID NO:220.

128. The method of any one of claims 125 to 127, wherein said at least one predetermined binding partner comprises at least one of: rituximab, tositumomab, veltuzumab, afutuzumab, blontuvetmab and obinutuzumab.

129. A polypeptide construct comprising:

a truncated non-immunogenic HER1 polypeptide consisting of a HER1 Domain III and a truncated HER1 Domain IV, wherein said HER1 polypeptide binds an anti-HER1 antibody;

a CD28 trans-membrane domain; and

a peptide linker for coupling said HER1 polypeptide to said CD28 transmembrane domain;

wherein said polypeptide construct is expressed in an engineered cell.

130. The polypeptide construct of claim 129, wherein said HER1 Domain III comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:200 and said HER1 Domain IV comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:203.

131. The polypeptide construct of claim 130, wherein said CD28 trans-membrane domain comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:36 and said peptide linker comprises a G4S peptide linker (SEQ ID NO: 221).

132. The polypeptide construct of claim 131, wherein said G4S peptide linker (SEQ ID NO: 221) comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:22.

133. The polypeptide construct of claim 132, wherein said polypeptide construct comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:57.

134. The polypeptide construct of any one of claims 129 to 133, wherein said anti-HER1 antibody comprises at least one of rituximab, cetuximab, futuximab, depatuxizumab, imgatuzumab, laprituximab, matuzumab, necitumumab, nimotuzumab, panitumumab, and zalutumumab.

135. A polypeptide construct comprising:


a truncated non-immunogenic CD20 polypeptide, wherein said CD20 polypeptide binds an anti-CD20 antibody;

wherein said polypeptide construct is expressed in an engineered cell.

136. The polypeptide construct of claim 135, wherein said polypeptide construct has at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the sequence shown in SEQ ID NO:109.

137. The polypeptide construct of claim 136, wherein said polypeptide construct comprises a polypeptide sequence comprising the sequence shown in SEQ ID NO:109.

138. The polypeptide construct of any one of claims 135 to 137, wherein said anti-CD20 antibody comprises at least one of rituximab, tositumomab, veltuzumab, afutuzumab, blontuvetmab and obinutuzumab.



Gated on FSC/SSC/LIVE cells

FIG. 1




FIG. 2




FIG. 3

Schematic of Truncated Cell Tags

WO 2018/226897

PCT/US2018/036357

4/20





FIG. 4A

Schematic of Chimeric Truncated Cell Tags




FIG. 4B

Schematic of Chimeric Truncated Cell Tags







FIG. 4C



Gated on FSC/SSC/LIVE/CD3+ cells
D163890 PBMCs

FIG. 4D



Gated on FSC/SSC/LIVE/CD3+ cells

FIG. 4E





FIG. 5A



Gated on FSC/SSC/LIVE/CD3+

FIG. 5B





FIG. 6



5:1 E:T ratio; normalized to EGFRt expressing cells

FIG. 7




FIG. 8






FIG. 9



First generation Truncated Cell Tags



Next generation Truncated Cell Tags




FIG. 10




FIG. 11




FIG. 12

Cetuximab mediated ADCC of CAR-T cells co-expressing HER1t





FIG. 13A

Cetuximab mediated ADCC of CAR-T cells co-expressing HER1t



E: Effector NK Cells
T: Target Cells Expressing Cell Tag
E:T Ratio= 1:1
C: Cetuximab at 0.1 µg/ml
R: Rituximab at 0.1 µg/ml

FIG. 13B




FIG. 14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US18/36357

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C12Q 1/68; C07K 14/71, 14/435, 14/705, 16/28, 16/46; A61K 35/17, 39/395 (2018.01)
 CPC - C07K 14/71, 14/435, 16/468, 14/705, 14/7051, 14/70517, 14/70503, 14/70521, 14/70575, 14/70578, 16/28, 16/46, 16/303, 16/2803, 16/2863, 16/2887, 16/2896; A61K 35/17, 39/0011, 38/179, 39/395; C12N 5/06, 5/10, 5/0636, 9/12, 15/62, 15/86, 15/867; C12Q 1/68; A61P 35/02; G01N 33/53; C12P 21/02; C07H 21/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 2016/0158359 A1 (JUNO THERAPEUTICS, INC.) 09 June 2016; paragraphs [0008], [0019], [0029]-[0031], [0046], [0049], [0059], [0068], [0079], [0106], [0122], [0133], [0146], [0175], [0275], [0298], [0538]; Figure 6	1-6, 7/1-6, 33-36, 41/33-36, 61-63, 64/61-63, 66/64/61-63, 67/66/64/61-63, 82-83, 84/82-93, 129-131 65/64/61-63, 131-132, 134/129-132
Y	WO 2007/146959 A2 (RECEPTOR BIOLOGIX INC.) 21 December 2007; paragraphs [0352], [0398], [0554], [0596]; Table 11	65/64/61-63
Y	WO 2015/018306 A1 (BIO-THERA SOLUTIONS, LTD.) 12 February 2015; paragraphs [0028], [0106], [0112]; Tables 2-3	131-132, 134/129-132
A	US 9,447,194 B2 (SEATTLE CHILDREN'S HOSPITAL) 20 September 2016; column 2, line 52; Sequence Listing	8/7/1-6, 133, 134/133
A	US 2016/0060345 A1 (IMMUNOGEN, INC.) 03 March 2016; paragraph [0155]; Figure 28	8/7/1-6, 133, 134/133
A	US 2015/0118228 A1 (LIGACEPT LLC) 30 April 2015; entire document	1-6, 7/1-6, 8/7/1-6, 33-36, 41/33-36, 61-63, 64/61-63, 65/64/61-63, 66/64/61-63, 67/66/64/61-



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

19 September 2018 (19.09.2018)

Date of mailing of the international search report

03 OCT 2018

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US18/36357

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	US 2018/0002397 A1 (INTREXON CORPORATION) 04 January 2018; entire document	1-6, 7/1-6, 8/7/1-6, 33-36, 41/33-36, 61-63, 64/61-63, 65/64/61-63, 66/64/61-63, 67/66/64/61-63, 82-83, 84/82-93, 129-133, 134/129-133
E, X	CN 108330133 A (SHANGHAI HRAIN BIOTECHNOLOGY CO LTD) 27 July 2018; entire document	1-6, 7/1-6, 8/7/1-6, 33-36, 41/33-36, 61-63, 64/61-63, 65/64/61-63, 66/64/61-63, 67/66/64/61-63, 82-83, 84/82-93, 129-133, 134/129-133

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US18/36357

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 9, 18-32, 42-60, 68-81, 85-105, 109-118
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

----Please See Supplemental Page----

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-8, 10-17, 33-41, 61-67, 82-84, 106-108, 119-138; SEQ ID NOs: 22, 36, 57, 200, 203, 221

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US18/36357

Continued from Box No. III: Observations where unity of invention is lacking

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Groups I+, Claims 1-8, 10-17, 33-41, 61-67, 82-84, 106-108, 119-138, a HER1 polypeptide (non-immunogenic polypeptide), a chimeric antigen receptor that binds CD19 (heterologous gene) and SEQ ID NOs: 221, 36, 57, 200, 203, and 211 are directed toward non-immunogenic cell surface polypeptides, polynucleotides encoding the polypeptides, and methods associated therewith.

The polypeptides, polynucleotides and methods will be searched to the extent they encompass a HER1 polypeptide (first exemplary non-immunogenic polypeptide) encompassing SEQ ID NO: 57 (first exemplary non-immunogenic polypeptide sequence), which includes a transmembrane domain encompassing SEQ ID NO: 36 (first exemplary transmembrane domain), and a G4S linker encompassing SEQ ID NO: 22 (first exemplary linker; wherein SEQ ID NO: 22 includes, as a sub-sequence, SEQ ID NO: 221); the HER1 polypeptide encompassing a domain IV encompassing SEQ ID NO: 203 (first exemplary HER1 domain IV sequence), and a domain III sequence encompassing SEQ ID NO: 200 (first exemplary HER1 domain III sequence); as well as a chimeric antigen receptor that binds CD19 (first exemplary heterologous gene). Applicant is invited to elect additional non-immunogenic polypeptide(s), or fragments thereof, including specific domain(s), with specified SEQ ID NO: for each, or with specified substitution(s) at specified site(s) of a SEQ ID NO:, such that the sequence of each elected species is fully specified (i.e. no optional or variable residues or substituents), and/or additional heterologous gene(s), to be searched. Additional non-immunogenic polypeptide sequence(s), and/or heterologous gene(s) will be searched upon the payment of additional fees. It is believed that claims 1, 2, 3-8 (each in-part), 33, 34-36 (each in-part), 41 (in-part), 61-65, 66 (in-part), 67 (in-part), 82, 83, 84 (in-part), and 129-134 encompass this first named invention and thus these claims will be searched without fee to the extent that they encompass a HER1 polypeptide (non-immunogenic polypeptide), SEQ ID NO: 57 (non-immunogenic polypeptide sequence), SEQ ID NO: 36 (transmembrane domain), SEQ ID NO: 22 (linker; wherein SEQ ID NO: 22 includes, as a sub-sequence, SEQ ID NO: 221); SEQ ID NO: 203 (HER1 domain IV sequence), SEQ ID NO: 200 (HER1 domain III sequence), and a chimeric antigen receptor that binds CD19 (heterologous gene). Applicants must specify the claims that encompass any additionally elected non-immunogenic polypeptide sequence(s) and/or heterologous gene(s). Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined. An exemplary election would be a HER1 non-immunogenic polypeptide domain IV encompassing SEQ ID NO: 204 (HER1 domain IV sequence).

No technical features are shared between the non-immunogenic polypeptide sequences and/or heterologous genes of Groups I+ and, accordingly, these groups lack unity a priori.

Additionally, even if Groups I+ were considered to share the technical features including: a polynucleotide encoding: a truncated non-immunogenic polypeptide, wherein said polypeptide binds an antibody, and wherein said polypeptide is expressed in an engineered cell; a polypeptide construct comprising: a cell surface polypeptide and a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide, and wherein said cell surface polypeptide binds a predetermined antibody or a variant or fragment thereof; a method of regulating activity of genetically engineered cells in a subject comprising: providing to said subject an amount of genetically engineered cells encoding a polypeptide construct comprising a cell surface polypeptide fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide, and wherein said cell surface polypeptide binds a predetermined binding partner or a variant or fragment thereof; and providing to said subject said predetermined binding partner in an amount sufficient to bind and thereby regulating activity of said genetically engineered cells; and a polynucleotide encoding a polypeptide construct comprising: a truncated non-immunogenic cell surface polypeptide fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide; wherein said polypeptide construct is expressed in an engineered cell; these shared technical features are previously disclosed by WO 2011/056894 A2 (JENSEN) in light of evidence provided by US 2010/0279932 A1 to Ledbetter et al. (hereinafter "Ledbetter").

Continued Within the Next Supplemental Box

-Continued from Previous Supplemental Box-

Jensen discloses a polynucleotide encoding: a truncated non-immunogenic polypeptide (a gene (polynucleotide) encoding: a truncated non-immunogenic polypeptide; abstract, paragraph [0005]), wherein said polypeptide binds an antibody (wherein said polypeptide binds an anti-EGFR antibody; abstract, paragraph [0005]), and wherein said polypeptide is expressed in an engineered cell (wherein said polypeptide is expressed in a genetically modified cell (an engineered cell); paragraphs [0004], [0005], [0010]); a polypeptide construct comprising: a cell surface polypeptide (a polypeptide construct comprising: a truncated EGFR (cell surface polypeptide); paragraph [0052]) and a trans-membrane dimerization domain (attached to a chimeric antigen receptor comprising a CD28 transmembrane domain; paragraphs [0052], [0063]; wherein the CD28 transmembrane domain functions as a dimerization domain, according to Ledbetter, paragraph [0853]), wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide (wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide; paragraphs [0052], [0063], wherein the CD28 transmembrane domain functions as a dimerization domain, according to Ledbetter, paragraph [0853]), and wherein said cell surface polypeptide binds a predetermined antibody or a variant or fragment thereof (wherein said cell surface polypeptide binds a predetermined antibody or a variant or fragment thereof abstract, paragraph [0005]); a method of regulating activity of genetically engineered cells in a subject (method of inducing antibody dependent cellular cytotoxic killing (regulating activity) of genetically engineered cells in a subject; paragraphs [0008], [0056], [0068]) comprising: providing to said subject an amount of genetically engineered cells encoding a polypeptide construct (comprising: providing to said subject an amount of genetically engineered cells encoding a polypeptide construct; paragraphs [0008], [0056], [0068]) comprising a cell surface polypeptide (comprising a cell surface polypeptide; paragraphs [0005], [0052]) fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide (fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide; paragraphs [0052], [0063]; wherein the CD28 transmembrane domain functions as a dimerization domain, according to Ledbetter, paragraph [0853]), and wherein said cell surface polypeptide binds a predetermined binding partner or a variant or fragment thereof (wherein said cell surface polypeptide binds a predetermined binding partner or a variant or fragment thereof; paragraphs [0005], [0056]); and providing to said subject said predetermined binding partner in an amount sufficient to bind and thereby regulating activity of said genetically engineered cells (and providing to said subject said predetermined binding partner in an amount sufficient to bind and thereby activate ADCC (regulating activity) of said genetically engineered cells; paragraphs [0008], [0056], [0068]); and a polynucleotide encoding a polypeptide construct comprising: a truncated non-immunogenic cell surface polypeptide (a gene (polynucleotide) encoding a polypeptide construct comprising: a truncated non-immunogenic cell surface polypeptide; abstract, paragraphs [0005]) fused to a trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide (attached (fused) to a CD28 trans-membrane dimerization domain, wherein said trans-membrane dimerization domain induces dimerization of said cell surface polypeptide; paragraphs [0052], [0063], wherein the CD28 transmembrane domain functions as a dimerization domain, according to Ledbetter, paragraph [0853]); wherein said polypeptide construct is expressed in an engineered cell (wherein said polypeptide is expressed in a genetically modified cell (an engineered cell); paragraphs [0004], [0005], [0010]).

Since none of the special technical features of the Groups I+ inventions is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by the Jensen reference, unity of invention is lacking.